

**UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION

MDL 2724
16-MD-2724
20-CV-721

CÉSAR CASTILLO, INC.;
FWK HOLDINGS, L.L.C.;
KPH HEALTHCARE SERVICES, INC., a/k/a
KINNEY DRUGS, INC.; and
ROCHESTER DRUG CO-OPERATIVE, INC.; on
behalf of themselves and all others similarly
situated,

HON. CYNTHIA M. RUFÉ

JURY TRIAL DEMANDED

Plaintiffs,

**DIRECT PURCHASER
PLAINTIFFS' AMENDED
CLASS ACTION COMPLAINT**

v.

PUBLIC VERSION

ACTAVIS HOLDCO U.S., INC.;
ACTAVIS PHARMA, INC.
ACTAVIS ELIZABETH, LLC
AKORN INC.;
ALVOGEN INC.;
AMNEAL PHARMACEUTICALS, INC.;
AMNEAL PHARMACEUTICALS, LLC;
APOTEX CORP.;
ASCEND LABORATORIES, LLC;
AUROBINDO PHARMA USA, INC.;
BAUSCH HEALTH AMERICAS, INC.;
BAUSCH HEALTH US, LLC;
BRECKENRIDGE PHARMACEUTICAL, INC.;
CAMBER PHARMACEUTICALS INC.
CITRON PHARMA LLC;
DAVA PHARMACEUTICALS, LLC;
DR. REDDY'S LABORATORIES, INC.;
EPIC PHARMA, LLC;
FOUGERA PHARMACEUTICALS INC.;
GENERICS BIDCO I LLC;
GLENMARK PHARMACEUTICALS INC., USA;
GREENSTONE LLC;
G&W LABORATORIES, INC.;
HERITAGE PHARMACEUTICALS, INC.;
HIKMA LABS, INC.;
HIKMA PHARMACEUTICALS USA, INC.;
HI-TECH PHARMACAL CO, INC.;
IMPAX LABORATORIES, LLC;
JUBILANT CADISTA PHARMACEUTICALS
INC.;
LANNETT COMPANY, INC.;
LUPIN PHARMACEUTICALS, INC.;
MALLINCKRODT INC.;

MAYNE PHARMA INC.;
MORTON GROVE PHARMACEUTICALS, INC.;
MYLAN INC.;
MYLAN PHARMACEUTICALS INC.;
OCEANSIDE PHARMACEUTICALS, INC.;
PAR PHARMACEUTICAL, INC.;
PERRIGO NEW YORK, INC.;
PFIZER, INC.;
SANDOZ, INC.;
SUN PHARMACEUTICAL INDUSTRIES, INC.;
TARO PHARMACEUTICALS USA., INC.;
TELIGENT, INC.;
TEVA PHARMACEUTICALS USA, INC.;
TORRENT PHARMA INC.;
UPSHER-SMITH LABORATORIES, INC.;
VERSAPHARM, INC.;
WEST-WARD COLUMBUS, INC.;
WOCKHARDT USA LLC, and
ZYDUS PHARMACEUTICALS (USA), INC.,

Defendants.

TABLE OF CONTENTS

I. INTRODUCTION 1

A. Each of the Generic Drugs is Part of An Overarching Fair Share Agreement Among Manufacturers in the Generic Drug Industry. 4

B. The Generic Drug Industry’s Closely-Knit and Highly Social Culture Enabled the Overarching Fair Share Agreement to Thrive for Years. 6

1. The Fair Share Agreement applied across multiple generic drugs at a time and was especially effective when new entrants came to market or when generic drug manufacturers decided to exit a market. 7

2. The conspirators monitored market share and disciplined conduct inconsistent with the Fair Share Agreement and took steps to conceal their activities. 9

C. The Existence of the Fair Share Agreement within the Generic Drug Industry and as to the Named Generic Drugs Is Supported by Other Factors. 10

D. Direct Purchasers Paid More Than They Would Have for the Named Generic Drugs But-For the Fair Share Agreement. 10

II. JURISDICTION AND VENUE 11

III. PARTIES 12

A. Plaintiffs 12

B. Defendants 13

1. Actavis 13

2. Akorn 14

3. Alvogen..... 14

4. Amneal..... 15

5. Apotex..... 15

6. Ascend..... 15

7. Aurobindo 16

8. Bausch..... 16

9. Breckenridge 17

10.	Cadista.....	17
11.	Camber.....	17
12.	Citron	17
13.	Dr. Reddy’s.....	18
14.	Epic	18
15.	Glenmark.....	18
16.	Greenstone	18
17.	G&W.....	19
18.	Heritage.....	19
19.	Impax	19
20.	Lannett	20
21.	Lupin.....	20
22.	Mallinckrodt.....	20
23.	Mayne	21
24.	Mylan	21
25.	Par	21
26.	Perrigo.....	22
27.	Sandoz.....	22
28.	Sun	23
29.	Taro	23
30.	Teligent	24
31.	Teva.....	24
32.	Torrent.....	24
33.	Upsher-Smith	24
34.	West-Ward	25

35.	Wockhardt.....	25
36.	Zydus.....	26
C.	Generic Manufacturer Co-Conspirators.....	26
1.	Rising.....	26
2.	Unknown Generic Manufacturer Co-Conspirators.....	26
IV.	INTERSTATE TRADE AND COMMERCE	27
V.	FACTUAL ALLEGATIONS	28
A.	Competition Between Generic Drugs Historically Has Been Keen.	28
1.	Generic drugs should lead to lower prices.....	28
2.	Prescription drug prices in the United States are governed by institutional safeguards, which are intended to keep drug prices competitive.....	31
B.	Defendants and Their Generic Manufacturer Co-Conspirators Participated in an Overarching Fair Share Agreement to Thwart Competition in the Generic Drug Industry.	34
1.	Fair Share Agreement Principle: Each manufacturer is entitled to a certain market share—no more and no less.	38
2.	Fair Share Agreement Principle: Manufacturers should achieve their fair share of the market cooperatively—not competitively.	41
3.	Fair Share Agreement Principle: Do not engage in price competition.	42
4.	Fair Share Agreement Principle: When customers request a competitive bid, the manufacturer’s response should be based on and consistent with the Fair Share Agreement—not customer’s wants and needs or competitive interests.	43
5.	The Fair Share Agreement was facilitated by coziness among generic drug manufacturers.....	44
C.	Individual Drug Allegations	48
1.	Adapalene	48
2.	Alclometasone Dipropionate	51
3.	Allopurinol.....	55

4.	Amantadine HCL	58
5.	Amiloride HCL/HCTZ.....	60
6.	Ammonium Lactate	62
7.	Amoxicillin/Clavulanate.....	64
8.	Amphetamine Salts (MAS).....	65
9.	Atenolol Chlorthalidone.....	71
10.	Atropine Sulfate	73
11.	Balsalazide Disodium	75
12.	Betamethasone Dipropionate	77
13.	Betamethasone Dipropionate Augmented	81
14.	Betamethasone Dipropionate Clotrimazole	83
15.	Betamethasone Valerate.....	86
16.	Bethanechol Chloride.....	90
17.	Bromocriptine Mesylate.....	91
18.	Budesonide.....	94
19.	Buspirone HCL	96
20.	Butorphanol Tartrate.....	97
21.	Capecitabine.....	99
22.	Captopril	101
23.	Carbamazepine, Clotrimazole, and Warfarin Sodium	103
24.	Carisoprodol.....	116
25.	Cefdinir and Cefprozil	117
26.	Cefuroxime Axetil	118
27.	Celecoxib	121
28.	Cephalexin (Cefalexin).....	122

29. Chlorpromazine HCL.....126

30. Cholestyramine130

31. Ciclopirox133

32. Cimetidine.....137

33. Clarithromycin139

34. Clindamycin Phosphate141

35. Clonidine TTS.....144

36. Desmopressin Acetate.....147

37. Desonide (Lotion 0.05%).....148

38. Desoximetasone152

39. Dexmethylphenidate HCL155

40. Dextroamphetamine Sulfate.....157

41. Diclofenac Potassium.....163

42. Diltiazem HCL.....166

43. Diphenoxylate Atropine HCL.....169

44. Doxazosin Mesylate and Etodolac.....171

45. Drospirenone and Ethinyl Estradiol.....181

46. Enalapril Maleate183

47. Entecavir187

48. Estradiol188

49. Estradiol and Norethindrone Acetate.....190

50. Ethinyl Estradiol and Levonorgestrel191

51. Exemestane193

52. Fenofibrate195

53. Fluconazole.....197

54.	Fluocinolone Acetonide	202
55.	Fluocinonide (Solution 0.05% and Cream 0.1%)	205
56.	Fluoxetine HCL	210
57.	Fluticasone Propionate.....	212
58.	Gabapentin	214
59.	Glimepiride	216
60.	Griseofulvin	217
61.	Halobetasol Propionate	218
62.	Haloperidol	221
63.	Hydrocodone Acetaminophen	224
64.	Hydrocortisone Valerate	227
65.	Irbesartan.....	229
66.	Isosorbide Dinitrate.....	230
67.	Ketoconazole.....	232
68.	Ketoprofen	237
69.	Ketorolac Tromethamine	239
70.	Labetalol HCL	240
71.	Lamivudine/Zidovudine.....	241
72.	Latanoprost	243
73.	Lidocaine HCL.....	245
74.	Loperamide HCL	247
75.	Metformin ER (F)	249
76.	Methadone HCL.....	251
77.	Methazolamide.....	254
78.	Methotrexate	257

79. Methylphenidate260

80. Methylprednisolone266

81. Metronidazole Gel (1%)268

82. Moexipril HCL and Moexipril HCL HCTZ270

83. Nadolol.....273

84. Naproxen Sodium278

85. Niacin.....280

86. Nitrofurantoin282

87. Neomycin Polymyxin Hydrocortisone285

88. Norethindrone/Ethinyl Estradiol.....287

89. Nortriptyline HCL.....288

90. Nystatin Triamcinolone291

91. Omega-3-Acid Ethyl Esters292

92. Oxaprozin.....294

93. Oxybutynin Chloride298

94. Oxycodone Acetaminophen.....300

95. Oxycodone HCL303

96. Paricalcitol307

97. Permethrin.....309

98. Perphenazine311

99. Phenytoin Sodium.....314

100. Pilocarpine HCL318

101. Piroxicam320

102. Potassium Chloride322

103. Prazosin HCL.....325

104.	Prednisolone Acetate	331
105.	Prednisone.....	333
106.	Prochlorperazine Maleate	337
107.	Promethazine HCL.....	340
108.	Raloxifene HCL	344
109.	Ranitidine HCL	346
110.	Silver Sulfadiazine	350
111.	Spironolactone HCTZ.....	352
112.	Tacrolimus	354
113.	Tamoxifen Citrate	356
114.	Temozolomide	361
115.	Terconazole.....	362
116.	Timolol Maleate.....	365
117.	Tizanidine HCL	368
118.	Tobramycin.....	372
119.	Tobramycin Dexamethasone	373
120.	Tolmetin Sodium	375
121.	Tolterodine.....	376
122.	Trazodone HCL	379
123.	Triamcinolone Acetonide.....	380
124.	Triamterene HCTZ.....	385
125.	Trifluoperazine HCL.....	388
126.	Valsartan HCTZ.....	392

D.	Defendants’ Anticompetitive Conduct Relating to the Other Named Generic Drugs Further Demonstrates Defendants’ Overarching Fair Share Agreement ..	394
----	---	-----

E.	The Existence of the Fair Share Agreement within the Generic Drug Industry and as to All of the Named Generic Drugs Is Supported by Other Factors.....	394
VI.	CLASS ACTION ALLEGATIONS	395
VII.	ANTITRUST INJURY	397
VIII.	TOLLING OF THE STATUTE OF LIMITATIONS.....	397
IX.	CLAIM FOR RELIEF	400
X.	PRAYER FOR RELIEF	408
XI.	JURY TRIAL DEMANDED.....	409

EXHIBITS

EXHIBIT A	DPP NAMED GENERIC DRUGS IN MDL 2724 AS OF OCTOBER 2020
EXHIBIT B	TIMELINE OF DPP NAMED GENERIC DRUGS IN MDL 2724
EXHIBIT C	HISTORY OF GOVERNMENT INVESTIGATIONS AND OTHER PUBLIC REPORTS CONCERNING ANTICOMPETITIVE CONDUCT IN THE GENERIC DRUG INDUSTRY
EXHIBIT D	LIST OF GENERIC DRUG MANUFACTURERS KNOWN TO HAVE RECEIVED A DOJ SUBPOENA AND/OR CID RELATING TO ANTICOMPETITIVE CONDUCT IN THE GENERIC DRUG INDUSTRY
EXHIBIT E	TRADE ASSOCIATION CONTACTS AS TO THE NAMED GENERIC DRUGS
EXHIBIT F	GENERIC PHARMACEUTICAL ASSOCIATION BOARD OF DIRECTORS 2010 TO 2017
EXHIBIT G	SUMMARY OF ECONOMIC FACTORS INDICATING COLLUSION IN THE GENERIC DRUG INDUSTRY
EXHIBIT H	SAMPLE OF DEFENDANTS' INVESTOR COMMUNICATIONS
EXHIBIT I	SAMPLE TELEPHONE RECORD SUMMARY

I. INTRODUCTION

1. In the pharmaceutical industry the entry of generic versions of branded drugs should result in aggressive price competition, which, in turn, dramatically reduces prices for drug wholesalers, retail pharmacies, consumers, and third-party payors. Thus, traditionally, generic drugs have been a relative bargain in healthcare. However, pricing dynamics in the generic drug industry have changed for a large number of drugs, leading to, among other things, many large and parallel price increases.

2. Documentary evidence has confirmed that these changes were the result of long-running collusion among generic drug manufacturers to thwart the economic benefits of generic competition. This collusion encompasses far more than one hundred drugs and involves nearly all of the significant generic drug manufacturers operating in the United States. *See* Exhibit A (DPP Named Generic Drugs in MDL 2724 as of October 2020); Exhibit B (Timeline of DPP Named Generic Drugs in MDL 2724). Pursuant to this overarching scheme (the “Fair Share Agreement”), generic drug manufacturers agreed to suppress competition among themselves so that they could fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation.

3. MDL 2724 encompasses claims that generic drug manufacturers engaged in an unlawful scheme or schemes to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations of generic drugs. In this Amended Complaint, filed by Direct Purchaser Class Plaintiffs’ (DPPs)¹ in this multidistrict litigation, DPPs add allegations concerning the below generic drugs, which were already at issue in the MDL:

¹ César Castillo, Inc., FWK Holdings, L.L.C., KPH Healthcare Services, Inc., a/k/a Kinney Drugs, Inc., and Rochester Drug Co-Operative, Inc.

- Ammonium Lactate (Cream 12% and Lotion 12%)
- Betamethasone Valerate (Lotion 0.1%)
- Ciclopirox (Cream 0.77%)
- Desonide (Lotion 0.05%)
- Desoximetasone (Ointment 0.25%)
- Fluocinonide (Solution/Emulsion 0.1%, Cream 0.1%)
- Methazolamide (Tablets 25, 50 mg)
- Methylphenidate HCL ER (Tablets 20 mg)
- Metronidazole (Gel 1%)
- Prochlorperazine Maleate (Suppositories 25 mg)
- Promethazine (Suppositories 12.5, 25 mg)
- Tacrolimus (Ointment 0.03%, 0.1%)
- Terconazole (Vaginal Cream 0.4%, 0.8%)

These drugs are in addition to the drugs sued on in DPPs' February 7, 2020 complaint, which were listed in paragraphs 4 and 5 of that complaint. DPPs also make edits, updates, and corrections to certain allegations in their February 7, 2020 complaint.

4. The generic drugs sued on in this Amended Complaint are in addition to the drugs that DPPs previously filed complaints on. Attached hereto is a list of all drugs that DPPs have sued on to date. *See Exhibit A (DPP Named Generic Drugs in MDL 2724 as of October 2020).*²

5. The drugs discussed above are referred to collectively as the Named Generic Drugs. The Defendants who have manufactured or sold one or more of these Named Generic Drugs are Actavis Holdco U.S., Inc., Actavis Pharma, Inc., and Actavis Elizabeth LLC (together, Actavis); Akorn, Inc., Hi-Tech Pharmacal Co., Inc., and Versapharm, Inc. (together, Akorn); Alvogen Inc. (Alvogen); Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals, LLC (together, Amneal); Apotex Corp. (Apotex); Aurobindo Pharma USA, Inc. (Aurobindo); Bausch Health Americas, Inc., Bausch Health US LLC, and Oceanside Pharmaceuticals, Inc. (together,

² DPPs' prior individual drug and multi-drug complaints are related to and are part of the same conspiracy alleged here. Accordingly, all Defendants in the existing DPP complaints have been named as Defendants here.

Bausch); Breckenridge Pharmaceutical, Inc. (Breckenridge); Jubilant Cadista Pharmaceuticals Inc. (Cadista); Camber Pharmaceuticals Inc. (Camber); Citron Pharma LLC (Citron); Dr. Reddy's Laboratories, Inc. (Dr. Reddy's or DRL); Epic Pharma, LLC (Epic); Glenmark Pharmaceuticals, Inc. (Glenmark); Greenstone LLC and Pfizer, Inc. (together, Greenstone); G&W Laboratories, Inc. (G&W); Heritage Pharmaceuticals, Inc. (Heritage); Impax Laboratories, LLC (Impax); Lannett Company, Inc. (Lannett); Lupin Pharmaceuticals, Inc. (Lupin); Mallinckrodt Inc. (Mallinckrodt); Mayne Pharma USA, Inc. (Mayne); Mylan Inc. and Mylan Pharmaceuticals, Inc. (together, Mylan); Par Pharmaceutical, Inc., DAVA Pharmaceuticals, LLC, and Generics Bidco I, LLC (together, Par); Perrigo New York, Inc. (Perrigo); Sandoz, Inc. and Fougera Pharmaceuticals Inc. (together, Sandoz); Sun Pharmaceutical Industries, Inc. (Sun); Taro Pharmaceuticals USA., Inc. (Taro); Teligent, Inc. (Teligent); Teva Pharmaceuticals USA, Inc. (Teva); Torrent Pharma Inc. (Torrent); Upsher-Smith Laboratories, Inc. (Upsher-Smith), West-Ward Columbus, Inc., Hikma Labs, Inc. (formerly Roxane Laboratories, Inc.), and Hikma Pharmaceuticals USA, Inc. (together, West-Ward), Wockhardt USA LLC and Morton Grove Pharmaceuticals, Inc. (together, Wockhardt), and Zydus Pharmaceuticals USA, Inc. (Zydus). Each of the Defendants and their co-conspirators are generic drug manufacturers.

6. The allegations herein are based on DPPs' personal knowledge of the matters relating to themselves and upon information and belief as to all other matters. Parts of DPPs' allegations are based on information made public or made available in the MDL during ongoing government investigations into anticompetitive conduct in the generic drug industry. Other parts of DPPs' allegations are based on investigation conducted by and under the supervision of DPPs' counsel. Yet other parts of DPPs' allegations are based on documentary evidence disclosed in the course of this multi-district litigation

A. Each of the Generic Drugs is Part of An Overarching Fair Share Agreement Among Manufacturers in the Generic Drug Industry.

7. MDL 2724 encompasses actions in which:

(a) plaintiffs assert claims for price fixing of generic drugs in violation of the Sherman Act and/or state antitrust laws on behalf of overlapping putative nationwide classes of direct or indirect purchasers of generic pharmaceuticals; (b) the average market price of the subject generic pharmaceutical is alleged to have increased between 2012 and the present; (c) defendants are alleged to have effectuated the alleged conspiracy through direct company-to-company contacts and through joint activities undertaken through trade associations, in particular meetings of the Generic Pharmaceutical Association; and (d) the allegations stem from the same government investigation into anticompetitive conduct in the generic pharmaceuticals industry.³

8. The DPPs' prior allegations of conspiratorial conduct and artificially inflated prices have repeatedly been sustained. In October 2018, the Court sustained allegations concerning individual drugs (clobetasol, digoxin, divalproex, doxycycline, econazole, and pravastatin)⁴. In August 2019, the Court sustained allegations of an overarching fair share conspiracy among generic drug manufacturers.⁵ The Court held that DPPs plausibly alleged "a single conspiracy with a common goal, facilitated by multiple schemes specific to various individual generic drugs."⁶ The Court further held that DPPs included sufficient detail as to the "how, when, or where needed to make plausible a claim that Defendants' actions regarding the prices of individual generic drugs in their portfolios were beneficial to and reinforced a broader scheme regarding generic drug prices."⁷

³ MDL Doc. No. 194; *see also* MDL Doc. Nos. 417, 425 (transferring state actions). It is now apparent that the conduct began before 2012.

⁴ *In re Generic Pharm. Pricing Antitrust Litig.*, 338 F. Supp. 3d 404 (E.D. Pa. Oct. 16, 2018).

⁵ *In re Generic Pharm. Pricing Antitrust Litig.*, 394 F. Supp. 3d 509 (E.D. Pa. Aug. 15, 2019).

⁶ *Id.* at 529.

⁷ *Id.* at 531.

9. As further described herein, Defendants’ and their generic manufacturer co-conspirators’ anticompetitive conduct as to the Named Generic Drugs is part of an industry-wide, overarching “fair share” conspiracy (Fair Share Agreement) involving the Named Generic Drugs. Under the Fair Share Agreement, generic drug manufacturers had no need to compete because each generic drug manufacturer was assured of receiving its fair share of the market for a particular generic drug by “playing nice in the sandbox.” Pursuant to this overarching scheme, generic drug manufacturers agreed to suppress competition among themselves so that they could fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation of far more than 100 generic drugs.

10. The Fair Share Agreement is premised on the shared understanding that each manufacturer is entitled to a certain percentage of the market for a particular drug, primarily based on the number of manufactures in the market for that drug. The Fair Share Agreement dictates that each manufacturer should obtain its designated market share without engaging in price competition. Conspirators expected incumbent manufacturers to cede the proper amount of market share to new entrants, and for new entrants to carefully target select customers sufficient to meet their fair share level but not exceeding that level. This market share allocation scheme reflects a common understanding that higher prices and market equilibrium are preferable to active price competition to achieve higher sales volume and market share. Stated differently, the goal of the Fair Share Agreement is for generic drug manufacturers to achieve artificially inflated prices because no generic manufacturer has incentive to compete for additional market share by eroding price. In Defendants’ terminology “Quality Competitors” are those that best adhere to the Fair Share Agreement.

11. “Playing nice in the sandbox” entailed, among other things, getting along with ostensible competitors and frequent communications to prevent disturbing their respective shares for particular drugs in the generic drug industry market, including communicating with them frequently about customers, new drug launches, prices, bids, and temporary shortages (which conspirators were expected to refrain from exploiting for long-term gain). If everyone adhered to the Fair Share Agreement and regularly socialized to keep information flowing, then additional profits were guaranteed for each generic drug manufacturer without the hassle of free market competition. This is what happened – at the expense of DPPs and the proposed Class.

B. The Generic Drug Industry’s Closely-Knit and Highly Social Culture Enabled the Overarching Fair Share Agreement to Thrive for Years.

12. Playing nice in the sandbox was facilitated by generic manufacturers’ employees, who frequently communicated and socialized both in-person at near constant trade association events, via telephone and texting, or via other electronic means (*e.g.*, email, social media platforms, LinkedIn, WhatsApp). *See, e.g.*, Exhibit E (Trade Association Contacts as to the Named Generic Drugs); Exhibit F (Generic Pharmaceutical Association Board of Directors 2010 to 2017);⁸ Exhibit I (Sample Telephone Record Summary). In addition to in-person communications at trade association events, generic drug manufacturers’ employees frequently met in less formal settings such as happy hours, events for women in the industry, dinners, lunches, golf outings, holiday parties, gambling events, etc. Impromptu gatherings were readily

⁸ Such trade associations include, but are not limited to, the Generic Pharmaceutical Association (GPhA) (now called the Association for Accessible Medicines), the Healthcare Distribution Management Association (HDMA) (now called the Healthcare Distribution Alliance), the Minnesota Multistate Contracting Alliance for Pharmacy (MMCAP), the National Association of Chain Drug Stores (NACDS), Efficient Collaborative Retail Marketing (ECRM), and the National Pharmacy Forum (NPF).

scheduled because many generic pharmaceutical manufacturers are headquartered in relatively close geographic proximity throughout the Mid-Atlantic region.

13. In addition to the numerous opportunities for interaction, many generic drug manufacturer employees and executives (including, for example, so called National Account Managers (NAMs) moved from generic drug manufacturer to generic drug manufacturer while preserving former co-worker contacts, and thus furthered the interwoven, cooperative generic drug industry culture.

14. The coziness and chattiness among generic drug manufacturer employees facilitated “playing nice in the sandbox” and allowed for the overarching fair share conspiracy to blossom. Open communications with ostensible competitors were merely part of the “toolkit” by which employees were successful in their jobs and achieved higher profits for their employers.

15. Because generic drug manufacturers and their employees are repeat players who routinely encounter the same ostensible competitors, their Fair Share Agreement – to eschew price competition and allocate markets and customers – became the “rules of the road” that govern their overarching conspiracy.

1. The Fair Share Agreement applied across multiple generic drugs at a time and was especially effective when new entrants came to market or when generic drug manufacturers decided to exit a market.

16. The anticompetitive conduct was often applied across multiple drugs. For instance, a Defendant might strategize as to how to implement the Fair Share Agreement with respect to another Defendant generally and assessed whether other generics manufacturers were “responsible” Quality Competitors who adhered to the principles of the Fair Share Agreement. *See, e.g.,* Teva’s Competitor Rankings. Reflecting this broad approach, Defendants’ conspiratorial communications often involved several generic drugs.

17. Generic drug manufacturers were generally aware of other manufacturers' entire portfolios of generic drugs, as well as pending and/or approved Abbreviated New Drug Applications (ANDAs),⁹ and, thus, were ostensible competitors on many drugs (even those which they did not manufacture or sell at any particular point in time). As such, achieving a fair share as to one generic drug could involve horse trading across other generic drugs. For instance, generic drug manufacturers might give up customers on one generic drug as a quid pro quo for customers from other generic drug manufacturers on a different generic drug (*i.e.*, "walking away" from business).

18. This understanding regarding fair share was particularly effective when a new generic drug manufacturer entered the market for a drug – a time when, in a competitive market, prices should go down. But under the Fair Share Agreement, a generic drug manufacturer set to launch a generic drug would often approach or be approached by existing generic drug manufacturers prior to market entry to discuss price, market share, and allocation of customers. Likewise, the incumbent manufacturers would conduct internal analyses to identify customers they would concede to the new entrant so that the new entrant could obtain its fair share without engaging in price competition. This allowed a fair share understanding to be reached prior to the new generic manufacturer entering the market and enabled artificially inflated prices to be maintained.

19. The Fair Share Agreement allowed generic drug manufacturers to enjoy high profits without the threat of competition. And as the industry grew more comfortable with the Fair Share Agreement, generic drug manufacturers became bolder and would, at times,

⁹ As discussed further below, to obtain marketing approval for a generic drug, an ANDA must be filed with the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, Office of Generic Drugs.

substantially raise generic drug prices. Although such large price increases would be risky in a competitive market where customers could simply buy from lower priced rivals, the conspirators knew that competition would not be forthcoming pursuant to their overarching Fair Share Agreement. The conspirators reached an understanding that their industry compatriots would not violate the rules of the road; that is, to maintain artificially inflated prices by allocating generic drugs and customers and avoid price competition.

2. The conspirators monitored market share and disciplined conduct inconsistent with the Fair Share Agreement and took steps to conceal their activities.

20. The manufacturer conspirators periodically rebalanced market share by allocating customers. For instance, if it was determined that Generic Drug Manufacturer A had less than its fair share of the market, then, pursuant to the overarching Fair Share Agreement, Generic Manufacturer B would “walk away” from a customer or customers by informing them of a significant price increase. Generic Drug Manufacturer A would then submit a bid at an amount slightly less than Generic Drug Manufacturer B. Generic Drug Manufacturer A and Generic Drug Manufacturer B would continue to engage in such conduct with different customers until they reached their agreed-upon fair share.

21. Rebalancing of market share could also occur prior to a new entrant launching a drug. Indeed, the Fair Share Agreement was particularly effective when new entrants came on the market for a particular drug and often there were communications in advance of such entry.

22. Generic drug manufacturers knew that their conduct was illegal, and they took extensive measures to conceal their activities even, in some instances, intentionally destroying evidence of their incriminating communications. For instance, conspirators warned their employees not to keep any written or electronic record of their collusive contacts with purported competitors.

C. The Existence of the Fair Share Agreement within the Generic Drug Industry and as to the Named Generic Drugs Is Supported by Other Factors.

23. In addition to the data analysis and conspiracy evidence set forth herein, other factors support the existence of the Fair Share Agreement among generic drug manufacturers as to the Named Generic Drugs:

- 1) the ongoing investigations by the States and DOJ of pervasive and industry-wide collusion among many generic pharmaceutical manufacturers, as well as other public reports indicating collusion;¹⁰
- 2) frequent communications and meetings among generic drug manufacturers' employees including the Defendants here;¹¹
- 3) factors showing that the generic pharmaceutical industry is susceptible to collusion;¹² and
- 4) investor communications reflecting, among other things, that Defendants' profits increased during the relevant time period, frequently as a result of price increases.¹³

D. Direct Purchasers Paid More Than They Would Have for the Named Generic Drugs But-For the Fair Share Agreement.

24. This Complaint provides specific allegations regarding illegal agreement and collusion as to specific Named Generic Drugs, but these Named Generic Drugs are each part of a larger overarching conspiracy as described in other DPP and State MDL complaints.

25. As a result of Defendants' and their generic manufacturer co-conspirators' efforts to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation of the

¹⁰ Exhibit C (History of Government Investigations and Other Public Reports Concerning Anticompetitive Conduct in the Generic Drug Industry); Exhibit D (List of Generic Drug Manufacturers Known to Have Received a DOJ Subpoena and/or CID Relating to Anticompetitive Conduct in the Generic Drug Industry).

¹¹ Exhibit E (Trade Association Contacts as to the Named Generic Drugs); Exhibit F (Generic Pharmaceutical Association Board of Directors 2010 to 2017); Exhibit I (Sample Telephone Record Summary).

¹² Exhibit G (Summary of Economic Factors Indicating Collusion in the Generic Drug Industry).

¹³ Exhibit H (Sample of Defendants' Investor Communications).

Named Generic Drugs, direct purchasers paid, and continue to pay, supracompetitive prices for the Named Generic Drugs.

26. DPPs, on behalf of themselves and members of the proposed Class, seek damages caused by Defendants' and their generic manufacturer co-conspirators' violations of Sections 1 and 3 of the Sherman Act, 15 U.S.C. §§ 1 and 3, as to the Named Generic Drugs.

II. JURISDICTION AND VENUE

27. This Court has jurisdiction over the subject matter of this action as it arises under Sections 1 and 3 of the Sherman Act, 15 U.S.C. §§ 1, 3, and Section 4 of the Clayton Act, 15 U.S.C. § 15. Further, this Court has jurisdiction under 28 U.S.C. §§ 1331, 1337(a).

28. Venue is proper in this District pursuant to 15 U.S.C. §§ 15 and 22, and 28 U.S.C. § 1391(b), (c), and (d), because, during the Class Period, Defendants transacted business throughout the United States, including in this District, Defendants resided, were found, or had agents within this District, and a portion of the affected interstate trade and commerce discussed below was carried out in this District.

29. During the Class Period, Defendants sold and distributed generic drugs in a continuous and uninterrupted flow of interstate commerce, which included sales of the Named Generic Drugs in the United States, including in this District. Defendants' conduct had a direct, substantial, and reasonably foreseeable effect on interstate commerce in the United States, including in this District.

30. This Court has personal jurisdiction over each Defendant because, *inter alia*, each Defendant: (a) transacted business throughout the United States, including in this District; (b) participated in the selling and distribution of the Named Generic Drugs throughout the United States, including in this District; (c) had and maintained substantial contacts within the United States, including in this District; and/or (d) was engaged in an unlawful conspiracy to artificially

inflate prices that was directed at and had the intended effect of causing injury to persons residing in, located in, or doing business throughout the United States, including in this District.

III. PARTIES

A. Plaintiffs

31. Plaintiff César Castillo, Inc. (CCI) is a Puerto Rico corporation with its principal place of business in Rio Piedras, Puerto Rico. During the Class Period, CCI purchased one or more of the Named Generic Drugs directly from one or more Defendants. As a result of Defendants' antitrust conspiracy, CCI paid supracompetitive prices for these purchases and was injured by the illegal conduct alleged herein.

32. Plaintiff FWK Holdings, LLC (FWK) is an Illinois corporation with its principal place of business in Glen Ellyn, Illinois. FWK is the assignee of antitrust claims possessed by Frank W. Kerr Company (Kerr) and brings this action as successor-in-interest to Kerr's claims arising from its purchase of one or more of the Named Generic Drugs directly from one or more Defendants. As a result of Defendants' antitrust conspiracy, FWK, through assignor Kerr, paid supracompetitive prices for these purchases and was injured by the illegal conduct alleged herein.

33. Plaintiff KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. (KPH) is a New York corporation with its principal place of business in Gouverneur, New York. KPH operates retail and online pharmacies in the Northeast under the name Kinney Drugs, Inc. During the Class Period, KPH purchased one or more of the Named Generic Drugs directly from one or more Defendants. As a result of Defendants' antitrust conspiracy, KPH paid supracompetitive prices for these purchases and was injured by the illegal conduct alleged herein.

34. Plaintiff Rochester Drug Co-Operative, Inc. (RDC) is a New York corporation with its principal place of business in Rochester, New York. During the Class Period, RDC

purchased one or more of the Named Generic Drugs directly from one or more Defendants. As a result of Defendants' antitrust conspiracy, RDC paid supracompetitive prices for these purchases and was injured by the illegal conduct alleged herein.

B. Defendants

1. Actavis

35. Defendant Actavis Holdco U.S., Inc. (Actavis Holdco) is a Delaware corporation with its principal place of business in Parsippany, New Jersey. In August 2016, Teva Pharmaceuticals USA, Inc. acquired the Actavis Generics business of Allergan plc, including Actavis, Inc. Upon the acquisition, Actavis, Inc.—the acquired Allergan plc generics operating company (formerly known as Watson Pharmaceuticals)—was renamed Allergan Finance, LLC, which in turn assigned all of the assets and liabilities of the former Allergan plc generic business to the newly formed Actavis Holdco, including subsidiaries Actavis Pharma, Inc. and Actavis Elizabeth LLC (a research, development and manufacturing entity for Actavis generic operations), among others. Actavis Holdco is a wholly-owned subsidiary of Teva Pharmaceuticals USA, Inc., which is a Delaware corporation with its principal place of business in North Wales, Pennsylvania. Teva Pharmaceuticals USA, Inc. is a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd., an Israeli entity.

36. Defendant Actavis Pharma, Inc. is Delaware corporation with its principal place of business in Parsippany, New Jersey. It is a wholly-owned subsidiary of Actavis Holdco and is a principal operating company in the U.S. for Teva's generic products acquired from Allergan plc. It manufactures, markets, and/or distributes generic drugs.

37. Actavis Elizabeth LLC is a Delaware company with its principal place of business in Elizabeth, New Jersey. It is a wholly-owned subsidiary of Actavis Holdco and is a research, development and manufacturing entity for Actavis generic operations.

38. Unless addressed individually, Actavis Holdco, Actavis Pharma, Inc., and Actavis Elizabeth LLC are collectively referred to herein as “Actavis.” During the Class Period, Actavis sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

2. Akorn

39. Defendant Akorn Inc. is a Louisiana corporation with its principal place of business in Lake Forest, Illinois. It is the parent company of Hi-Tech Pharmacal Co., Inc.

40. Defendant Hi-Tech Pharmacal Co., Inc. (Hi-Tech) is a Delaware corporation with its principal place of business in Amityville, New York. It is a wholly-owned subsidiary of Akorn, Inc. Akorn Inc. acquired and integrated Hi-Tech into its operations in April 2014.

41. Defendant Versapharm, Inc. (Versapharm) is a wholly-owned subsidiary of Akorn Inc.

42. Unless addressed individually, Akorn Inc., Hi-Tech, and Versapharm are collectively referred to herein as “Akorn.” During the Class Period, Akorn sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

43. On May 20, 2020, Akorn filed for bankruptcy. By operation of 11 U.S. Code § 362, further action against Akorn is enjoined.

3. Alvogen

44. Defendant Alvogen Inc. is a privately-held Delaware corporation with its principal place of business in Pine Brook, New Jersey. During the Class Period, Alvogen sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout

the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

4. Amneal

45. Defendant Amneal Pharmaceuticals, Inc. is a Delaware corporation with its principal place of business in Bridgewater, New Jersey. In May 2018, Impax completed a merger with Amneal Pharmaceuticals, Inc. to become the fifth largest generics business in the United States.

46. Defendant Amneal Pharmaceuticals, LLC is a Delaware limited liability company with its principal place of business in Bridgewater, New Jersey.

47. Unless addressed individually, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC are together referred to as “Amneal.” During the Class Period, Amneal sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

5. Apotex

48. Defendant Apotex Corp. is a Delaware corporation with its principal place of business in Weston, Florida. During the Class Period, Apotex sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

6. Ascend

49. Defendant Ascend Laboratories, LLC is a New Jersey company with its principal place of business in Parsippany, New Jersey. It is a wholly-owned subsidiary of Alkem Labs, an Indian pharmaceutical company. During the Class Period, Ascend sold one or more of the

Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

7. Aurobindo

50. Defendant Aurobindo Pharma USA, Inc. is a Delaware corporation with its principal place of business in Dayton, New Jersey. During the Class Period, Aurobindo sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

8. Bausch

51. Defendant Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International, Inc.) is a Delaware corporation with its principal place of business in Bridgewater, New Jersey.

52. Defendant Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) is a Delaware limited liability company with its principal place of business in Bridgewater, New Jersey.

53. Defendant Oceanside Pharmaceuticals, Inc. is a wholly-owned subsidiary of Bausch Health Americas, Inc. It is a Delaware corporation with its principal place of business in Bridgewater, New Jersey.

54. Unless addressed individually, Bausch Health Americas, Inc., Bausch Health US, LLC, and Oceanside Pharmaceuticals, Inc. are collectively referred to herein as “Bausch.” During the Class Period, Bausch sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

9. Breckenridge

55. Defendant Breckenridge Pharmaceutical, Inc. is a Delaware corporation with its headquarters in Boca Raton, Florida. During the Class Period, Breckenridge sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

10. Cadista

56. Defendant Jubilant Cadista Pharmaceuticals Inc. is a Delaware corporation with its principal place of business in Salisbury, Maryland. It is a wholly-owned subsidiary of Jubilant Life Sciences Company, an Indian pharmaceutical company. During the Class Period, Cadista sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

11. Camber

57. Defendant Camber Pharmaceuticals, Inc. is a Delaware corporation with its principal place of business in Piscataway, New Jersey. Camber is a wholly-owned subsidiary of Hetero Drugs, an Indian pharmaceutical company. During the Class Period, Camber sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

12. Citron

58. Defendant Citron Pharma, LLC is a New Jersey corporation with its principal place of business in East Brunswick, New Jersey. During the Class Period, Citron sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the

United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

13. Dr. Reddy's

59. Defendant Dr. Reddy's Laboratories is a Delaware corporation with its principal place of business in Princeton, New Jersey. It is a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., an Indian pharmaceutical company. During the Class Period, Dr. Reddy's sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

14. Epic

60. Defendant Epic Pharma, LLC ("Epic") is a Delaware limited liability company with its principal place of business in Laurelton, New York. During the Class Period, Epic marketed and sold generic pharmaceuticals in this District and throughout the United States.

15. Glenmark

61. Defendant Glenmark Pharmaceuticals, Inc. is a Delaware corporation with its principal place of business in Mahwah, New Jersey. During the Class Period, Glenmark sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

16. Greenstone

62. Defendant Greenstone LLC is a limited liability company with its principal place of business in North Peapack, New Jersey. Greenstone is a wholly-owned subsidiary of Defendant Pfizer, Inc., and operated as the generic drug division of Pfizer, Inc. during the Class Period.

63. Defendant Pfizer, Inc. is a Delaware corporation with its principal place of business in New York, New York. Pfizer is the parent company of Defendant Greenstone.

64. Unless addressed individually, Greenstone and Pfizer are referred to together as “Greenstone.” During the Class Period, Greenstone sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

17. G&W

65. Defendant G&W Laboratories, Inc. is a New Jersey corporation with its principal place of business in South Plainfield, New Jersey. During the Class Period, G&W sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

18. Heritage

66. Defendant Heritage Pharmaceuticals, Inc. (Heritage) is a Delaware corporation with its principal place of business in East Brunswick, New Jersey. Heritage is a subsidiary of Emcure Pharmaceuticals Ltd. (Emcure). During the Class Period, Heritage sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

19. Impax

67. Defendant Impax Laboratories, LLC is a Delaware limited liability company that is the successor entity of Impax Laboratories, Inc. In 1999, Global Pharmaceutical Corporation merged with Impax Pharmaceuticals, Inc. In September 2014, Impax acquired Corepharma. In May 2018, Impax completed a merger with Amneal to become the fifth largest generics business

in the United States. Impax is now a wholly-owned subsidiary of Amneal. During the Class Period, Impax sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

20. Lannett

68. Defendant Lannett Company, Inc. is a Delaware corporation with its principal place of business in Philadelphia, Pennsylvania. During the Class Period, Lannett sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

21. Lupin

69. Defendant Lupin Pharmaceuticals, Inc. is a Delaware corporation with its principal place of business in Baltimore, Maryland. It is a wholly-owned subsidiary of Lupin Ltd., an Indian pharmaceutical company. During the Class Period, Lupin sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

22. Mallinckrodt

70. Defendant Mallinckrodt Inc. is a Delaware corporation with its principal place of business in Webster Groves, Missouri. As a result of a tax inversion acquisition, as of 2013 it is a wholly owned subsidiary of Mallinckrodt plc, which is based in the United Kingdom. During the Class Period, Mallinckrodt sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

23. Mayne

71. Defendant Mayne Pharma Inc. is a Delaware corporation with its principal place of business in Raleigh, North Carolina. During the Class Period, Mayne sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

24. Mylan

72. Defendant Mylan Inc. is a Pennsylvania corporation with its principal place of business in Canonsburg, Pennsylvania.

73. Defendant Mylan Pharmaceuticals Inc. is a West Virginia corporation with its principal place of business in Morgantown, West Virginia.

74. Mylan Inc. and Mylan Pharmaceuticals Inc. are wholly-owned subsidiaries of Mylan N.V., a Dutch pharmaceutical company. Unless addressed individually, Defendants Mylan Inc. and Mylan Pharmaceuticals Inc. are referred to together as “Mylan.” During the Class Period, Mylan sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

25. Par

75. Defendant Par Pharmaceutical, Inc. is a New York corporation with its principal place of business in Chestnut Ridge, New York.

76. Defendant Generics Bidco I, LLC is a Delaware company with its principal place of business in Huntsville, Alabama. Generics Bidco formerly conducted business as Qualitest Pharmaceuticals.

77. Defendant DAVA Pharmaceuticals, LLC is a Delaware company with its principal place of business in Fort Lee, New Jersey.

78. Par Pharmaceutical, Inc., Generics Bidco I, LLC, and DAVA Pharmaceuticals, LLC are wholly-owned subsidiaries of Endo International plc, an Irish corporation with its principal place of business located in Dublin, Ireland and its U.S. headquarters in Malvern, Pennsylvania. Unless addressed individually, Par Pharmaceutical, Inc., Generics Bidco I, LLC, and DAVA Pharmaceuticals, LLC are collectively referred to as “Par.”

79. During the Class Period, Par sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

26. Perrigo

80. Defendant Perrigo New York, Inc. is a Delaware corporation with its executive offices in Allegan, Michigan and its primary business location in the Bronx, New York. During the Class Period, Perrigo sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

27. Sandoz

81. Defendant Sandoz, Inc. is a Colorado corporation with its principal place of business in Princeton, New Jersey.

82. Defendant Fougera Pharmaceuticals Inc. is a New York corporation with its principal place of business in Melville, New York. Fougera is a wholly-owned subsidiary of Defendant Sandoz, Inc,

83. Unless addressed individually, Sandoz Inc. and Fougera Pharmaceuticals Inc. are referred to together as “Sandoz.” During the Class Period, Sandoz sold one or more of the

Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

28. Sun

84. Defendant Sun Pharmaceutical Industries, Inc. (Sun) is a Michigan corporation with its principal place of business in Cranbury, New Jersey. In late 2012, Sun acquired URL Pharma, Inc. (URL) with its principal place of business in Philadelphia, Pennsylvania. URL is a wholly-owned subsidiary of Sun. Sun as a group includes multiple wholly-owned subsidiaries, also including Mutual Pharmaceutical Company, Inc. (Mutual). Additionally, Sun does business under the name Caraco Pharmaceutical Laboratories (Caraco), a company Sun acquired in 1997. Further, in 2010, Sun Pharmaceutical Industries, Inc.'s Indian-parent company Sun Pharmaceutical Industries Ltd. acquired a controlling stake in Taro Pharmaceutical Industries, Ltd. During the Class Period, Sun sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

29. Taro

85. Defendant Taro Pharmaceuticals USA, Inc. is a New York corporation with its principal place of business in Hawthorne, New York. Taro is a wholly-owned subsidiary of Taro Pharmaceutical Industries, Ltd., an Israeli pharmaceutical company. As noted above, in 2010 Sun Pharmaceutical Industries Ltd. acquired a controlling stake in Taro Pharmaceutical Industries, Ltd. During the Class Period, Taro sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

30. Teligent

86. Defendant Teligent, Inc., formerly known as IGI Laboratories, Inc., is a Delaware corporation with its principal place of business in Buena, New Jersey. During the Class Period, Teligent sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

31. Teva

87. Defendant Teva Pharmaceuticals USA, Inc. is a Pennsylvania corporation with its principal place of business in North Wales, Pennsylvania. During the Class Period, Teva sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

32. Torrent

88. Defendant Torrent Pharma Inc. is a Delaware corporation with its principal place of business in Basking Ridge, New Jersey. Torrent is a wholly-owned subsidiary of Torrent Pharmaceuticals Ltd., an Indian pharmaceutical company. During the Class Period, Torrent sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

33. Upsher-Smith

89. Defendant Upsher-Smith Laboratories, LLC is a Minnesota limited liability company with its principal place of business in Maple Grove, Minnesota. It is a wholly owned by Sawai Pharmaceutical Co., Ltd., a Japanese pharmaceutical company. Sawai acquired Upsher-Smith in June 2017.

90. During the Class Period, Upsher-Smith sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

34. West-Ward

91. Defendant West-Ward Columbus, Inc. is a Delaware corporation with its principal place of business in Eatontown, New Jersey.

92. Defendant Hikma Pharmaceuticals USA Inc. is a Delaware corporation with its principal place of business in Eatontown, New Jersey.

93. Defendant Hikma Labs Inc., formerly known as Roxane Laboratories, Inc., is a Nevada corporation with its principal place of business in Eatontown, New Jersey.

94. West-Ward Pharmaceuticals Inc., Hikma Pharmaceuticals USA Inc., and Hikma Labs Inc. are subsidiaries of Hikma Pharmaceuticals PLC, a London-based pharmaceutical company.

95. Unless addressed individually, West-Ward Pharmaceuticals Inc., Hikma Pharmaceuticals USA Inc., and Hikma Labs Inc. are referred to together as “West-Ward.” During the Class Period, West-Ward sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

35. Wockhardt

96. Defendant Wockhardt, USA LLC is a Delaware limited liability company with its principal place of business in Parsippany, New Jersey.

97. Defendant Morton Grove Pharmaceuticals, Inc. is a Delaware corporation with its principal place of business in Morton Grove, Illinois.

98. Unless addressed individually, Defendants Wockhardt USA LLC and Morton Grove Pharmaceuticals, Inc. are referred to together as “Wockhardt.” During the Class Period, Wockhardt sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

36. Zydus

99. Defendant Zydus is a New Jersey corporation with its principal place of business in Pennington, New Jersey. It is a subsidiary of Cadila Healthcare, an Indian pharmaceutical company. During the Class Period, Zydus sold one or more of the Named Generic Drugs directly to purchasers in this District and throughout the United States and engaged in unlawful conduct in violation of Sections 1 and 3 of the Sherman Act as alleged herein.

C. Generic Manufacturer Co-Conspirators

1. Rising

100. Rising Pharmaceuticals Inc. (Rising) is a Delaware corporation with its principal place of business in East Brunswick, New Jersey. Rising is a wholly-owned subsidiary of Aceto Corp., which filed for bankruptcy in 2019. On December 3, 2019, the Department of Justice announced that Rising entered into a deferred prosecution agreement relating to price-fixing and that Rising has agreed to cooperate with the ongoing investigation into anticompetitive conduct in the generic pharmaceutical industry.

2. Unknown Generic Manufacturer Co-Conspirators

101. Various other generic drug manufacturer persons, firms, entities, and corporations, not named as Defendants herein, have participated as co-conspirators in the violations alleged herein, and have aided, abetted, and performed acts and made statements in furtherance of the conspiracy.

102. The true names and capacities of additional generic manufacturer co-conspirators, whether individual, corporate, associate, or representative, are presently unknown to Plaintiffs. Plaintiffs may amend this Complaint to allege the true names and capacities of additional co-conspirators as they are discovered.

103. The wrongful acts alleged to have been done by any one Defendant or generic manufacturer co-conspirator were authorized, ordered, or done by its directors, officers, managers, agents, employees, or representatives while actively engaged in the management, direction, or control of such Defendant's or generic manufacturer co-conspirator's affairs.

IV. INTERSTATE TRADE AND COMMERCE

104. Defendants are among the leading manufacturers and suppliers of the Named Generic Drugs sold in the United States.

105. The Named Generic Drugs are produced by, or on behalf of Defendants, or their affiliates, in the United States or overseas.

106. During the Class Period, Defendants, directly or through one or more of their affiliates, sold the Named Generic Drugs throughout the United States in a continuous and uninterrupted flow of interstate commerce, including through and into this District.

107. The activities of Defendants and their generic manufacturer co-conspirators were within the flow of, intended to, and had a substantial effect on interstate commerce in the United States.

108. Defendants' and their generic manufacturer co-conspirators' conduct, including the marketing and sale of the generic drugs in question, took place within, has had, and was intended to have, a direct, substantial, and reasonably foreseeable anticompetitive effect upon interstate commerce within the United States.

109. The combination and conspiracy alleged herein has directly and substantially affected interstate commerce, in that Defendants deprived DPPs of the benefits of free and open competition in the purchase of the Named Generic Drugs within the United States.

110. The agreement and conspiracy between Defendants and their generic manufacturer co-conspirators to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocation of generic drugs, and their actual inflating, fixing, raising, maintaining, or artificially stabilizing the prices of generic drugs, including the Named Generic Drugs, were intended to have, and had, a direct, substantial, and reasonably foreseeable effect on interstate commerce within the United States.

V. FACTUAL ALLEGATIONS

A. Competition Between Generic Drugs Historically Has Been Keen.

1. Generic drugs should lead to lower prices.

111. Generic drugs provide a lower-cost but bioequivalent alternative to brand drugs. Before any generic drug can be marketed, the FDA requires rigorous testing to ensure it has the same strength, quality, safety, and performance as the brand. By law, generics must have the same amount of active ingredient and must be “therapeutically equivalent” to the brand, meaning they must meet exacting bioequivalence testing specifications so patients can expect “equal effect and no difference when [generics are] substituted for the brand name product.”¹⁴

112. To encourage the production and sale of generic drugs, the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) simplified the regulatory hurdles that generic drug manufacturers must clear before marketing and selling

¹⁴ FDA, *Drugs@FDA Glossary of Terms*, available at <https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms..>

generic drugs. Instead of filing a lengthy and costly New Drug Application, the Hatch-Waxman Act allows generic drug manufacturers to obtain FDA approval in an expedited fashion.

113. To obtain marketing approval for a generic drug, an ANDA must be filed with the FDA's Center for Drug Evaluation and Research, Office of Generic Drugs; "abbreviated" because so long as the ANDA includes data showing bioequivalence to the brand, the ANDA sponsor can reference efficacy data supporting approval of the brand (described in the regulations as the "Reference Listed Drug" or "RLD" for short) instead of repeating all the same clinical trials. Upon the FDA's determination that bioequivalence to the brand has been established, the ANDA will be approved and may be marketed in the United States as substitutable with the RLD.

114. Although equivalent from a safety and efficacy standpoint, generic versions of brand name drugs are priced significantly below their brand counterparts, and because of this, they rapidly gain market share from the brand beginning immediately following launch. Indeed, in every state, pharmacists are permitted (and in many states required) to substitute a generic product for a brand product barring a note from a doctor that the brand product must be dispensed as written.

115. It is well established in economic literature that competition by generic products should result in lower prices for drug purchasers. In the period before generic entry, a brand drug commands 100% of the market share for that drug and the brand manufacturer can set the price largely free from normal competitive market forces. But once the first lower-priced generic enters, a brand drug rapidly loses sales due to automatic pharmacy substitution, and generics capture as much as 80% of the market or more within months of launch. And as more generics become available, generic prices only decline further due to competition among

generics. These cost reductions to drug purchasers were the very legislative purpose behind the abbreviated regulatory pathway for generic approval under the Hatch-Waxman Act.

116. Generic competition, under lawful and competitive circumstances, reduces drug costs by driving down the prices of both generic versions of the brand drug and often the brand drug itself, and every year generic drugs should result in hundreds of billions of dollars in savings to direct purchasers, consumers, and insurers.

117. A Federal Trade Commission study found that in a “mature generic market, generic prices are, on average, 85% lower than the pre-entry branded drug prices.”¹⁵ A mature generic market has several generic competitors. Because each generic is readily substitutable for another generic of the same brand drug, pricing is the main differentiating feature and the basis for competition among manufacturers.¹⁶ Over time, generics’ pricing should near the generic manufacturers’ marginal costs.

118. Generic competition usually enables purchasers to purchase generic versions of the brand drug at a substantially lower price than the brand drug. Generic competition to a single blockbuster brand drug can result in billions of dollars in savings to direct purchasers, consumers, insurers, local, state, and federal governments, and others.

¹⁵ Federal Trade Commission, *Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions*, at 8 (Jan. 2010), available at <https://www.ftc.gov/sites/default/files/documents/reports/pay-delay-how-drug-company-pay-offs-cost-consumers-billions-federal-trade-commission-staff-study/100112payfordelayrpt.pdf>.

¹⁶ See, e.g., Federal Trade Commission, *Authorized Generic Drugs: Short-Term Effects and Long-Term Impact*, at 17 (Aug. 2011) (“[G]eneric drugs are commodity products marketed to wholesalers and drugstores primarily on the basis of price.”), available at <https://www.ftc.gov/sites/default/files/documents/reports/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission.pdf>; U.S. Cong. Budget Office, *How Increased Competition from Generic Drugs Has Affected Proceed and Returns in the Pharmaceutical Industry* (July 1998), available at <https://www.cbo.gov/sites/default/files/105th-congress-1997-1998/reports/pharm.pdf>.

2. Prescription drug prices in the United States are governed by institutional safeguards, which are intended to keep drug prices competitive.

119. Ordinarily, the price for a consumer product is set by the retailer based on the amount the typical consumer is willing to pay. But because of the unique features of the prescription drug marketplace, prescription drug pricing for most consumers is not determined between the retailer and the consumer. Rather, because most consumers' prescription drug purchases are reimbursed by public or private health plans, consumer pricing for prescription drugs is often set in reference to reimbursement agreements between these prescription drug payers, *i.e.*, health plans and their prescription benefit managers, and the pharmacies that dispense drugs to the payers' insured customers.

120. Generic manufacturers typically report a Wholesale Acquisition Cost (WAC) for their drugs. WAC prices represent the manufacturer's benchmark or reported list price. The WAC typically functions as the manufacturer's list or benchmark price in sales to wholesalers or other direct purchasers and typically does not include discounts that may be provided, *e.g.*, for volume sales. Manufacturers generally provide their WACs to purchasers or report them to publishers that compile that information for the market.

121. Generic drug manufacturers may charge different amounts for an equally interchangeable, *i.e.*, therapeutically equivalent, multisource drug. But manufacturers are usually constrained in their ability to price generic drugs by the Maximum Allowable Cost (MAC).¹⁷ MAC is a contractually based payment model that, in the private sector, is commonly established

¹⁷ To define therapeutic categories, MAC pricing typically relies on the FDA's Orange Book, which lists approved prescription drugs and their therapeutic equivalents. An "A"-rated drug is one that the FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products. *See* U.S. FDA Website, Orange Book Preface, *available at* <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#tecode>.

by a pharmacy benefits manager (PBM), who manages an insurance plan, and that is paid to the pharmacies within the plan's network.¹⁸ A MAC price sets the upper limit that a pharmacy will be paid by the PBM for procuring and dispensing a particular generic medication.

122. While PBMs usually do not disclose publicly which drugs they subject to MAC pricing, what the MAC price is, or what factors they apply to set MAC prices, it is believed that PBMs rely on a wide variety of market-wide pricing information or plan-specific data.¹⁹ In recent years, 79% of employer prescription drug plans and 45 state Medicaid programs have been using MAC prices to control the cost of generic drugs.²⁰

123. MAC prices give pharmacies an incentive to procure and dispense the lowest-priced drug product available for a particular multisource drug. If a generic drug is subject to MAC pricing, a pharmacy purchasing a higher-priced generic product will make less profit or potentially even lose money when it dispenses a higher-priced product.²¹

124. MAC pricing is neither uniform nor transparent, and it may be subject to frequent changes. Whether a generic manufacturer's products are even subject to MAC pricing, or how that MAC pricing is set for any particular generic drug, is not easy for the manufacturers to decipher. PBMs typically exercise control over the selection of generic drugs that will be

¹⁸ Academy of Managed Care Pharmacy, *Where We Stand, Maximum Allowable Cost (MAC) Pricing* (Dec. 2013), available at <https://www.amcp.org/policy-advocacy/policy-advocacy-focus-areas/where-we-stand-position-statements/maximum-allowable-cost-mac-pricing>. For the purposes of this Complaint, MAC prices refer solely to prices that limit a pharmacy's reimbursement for generic drugs, not the amounts PBMs charge to the insurance plans, which may also be referred to as a MAC price. See National Community Pharmacists Association, *The Need for Legislation Regarding "Maximum Allowable Cost" (MAC) Reimbursement*, available at <http://www.ncpa.co/pdf/leg/mac-one-pager.pdf>.

¹⁹ See *supra* Academy of Managed Care Pharmacy article.

²⁰ Express Scripts, Adam Kautzner, Chief Pharma Trade Relations Officer, *MAC Pricing Keeps Generics Affordable* (Apr. 6, 2019), available at <https://www.express-scripts.com/corporate/articles/mac-pricing-keeps-generics-affordable>.

²¹ See *supra* Academy of Managed Care Pharmacy article.

subjected to MAC pricing, and they fiercely guard the secrecy of their MAC price lists.²²

Industry groups, like the Academy of Managed Care Pharmacy, actively oppose government regulation of MAC pricing and any efforts to disclose MAC prices or the methods of calculating them.²³

125. By setting a ceiling for reimbursement of any particular generic drug at the pharmacy level, MAC prices indirectly affect the price at which generic drug manufacturers may sell their products to direct purchasers. Because many generic drugs are subject to MAC pricing, generic drug manufacturers have an incentive to price their generic drug products competitively to maintain demand by pharmacies.

126. MAC pricing can penalize the generic drug manufacturer that raises price on its own when its competitors do not. A unilateral price increase in a competitive generic drug market that is subject to MAC pricing is likely to send buyers to a lower-priced alternative.

127. MAC pricing has little effect, however, if generic drug manufacturers collectively increase their prices for a multi-source drug. First, PBMs generally permit pharmacies – who may be contractually obligated to dispense an unprofitable prescription – to challenge MAC prices under a MAC appeals process.²⁴ If the price of a generic drug has been increased by a majority of generic drug manufacturers, then these MAC appeals may be successful in getting the PBM to increase the MAC price allowed. Second, PBMs typically have a policy of revising

²² See *supra* National Community Pharmacists Association article.

²³ See *supra* Academy of Managed Care Pharmacy article.

²⁴ *Id.*

MAC prices under certain contingencies.²⁵ One large PBM, Express Scripts, for example, states that its MAC price list is frequently updated to reflect “the current market dynamics.”²⁶

128. MAC pricing provides yet another reason that Defendants’ stark increases in the price of the generic drugs in question are indicative of coordinated pricing activity. Knowing that they hold an overwhelming majority share of the market for these drugs, Defendants had the capacity to dictate the market price and to influence the MAC prices set by PBMs, but only if they acted collectively. Absent collusion, individual Defendants and generic manufacturer co-conspirators could not have increased their prices to the high levels they did (or maintain high prices in the face of a competitor’s significantly lower price) without incurring the loss of a significant volume of sales.

B. Defendants and Their Generic Manufacturer Co-Conspirators Participated in an Overarching Fair Share Agreement to Thwart Competition in the Generic Drug Industry.

129. During at least the Class Period, generic drug manufacturers – including Defendants and their generic manufacturer co-conspirators – conspired, combined, and contracted with one another pursuant to the Fair Share Agreement to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation of generic drugs, including the Named Generic Drugs.

130. This Fair Share Agreement had the effect of maintaining artificially inflated pricing for the Named Generic Drugs, and creating an appearance of competition when in fact none existed. It also had the intended and actual effect of causing DPPs and the other members

²⁵ *Id.*

²⁶ *See supra* Express Scripts article.

of the proposed Class to pay artificially inflated prices above prices that would exist if a competitive market had determined prices.

131. Each of Defendants' conspiratorial actions described herein sought to further this Fair Share Agreement by achieving either or both of its two main goals:

- a. Defendants and their generic manufacturer co-conspirators sought to avoid competition within the generic drug industry, instead maintaining the stability of the relative market shares for particular drugs assigned to each competitor.
- b. Without the threat of competition, Defendants and their generic manufacturer co-conspirators sometimes dramatically raised prices on a generic drug or drugs. Defendants' agreements also artificially inflated pricing even where dramatic price increases were not observed as might be the case where a *quid pro quo* market or customer allocation had taken place.

132. Defendants and their generic manufacturer co-conspirators communicated their respective priorities and goals in order to divide generic drugs among each other. Once appropriate share was set, Defendants and their generic manufacturer co-conspirators would jointly evaluate customer bids and contracts with an eye towards maintaining these ratios.

133. Defendants and their generic manufacturer co-conspirators repeatedly engaged in decision-making that was against their financial self-interest absent a conspiratorial agreement, turning down or walking away from potentially profitable business opportunities in order to uphold their Fair Share Agreement and allow other Defendants or generic manufacturer co-conspirators to gain or maintain predetermined market share.

134. Generic drug manufacturers – including Defendants and their generic manufacturer co-conspirators – also planned and executed coordinated price increases. Before

raising prices for their customers, generic manufacturers would communicate and agree on a price increase strategy. Typically, this involved – pursuant to the Fair Share Agreement – one manufacturer taking the lead with the price increase, and the other manufacturers matching by increasing their pricing in step with the leader (knowing that their ostensible competitors would not undercut the elevated pricing).

135. There was an understanding between all Defendants and their generic manufacturer co-conspirators that it was permissible to initiate and maintain collusive communications at any time in order to effectuate the goals of this Fair Share Agreement and more effectively manipulate the generic drug industry. This behavior was repeated again and again in the individual generic drug examples described herein and in previous MDL Complaints.

136. In its ruling on the motions to dismiss the first set of Overarching Complaints alleging a Fair Share Agreement, the Court found:

The allegations in Plaintiffs' Overarching Complaints plausibly allege that Defendants engaged in a conspiracy regarding the broader market for generic drugs, and not just the market for any individual drug. The connective tissue Plaintiffs have alleged in the Overarching Complaints gives credence to a claim that Defendants engaged in 'behavior that would probably not result from chance, coincidence, independent response to common stimuli, or mere interdependence unaided by an advance understanding among the parties.' Plaintiffs make plausible claims that the alleged individual drug conspiracies were connected by common goals, methods, or actors so as to form a broader overarching conspiracy.²⁷

²⁷ *Generic Pharm. Pricing*, 394 F. Supp. 3d at 526-27 (quoting *Bell Atl. Corp. v. Twombly*, 550 U.S. 544, 556, n.4 (2007)).

137. The already strong plausibility of the existence of an overarching Fair Share conspiracy has been significantly enhanced through documentary investigation and data analysis that has taken place since the filing of previous Complaints.

138. As discussed in further detail below, Defendants' records demonstrate a consistent, agreed-upon approach—the Fair Share Agreement—to avoid competition, allocate and stabilize market shares, and achieve and maintain artificially inflated prices. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

139. [REDACTED] the Fair Share Agreement was comprised of several “core principles,” including, but not limited to: (1) each manufacturer is entitled to a certain share of sales; (2) manufacturers should obtain their allocated market share cooperatively—not

competitively; (3) do not engage in price competition; higher prices are more important than additional sales or market share; and (4) responses to customer's requests for bids should be consistent with the Fair Share Agreement. As discussed below, these principles of the Fair Share Agreement are repeated across Defendant companies and applied to the various generic drugs with remarkable consistency.

1. Fair Share Agreement Principle: Each manufacturer is entitled to a certain market share—no more and no less.

140. The Fair Share Agreement proceeds from the shared understanding that each manufacturer is entitled to a certain share of the market for a particular drug based primarily on the number of manufacturers in the market. This guiding tenet was ingrained in Defendants' sales executives, as reflected, for example, by the following documents:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

141. Defendants subscribed to data services, such as IMS, which provided them with detailed market information that enabled them to understand their market share and the market share of their purported competitors. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

142. [REDACTED]

[REDACTED]



143. In fact, the understanding that each manufacturer was entitled to a certain market share was so ingrained that Defendants actually based their business planning on it. For instance:



2. Fair Share Agreement Principle: Manufacturers should achieve their fair share of the market cooperatively—not competitively.

144. In a competitive market, an established manufacturer would be expected to aggressively defend its customers and market share from a new entrant. Not so under the Fair Share Agreement. The Fair Share Agreement dictates that the established manufacturers should cede customers to the new entrant so that the new entrant could obtain its rightful share. Meanwhile, the new entrant was expected to carefully target both customers and competing manufacturers in order to ensure that all manufacturers arrived at the expected share of the market with minimal market disruption. The ultimate goal was to attain a market share equilibrium where no manufacturer was jockeying for additional market share. For instance:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

3. Fair Share Agreement Principle: Do not engage in price competition.

145. In a typical market, a new entrant would price its product below the prevailing market price in order to gain market share. Here, no such price competition was required. New entrants knew that they would be allocated a certain market share, and they also knew that their fellow market participants would expect them not to undercut the current market prices as a condition of receiving an allocated share of the market. In other words, under the Fair Share Agreement, new entrants were actively disincentivized from engaging in price competition.

146. In addition to avoiding price competition, Defendants conspired to impose coordinated price increases. As discussed below, Defendants communicated and agreed upon a price increase strategy. Pursuant to the Fair Share Agreement, one manufacturer would lead the price increase, and the other manufacturers would raise prices in step with the leader. All of the manufacturers were secure in the knowledge that their ostensible competitors would not undercut their elevated prices. Indeed, Defendants were very careful to indicate to their fellow manufacturers that they were on board with price increases. For instance:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

4. Fair Share Agreement Principle: When customers request a competitive bid, the manufacturer’s response should be based on and consistent with the Fair Share Agreement—not customer’s wants and needs or competitive interests.

147. Consistent with the Fair Share principles discussed above, when a Defendant received a request for a competitive bid from a customer, it first considered how its response would impact the agreed-upon market share allocations. It also considered how a competitive bid could potentially erode the inflated prices and upset purported competitors. For instance:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

148. These core principles supported Defendants’ overarching goals to maintain established market share ratios and artificially inflated prices. Adherence to these agreed-upon principles required Defendants to repeatedly engage in behavior that was contrary to the independent self-interest absent a conspiracy, including ceding market share to new entrants and declining to pursue profitable business opportunities. Defendants were willing to take these actions because they understood that their purported competitors were also “playing nice in the sandbox” or being “responsible.”

5. The Fair Share Agreement was facilitated by coziness among generic drug manufacturers.

149. Indeed, the fact that the Fair Share Agreement spanned numerous drugs also incentivized Defendants to take actions against their independent self-interest. For instance, a Defendant in the position of the established manufacturer for one drug might be required to give up market share to a new entrant. But, the same Defendant might enter the market for another drug and thus would be the beneficiary of market share ceded by the established suppliers.

150. The Fair Share Agreement had the effect of maintaining artificially inflated pricing for the Named Generic Drugs, and creating an appearance of competition when in fact none existed. It also had the intended and actual effect of causing Direct Purchaser Class Plaintiffs and the other members of the proposed Class to pay artificially inflated prices above prices that would exist if a competitive market had determined prices.

151. Defendants were aware that the Fair Share Agreement was illegal, and they took substantial steps to conceal their conspiratorial conduct, including by cautioning against discussing price increases for the Named Generic Drugs in emails, text messages and other communications – both internal to and between various Defendants. Instead, Defendants opted to speak by telephone when an in-person meeting was not practical, and they met and discussed

their plans at industry events and other venues when possible. For instance, [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

152. Out of fear of detection, Defendants and their generic manufacturer co-conspirators intentionally destroyed many communications.

153. In formulating and effectuating the combination and conspiracy, Defendants and their generic manufacturer co-conspirators engaged in numerous anticompetitive activities, including, among other things:

- (a) Participating, directing, authorizing, or consenting to the participation of subordinate employees in meetings, conversations, and communications with generic manufacturer co-conspirators to discuss the sale and pricing of at least the generic drugs identified in this Amended Complaint;
- (b) Participating, directing, authorizing, or consenting to the participation of subordinate employees in meetings, conversations, and communications with generic manufacturer co-conspirators to engage in market and customer allocation or bid rigging for at least the generic drugs identified in this Amended Complaint;
- (c) Agreeing during those meetings, conversations, and communications to engage in market and customer allocation or bid rigging for at least the generic drugs identified in this Amended Complaint;
- (d) Agreeing during those meetings, conversations, and communications not to compete against each other for certain customers regarding at least the generic drugs identified in this Amended Complaint;
- (e) Submitting bids, withholding bids, and issuing price proposals in accordance with the agreements reached;
- (f) Selling at least the generic drugs identified in this Amended Complaint in the United States at collusive and noncompetitive prices; and

- (g) Accepting payment for at least the generic drugs identified in this Amended Complaint sold in the United States at collusive and noncompetitive prices.

154. The linchpin of the Fair Share Agreement was frequent communications among purported competitors. These communications were made via telephone, text message, email, and through messaging platforms such as LinkedIn or WhatsApp. The inter-competitor communications sometimes took place between very high-level executives. More often, however, the conspiratorial communications involved National Account Managers and employees at comparable positions. However, very senior executives sometimes directed their subordinates to reach out to competitors and to report back.

155. The substance of these inter-competitor communications varied depending on the particular issues presented by a drug. For example, if the conspirators believed they could increase prices for a particular drug, collusive communications focused on a future price increase. If a new market for a generic drug was opening up due to the expiration of a patent, conspiratorial communication sometimes consisted of a discussion of market share allocation.

156. Consistent with the overarching Fair Share Agreement, a single communication between conspirators would often span multiple drugs. Additional individual drug allegations are set forth below demonstrating how the Fair Share Agreement was applied across multiple drugs at a time. Further, Defendants' agreements on one drug were interrelated with agreements concerning other drugs.

157. Keeping the existence of these communications secret was of paramount importance. Senior level executives repeatedly directed their subordinates not to leave any written documentation of their communications with competitors.

158. In addition to the inter-competitor communications at the heart of the Fair Share Agreement, Defendants also worked internally to ensure the execution of the Fair Share Agreement.

159. The effectiveness of the Fair Share Agreement was facilitated by certain characteristics of the generic drug industry.

160. First, the generic drug industry is a tight-knit community. For instance, many generic drug manufacturer employees and executives (including, for example, so called National Account Managers or “NAMs” as well as certain senior executives) moved from generic drug manufacturer to generic drug manufacturer while preserving former co-worker contacts, and thus furthered the interwoven, cooperative culture of the generic drug industry. Some examples include: Rajiv Malik worked at Ranbaxy (now Defendant Sun) and Defendant Sandoz before working at Defendant Mylan; Dan Lukasiewicz worked at Defendants Aurobindo and Zydus before working at Defendant Heritage; Susan Knoblauch worked at Defendant Sun before leaving to work as a NAM at Citron; Jan Bell worked at Defendant G&W before working at Defendant Mylan; Joseph Papa left Defendant Perrigo to become Chairman and CEO of Defendant Valeant; Carole Ben-Maimon worked in different roles at Defendants Impax, Par, and Teva; and Bhaskar Chaudhuri was the General Manager of the Dermatology Division at Defendant Mylan before later becoming President of Defendant Valeant and a member of MDL Defendant Teligent’s board of directors.

161. Second, there are myriad opportunities in the generic drug industry for employees of various generic drug manufacturers to interact with one another. As shown in Exhibit E, numerous trade association meetings and industry events were held during the time period where collusion was taking place.

162. The casual nature by which this combination and conspiracy was executed further illustrates its pervasive, comprehensive nature. For instance, the allegations below highlight at least several examples where a Defendant was invited into an ongoing price increase scheme merely upon expressing its intention to enter the market for that drug. In these situations, the other Defendants were not concerned about involving an additional party, because that party had already expressed, both impliedly and through overt communication, its willingness to participate in the Fair Share Agreement.

163. Further, the regularity of Defendants and their generic manufacturer co-conspirators' illegal communications, contacts, and meetings at trade associations and elsewhere demonstrates that they were complicit in the overarching Fair Share Agreement.

164. Defendants' Fair Share Agreement began at least as early as the summer of 2009. Over time, and with the success of Defendants' collusive efforts, the Fair Share Agreement expanded to encompass more generic drugs. Exhibit B (Timeline of Known Collusive Conduct for Drugs Named by DPPs).

C. Individual Drug Allegations

1. Adapalene

165. Adapalene is a medication used to treat acne. It is available in several forms, including Cream and Gel formulations. Adapalene has been available in the United States in a generic form for many years.

166. The market for Adapalene is mature. At all relevant times, there have been multiple manufacturers of Adapalene.

167. During the relevant time frame, Defendants Sandoz and Perrigo were the primary manufacturers of Adapalene Cream.

168. Plaintiffs allege that as part of Defendants' Fair Share Agreement, Defendants Sandoz and Perrigo conspired to fix, raise, maintain or stabilize the prices of Adapalene Cream beginning at least as early as the summer of 2010.

169. In July of 2010, Sandoz was the only company in the market for generic Adapalene Cream. By August 2010, however, Sandoz learned that Perrigo would soon be entering the market. At an August trade event attended by T.P., Perrigo's Director of National Accounts, a Sandoz representative relayed to colleagues: "I am at NACDS Summer Mtg in San Diego. I learned today that Perrigo will launch Adapalene Cream within a matter of weeks."

170. To facilitate Perrigo's entry into the Adapalene Cream market, and to allow it to gain a Fair Share of the market, Perrigo and Sandoz began coordinating pricing, and sharing information to divide up the market for Adapalene Cream.

171. For example, in September and October 2010, Perrigo's T.P. communicated with A.T., Sandoz's National Account Executive, multiples times by phone to discuss Adapalene Cream. T.P. and A.T. both kept their respective bosses informed of the inter-competitor communications.

172. On the day Perrigo entered the Adapalene Cream market on October 25, 2010, Perrigo's T.P. and Sandoz's A.T. communicated by phone multiple times. Perrigo's list (WAC) price at launch matched Sandoz's list (WAC) price.

173. Internally, upon Perrigo's entry into the Adapalene Cream market, Sandoz prepared to relinquish customers/market share to Perrigo, as was contemplated by the Fair Share Agreement.

174. Through October 2010, T.P. and A.T. continued to communicate by phone. To ensure that Fair Share for Adapalene Cream was maintained, T.P. and A.T. discussed specific

customers that Perrigo would target, and that Sandoz would cede. By the end of October, Perrigo had targeted the agreed upon customers, and Sandoz had relinquished those customers.

175. Toward the end of 2012, Sandoz experienced supply disruptions for Adapalene Cream, and left the market until mid-2013, leaving Perrigo as the sole manufacturer of the generic product. When Sandoz resolved its supply issues and was prepared to reenter the market, Sandoz and Perrigo communicated by phone to coordinate Sandoz's reentry.

176. In June and July of 2013, Perrigo's T.P. spoke multiple times to C.B., Sandoz's National Account Executive, and discussed which customers Perrigo would cede to Sandoz, and which customers Sandoz intended to keep. T.P. also provided C.B. with Perrigo's nonpublic customer pricing, so that Sandoz knew where to price its offers to those customers. C.B. kept contemporaneous notes of the discussions.

177. In accordance with the agreement, Sandoz targeted the agreed upon customers at the agreed upon prices, and avoided the customers Perrigo indicated it intended to keep. Perrigo, for its part, ceded the customers it had agreed to relinquish to Sandoz.

178. Perrigo and Sandoz continued to communicate and abide by the Fair Share Agreement during the following months. Perrigo's T.P. and Sandoz's C.B. communicated by phone during the summer of 2013. C.B. also communicated with A.F., Perrigo's National Account Director, during that period.

179. As a result of the agreement and anticompetitive coordination between Perrigo and Sandoz, prices for Adapalene Cream were higher than they would have been in a competitive market.

180. Defendants Glenmark, Taro, and Teva were the primary manufacturers of Adapalene Gel during the relevant time frame.

181. In May 2013, Teva, Taro and Glenmark wanted to fix, raise or stabilize the prices of Adapalene Gel. Accordingly, the manufacturers engaged in a series of direct telephone communications to put their plan into action.

182. For example, Teva's Patel communicated multiple times with multiple contacts at Glenmark during May of 2013 to discuss prices of Adapalene Gel and other drugs. Patel also spoke with Ara Aprahamian, Taro's Vice President of Sales and Marketing, in May to coordinate Adapalene Gel prices.

183. As a result of the agreement and anticompetitive coordination between Glenmark, Taro, and Teva, prices for Adapalene Gel were higher than they would have been in a competitive market.

184. The ability of Glenmark, Perrigo, Sandoz, Taro, and Teva to reach agreements on Adapalene was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

185. The coordination by Glenmark, Perrigo, Sandoz, Taro, and Teva is consistent with the Fair Share Agreement.

186. The agreement between Defendants Glenmark, Perrigo, Sandoz, Taro, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Adapalene Gel and Cream.

2. Alclometasone Dipropionate

187. Alclometasone Dipropionate is a commonly prescribed corticosteroid used to treat a variety of skin conditions (*e.g.*, eczema, dermatitis, allergies, rash). It has been on the market for decades and is available in several forms, including Ointment (0.05%) and Cream (0.05%).


188. The market for Alclometasone Dipropionate is mature. At all relevant times, there have been multiple manufacturers. Defendants Glenmark, Sandoz, and Taro dominated sales of Alclometasone Dipropionate in the relevant period.


189. [REDACTED]

[REDACTED]

[REDACTED]

as illustrated below:





190. Defendants' WAC pricing also rose in a coordinated fashion. Taro and Sandoz announced new pricing on May 1, 2013 and May 10, 2013 respectively, which doubled and tripled their prior WAC prices for Alclometasone Dipropionate Cream. Glenmark announced new WAC prices on May 16, 2013. Weeks later, on June 10, 2013, Glenmark introduced WAC prices for Alclometasone Dipropionate Ointment that far exceeded its co-Defendants' existing WAC prices. This was a price it would not have risked without knowledge that Taro would essentially match Glenmark's price two days later with a WAC price that more than tripled Taro's prior WAC price for Alclometasone Dipropionate Ointment.

191. 


192. [REDACTED]

193. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including Glenmark, Sandoz, and Taro. Defendant Teva identified Glenmark, Sandoz, and Taro as “quality” competitors, *i.e.*, competitors willing to coordinate price increases under the Fair Share Agreement. Defendants’ coordination included raising Alclometasone Dipropionate prices.

194. For example, documents show that Taro planned a “[REDACTED]” increase in the price of at least the Alclometasone Dipropionate Cream in mid-2012. When it was announced on May 1, 2013, Sandoz internally described Taro’s increase as “[REDACTED]” and noted that Taro represented only a quarter of the market at that time. Given its minority share, Taro would not have risked this [REDACTED] without assurances. As reflected in an internal email between Sandoz executives on May 9, 2013, competitors viewed Sandoz “[REDACTED] [REDACTED].” In addition, Defendants’ frequent communication by telephone and text facilitated their price coordination. For example, Taro’s Arahamian exchanged 190 phone calls and texts with Sandoz’s C.B. between March 19, 2013 and August 8, 2016, and eleven times with Glenmark’s employee M.B., beginning on May 7, 2013, approximately a week before Glenmark matched Taro’s WAC price for Alclometasone Dipropionate Cream. A Sandoz executive, who had advance knowledge of Taro’s June 12, 2013 WAC increase for Alclometasone Dipropionate, remarked approvingly: “[REDACTED] [REDACTED].”

195. The ability of Glenmark, Sandoz, and Taro to reach agreement regarding Alclometasone Dipropionate Ointment and Cream was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

196. [REDACTED]

[REDACTED] For example, on May 26, 2013, to avoid taking more than its fair share of the market, Taro's Aprahamian instructed Taro's employees [REDACTED]

[REDACTED] On May 29, 2013, Sandoz's Kellum informed its customers that it would [REDACTED]

[REDACTED]

197. The agreement between Defendants Glenmark, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Alclometasone Dipropionate Ointment (0.05%) and Cream (0.05%).

3. Allopurinol

198. Allopurinol is a xanthine oxidase inhibitor used to treat gout and certain kinds of kidney stones. It is available in, for example, Tablet and Injection formulations. It has been available in the United States for decades in a generic form. Due to, among other things, its clinical efficacy and safety, Allopurinol has been designated as an essential medicine by the World Health Organization.

199. The market for Allopurinol is mature. At all relevant times, there have been multiple manufacturers of Allopurinol.

200. Defendants Actavis, Dr. Reddy's, Mylan, and Par dominate sales of Allopurinol Tablets (100 and 300 mg). [REDACTED]

[REDACTED]


201. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



202. The GAO noted that Allopurinol had an “extraordinary price increase” in the years 2014-2015.

203. [REDACTED]

Under the Fair Share Agreement, Actavis, Dr. Reddy’s, Mylan, Par, and Sun did not attempt to undercut competitors’ prices in order to gain additional market share. For example, in March 2015, J.P. of Dr. Reddy’s was discussing Allopurinol with a colleague at Dr. Reddy’s, Kate Neely. J.P. said, “[REDACTED]

[REDACTED]

[REDACTED] Later in the email chain, J.P. and Neely decided not to pursue additional business on Allopurinol, based on the “[REDACTED]” and not wanting to “[REDACTED].”

204. The ability of Actavis, Dr. Reddy’s, Mylan, and Par to reach agreements on Allopurinol was aided by the prevalence of trade association meetings and conferences where the

parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

205. [REDACTED]

206. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

207. The agreement between Defendants Actavis, Dr. Reddy's, Mylan, and Par was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Allopurinol Tablets (100 and 300 mg).


4. Amantadine HCL

208. Amantadine Hydrochloride (HCL) is a drug used to treat Parkinson's disease and is available in a Capsule formulation. It has been available in the United States for decades in a generic form.

209. The market for Amantadine HCL is mature. At all relevant times, there have been multiple manufacturers of Amantadine HCL.

210. Defendants Lannett, Sandoz, and Upsher-Smith dominate sales of Amantadine HCL Capsules (100 mg). [REDACTED]

211. [REDACTED]



212. The GAO noted that Amantadine HCL had an “extraordinary price increase” in the years 2012-2013.

213. [REDACTED]

214. The ability of Lannett, Sandoz, and Upsher-Smith to reach agreement regarding Amantadine HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

215. [REDACTED]

216. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

217. The agreement between Defendants Lannett, Sandoz, and Upsher-Smith was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Amantadine HCL Capsules (100 mg).


5. Amiloride HCL/HCTZ

218. Amiloride HCL/HCTZ is a medication used to treat high blood pressure. It is available in a Tablet formulation. It has been available in the United States in a generic form for many years.

219. The market for Amiloride HCL/HCTZ is mature. At all relevant times, there have been multiple manufacturers of Amiloride HCL/HCTZ.

220. During the relevant time frame, Defendants Mylan and Teva were the primary manufacturers of Amiloride HCL/HCTZ.

221. [REDACTED]



222. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

223. Throughout this period, Teva and Mylan met at trade conferences and communicated directly with each other.

224. Teva's Rekenhaller communicated consistently with Mylan at least as early as April 2010, and continued thereafter with Mylan's J.K. (VP and Executive Director of Sales), B.P. (Senior VP of Sales) and Jim Nesta over the following months and years.

225. In the spring and summer of 2013, Teva wanted to raise its Amiloride prices again. Accordingly, Teva's Kevin Green and Mylan's Nesta spoke numerous times via telephone to coordinate and agree to the price increase. They spoke at least on May 7, 8, 9, and 10; July 10, 11, and 23; and August 1, 2, 6, and 8, 2013.

226. In 2014, Teva was eager to impose yet another price increase, and again coordinated with Mylan to do so. This time, Teva's Rekenhaller communicated with Mylan's Nesta. They spoke by phone at least on May 9, 20 and 27, 2014

227. The coordination by Mylan and Teva is consistent with the Fair Share Agreement.

228. The agreement between Defendants Mylan and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Amiloride HCL/HCTZ Tablets.

6. Ammonium Lactate

229. Ammonium Lactate is a topical medication used to treat dry, scaly, itchy skin. It is available in a Cream (12%) and a Lotion (12%). Ammonium Lactate has been available in the United States in a generic form for many years.

230. The market for Ammonium Lactate is mature. At all relevant times there have been multiple manufacturers of the product.

231. During the relevant time frame, Defendants Actavis, Perrigo, and Taro were the primary manufacturers of Ammonium Lactate Cream and Lotion.

232. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Ammonium Lactate as early as April 2013.

233. [REDACTED]

[REDACTED]

[REDACTED]

234. Before instituting its price increases, Taro reached out to Actavis and Perrigo to coordinate. In April 2013, Ara Aprahamian and Mike Perfetto, Taro's Vice President of Sales and Marketing, and Chief Commercial Officer, respectively, had multiple phone calls with representatives at Actavis and Perrigo. Perfetto spoke with Douglas Boothe, Perrigo's Executive Vice President and General Manager, and M.D., Actavis's Director of National Accounts. Aprahamian communicated with M.D. and A.G. (another Actavis Director of National Accounts).

235. Actavis and Perrigo also communicated directly with one another during April 2013. For example, after Actavis's M.D. spoke with a representative from Taro, M.D. communicated by phone with T.P., Perrigo's Director of National Accounts.

236. In April 2013, representatives from Actavis, Perrigo, and Taro also convened at the NACDS Annual Meeting.

237. Actavis, Perrigo, and Taro's Ammonium Lactate prices remained elevated.

238. The ability of Actavis, Perrigo, and Taro to reach agreement regarding Ammonium Lactate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

239. [REDACTED]

240. No non-collusive market factors (e.g., product shortages) can explain the artificially inflated prices.

241. The agreement between Defendants Actavis, Perrigo, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Ammonium Lactate Cream and Lotion.

7. Amoxicillin/Clavulanate

242. Amoxicillin/Clavulanate is a medication used to treat bacterial infections. It is available in a Chewable Tablet formulation. It has been available in the United States in a generic form for many years.

243. The market for Amoxicillin/Clavulanate is mature. At all relevant times, there have been multiple manufacturers of Amoxicillin/Clavulanate.

244. During the relevant time frame, Defendants Sandoz and Teva were the primary manufacturers of Amoxicillin/Clavulanate.

245. In late summer and early fall of 2014, Teva and Sandoz orchestrated price increases on Amoxicillin/Clavulanate Chewable Tablets. Throughout this period, Teva and Sandoz were in regular contact. Teva's Patel spoke with the Associate Director of Pricing at Sandoz multiple times to fix the prices of Amoxicillin/Clavulanate and other drugs.

246. For example, on October 10, 2014, the day that Sandoz followed Teva's price increase for Amoxicillin/Potassium Clavulanate, Teva's Patel spoke to the Associate Director of Pricing at Sandoz.

247. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

248. The ability of Sandoz and Teva to reach agreements on Amoxicillin/Clavulanate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

249. The coordination by Sandoz and Teva is consistent with the Fair Share Agreement.

250. The agreement between Defendants Sandoz and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Amoxicillin/Clavulanate.

8. Amphetamine Salts (MAS)

251. Amphetamine Salts (amphetamine/dextroamphetamine), also known by the brand name Adderall, are a commonly prescribed medication for the treatment of attention deficit hyperactivity disorder that have been available in the United States for decades. They are available in the United States in several dosage strengths, including IR and ER versions of Tablets (5, 10, 20, 30 mg) and Capsules (5, 10, 15, 20, 25, 30 mg).


252. The market for Amphetamine Salts tablets is mature. At all relevant times, there have been multiple manufacturers. Defendants Actavis, Aurobindo, Impax, Mallinckrodt, Sandoz, and Teva dominated sales of Amphetamine Salts in the relevant period. Defendants Aurobindo, Impax, Mallinckrodt, Sandoz, and Teva were the primary manufacturers of Tablets. Defendants Actavis, Impax, and Teva were the primary manufacturers of Capsules.


253. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]





254. The GAO found that Amphetamine Salts had “extraordinary price increases” in 2011-2012.

255. [REDACTED]

256. The ability of Aurobindo, Impax, Mallinckrodt, Sandoz, and Teva to reach agreement regarding Amphetamine Salts was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

257. [REDACTED]

258. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

259. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers.

260. At least as early as the summer of 2011, Defendants became aware of the potential for coordinating price increases on Amphetamine Salts. Teva raised its WAC prices as much as three times its existing prices on August 17, 2011. Sandoz matched Teva's prices a week later, effectively doubling its prior WAC prices. Teva's Kevin Green had multiple contacts at Sandoz at this time to facilitate the price coordination. Impax, who had no WAC prices, benefitted from its co-Defendants' price increases.

261. By March 2014, Teva became aware that Aurobindo had immediate plans to enter the market. In preparation for its entry on March 4, 2014, Teva undertook a [REDACTED]. On March 18, 2014, Teva's J.P. shared with her colleagues that Aurobindo's market share target for the impending launch was 10% and that it was prepared to undercut price. On March 18, 2014, the day of the email, Teva's Rekenthaler and R.C., a senior executive at Aurobindo, had a thirty-minute telephone conversation. The next day Aurobindo introduced WAC prices that matched Teva and Sandoz's WACs. Following Aurobindo's price announcement, Rekenthaler and R.C. spoke again seven times on March 20, 2014. These communications facilitated Defendants' agreement that Aurobindo enter the market at the existing supracompetitive prices in exchange for its expected share.

262. The next morning, Teva's Patel sent a calendar invite to colleagues Rekenthaler and K.G., scheduling a meeting to discuss "[REDACTED]". In the next several days, Teva internally debated whether it would concede contracts to make way for Aurobindo.

263. Teva characterized Amphetamine Salts Tablets in June 2014 as having three “ [REDACTED] and calculated that it had [REDACTED] of Amphetamine Salts Tablets sales, while “ [REDACTED]” Impax (then Corepharma) and Sandoz had [REDACTED] respectively. In furtherance of the conspiracy, Defendants continued to maintain high prices by declining to bid on customer’s supply contracts, *e.g.*, Econdisc. Rather than offering a competitive price to maintain its market share, Teva conceded multiple supply contracts. To facilitate this process, Defendants’ shared “ [REDACTED].” For example, in contemplating a bid in May 2014, Teva considered Aurobindo and Impax’s Amphetamine Salts Tablets prices to determine whether it was worth “ [REDACTED] [REDACTED].”

264. Following such concessions, Teva estimated in July 2014, that it lost about [REDACTED] market share. Later that year, Teva also declined to bid on one of Impax’s major customers because Teva concluded that it did not “ [REDACTED] [REDACTED]” on Amphetamine Salts Tablets.

265. Similarly, in March 2016, in response to a request for proposal from Red Oak, Teva recalculated market share for Amphetamine Salts Tablets and concluded that [REDACTED] [REDACTED].”

266. As to Capsules, in April 2012, a large customer contacted Teva to request a price reduction because a new competitor had expressed an interest in “all or some” of its MAS-XR business. When Teva learned the new competitor was Actavis, which was expecting approval for the drug soon, Teva deferred its decision in pricing until Actavis entered the market.

267. In June 2012, Actavis obtained FDA approval for Amphetamine Salts Capsules. Teva and Actavis immediately began coordinating regarding market share.

268. That evening, Teva's Rekenthaler instructed Teva employees to find out Actavis's plans, including shipping details and inventory levels. The next morning, T.S., a National Account Manager at Teva, confirmed that she had spoken to a contact at Actavis. She conveyed to Rekenthaler what she had learned.

269. The ability of Actavis Impax, and Teva to reach agreement Amphetamine Salts Capsules was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

270. The agreement(s) between Defendants Actavis, Aurobindo, Impax, Mallinckrodt, Sandoz, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Amphetamine Salts Tablets and Capsules

9. Atenolol Chlorthalidone

271. Atenolol Chlorthalidone is a combination beta blocker and water pill used to treat high blood pressure. It has been available in the United States for decades in a generic form.

272. The market for Atenolol Chlorthalidone is mature. At all relevant times, there have been multiple manufacturers of Atenolol Chlorthalidone.



273. Defendants Actavis and Mylan dominate sales of Atenolol Chlorthalidone Tablets (50-25 and 100-25 mg). [REDACTED]

[REDACTED]

274. [REDACTED]

[REDACTED]

[REDACTED]



275. The GAO noted that the Atenolol Chlorthalidone had “extraordinary price increases” in the years 2014-2015.

276. [REDACTED]

277. The ability of Actavis and Mylan to reach agreement regarding Atenolol Chlorthalidone was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

278. [REDACTED]

279. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

280. The agreement between Defendants Actavis and Mylan was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Atenolol Chlorthalidone Tablets (100-25mg and 50-25mg).

10. Atropine Sulfate

281. Atropine Sulfate is an anticholinergic and is available as, for example, a 1% Ophthalmic Solution for use in eye examinations to dilate the pupil and to treat certain eye conditions. It has been available in the United States for over a decade in a generic form.

282. The market for Atropine Sulfate Ophthalmic Solution is mature. At all relevant times, there have been multiple manufacturers.

283. Defendants Bausch and Sandoz dominated the sales of Atropine Sulfate with close to an 80/20 split at all relevant times.

284. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

285. The GAO noted that Atropine Sulfate had “extraordinary price increases” in the years 2010-2011.

286. [REDACTED]

287. The ability of Bausch and Sandoz to reach agreements on Atropine Sulfate Ophthalmic Solution was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

288. [REDACTED]

[REDACTED]

289. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

290. The agreement between Defendants Bausch and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Atropine Sulfate Ophthalmic Solution (1%).

11. Balsalazide Disodium

291. Balsalazide Disodium is an aminosalicylate medication used to treat ulcerative colitis. It has been available in the United States for over a decade in a generic form. It is available in, for example, a Capsule (750 mg) formulation.

292. The market for Balsalazide Disodium is mature. At all relevant times, there have been multiple manufacturers of Balsalazide Disodium.


293. Defendants Apotex and West-Ward dominate sales of Balsalazide Disodium Capsules (750 mg). [REDACTED]

[REDACTED]

294. [REDACTED]

[REDACTED]

[REDACTED]



295. [REDACTED]

[REDACTED]

296. The ability of Apotex and West-Ward to reach agreement regarding Balsalazide Disodium was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

297. [REDACTED]

[REDACTED]

298. No non-collusive market factors (e.g., product shortages) can explain the artificially inflated prices.

299. The agreement between Defendants Apotex and West-Ward was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Balsalazide Disodium Capsules (750 mg).

12. Betamethasone Dipropionate



300. Betamethasone Dipropionate is a corticosteroid used to treat a variety of skin conditions. It has been available in the United States for over a decade in a generic form. It is available in Ointment, Cream, Lotion, and Jelly formulations. Due to, among other things, its clinical efficacy and safety, betamethasone has been designated as an essential medicine by the World Health Organization.


301. The market for Betamethasone Dipropionate is mature. At all relevant times, there have been multiple manufacturers of Betamethasone Dipropionate.

302. Defendants Actavis, Perrigo, Sandoz, and Taro dominate sales of Betamethasone Dipropionate Ointment (0.05%), Cream (0.05%), and Lotion (0.05%).

303. [REDACTED]

[REDACTED]





304. The GAO noted that Betamethasone Dipropionate had an “extraordinary price increase” in the years 2011-2012.

305. Documentary evidence confirms that these parallel price increases were the result of collusion among Actavis, Perrigo, Sandoz, and Taro.

306. By late 2010, Actavis had increased its price on Betamethasone Dipropionate Cream, knowing that its competitors would mirror the increase. On December 10, 2010, W.K. of Sandoz wrote to a colleague, [REDACTED]

[REDACTED],” including Betamethasone Dipropionate Cream. “[REDACTED]

[REDACTED].” [REDACTED]

[REDACTED]

307. [REDACTED] Because of the ongoing understanding of the Fair Share Agreement between the companies, they did not worry about their ostensible competitors cutting prices to gain market share. They also did not attempt to undercut their ostensible competitors' prices in order to gain additional market share.

308. For example, a Sandoz "[REDACTED]" from November 2013 indicates that Sandoz would not be pursuing more market share on Betamethasone Dipropionate Cream due to the Fair Share Agreement. The spreadsheet shows the relative market shares of each competitor on betamethasone dipropionate cream, as well as the implications for market share acquisition:

[REDACTED]
[REDACTED].” Along similar lines, a Sandoz presentation entitled “[REDACTED]
[REDACTED]” from November 2013 advises that Sandoz pursue the following strategy for Betamethasone Dipropionate in order to maximize fourth quarter sales: “[REDACTED]
[REDACTED].”

309. Likewise, a Sandoz presentation entitled “[REDACTED]” from May 2014 describes the market approach to Betamethasone Dipropionate Cream in the following manner: “[REDACTED].” Similarly, on May 22, 2015, D.S. of Taro wrote to A.L. of Taro about opportunities to pick up market share on items including Betamethasone Dipropionate Cream. D.S. wrote, [REDACTED]
[REDACTED].” These ostensible competitors were unwilling to compete for additional market share due to their obligations under the Fair Share Agreement.

310. The same was true for Betamethasone Dipropionate Lotion and Ointment. For example, the market for Betamethasone Dipropionate Lotion [REDACTED]

[REDACTED]. A Sandoz presentation entitled “[REDACTED]
[REDACTED]” indicates that the target for Betamethasone
Dipropionate Lotion was to [REDACTED].”

311. The ability of Actavis, Perrigo, Sandoz, and Taro to reach agreement regarding Betamethasone Dipropionate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

312. The coordinated price increases among Actavis, Perrigo, Sandoz, and Taro are consistent with the Fair Share Agreement.

313. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices. Like other Named Generic Drugs, prices for Betamethasone Dipropionate remain artificially elevated to this day.

314. The agreement between Defendants Actavis, Perrigo, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Betamethasone Dipropionate Ointment (0.05%), Cream (0.05%), and Lotion (0.05%).

13. Betamethasone Dipropionate Augmented

315. Betamethasone Dipropionate Augmented is a corticosteroid used to treat a variety of skin conditions. It has been available in the United States for over a decade in a generic form. Betamethasone Dipropionate Augmented is a more potent version of Betamethasone Dipropionate. It is available in multiple formulations including Lotion (0.05%). Due to, among other things, its clinical efficacy and safety, betamethasone has been designated as an essential medicine by the World Health Organization.

316. The market for Betamethasone Dipropionate Augmented is mature. At all relevant times, there have been multiple manufacturers of Betamethasone Dipropionate.

317. Defendants Sandoz and Taro dominate sales of Betamethasone Dipropionate Augmented Lotion. [REDACTED]

[REDACTED]

318. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

319. [REDACTED]

[REDACTED] Because of the ongoing understanding of the Fair Share Agreement between the

companies, they did not worry about their ostensible competitor cutting prices to gain market share. They also did not attempt to undercut their ostensible competitor's prices in order to gain additional market share. For example, a Sandoz spreadsheet from August 2012 detailing the expected response to a Cardinal Request for Proposal (RFP) indicates that Sandoz did not intend to bid on Betamethasone Dipropionate Augmented Lotion because [REDACTED]." In another example, in April 2013, several months after the dramatic price increases, Publix requested a bid from Sandoz on Betamethasone Dipropionate Augmented due to the Taro price increase. A Senior Sales Executive at Sandoz forwarded the request to several colleagues. C.P. of Sandoz responded, "[REDACTED]."

320. The ability of Sandoz and Taro to reach agreement regarding Betamethasone Dipropionate Augmented was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

321. [REDACTED]

322. No non-collusive market factors (e.g., product shortages) can explain the artificially inflated prices.

323. The agreement between Defendants Sandoz and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Betamethasone Dipropionate Augmented Lotion (0.05%).

14. Betamethasone Dipropionate Clotrimazole

324. Betamethasone Dipropionate Clotrimazole is a combination medication used to treat inflamed fungal skin infections. This product contains two medications: clotrimazole is an

azole antifungal that prevents the growth of fungus and betamethasone is a corticosteroid that works by reducing the swelling, redness, and itching that occurs in a skin infection.

325. Betamethasone Dipropionate Clotrimazole has been available in the United States for over a decade in a generic form. It is available in, for example, Cream and Lotion formulations. Due to, among other things, their clinical efficacy and safety, the component drugs of Betamethasone Dipropionate Clotrimazole have both been designated as essential medicines by the World Health Organization.

326. The market for Betamethasone Dipropionate Clotrimazole is mature. At all relevant times, there have been multiple manufacturers of Betamethasone Dipropionate Clotrimazole.



327. Defendants Actavis, Sandoz, and Taro dominate sales of Betamethasone Dipropionate Clotrimazole Cream (0.05%) and Lotion (0.05%). For much of the relevant time period, [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



329. The GAO noted that Betamethasone Dipropionate Clotrimazole had an “extraordinary price increase” in the years 2011-2012.

330. [REDACTED]

[REDACTED] Because of the ongoing understanding of the Fair Share Agreement between the companies, they did not worry about their ostensible competitor cutting prices to gain market share. They also did not attempt to undercut their ostensible competitor's prices in order to gain additional market share. For example, a Sandoz presentation from June 2014 titled "[REDACTED] [REDACTED]" described Sandoz's market approach with respect to Betamethasone Dipropionate Clotrimazole : "[REDACTED] [REDACTED]."

331. The ability of Actavis, Sandoz, and Taro to reach agreement regarding Betamethasone Dipropionate Clotrimazole was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

332. The coordinated price increases by Actavis, Sandoz, and Taro are consistent with the Fair Share Agreement.

333. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

334. The agreement between Defendants Actavis, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Betamethasone Dipropionate Clotrimazole Cream (0.05%) and Lotion (0.05%).

15. Betamethasone Valerate

335. Betamethasone Valerate is a corticosteroid used to treat a variety of skin conditions. It is available in, for example, Ointment, Cream, and Lotion formulations. Betamethasone Valerate has been available in the United States for decades in a generic form.

Due to, among other things, its clinical efficacy and safety, Betamethasone has been designated as an essential medicine by the World Health Organization.

336. The market for Betamethasone Valerate is mature. At all relevant times, there have been multiple manufacturers of Betamethasone Valerate.

337. Plaintiffs allege that as part of Defendants' Fair Share Agreement, Defendants Actavis, G&W, Sandoz and Taro conspired to fix, raise, maintain or stabilize the prices of Betamethasone Valerate beginning at least as early as 2009.

338. For much of the relevant time period, Actavis, Sandoz, and Taro were the primary manufacturers of Betamethasone Valerate Cream and had roughly equal shares of the market. Defendants Actavis and Sandoz dominate sales of Betamethasone Valerate Ointment.

339. [REDACTED]

[REDACTED]

340. [REDACTED]

[REDACTED]

341. The GAO noted that Betamethasone Valerate had “extraordinary price increases” in the years 2011-2012 and 2012-2013.

342. Documentary evidence confirms that these parallel price increases were the result of collusion among Actavis, Sandoz, and Taro.

343. By late 2010, Actavis had increased its prices on Betamethasone Valerate Cream and Ointment, knowing that its competitors would mirror the increase. On December 10, 2010, W.K. of Sandoz wrote to a colleague, [REDACTED]

[REDACTED],” including Betamethasone Valerate Cream and Ointment.

“ [REDACTED].” [REDACTED]

[REDACTED]

344. Similarly, in December 2011, Sandoz planned a large price increase on Betamethasone Valerate Lotion. In preparation for the increase, A.T., Sandoz's National Account Executive spoke with Jim Grauso, G&W's Vice President of Sales, to coordinate pricing. [REDACTED]:

[REDACTED]

345. [REDACTED].

346. As a result of the agreement and anticompetitive coordination between Actavis, G&W, Sandoz, and Taro, prices for Betamethasone Valerate were higher than they would have been in a competitive market.

347. Because of the ongoing understanding of the Fair Share Agreement between the companies, they did not worry about their ostensible competitor cutting prices to gain market

share. They also did not attempt to undercut their ostensible competitor's prices in order to gain additional market share.

348. For example, in February 2013, Armando Kellum of Sandoz wrote to C.P., also of Sandoz: "[REDACTED]". The email chain indicated that their market share goal was [REDACTED].

349. The ability of Actavis, G&W, Sandoz and Taro to reach agreement regarding Betamethasone Valerate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

350. [REDACTED]

351. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

352. The agreement between Defendants Actavis, G&W, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Betamethasone Valerate Cream, Ointment, and Lotion.

16. Bethanechol Chloride

353. Bethanechol Chloride is a medication used to treat bladder problems. It is available as a Tablet and has been available in the United States in a generic form for many years.

354. The market for Bethanechol Chloride is mature. At all relevant times, there have been multiple manufacturers of Bethanechol Chloride.

355. During the relevant time frame, Defendants Amneal, Teva, and Upsher-Smith were the primary manufacturers of Bethanechol Chloride Tablets.

356. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Bethanechol Chloride beginning at least as early as the fall of 2014.

357. In the fall of 2014, Amneal, Teva, and Upsher-Smith [REDACTED]. Amneal announced a list (WAC) price increase in early November, and Teva followed the list price increase. Teva's price increase spreadsheet identified the reason for the increase as "Follow Competitor – Amneal." Prior to Teva's increase, Teva's Patel had a 51-minute phone call with an executive at Amneal.

358. During this period, Amneal, Teva, and Upsher-Smith also met at trade conferences and communicated directly in furtherance of their agreement on Bethanechol Chloride and the Fair Share Agreement.

359. [REDACTED]
[REDACTED]

360. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

361. The agreement between Defendants Amneal, Teva, and Upsher-Smith was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Bethanechol Chloride Tablets.

17. Bromocriptine Mesylate

362. Bromocriptine Mesylate is a dopamine promoter used to treat menstrual problems, growth hormone overproduction, Parkinson's disease, and pituitary tumors. It is

available in, for example, a Tablet (2.5 mg) formulation. It has been available in the United States for over a decade in a generic form.

363. The market for Bromocriptine Mesylate is mature. At all relevant times, there have been multiple manufacturers of Bromocriptine Mesylate.

364. Defendants Mylan, Perrigo, and Sandoz dominate sales of Bromocriptine Mesylate Tablets (2.5 mg). [REDACTED]

[REDACTED]


365. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED].



366. [REDACTED]

367. Under the Fair Share Agreement, Mylan, Perrigo, and Sandoz did not attempt to undercut competitors' prices in order to gain additional market share. By way of example, an internal Sandoz planning document from June 2013 indicates that Sandoz did not want more share on Bromocriptine Mesylate because they [REDACTED]" and thought that they had a "[REDACTED]." Another internal Sandoz planning document from October 2014 indicated that Sandoz and Perrigo had "[REDACTED]" on Bromocriptine Mesylate Tablets.

368. The ability of Mylan, Perrigo, and Sandoz to reach agreement regarding Bromocriptine Mesylate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

369. [REDACTED]

370. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

371. The agreement between Defendants Mylan, Perrigo, and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Bromocriptine Mesylate Tablets (2.5 mg).

18. Budesonide

372. Budesonide is a steroid. It is available in Inhalation and Capsule formulations. It has been available in the United States in a generic form for many years.

373. The market for Budesonide is mature. At all relevant times, there have been multiple manufacturers of Budesonide.

374. During the relevant time frame, Defendants Actavis, Mylan, Par, Sandoz, and Teva were the primary manufacturers of Budesonide.

375. As of February 2013, Teva was the only company in the market for generic Budesonide Inhalation. Teva knew, however, that there was a good chance that Actavis would soon be entering the market, followed by others. In anticipation of needing to cede market share to the new entrants, Teva pre-emptively decided to raise prices, so that when it eventually ceded share it would not lose as much dollar revenue.

376. Teva raised the list price for its Budesonide Inhalation.

377. On April 1, 2013, Actavis won a legal challenge that would enable it to enter the market. That day, Teva's Rekenhaller called A.B., his counterpart at Actavis – a senior sales and marketing executive – and they spoke for two (2) minutes.

378. The next day, April 2, 2013, Rekenhler spoke to A.B of Actavis two more times. Actavis then immediately began shipping the product. Instead of offering better prices to win over customers, Actavis entered the market with the same list (WAC) price as Teva.

379. At some point thereafter, further legal action from the brand manufacturer delayed Actavis (or any other manufacturer) from fully entering the market until February 2015. As Actavis was (again) preparing to ramp up sales of Budesonide, Teva's Rekenhler and Falkin of Actavis were communicating by phone to coordinate Actavis's entry into the market and the ceding of market share to Actavis by Teva.

380. A few months later, Sandoz was the next to enter the market. The same pattern held. Rather than compete for customers with better prices, Sandoz announced identical WAC prices to those of Teva and Actavis. Owing to their Fair Share Agreement, Sandoz was able to gain market share as Teva ceded customers to it.

381. Teva was preparing to enter the market for Budesonide Capsules in the spring of 2014. At the time, Par and Mylan were the only other manufacturers in the market.

382. Just as Teva had done in anticipation of Actavis's entry into the Budesonide Inhalation, shortly before Teva entered with Budesonide Capsules, Par increased the price of the drug.

383. As Teva was preparing to enter the market, and as Par was raising prices, all three manufacturers were communicating with each other by phone. Teva's Rekenhler was in touch with a senior national account executive at Par and with Nesta at Mylan. Meanwhile, another account executive at Par was in touch with a counterpart at Mylan.

384. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

385. The ability of Actavis, Mylan, Par, Sandoz, and Teva to reach agreements on Budesonide was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

386. The coordination by Actavis, Mylan, Par, Sandoz, and Teva is consistent with the Fair Share Agreement.

387. The agreement between Defendants Actavis, Mylan, Par, Sandoz, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Budesonide Inhalation and Capsules.

19. Buspirone HCL

388. Buspirone HCL, also known by the brand name Buspar is a medication used to treat, among other things, anxiety disorders or to relieve the symptoms of anxiety. It has been available in the United States in a generic form for many years.

389. The market for Buspirone HCL is mature. At all relevant times, there have been multiple manufacturers of Buspirone HCL.

390. During the relevant time frame, Defendants Teva, Mylan and Actavis (Watson) were the primary manufacturers of Buspirone HCL Tablets.

391. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Buspirone HCL beginning at least as early as the summer of 2012.

392. [REDACTED] Before this price increase, Teva coordinated with its competitors. In the weeks leading up to the price increase, Teva's Green spoke to Nesta of Mylan on July 23, 24, 25, 26, 30, and 31, 2012. In

addition, Teva's Rekenhalel spoke to A.S., VP of Sales at Actavis (Watson), twice on July 11, 2012.

393. The ability of Teva, Mylan and Actavis (Watson) to reach agreements on Buspirone HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

394. [REDACTED]

395. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

396. The agreement between Defendants Teva, Mylan and Actavis (Watson) was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Buspirone HCL Tablets.

20. Butorphanol Tartrate

397. Butorphanol Tartrate is a narcotic pain reliever used to treat moderate to severe pain. It is available in a Nasal Spray formulation and has been available in the United States for decades in a generic form.

398. The market for Butorphanol Tartrate is mature. At all relevant times, there have been multiple manufacturers of Butorphanol Tartrate.

399. Defendants Apotex, Mylan, and West-Ward dominate sales of Butorphanol Tartrate. During much of the relevant time period, Mylan and West-Ward divided the market in roughly a 40/60 split. Apotex briefly left the market around the time of the price increase, but

when it reentered the market, it regained about 20% market share, leading to a 20/20/60 split between Apotex, Mylan, and West-Ward, respectively.

400.

[REDACTED]

[REDACTED]

401. The GAO noted that the Butorphanol Tartrate had an “extraordinary price increase” in the years 2014-2015.

402.

[REDACTED]

403. The ability of Apotex, Mylan, and West-Ward to reach agreements regarding Butorphanol Tartrate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

404. [REDACTED]

405. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

406. The agreement between Defendants Apotex, Mylan, and West-Ward was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Butorphanol Tartrate Nasal Spray.

21. Capecitabine

407. Capecitabine, also known by the brand name Xeloda, is a chemotherapy medication used to treat multiple types of cancer, including breast and colon cancer. It is available as a Tablet and has been available in the United States in a generic form for years.

408. The market for Capecitabine is mature. At all relevant times, there have been multiple manufacturers of Capecitabine.

409. During the relevant time frame, Teva and Mylan were the primary manufacturers of Capecitabine Tablets.

410. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Capecitabine beginning at least as early as the winter of 2013-2014.

411. As early as the winter of 2013-2014, Teva and Mylan shared commercially sensitive information about their preparations to launch Capecitabine, which was just opening up to generic competition. For example, Teva and Mylan shared customer-specific sales information, which they provided to one another in order to allocate the Capecitabine market between them.

412. By late February, Mylan had informed Teva that its launch would be delayed. Teva proceeded with its launch and became the exclusive generic Capecitabine manufacturer in early March 2014.

413. Leading up to Mylan's launch in August 2014, Mylan and Teva communicated by phone on multiple occasions about the drug and Fair Share allocation of the market. For example, Teva's Rekenenthaler and Mylan's Nesta discussed three large customers and a targeted market share of 35% for Mylan. Mylan ultimately sought business from each of the three customers that Rekenenthaler and Nesta had spoken about, and Teva conceded each of them, pursuant to an agreement the two had reached around the time of Mylan's launch.

414. The ability of Teva and Mylan to reach agreements on Capecitabine was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

415. The coordination by Teva and Mylan is consistent with the Fair Share Agreement.

416. The agreement between Teva and Mylan as to these three customers was part of broader market allocation scheme for Capecitabine, as further demonstrated by Teva's concession of other smaller customers to Mylan as well. This agreement was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig

bids, and engage in market and customer allocation for generic drugs, including Capecitabine Tablets.

22. Captopril

417. Captopril is an angiotensin converting enzyme (ACE) inhibitor prescribed for treating high blood pressure, heart failure, and for preventing kidney failure due to high blood pressure and diabetes. It is available in Tablet (12.5, 25, 50, and 100 mg) and Oral Liquid formulations. It has been available in the United States for decades in a generic form.

418. The market for Captopril is mature. At all relevant times, there have been multiple manufacturers of Captopril.


419. Defendants Mylan, West-Ward and Wockhardt dominate sales of Captopril Tablets (12.5, 25, 50, and 100 mg). During much of the relevant time period, Wockhardt had approximately 85% of the market and Mylan had approximately 15%. West-Ward re-entered the market after the price increase and had a small share.

420. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED].



421. The GAO noted Captopril Tablets had “extraordinary price increases” in the years 2013-2015.

422. [REDACTED]

423. The ability of Mylan, West-Ward, and Wockhardt to reach agreements regarding Captopril was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

424. [REDACTED]

425. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

426. The agreement between Defendants Mylan, West-Ward, and Wockhardt was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Captopril Tablets (12.5 mg, 25 mg, 50 mg, and 100 mg).

23. Carbamazepine, Clotrimazole, and Warfarin Sodium

427. Carbamazepine, which is known by other names such as Epitol, is an anticonvulsant medication used to treat seizure disorders and neuropathic pain that has been available in the United States for decades. The World Health Organization includes it on its List of Essential Medicines. In the United States, where it is sold in Capsules and Tablets in various forms such as ER and Chewable. It ranks within the top 200 most prescribed medications.

428. The market for Carbamazepine is mature. At all relevant times, there have been multiple manufacturers of Carbamazepine. [REDACTED]



[REDACTED]

[REDACTED]

[REDACTED]


429. [REDACTED]


[REDACTED]



430. The GAO noted that Carbamazepine had “extraordinary price increase[s]” in the years 2014-2015.

431. Defendants coordinated their increases and raised their list (WAC) prices in lockstep, beginning on June 3, 2014, when Taro drastically raised its WAC prices on several drugs, including Carbamazepine (increasing the price of 200 mg tablets a whopping 2,328%). Teva and Apotex soon matched:





432. Similarly, in May 2013, Taro and Sandoz almost simultaneously began to increase their Carbamazepine Tablets ER prices by announcing identical list (WAC) prices. In the spring and summer of 2014, Taro instituted more price increases on Carbamazepine Tablets ER that Sandoz quickly followed.

433. Documentary evidence confirms that these parallel price increases were the result of collusion among Apotex, Sandoz, Taro, Teva, and Torrent. Notably, Teva's Nisha Patel knew of these (and other) Taro increases well in advance, and had prepared so that Teva could quickly match the price increases.

434. Patel likely obtained this information from Taro's Ara Aprahamian on May 14, 2014, when the two exchanged eight text messages and spoke for more than four minutes by phone. It was understood in advance that Teva would match the Taro price increases based on these and earlier conversations. In fact, Teva agreed and made plans to match them before Taro had even put them into effect.

435. After speaking with Aprahamian, Patel directed a colleague to create a list of future price increase candidates, based on a set of instructions and data she had given him. On May 28, 2014, that colleague sent her a list titled “2014 Future Price Increase Candidate Analysis.” The list included several drugs sold by Taro with the notation “Follow/Urgent” listed as the reason for the increase. That list included two drugs, Carbamazepine and Clotrimazole, even though Taro had not yet increased its price on those drugs or notified its customers that it would be doing so:

Item Description	BUCKET
CARBAMAZEPINE TABLETS 200 MG 100	Follow/Urgent
CARBAMAZEPINE TABLETS 200 MG 1000	Follow/Urgent
CLOTRIMAZOLE TOPICAL SOLUTION 1% 10 ML	Follow/Urgent
CLOTRIMAZOLE TOPICAL SOLUTION 1% 30 ML	Follow/Urgent

436. On June 3, 2014 – the date of the Taro price increases on Carbamazepine and other drugs – Patel and Aprahamian exchanged five text messages. After texting Aprahamian, Patel confirmed to Teva’s Kevin Green and another Teva representative that Taro had in fact raised its pricing on one of the drugs, Fluocinonide, and then added: “I expect to provide guidance at some point in the morning” on “Carbamazepine as well. I’ll be looking at shares and intel tomorrow and will provide commentary. (Taro is a high-quality competitor. It’s just a matter of who the others are.)” At 5:08 pm that evening, Patel called Aprahamian and the two spoke for nearly seven minutes.

437. First thing the next morning, Patel and Aprahamian exchanged two text messages. Then, at 9:56 am, the two spoke again for almost twenty-six minutes. Shortly after hanging up the phone with Aprahamian, Patel sent an email to Teva’s K.G. making it clear that she had obtained additional “intel” regarding the Taro price increases that she did not want to put into writing, stating: “I have additional intel (I can discuss with you) that will be useful.”

438. That same day, Teva received a bid request from a large customer, Walmart. Shortly after it was forwarded to her, Patel responded by making it clear that Teva would play nice in the sandbox with Taro and would not bid on any of the Walmart business.

439. On June 12, 2014, Teva internally discussed future projections regarding Carbamazepine – including the fact that its API supplier might run out of supply sometime in 2015. One of the options discussed was a price increase. K.G., a senior marketing executive at Teva – aware that Patel had been in discussions with Aprahamian and had “intel” regarding the Taro price increase on Carbamazepine (and other drugs) – stated: “Nisha [Patel] would be able to provide guidance relative to [the Carbamazepine] price increase for the analysis being put together.” In fact, Patel had communicated with Aprahamian earlier that day on the phone for more than nine minutes,

440. On June 13, 2014, Patel sent an internal email alerting her group, including K.G., about a list of drugs on which Teva planned to raise prices. A number of them – including Carbamazepine — included the notation “Follow/Urgent - Taro” as the reason for the increase. The next day Patel and Aprahamian exchanged two text messages. Then, at 9:56 am, the two spoke again for almost twenty-six minutes. Shortly after hanging up the phone with Aprahamian, Patel sent an email to K.G., making it clear that she had obtained additional “intel” regarding the Taro price increases that she did not want to put in writing, stating: “I have additional intel (I can discuss with you) that will be useful.”

441. For that list of drugs, Patel directed that “we should not provide any decreases on these products.” Patel’s directive meant that Teva would not seek to compete for market share against Taro (or other Defendants) when approached by customers due to the competitors’ price increases.

442. On June 18, 2014, Patel emailed the entire sales team at Teva to inform them of the status of Teva's next price increase. She noted that Teva had already been "receiving multiple requests on several items that are prioritized as increase candidates." Patel continued: "While we do not have an exact date of increase, we are taking our increase plans into consideration and are bidding on new business at the planned increase price where our WAC allows." Finally, Patel stated:

This is all in consideration of market factors, quality of competitors, current market share (including McK RFP results) and intelligence we have been able to gather. As you know, each situation is unique, but this should provide a high level overview.

443. Some of the "intelligence" referred to by Patel was gathered during a phone conversation she had with Aprahamian of Taro the day before, on June 17, 2014, which lasted more than fifteen minutes.

444. The next day, Patel continued to gather "intelligence" and made concerted efforts to simultaneously coordinate with Aprahamian, including a thirteen- minute phone call on June 19, 2014.

445. Teva again demonstrated that it would play nice with Taro, when it chose to forego an opportunity to compete on an RFP from McKesson. In an internal email, Patel wrote to her colleague, K.G.: "For Carbamazepine and Clotrimazole, I would suggest bidding on a smaller customer when there is an opportunity. Taking the volume would put [us] at a disproportionately high market share. I think Taro will pursue elsewhere and would be concerned about an increase sticking." Patel's recommendation was based on a market share analysis, which computed that additional market share that Teva would accrue if it competed for Taro's largest customer:

Product Family	Teva current market share	Teva current market share w/ McK award	McKesson market share%	Walmart	Walmart market share%	Kaiser	Kaiser market share%	Possible market share w/ all awards
CARBAMAZEPINE TABLETS	41.5%	71.3%	29.8%					71.3%
CLOTRI MAZOLE TOPICAL SOLUTION	46.0%	71.8%	25.8%					71.8%
FLUOCINONIDE OINTMENT	50.5%	61.4%	10.9%	75,600	6.8%			68.2%
WARFARIN SODIUM TABLETS	20.9%	28.4%	7.5%			348,495	2.4%	30.8%

446. On August 28, 2014, Teva matched the Taro price increases on Carbamazepine, and numerous other drugs. Teva coordinated its increases with Taro (and other Defendants) through direct communications with its purported competitors in the days leading up to the increase. At 8:27 am on August 27, 2014, the day before the increase became effective, Patel had a two-minute call with Aprahamian as well as other calls during the course of the day with her contacts at Sandoz, Actavis, Taro, Zydus and Glenmark to discuss the price increases:

Date	Call	Target Name	Direction	Contact Name	Time	Duration
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	CW-1(Sandoz)	7:11:03	0:11:13
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	8:02:19	0:00:00
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	8:02:42	0:00:03
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	8:27:27	0:02:25
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	CW-1(Sandoz)	8:31:03	0:00:33
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	8:32:42	0:20:31
8/27/2014	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)	8:41:01	0:00:00
8/27/2014	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)	8:41:06	0:00:25
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	8:58:01	0:16:23
8/27/2014	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	9:23:26	0:18:34
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	Brown, Jim (Glenmark)	10:34:34	0:00:06
8/27/2014	Voice	Patel, Nisha (Teva)	Incoming	Brown, Jim (Glenmark)	16:29:08	0:07:52
8/27/2014	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	17:09:15	0:00:06

447. Meanwhile Patel coordinated with Apotex to raise prices on a large number of drugs, in which Carbamazepine 200 mg Tablets are believed to be included. Previously, in May 2013, Teva ranked Apotex as one of the competitors that was least likely to coordinate on prices (*i.e.*, competitor “quality”) with a ranking of -3. When Patel updated her Quality Competitor

rankings in May 2014, however, Apotex was rated +2 – an increase in five points over that twelve-month period. Apotex made this jump in Teva’s Quality Competitor rankings in large part due to Patel’s relationship with B.H., a senior sales executive at Apotex, and the successful coordination between Apotex and Teva in 2013 on various drugs.

448. For example, from May 20-24, 2013, Patel had the following series of phone calls with B.H. during which Apotex agreed to raise drug prices:

- 5/20/2013 Voice Patel, Nisha Patel (Teva) Incoming B.H. (Apotex) 0:21:56
- 5/21/2013 Voice Patel, Nisha Patel (Teva) Incoming B.H. (Apotex) 0:11:28
- 5/23/2013 Voice Patel, Nisha Patel (Teva) Incoming B.H. (Apotex): 0:06:13
- 5/24/2013 Voice Patel, Nisha Patel (Teva) Incoming B.H. (Apotex) 0:00:39
- 5/24/2013 Voice Patel, Nisha Patel (Teva) Outgoing B.H. (Apotex) 0:12:07

These were the first documented phone calls between Patel and B.H. since Patel had joined Teva.

449. Apotex matched Teva’s price on Carbamazepine on July 11, 2013. In the weeks leading up to the Teva price increases, Patel spoke to B.H. at Apotex three times to coordinate, including one call on August 1, 2013, between Patel and B.H. that lasted over 14 minutes. On information and belief, Defendant Apotex destroyed additional communications with Teva and Taro when it destroyed B.H.’s entire custodial file after the States requested it through an investigatory subpoena in July 2017—without informing the States for a year.

450. Along with the phone communications, representatives from Teva and every other Defendant met in Boston, Massachusetts shortly before the increase, from August 23-26, 2014, for the NACDS annual event, which was the largest pharmaceutical industry meeting of the year. Teva executives Cavanaugh, Rekenhaler and Patel, along with many other Teva executives, as

well as executives from every other corporate Defendant, attended, providing further opportunities to discuss their overarching conspiracy.

451. Teva and Taro's coordination over the price of Carbamazepine occurred at the same time these Defendants conspired to raise the prices of Warfarin Sodium and Clotrimazole.


452. For example, the 2014 Future Price Increase Candidate Analysis spreadsheet that Teva internally circulated on May 28, 2014, included Clotrimazole in the bucket marked "FOLLOW/URGENT." After exchanging five texts with Taro's Aprahamian, on June 3, 2014—when Taro increased its price on Carbamazepine, Clotrimazole, Warfarin, and other drugs—Teva's Patel and Taro's Aprahamian exchanged five text messages. Patel internally communicated with other Teva executives that she expected to get more information the next day and to be able to provide guidance on Warfarin pricing along with other drugs. At 5:08 pm that evening, Patel called Aprahamian and the two spoke for nearly seven minutes. And on June 13, 2014, when Zydus increased its price for Warfarin, Patel observed that its competitors' price increases would "likely increase the demand on [the] Teva product." That same day Teva was presented with an offer from a customer for a one-time buy on that drug. Despite the clear opportunity to increase market share, Patel responded: "We will review, but note that we intend to follow Taro and Zydus [to] increase price." And on August 27, 2014, the day before Teva's price increases took effect, Patel spent much of her day discussing the price increases with her contacts at Taro, Zydus and other Defendants, including a 20-minute call with Zydus at 8:32 am, a 16-minute call with Zydus at 8:58 am and a two-minute call with Aprahamian.

453. Clotrimazole is an antifungal medication. The GAO reported that Clotrimazole had an "extraordinary price increase." Defendants Taro and Teva have long dominated the

market for that drug. After years of stability, the prices began to increase drastically, [REDACTED]
[REDACTED]:



454. As they did with Carbamazepine, Defendants coordinated their price increases by raising WACs in lockstep:




455. The World Health Organization includes Warfarin Sodium on its list of essential medications. Warfarin has been on the market in the United States for half a century and is used to treat blood clots such as deep vein thrombosis and pulmonary embolism and to prevent stroke in people who have atrial fibrillation, valvular heart disease or artificial heart valves. At all relevant times, Defendants Amneal, Teva, Taro, and Zydus have dominated the Warfarin Sodium Tablet market.

456. Previously, in May 2013, Zydus had been one of Teva's lowest-ranked competitors, but the following year Patel updated her quality competitor and increased Zydus's rank five points to +2. This change is directly related to Kevin Green, who had himself conspired with a number of competitors while at Teva, and moved from Teva to Zydus in November 2013. With Green firmly installed at Zydus, Patel was emboldened to more fully include Zydus in the conspiracy. Warfarin Sodium is just one of their price fixing conspiracies.

457. Amneal is another example of a Defendant, who moved up the ranks on Teva's list of "quality competitors," *i.e.*, those most likely to coordinate prices. It was ranked +1 in May 2013 and improved to a ranking of +2 the following year. Amneal's dubious distinction of ranking high on Teva's collusion list was partly the result of David Rekenthaler of Teva's strong relationship with S.R.(2), a senior sales executive at Amneal. From May 2013 to May 2014, the two spoke eight times by phone, and attended many trade association meetings and customer conferences together as well. Rekenthaler and S.R.(2) were regular participants in an annual golf outing hosted by a packaging contractor in Kentucky, where – as discussed above – the generic drug manufacturer participants (competitors) played golf by day and gathered socially by night, referring to each other as "friends" and "fraternity brothers." Teva's Patel also had a strong

relationship with S.R.(2) as well as S.R.(1), a senior sales and finance executive at Amneal, with whom Patel coordinated the price increases of several drugs.

458. As a result of their collusion, after years of stable prices, Defendants Amneal and Zydus joined Teva and Tara and significantly increased Warfarin Sodium prices during [REDACTED], as illustrated in the following graph depicting 1 mg prices:



459. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

460. The agreement between these Defendants was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Carbamazepine, Clotrimazole, and Warfarin Sodium.

24. Carisoprodol

461. Carisoprodol is a muscle relaxant and pain reliever. It is available in Tablet form, including a 350 mg strength and has been available in the United States for many years in a generic form.

462. The market for Carisoprodol is mature. At all relevant times, there have been multiple manufacturers.

463. Defendants Par and Teva dominate sales of Carisoprodol Tablets with each accounting for roughly 55% and 35% of the market, respectively in the relevant times.

464. [REDACTED]

[REDACTED]

465. The GAO noted that Carisoprodol had “extraordinary price increases” in the years 2013-2014.

466. The ability of Par and Actavis to reach agreements on Carisoprodol was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

467. [REDACTED]

468. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

469. The agreement between Defendants Par and Actavis was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Carisoprodol Tablets (350 mg).

25. Cefdinir and Cefprozil

470. Cefdinir and Cefprozil are medications used to treat bacterial infections. Cefdinir is available in Capsule and Oral Suspension formulations. Cefprozil is available in Tablet formulation. They have been available in the United States in a generic form for many years.

471. The market for Cefdinir and Cefprozil is mature. At all relevant times, there have been multiple manufacturers of Cefdinir and Cefprozil.

472. During the relevant time frame, Defendants Lupin, Sandoz, and Teva were the primary manufacturers of Cefdinir and Cefprozil.

473. Not long after Patel started at Teva, she sent her first list of proposed price increases to her supervisor on May 24, 2013. The list included Cefdinir and Cefprozil.

474. Patel communicated with competitors to coordinate the proposed price increases. For example, Patel spoke to Berthold of Lupin six (6) times on May 16, two (2) times on May 17, once on May 20, once on May 21, and three (3) times on May 23, 2013.

475. By summer, Teva and Lupin had raised prices on Cefdinir and Cefprozil, as agreed. Patel and Reckenthaler at Teva also communicated with contacts at Sandoz, which joined the price-fixing agreement on Cefdinir and Cefprozil.

476. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

477. The ability of Lupin, Sandoz, and Teva to reach agreements on Cefdinir and Cefprozil was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

478. The coordination by Lupin, Sandoz, and Teva is consistent with the Fair Share Agreement.

479. The agreement between Defendants Lupin, Sandoz, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Cefdinir Capsules and Suspension and Cefprozil Tablets.

26. Cefuroxime Axetil

480. Cefuroxime Axetil is an antibiotic used to treat bacterial infections. It is available in Tablet and Oral Suspension formulations. It has been available in the United States for over a decade in a generic form.

481. The market for Cefuroxime Axetil is mature. At all relevant times, there have been multiple manufacturers of Cefuroxime Axetil.

482. Defendants Aurobindo, Citron, and Lupin dominate sales of Cefuroxime Axetil Tablets (250 and 500 mg). During much of the relevant period, [REDACTED]

[REDACTED] with other competitors sharing

the remainder. Mylan [REDACTED]

[REDACTED]

483. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



484. The GAO noted that the Cefuroxime Axetil had “extraordinary price increases” in the years 2014-2015.

485. [REDACTED]

Under the Fair Share Agreement, Aurobindo, Citron, and Lupin did not attempt to undercut competitors’ prices in order to gain additional market share. For example, in April 2014, Aurobindo submitted a bid to OptiSource for Cefuroxime Axetil. OptiSource responded asking Aurobindo to match a lower price. In discussing the proposal internally at Aurobindo, Tim Gustafson wrote to colleagues, “[W]e don’t need to be competitive (my opinion)...If we want to hold firm, I can convey that message.” Ultimately, Aurobindo declined to decrease its pricing to the level requested by OptiSource and instead lowered its price slightly to move closer to Lupin’s pricing.

486. The ability of Aurobindo, Citron, and Lupin to reach agreement regarding Cefuroxime Axetil 250 mg and 500 mg Tablets was aided by the prevalence of trade association

meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

487. [REDACTED]

488. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

489. The agreement between Defendants Aurobindo, Citron, and Lupin was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Cefuroxime Axetil Tablets (250 and 500 mg).

27. Celecoxib

490. Celecoxib is a medication used to treat pain. It is available in a Capsule formulation. It has been available in the United States in a generic form for several years.

491. The market for Celecoxib is mature. At all relevant times, there have been multiple manufacturers of Celecoxib.

492. During the relevant time frame, Defendants Actavis and Teva were the primary manufacturers of Celecoxib.

493. In November 2014, as Actavis and Teva were preparing to launch Celecoxib, they communicated directly with each other to coordinate Fair Shares. For example, Actavis's Falkin communicated by phone with Teva's Rekenhler on November 17, 18, and 25, and with Maureen Cavanaugh (Teva's Senior Vice President of Sales) on November 11 and 14.

494. The lines of communication remained open the following month as well. In the days leading up to and following Teva's December 10, 2014 launch of Celecoxib, Teva's Patel

and the Senior Vice President of U.S. Sales at Actavis communicated by phone on December 5 and 8.

495. In addition, Actavis's Falkin communicated by phone with Teva's Rekenhaller (December 3, 9, 10, 17, and 18), including at least three times on the day of the launch.

496. The ability of Actavis and Teva to reach agreements on Celecoxib was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

497. The coordination by Actavis and Teva is consistent with the Fair Share Agreement.

498. The agreement between Defendants Actavis and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Celecoxib Capsules.



28. Cephalexin (Cefalexin)

499. Cephalexin (also spelled Cefalexin) is an antibiotic that has been available in the United States for decades. It is available in Capsule, Tablet, and Suspension formulations. Due to, among other things, its clinical efficacy and safety, Cephalexin has been designated as an essential medicine by the World Health Organization.

500. The market for Cephalexin is mature. At all relevant times, there have been multiple manufacturers of Cephalexin.

501. Defendants Lupin and Teva dominate sales of Cephalexin Suspension, which comes in two dosage strengths: 125mg/5ml and 250mg/5ml.

502. [REDACTED]



503. The GAO noted that Cephalexin had an “extraordinary price increase.”

504. Documentary evidence confirms that these parallel price increases were the result of collusion among Lupin and Teva.

505. The ongoing understanding between Lupin and Teva was institutional, not dependent upon a relationship between specific individuals. For example, David Berthold of Lupin colluded with numerous individuals at Teva on a variety of drugs.

506. By mid-2013, Lupin and Teva became aware of the potential for price increases on Cephalexin. For example, on August 26, 2013, Teva's T.S. sent an internal email to Rekenthaler, Patel, K.G., and J.L. commenting on Cephalexin stating: "Possible price increase product? Perhaps this is old intel? Cephalexin Suspensions – Karalex is out of the market. Leaves Teva and Lupin."

507. By early October 2013, Lupin had decided to raise price on Cephalexin knowing that Teva would match the increase.

508. On October 14, 2013, Lupin's Berthold called Teva's Rekenthaler. They spoke for sixteen minutes that day. During that conversation, Lupin conveyed its intention to raise prices on Cephalexin.

509. On October 31, 2013, which was the day before Lupin was scheduled to increase its price on Cephalexin, Lupin's Berthold called Teva's T.S. Berthold called T.S. at 9:18 am that morning and left a message. T.S. returned the call at 9:57 am and the two spoke for nearly five minutes. Within minutes of hanging up the phone, T.S. notified others internally at Teva about the substantial Lupin price increase, stating: "I have heard [] Lupin is implementing a price increase today on Cephalexin Oral Suspension (4-6x's current price)." K.G. responded later that day asking: "Did Lupin increase the Caps as well?" Rekenthaler answered immediately, with

information he had learned from Lupin's Berthold in mid-October: "Lupin did not increase the caps, only the susp[ension]."

510. The Lupin price increase on Cephalexin became effective the next day, November 1, 2013.

511. On November 22, 2013, a large customer requested a bid from Teva on Cephalexin due to the Lupin price increase. Teva's T.S. forwarded the email from the customer to Rekenenthaler, K.G., and others with the suggestion that, because Teva already had the majority share, it should not bid for the business. K.G. agreed, and simultaneously forwarded the email to Teva's Patel stating: "Nisha, let's add this to our list to discuss." Patel called Lupin's Berthold the same day and left a message.

512. In January 2014 Patel sent an initial list of possible Teva price increase candidates and forwarded it to K.G. Cephalexin was on the list. By April 2014, Teva raised its prices on Cephalexin to match Lupin's prices. Patel coordinated the increase consistently with Lupin throughout this period.

513. [REDACTED]

514. [REDACTED] Because

of the ongoing understanding of the Fair Share Agreement between the two companies, they did not worry about their ostensible competitor cutting prices to gain market share. For example, on March 25, 2015, a Teva employee emailed a customer about Cephalexin in response to a request for lower pricing stating: "I see Lupin and Teva around the same market share. Not sure why Lupin would be decreasing price."

515. The ability of Lupin and Teva to reach agreement regarding Cephalexin was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

516. [REDACTED]

517. No non-collusive market factors (e.g., product shortages) can explain the artificially inflated prices.

518. The agreement between Defendants Lupin and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Cephalexin Suspension.



29. Chlorpromazine HCL



519. Chlorpromazine HCL is an antipsychotic used to treat mood disorders such as schizophrenia or bipolar disorder. It is available in Tablet, Injection, and Oral Liquid formulations. It has been available in the United States for decades in a generic form. Due to, among other things, its clinical efficacy and safety, Chlorpromazine HCL has been designated as an essential medicine by the World Health Organization.


520. The market for Chlorpromazine HCL is mature. At all relevant times, there have been multiple manufacturers of Chlorpromazine HCL.

521. Defendants Sandoz and Upsher-Smith dominate sales of Chlorpromazine HCL Tablets. During much of the relevant time period, Sandoz and Upsher-Smith divided the market in a roughly 50/50 split.

522. [REDACTED]







523. The GAO noted that the Chlorpromazine HCL had “extraordinary price increases” in the years 2011-2012.²⁸

524. [REDACTED]

Under the Fair Share Agreement, the defendants expected that their ostensible competitor would not undercut their prices in order to gain additional market share. When their ostensible competitor did seek additional market share, defendants showed surprise and dismay that one would not expect in a competitive market. For instance, in May 2015, B.P. of Upsher-Smith complained to B.L. and C.O. of Upsher-Smith that Sandoz challenged them at Armada for Chlorpromazine HCL. B.P. said, “I can’t believe they have chosen to compete against us since we had this business. How does this help us? We play fair and they don’t?”

²⁸ The chlorpromazine hydrochloride 100 mg and 200 mg tablets also experienced “extraordinary price increases” in the years 2014-2015, according to the GAO.

525. The ability of Sandoz and Upsher-Smith to reach agreement regarding Chlorpromazine HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

526. [REDACTED]

527. No non-collusive market factors (e.g., product shortages) can explain the artificially inflated prices.



528. The agreement between Defendants Sandoz and Upsher-Smith was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Chlorpromazine HCL Tablets (10, 25, 50, 100, 200 mg).

30. Cholestyramine

529. Cholestyramine is a commonly prescribed medication to reduce cholesterol levels in the blood. It has been on the market for decades and is available in several forms, including Powder (4 gm) and Oral Solids (4 gm).

530. The market for Cholestyramine is mature. At all relevant times, there have been multiple manufacturers. Defendants Par, Sandoz, and Upsher-Smith dominated sales of Cholestyramine in the relevant period.

531. For many years the price of Cholestyramine remained stable. However, prices began to rise dramatically [REDACTED], some months after Upsher-Smith entered the market, as illustrated below:



532. WAC pricing also rose in a coordinated fashion. Upsher-Smith raised prices on June 7, 2013, roughly doubling its prior WAC prices, a decision it would not have made unless it had pre-existing knowledge that the others would quickly match, as they did. Sandoz matched Upsher-Smith's WAC prices on July 26, 2013, which also resulted in significant increases, including a 130% increase over its prior WAC price for 4gm Powder. On August 27, 2013, Par also matched Defendants' pricing, causing as much as a fourfold increase in its prior WAC prices.

533. [REDACTED]

534. Pursuant to Defendants' agreement, their price increases had no significant impact of their respective market shares. Par and Sandoz roughly split the market with Upsher-Smith having a small but steady market share after its entry.

535. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including Par, Sandoz, and Upsher-Smith. Defendant Teva identified both Par and Sandoz in this timeframe as "quality" competitors, *i.e.*, competitors willing to coordinate price increases under the Fair Share Agreement. Defendants' coordination included raising Cholestyramine prices.

536. The ability of Par, Sandoz, and Upsher-Smith to reach agreement regarding Cholestyramine was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

537. [REDACTED]

538. The agreement between Defendants Par, Sandoz, and Upsher-Smith was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Cholestyramine Powder (4 gm) and Oral Solids (4 gm).

31. Ciclopirox

539. Ciclopirox is a commonly prescribed antifungal medication that has been on the United States market for decades and is available in several forms, including a Cream (0.77%) and a Shampoo/Liquid/Solution (1%, 8%).

540. The market for Ciclopirox is mature. At all relevant times, there have been multiple manufacturers of Ciclopirox.

541. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Ciclopirox Cream at least as early as February 2012, Shampoo/Liquid at least as early as September 2012, and Liquid/Solution at least as early as April 2013.

542. In January 2012, Perrigo and Glenmark were the only manufacturers of Ciclopirox Cream. G&W, however, planned to enter the market. To facilitate its entry into the market, and to gain a Fair Share, G&W communicated by phone with Perrigo and Glenmark.

543. In February and April of 2012, Kurt Orlofski, G&W's President, communicated by phone multiple times with S.K, Perrigo's General Manager and Executive Vice President.

544. Similarly, in March of 2012, Erika Vogel-Baylor, G&W's Vice President of Sales, communicated with P.D., Glenmark's Executive Vice President, after meeting at a trade event. Throughout the month of March, Vogel-Baylor and P.D. exchanged dozens of communications to coordinate pricing, including the price for Ciclopirox Cream.

545. In April 2012, G&W's Orlofski and Vogel-Baylor, Perrigo's S.K., and Glenmark's P.D. convened at the NACDS annual meeting in Palm Beach, Florida. After the meeting and throughout the month of April, the four continued to communicate with each other over the phone.

546. These communications continued through the summer of 2012, and that summer G&W, Glenmark, and Perrigo were able to raise prices for Ciclopirox Cream while maintaining a Fair Share of the market.

547. To facilitate another price increase the following year, Glenmark's P.D. and Jim Brown, Glenmark's Vice President of Sales, exchanged several phone calls with G&W's Vogel-Baylor. Vogel-Baylor also relayed messages to T.P., Perrigo's Director of National Accounts, through A.T., Aurobindo's Director of National Accounts.

548. In May 2013, G&W, Glenmark, and Perrigo successfully coordinated another price increase on Ciclopirox Cream.

549. As a result of the agreement and anticompetitive coordination between G&W, Glenmark, and Perrigo, prices for Ciclopirox Cream were higher than they would have been in a competitive market.

550. Defendants Perrigo, Actavis, Taro, and Sandoz were the primary manufacturers of Ciclopirox Shampoo/Liquid.

551. In the summer of 2012, Perrigo, Actavis, and Taro were the three manufacturers of Ciclopirox Shampoo. Sandoz had exited the market in 2011, but planned to reenter in July 2012.

552. To facilitate Sandoz's reentry into the Ciclopirox Shampoo market, Actavis, Perrigo, Taro, and Sandoz started communicating.

553. In September 2012, C.B., Sandoz's Director of National Accounts, communicated by phone with Perrigo's T.P. and H.M., Taro's Director of Corporate Accounts, to coordinate Sandoz's reentry.

554. In November 2012, Sandoz's C.B. made multiple phone calls to Ara Aprahamian, Actavis's Vice President of Sales and Marketing, to coordinate on Ciclopirox Shampoo. C.B. also continued communicating with Perrigo's T.P. in November to coordinate pricing and market share for Ciclopirox Shampoo.


555. Sandoz reentered the Ciclopirox Shampoo market in early December 2012. The week of Sandoz's reentry, C.B. communicated with Actavis's Aprahamian. Meanwhile, Perrigo's T.P. communicated by phone directly with M.D., Actavis's Director of National Accounts. C.B. also communicated with Taro's H.M. in mid-December 2012. During these communications, the companies discussed pricing and market share, including which customers Sandoz would target.

556. The communications between Perrigo, Actavis, Taro, and Sandoz facilitated Sandoz's successfully reentry into the Ciclopirox Shampoo market, and its quick attainment of its Fair Share, as it had agreed with Actavis, Perrigo, and Taro.

557. As a result of the agreement and anticompetitive coordination between Perrigo, Actavis, Taro, and Sandoz, prices for Ciclopirox Shampoo were higher than they would have been in a competitive market.

558. Defendants Akorn, G&W, and Perrigo were the primary manufacturers of Ciclopirox Dermatological Liquid.

559. For many years the price of Ciclopirox remained stable. However, prices began to rise dramatically [REDACTED], as illustrated below:



560. Defendants’ WAC pricing also rose in a coordinated fashion. G&W and Akorn announced new pricing on May 9, 2013 and May 10, 2013 respectively, which doubled and tripled their prior WAC prices for Ciclopirox. Perrigo also substantially increased its WAC price on August 1, 2013.

561. [REDACTED]

562. Pursuant to Defendants’ agreement, their price increases had no significant impact of their respective market shares. G&W and Akorn roughly split the market with Perrigo having a small but steady market share.

563. The GAO found that Ciclopirox had “extraordinary price increases” in 2013-2014.

564. The ability of Actavis, Akorn, G&W, Glenmark, Perrigo, Sandoz, and Taro to reach agreement regarding Ciclopirox was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

565. [REDACTED]

566. The agreement between Defendants Actavis, Akorn, G&W, Glenmark, Perrigo, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Ciclopirox Cream (0.77%), a Shampoo (1%), and a Dermatological Liquid (8%).


32. Cimetidine

567. Cimetidine is a medication used to ulcers. It is available in a Tablet formulation. It has been available in the United States in a generic form for many years.

568. The market for Cimetidine is mature. At all relevant times, there have been multiple manufacturers of Cimetidine.

569. During the relevant time frame, Defendants Mylan and Teva were the primary manufacturers of Cimetidine.

570. Beginning in the summer of 2012, Teva and Mylan began steady and coordinated price increases for Cimetidine.



571. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

572. Throughout this period, Teva and Mylan met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreement on Cimetidine Tablets and of their Fair Share Agreement.

573. For example, in order to coordinate the pricing of their products, including Cimetidine tablets, Teva's Green spoke to Jim Nesta at Mylan on May 7, 2013 three times. Green and Nesta also spoke a number of times over the next several days, including on May 8, May 9, and May 10, 2013. On May 17, 2013, Green spoke to Nesta six (6) times.

574. Meanwhile, Teva's Patel—who was receiving regular updates from Green—expressed the expectation that Mylan would soon be raising prices on Cimetidine and was preparing Teva to do the same. Both manufacturers did raise prices.

575. As Mylan and Teva imposed price increases for Cimetidine, they were careful to maintain Fair Share and not to disrupt pricing or steal customers. To that end, Teva and Mylan continued to communicate throughout this period. For example, on May 9, 2014, Teva's Rekenthaler and Nesta at Mylan spoke for nearly eight (8) minutes. Rekenthaler and Nesta spoke again on May 20 and 27, 2014. The two spoke several more times that summer, including at least on August 4, 7, 11, 18, and 21, 2014 in order to coordinate the prices of Cimetidine and other drugs.

576. The coordination by Mylan and Teva is consistent with the Fair Share Agreement.

577. The agreement between Defendants Mylan and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Cimetidine Tablets.

33. Clarithromycin

578. Clarithromycin is an antibiotic used to treat bacterial infections affecting the skin and respiratory system. It is available in, for example, Tablet ER and Suspension formulations. It has been available in the United States for over a decade in a generic form. Due to, among other things, its clinical efficacy and safety, Clarithromycin has been designated as an essential medicine by the World Health Organization.

579. The market for Clarithromycin is mature. At all relevant times, there have been multiple manufacturers of Clarithromycin.

580. Defendants Actavis and Teva dominate sales of Clarithromycin Tablets ER and had [REDACTED]

581. [REDACTED]

[REDACTED]

[REDACTED]

582. [REDACTED]

[REDACTED] The GAO noted that Clarithromycin had “extraordinary price increases” in the years 2011-2012.

583. [REDACTED]

584. The ability of Actavis and Teva to reach agreements on Clarithromycin Tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

585. [REDACTED]

586. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.



587. The agreement between Defendants Actavis and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Clarithromycin Tablets ER.



34. Clindamycin Phosphate

588. Clindamycin Phosphate is an antibiotic used to treat certain types of bacterial infections such as middle ear infections, vaginal infections, and acne. It is available in, for example, Lotion (1%), Gel (1%), Vaginal Cream (2%), and Solution (1%) formulations. It has been available in the United States for decades in a generic form.

589. The market for Clindamycin Phosphate is mature. At all relevant times, there have been multiple manufacturers of Clindamycin Phosphate.

590. Defendants Actavis, Greenstone, Perrigo, Sandoz, and Taro dominate sales of Clindamycin Phosphate. Greenstone and Sandoz dominate sales of Clindamycin Phosphate 1% Lotion, 1% Gel, and 2% Vaginal Cream. During much of the relevant time period, Greenstone and Sandoz had a roughly 60/40 split on the Lotion and Vaginal Cream/Gel. Greenstone and Sandoz had a roughly 50/50 split on the Clindamycin Phosphate Gel. On the Liquid Solution, Greenstone had a majority share, and Sandoz, Perrigo, Taro, and Teva had smaller shares.





592. The GAO noted that Clindamycin Phosphate had extraordinary price increases in the years 2012-2014.

[REDACTED]

[REDACTED] Under the Fair Share Agreement, Defendants did not attempt to undercut competitors' prices in order to gain additional market share. For example, in December 2012, after he heard that Greenstone took a price increase on Clindamycin, Armando Kellum of Sandoz wrote to colleagues at Sandoz and said, "[REDACTED]."

594. The ability of Actavis, Greenstone, Perrigo, Sandoz, and Taro to reach agreements regarding Clindamycin Phosphate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

[REDACTED]

[REDACTED]

596. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

597. The agreement between Defendants Actavis, Greenstone, Perrigo, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Clindamycin Phosphate Lotion (1%), Gel (1%), Vaginal Cream (2%), and Solution (1%).

35. Clonidine TTS

598. Clonidine TTS Patch, also known by the brand name Catapres-TTS, is a medication in the form of a transdermal patch that is used to treat high blood pressure. It has been available in the United States in a generic form for many years.

599. The market for Clonidine TTS is mature. At all relevant times, there have been multiple manufacturers of Clonidine TTS.

600. During the relevant time frame, Defendants Teva and Mylan were the primary manufacturers of Clonidine-TTS. Defendant Actavis joined the Clonidine-TTS market and the Clonidine-TTS conspiracy in 2014.

601. Teva and Mylan had [REDACTED], as contemplated by their Fair Share Agreement. Mylan, however, encountered some supply disruptions that skewed market share in favor of Teva. In order to navigate and reallocate the market, Teva and Mylan communicated frequently to ensure that each of them had a Fair Share.

602. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Clonidine-TTS beginning at least as early as the fall of 2011.

603. For example, in early 2012, after the first of Mylan's supply issues were resolved, Teva conceded two large customers to Mylan to help it regain its Fair Share.

604. In May, not long after ceding the Clonidine-TTS business to Mylan, Teva was approached by another large customer seeking bids on a different drug, Doxazosin. Teva declined the opportunity to the Doxazosin business in an effort to "be cautious after what happened with Clonidine."

605. Later in 2012, Mylan again experienced supply disruptions, this time severe enough to force it out of the market entirely on certain dosages from approximately September 2012 through February 2013. To coordinate how to deal with this, on September 28, 2012, Mylan's Nesta and Teva's Green spoke by phone at least twice. Mylan and Teva maintained regular contact as former Mylan customers approached Teva because of Mylan's supply issues.

For example, Teva's Rekenthaler spoke to a contact at Mylan on October 1, and Green spoke to Nesta on October 1 and 4, 2012. On October 10, 2012, Green and Nesta spoke again.

606. When Mylan relaunched Clonidine-TTS in early 2013, Teva conceded accounts to Mylan to allow it to regain a Fair Share of the market. For example, Teva's internal documents state that they chose to "concede" a number of large customers to Mylan. Teva's internal documents are explicit that it had no intention of competing on price, but instead was "trying to concede the Clonidine business" to Mylan.

607. Teva and Mylan remained in regular contact in order to coordinate and maintain Fair Shares. In February and March 2013 alone, Teva and Mylan representatives called each other at least 33 different times.

608. In the spring of 2014, another manufacturer, Actavis, was preparing to enter the market for Clonidine-TTS. Teva and Actavis immediately commenced an extensive negotiation with Actavis over price and market share. Teva's Rekenthaler and Actavis's Falkin were in direct phone contact to hammer out the details. Teva considered which customers to concede, and encouraged Actavis to enter the market with high prices.

609. Teva's Patel also communicated with Actavis to work out the details of Actavis's entry into the market. She spoke with Actavis's Rogerson multiple times, learning that Actavis wanted 25% of the market and expected that 10%-15% of its share would come from Teva.

610. Teva's Rekenthaler expressed his view that Actavis could have no more than a 15% market share from Teva, which prompted a Teva executive to admonish Rekenthaler to "play nice in the sand box" so that Actavis would be "responsible in the market."

611. Rekenthaler heeded the advice and Teva conceded share to Actavis in order to allow it to gain its Fair Share of the market for Clonidine-TTS.

612. The ability of Teva, Mylan and Actavis to reach agreements on Clonidine-TTS was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

613. The coordination among Teva, Mylan, and Actavis is consistent with the Fair Share Agreement.

614. The agreement between Defendants Teva, Mylan and Actavis was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including the Clonidine-TTS Patch.

36. Desmopressin Acetate

615. Desmopressin Acetate, also known by the brand names Concentraid, DDAVP, and Stimate, is an antidiuretic agent used in the treatment of central diabetes insipidus and is available as a Tablet. It has been available in the United States in a generic form for many years.

616. The market for Desmopressin Acetate is mature. At all relevant times, there have been multiple manufacturers of Desmopressin Acetate.

617. During the relevant time frame, Teva and Actavis were the primary manufacturers of Desmopressin Acetate Tablets.

618. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Desmopressin Acetate tablets beginning at least as early as the summer of 2014.

619. In August 2014, Teva increased prices on Desmopressin Acetate Tablets, along with a number of other drugs. In the lead up and follow-up to the price increases, Teva was in

frequent contact with other drug manufacturers to coordinate price increases and Fair Shares. Actavis, which was the only other manufacturer of Desmopressin Acetate, was no exception.

620. On October 15, 2014, Teva received a request from a customer asking Teva to reduce prices for Desmopressin Acetate. Teva's Patel—who already knew that Actavis would be raising prices—responded to the customer by declining to lower the price with the explanation: “[w]e believe the market is still settling on this product.”

621. On December 19, 2014, Actavis followed Teva's price increase on Desmopressin Acetate, announcing identical list (WAC) prices.

622. Leading up to Actavis's price increase, Rekenhaller of Teva and Falkin of Actavis spoke frequently, including calls on November 18, November 21, and November 25, 2014.

623. The ability of Teva and Actavis to reach agreements on Desmopressin Acetate Tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

624. The coordination between Teva and Actavis is consistent with the Fair Share Agreement.

625. The agreement between Defendants Teva and Actavis was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rid bids, and engage in market and customer allocation for generic drugs, including Desmopressin Acetate Tablets.

37. Desonide (Lotion 0.05%)

626. Desonide is a topical steroid that treats a variety of skin conditions, including eczema, dermatitis, allergies, and rash. It is available in a Lotion formulation, among others

previously sued on in individual drug complaints. Desonide has been available in the United States in a generic form for many years.

627. The market for Desonide Lotion is mature. At all relevant times, there have been multiple manufactures of Desonide Lotion.

628. During the relevant timeframe, Defendants Actavis and Sandoz were the primary manufacturers of Desonide Lotion.

629. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Desonide Lotion as early as the summer of 2011.

630. Between 2009 and 2011, Defendants Actavis and Sandoz were the only two generic manufacturers of Desonide Lotion. In July of 2011, Actavis instituted a list (WAC) price increase, which Sandoz followed three days later.

631. Following the price increases, and consistent with the Fair Share Agreement, Actavis and Sandoz declined opportunities to bid on each other's business and gain market share, choosing not to take advantage of the price increases.

632. As of August 2012, the market for Desonide Lotion was relatively evenly split between the two competitors.

633. On August 23, 2012, Sandoz began to prepare a price increase on Desonide Lotion.

634. Between August 25 and August 28, 2012, representatives from Actavis and Sandoz attended the NACDS Pharmacy and Technology Conference in Denver Colorado. Among those in attendance were C.B. and Armando Kellum of Sandoz, and Ara Aprahamian of Actavis.

635. At the Conference, Aprahamian approached C.B. and told him that Actavis was having supply issues on Desonide Lotion 118ml, and would be exiting the market for a period of time. C.B. passed this information along to Kellum, who he knew was interested in raising the price of Desonide Lotion and would view Actavis's temporary exit from the market as an opportunity.

636. As Sandoz prepared to increase its prices for Desonide Lotion, it internally concluded that Actavis would follow any Sandoz price increase.


637. In October 2012, Sandoz's C.B. exchanged several phone calls with Actavis's Aprahamian. After confirming that Sandoz could continue to supply Desonide Lotion, Sandoz generated a price increase analysis for the product.

638. On December 5, 2012, Sandoz instituted a Desonide Lotion list (WAC) price increase. On the day of the price increase, C.B. called Aprahamian twice to keep him apprised of the details of Sandoz's increase.

639. Several months later, on May 20, 2013, Sandoz again increased the list (WAC) price for Desonide Lotion.

640. On August 22, 2013, Actavis reentered the Desonide Lotion 118ml market and matched Sandoz's increased pricing for both Desonide Lotion 59ml and 118ml. On the same day, A.G., a sales executive at Actavis, sent C.B. a text message.

641. The chart below illustrates Actavis, Sandoz, and Taro's 



642. [REDACTED]

643. When Sandoz learned that Actavis had reentered the market, Sandoz’s Kellum suggested they relinquish market share to Actavis, instead of lowering prices to remain competitive. In the following months, Sandoz relinquished several customers to Actavis. The same pattern played out when Taro entered the market.

644. As a result of the agreement and anticompetitive coordination between Actavis, Sandoz, and Taro, prices for Desonide Lotion were higher than it would have been in a competitive market.

645. The ability of Actavis, Sandoz, and Taro to reach agreements on Desonide Lotion was aided by the prevalence of trade association meetings and conferences where the parties

were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

646. The coordination between Actavis, Sandoz, and Taro is consistent with the Fair Share Agreement.

647. The agreement between Defendants Actavis, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Desonide Lotion.

38. Desoximetasone

648. Desoximetasone is a corticosteroid used to treat a variety of skin conditions, including eczema and dermatitis. It is available in several forms, including an Ointment (0.25%). Desoximetasone has been available in the United States in a generic form for many years.

649. The market for Desoximetasone is mature. At all relevant times, there have been multiple manufacturers of Desoximetasone.

650. During the relevant timeframe, Defendants Taro, Sandoz, and Glenmark were the primary manufacturers of Desoximetasone.

651. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Desoximetasone as early as August 2012.

652. In 2012, Taro was the exclusive manufacturer of Desoximetasone. In August 2012, however, Sandoz began making plans to enter the market.

653. To facilitate Sandoz's entry into the Desoximetasone market, and to allow it to gain its Fair Share, Sandoz and Taro began sharing information about pricing, and coordinating to divide the market for Desoximetasone.

654. For example, in August 2012, K.K., Sandoz's Senior National Account Executive, spoke with D.S., Taro's Assistant Vice President of National Accounts, over the phone two times. Using the information K.K. learned during those two calls, Sandoz devised its pricing strategy for Desoximetasone, and decided to target certain customers in a way that was consistent with the Fair Share Agreement.

655. C.B., a Sandoz Director of National Accounts, also spoke multiple times with H.M., Taro's Director of Corporate Accounts. The two discussed pricing, and which customers Sandoz should target for Desoximetasone.


656. Sandoz announced pricing for Desoximetasone in late September 2012, and matched Taro's list (WAC) pricing.

657. In October 2012, Sandoz's C.B. and Taro's H.M. continued to communicate by phone. Sandoz began targeting customers for Desoximetasone to acquire its Fair Share, and, consistent with the Fair Share Agreement, Taro relinquished those customers.

658. In September 2013, Glenmark prepared to enter the Desoximetasone market. To facilitate Glenmark's entry into the market, Glenmark, Sandoz, and Taro began coordinating to make sure each company would have a Fair Share of the market without eroding prices.

659. Mitchell Blashinsky, Glenmark's Vice President of Sales and Marketing—who was a former Taro employee—joined web communications with representatives from Sandoz and Taro. In August and September 2013, Blashinsky spoke with Taro's Aprahamian, Perfetto, and D.S. Blashinsky also spoke with Sandoz's C.B. multiple times. Representatives of Taro and Sandoz also communicated with each other: Taro's Aprahamian spoke with Sandoz's C.B., and Taro's D.S. spoke with Sandoz's D.L.

660. Taro, Sandoz, and Glenmark's parallel pricing strategy is illustrated in the chart below:



661. In keeping with the Fair Share Agreement, Taro and Sandoz ceded customers to Glenmark, so that Glenmark could obtain its Fair Share of the Desoximetasone market.

662. For example, when a customer approached Taro about Desoximetasone in November 2012, Taro declined to pursue the opportunity, not because the account would not have been profitable, but because Taro already had a Fair Share of the market. Internally, Taro explained that "[REDACTED] [REDACTED]"

663. As a result of the agreement and anticompetitive coordination between Glenmark, Sandoz, and Taro prices for Desoximetasone were higher than they would have been in a competitive market.

664. The ability of Glenmark, Sandoz, and Taro to reach agreements on Desoximetasone Ointment, was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

665. The coordination by Glenmark, Sandoz, and Taro on Desoximetasone Ointment, is consistent with the Fair Share Agreement.

666. The agreements between Defendants Glenmark, Sandoz, and Taro, were part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Desoximetasone Ointment (0.25%).

39. Dexmethylphenidate HCL

667. Dexmethylphenidate HCL, also known as Dexmeth ER or by the brand name Focalin, is a muscle relaxant used to treat attention deficit hyperactivity disorder (ADHD). It has been available in the United States in a generic form for many years, and is available in, for example, ER Capsule (5, 15, 20, 40 mg) formulation.

668. The market for Dexmeth ER is mature. At all relevant times, there have been multiple manufacturers of Dexmeth ER. During the relevant time frame, Teva, Sandoz, and Par were the primary manufacturers of Dexmeth ER.

669. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Dexmeth ER Capsules beginning at least as early as February 2014.

670. In February 2014, Sandoz was preparing to enter the market for Dexmeth ER. To coordinate, Teva's Patel spoke frequently with the Associate Director of Pricing at Sandoz about how to divide the market in order to permit Sandoz to obtain a Fair Share.

671. Following multiple conversations between Patel and her contact at Sandoz, Teva conceded two large customers to Sandoz. As Patel explained in a February 12 internal email reflecting the understanding reached between Teva and Sandoz, "Sandoz is being responsible with their pricing. We should be responsible with our share."

672. Around the same time, on February 14, 2014, Teva also refused to lower its price for Dexmeth ER when approached by yet another large customer, thereby conceding the business to Sandoz.

673. On February 20, 2014, another large retail customer approached Teva seeking price protection terms. Patel spoke to the Associate Director of Pricing at Sandoz that same day, and the next day, internal emails indicated that Patel had inside information about Sandoz's plans for Dexmeth ER.

674. Par also abided by the Fair Share Agreement when Sandoz entered, and when faced with a decision to cede share, "gave up the business to keep the market share even."

675. Again, to coordinate Fair Share, Rekenhler of Teva was speaking to the Vice President of National Accounts at Par, right around the same time that Patel had been speaking to Sandoz Associate Director of Pricing, to confirm their agreement.

676. In May 2015, Teva again passed on an opportunity to sell more than its Fair Share of Dexmeth ER. It declined to bid for the Dexmeth ER business with a large customer, because "there is equal share in the market between competitors."

677. Similarly, in June 2015, Sandoz declined to bid on Dexmeth ER business because it already had more than its Fair Share. When a Sandoz national account representative communicated the decision to the customer, he misrepresented the reason, falsely explaining that the decision not to bid was based on limited supply. In fact, it was because of the Fair Share Agreement between Teva, Sandoz and Par.

678. As a result of the agreement and anticompetitive coordination between Teva, Sandoz, and Par, prices for Dexmeth ER were higher than they would have been in a competitive market.

679. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

680. The ability of Teva, Sandoz, and Par to reach agreements on Dexmeth ER was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

681. The agreement between Defendants Teva, Sandoz, and Par was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Dexmeth ER Capsules (5, 15, 20, 40 mg).

40. Dextroamphetamine Sulfate

682. Dextroamphetamine Sulfate, also known as Dex Sulfate or by the brand name Dexedrine, among others, is a medication used to treat attention deficit hyperactivity disorder (ADHD). It has been available in the United States in a generic form for many years, and is available in a Capsule (ER) and Tablet (ER) formulation.

683. During the relevant time frame, Defendants Teva, Impax, Mallinckrodt and Actavis were the primary manufacturers of Dextroamphetamine Sulfate Capsules (ER).

684. Teva, Mallinckrodt, and Aurobindo were the primary manufacturers of Dextroamphetamine Sulfate Tablets (ER).

685. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Dextroamphetamine Sulfate Tablets and Capsules beginning at least as early as the summer of 2011.

686. For years, Teva was effectively the sole supplier of Dextroamphetamine Sulfate Capsules and Tablets. Mallinckrodt, which had been a supplier, exited both in late 2008. Without competitive pressure to keep prices low, Teva slowly and steadily raised prices. Eventually, however, both Capsules and Tablets attracted additional manufacturers. Typically, this would have driven prices lower; the addition of suppliers tends to spur price competition which drives down prices. Here, however, because of Defendants' Fair Share Agreement, the addition of suppliers to the market caused the prices of Dextroamphetamine Sulfate Capsules and Tablets to rise.

687. As to Capsules, Impax was the first competitor to enter in the fall of 2011. In anticipation of Impax's entry, Teva announced a large list (WAC) price increase in August 2011. Teva immediately raised the prices it charged customers, [REDACTED]. When Impax entered the market, rather than offer lower prices to win customers, it matched Teva's market prices. Impax did not announce list (WAC) prices until later, but when it did so, they were even higher than Teva's.

688. Similarly, when Mallinckrodt re-entered with Capsules in the summer of 2012, it did so at the high prices that Teva and Impax already had coordinated. Even before it began

shipping product, Mallinckrodt announced list (WAC) prices in April 2012 that matched Teva's, and which were more than five times higher than Mallinckrodt's former prices for Dextroamphetamine Sulfate Capsules.

689. Not long after Mallinckrodt entered with Capsules, it also re-launched its Tablets. The same pattern as Capsules followed. In anticipation of Mallinckrodt's entry, Teva drastically increased its prices. At the end of July 2012, Teva increased its list (WAC) prices on Tablets by more than 800%. Within weeks, Mallinckrodt matched the price increase. As it had done with Capsules, rather than offer lower prices to win customers, Mallinckrodt coordinated with Teva to impose higher prices.

690. In 2014, Actavis joined with Capsules and Aurobindo joined with Tablets. Like Mallinckrodt and Impax before them, they eschewed price competition and instead announced identical list (WAC) prices as Teva and Mallinckrodt. Adding yet more suppliers of Capsules and Tablets did not drive prices back down to a competitive level. Instead, the Fair Share Agreement kept prices high.

691. Throughout this period, Defendants monitored their Fair Share Agreement, and made sure to cede share where necessary to keep prices high. For example, in January 2013, Teva was confronted with a request for pricing from a large customer that had been approached by Mallinckrodt. This prompted Teva to assess Fair Shares of Tablets. Teva's David Rekenhaller pointed out that Teva was expecting to cede share to Mallinckrodt: [REDACTED]

[REDACTED]

[REDACTED] Teva's

Director of Marketing responded, [REDACTED]

[REDACTED] Ultimately, however, Teva's Senior Director of Sales signed

off, [REDACTED] By ceding customers, Teva ensured that each manufacturer obtained a Fair Share of the market, and all manufacturers ensured that prices for Dextroamphetamine Sulfate remained high.

692. Similarly, in February 2014, Teva again recognized the need to walk away from business in order to maintain Fair Shares and higher prices. In an internal analysis describing Dextroamphetamine Sulfate, Teva noted: [REDACTED]


[REDACTED]



The underlying premise of the Fair Share Agreement—less sales but higher prices—continued to work throughout the period. That same month, Teva confirmed in an internal document [REDACTED]

[REDACTED]

[REDACTED]

693. The NSP price chart and list (WAC) price chart below highlight the large and sustained price increases for Dextroamphetamine Sulfate.





694. Throughout this period, Teva, Mallinckrodt, Impax, Actavis and Aurobindo met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreement on Dextroamphetamine Sulfate and of the Fair Share Agreement.

695. For example, representatives from Teva and Impax attended the NACDS 2011 Pharmacy & Technology Meeting in Boston from August 27 to 30, 2011, shortly before Impax entered with Capsules in September 2011 at the inflated prices that Teva had recently imposed.

696. Similarly, representatives of Mallinckrodt and Teva attended the HDMA 2012 Business and Leadership Conference in San Antonio on June 13, 2012, not long before Teva announced list (WAC) price increases on Tablets in July that Mallinckrodt quickly followed.

697. Defendants also communicated directly with each other by phone to coordinate pricing. For example, in January and February 2014—when Aurobindo was entering with Tablets—Teva’s Rekenhaller spoke to R.C., the CEO of Aurobindo multiple times.

698. Teva’s Rekenhaller also coordinated with Actavis when it entered with Capsules that year. On June 19, 2014, as Actavis was entering the market, Rekenhaller spoke twice with Falkin of Actavis, and they discussed Actavis’s market share goal of “20-25%.” Actavis entered not long after, and, as contemplated by the Fair Share Agreement between them, Teva conceded a large Dextroamphetamine Sulfate customer to Actavis. Meanwhile (on June 13, 20, 23, and 26), Falkin (Actavis) communicated by phone with T.E., Impax’s Senior Director of Sales Operations.

699. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

700. The ability of Teva, Mallinckrodt, Impax, Actavis and Aurobindo to reach agreements on Dextroamphetamine Sulfate Capsules and Tablets was aided by the prevalence of

trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

701. The coordination by Teva, Mallinckrodt, Impax, Actavis, and Aurobindo is consistent with the Fair Share Agreement.

702. The agreement between Defendants Teva, Mallinckrodt, Impax, Actavis and Aurobindo was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, Dextroamphetamine Sulfate Capsules (ER) and Tablets (ER).

41. Diclofenac Potassium

703. Diclofenac Potassium, also known by the brand name Cataflam, among others, is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and swelling. It is available as a Tablet and has been available in the United States in a generic form for many years.



704. The market for Diclofenac Potassium was mature and at all relevant times had multiple manufacturers.

705. During the relevant time frame, Defendants Teva, Mylan, and Sandoz were the primary manufacturers of Diclofenac Potassium Tablets.

706. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Diclofenac Potassium beginning at least as early as the fall of 2012.

707. For years, the prices for Diclofenac Potassium tablets were relatively low and stable. In late 2012, however, Mylan, Teva and Sandoz began a series of coordinated price increases that resulted in list (WAC) prices nearly double the prior levels, and [REDACTED]

[REDACTED].



708. Throughout this period, Mylan, Teva, and Sandoz met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreements on Diclofenac Tablets and their Fair Share Agreement.

709. For example, on August 9, 2013, Teva raised its list price on Diclofenac Potassium to match that of Mylan. [REDACTED]

[REDACTED] but had not yet raised its list price.

710. As with numerous other drugs during this period, Teva coordinated with Mylan and Sandoz before announcing a price increase. For example, Green of Teva spoke to Nesta of Mylan on August 1 (two times), August 2, August 6 (three times), and August 8 (three times), 2013. The day before the price increase went into effect – August 8, 2013, Teva’s Patel called Nesta of Mylan twice and also called a contact at Sandoz.

711. On August 28, 2014, Teva again raised list prices on Diclofenac Potassium Tablets. This time it was the first manufacturer to increase prices. Leading up to the price increase, Teva’s Patel and Rekenhaller were communicating with Mylan and Sandoz to coordinate. For example, Rekenhaller spoke to Nesta on August 4, 7, 11 (2 calls), 18 (2 calls), and 21. Patel spoke to a contact at Sandoz on August 11, 26, 27 (2 calls), and 28, 2014.

712. The coordination worked. Sandoz followed Teva’s price increases on Diclofenac Potassium Tablets and announced an identical list price approximately 6 weeks later. Mylan followed, also matching Teva and Sandoz’s list prices, on March 4, 2015. Rekenhaller coordinated with Nesta of Mylan during two phone calls on February 18 and one call on February 19, 2015.

713. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

714. The ability of Teva, Mylan, and Sandoz to reach agreements on Diclofenac Potassium tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

715. [REDACTED]

716. The agreements between Mylan, Teva, and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Diclofenac Potassium Tablets.

42. Diltiazem HCL

717. Diltiazem HCL, also known by the brand name Cardizem, among others, is a medication to treat angina (severe chest pain) or hypertension (high blood pressure). It is available as a Tablet (30, 60, 90, 120 mg) and has been available in the United States in a generic form for many years.

718. The market for Diltiazem HCL Tablets was mature and at all relevant times had multiple manufacturers. During the relevant time frame, Defendants Teva and Mylan were the primary manufacturers of Diltiazem HCL Tablets (30, 60, 90, 120 mg).


719. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Diltiazem HCL beginning at least as early as the spring of 2013.

720. For years, the prices for Diltiazem HCL tablets were relatively low and stable. In the spring of 2013, however, Teva and Mylan imposed a series of coordinate price increases, first in mid-2013, then again in late 2014 and early 2015. By January 2015, Teva and Mylan list

(WAC) prices [REDACTED] were nearly three times higher than they were before the collusive price increases.

721. The NSP price chart below shows [REDACTED]

[REDACTED]



722. Throughout this period, Mylan and Teva met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreement on Diltiazem HCL Tablets and of their Fair Share Agreement.

723. For example, immediately after she began at Teva, Patel began to investigate Mylan drugs as a potential source for coordinated price increases. She asked her colleague, Kevin Green, to “gather as much market intelligence as possible” for certain, specific items, including Diltiazem HCL Tablets.

724. On, May 7, 2013, Teva's Green spoke to Nesta at Mylan three times. Green and Nesta also spoke a number of times over the next several days, including on May 8, May 9, and May 10, 2013.

725. On May 14, 2013, Patel asked several Teva account managers, including Green, to obtain "price points" on certain drugs in preparation for a potential price increase. She indicated internally to another Teva colleague that she was expecting "additional Mylan intel" and that she was expecting Mylan "to take an additional increase" on those items. On May 17, 2013, Green spoke to Nesta six times.

726. Green communicated extensively with Mylan to coordinate the price increases. For example, on July 10, 2013, Green and Mylan's Nesta spoke twice. Shortly after the second call, Green called Patel, and the two spoke for just over seven (7) minutes. The next day, on July 11, Nesta and Green exchanged several more calls.

727. Patel and Green coordinated the increase with Mylan in the days and weeks leading up to the increase. For example, Green spoke to Nesta (Mylan) twice on August 1, once on August 2 and three times on August 6.

728. The day before the price increase went into effect – August 8, 2013 – Patel had three calls with Nesta of Mylan, and on August 9, 2013, Teva raised prices on numerous drugs, including Diltiazem HCL.

729. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

730. The ability of Teva and Mylan to reach agreements on Diltiazem HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

731. [REDACTED]

[REDACTED]

732. The agreement between Defendants Teva and Mylan was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Diltiazem HCL Tablets (30, 60, 90, 120 mg).

43. Diphenoxylate Atropine HCL

733. Diphenoxylate Atropine is a combination medicine used to treat diarrhea. It is available in Tablet and Oral Liquid formulations. It has been available in the United States for decades in a generic form.


734. The market for Diphenoxylate Atropine is mature. At all relevant times, there have been multiple manufacturers of Diphenoxylate Atropine.

735. Defendants Greenstone and Mylan dominate sales of Diphenoxylate Atropine Tablets (2.5-0.025 mg). During much of the relevant time period, Mylan had approximately 75% of the market, and Greenstone had approximately 25% of the market.

736. [REDACTED]

[REDACTED]

[REDACTED]



737. The GAO noted that the Diphenoxylate Atropine had “extraordinary price increases” in the years 2014-2015.

738. [REDACTED]

739. The ability of Greenstone and Mylan to reach agreement regarding Diphenoxylate Atropine was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

740. [REDACTED]

741. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

742. The agreement between Defendants Greenstone and Mylan was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Diphenoxylate Atropine Tablets (2.5-0.025mg).

44. Doxazosin Mesylate and Etodolac


743. Doxazosin Mesylate is a commonly prescribed medication for the treatment of high blood pressure and the symptoms of benign prostatic hyperplasia (*i.e.*, enlarged prostate gland). It has been available in the United States for decades and is one of the 200 most prescribed drugs in the United States. Doxazosin Mesylate Tablets are available in 1 mg, 2 mg, 4 mg, and 8 mg dosage strengths.

744. The market for Doxazosin Mesylate is mature. At all relevant times, there have been multiple manufacturers of Doxazosin Mesylate. Defendants Apotex, Mylan, and Teva dominated sales of Doxazosin Mesylate. Greenstone and Par also sell Doxazosin Mesylate and together with Apotex, Mylan, and Teva [REDACTED]

[REDACTED].

745. [REDACTED]

[REDACTED]:



746. The GAO noted that all four dosage strengths of Doxazosin Mesylate had an “extraordinary price increase.” Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including Apotex, Greenstone, Mylan, Par, and Teva.

747. As explained above, Mylan was Teva’s highest-ranked competitor by “quality.” Teva is also known to have viewed at least Apotex and Greenstone as “high quality” competitors.

748. For years Mylan and Teva were highly conscious of their respective shares in the Doxazosin Mesylate market and generally dared not cross each other. For example, on May 7, 2012, when Dale Hill at Cardinal Health asked if Teva had any interest in becoming its primary supplier, the first response of Teva’s K.G. (Senior Director of Marketing) was to ask his colleague T.C. (Senior Director of National Sales): “Is Mylan having problems? The market is primarily supplied by Teva (76%) and Mylan (22%).” T.C. reported back that Mylan was

“having [an] issue on the 4mg backordered until 6-30,” but Cardinal Health wanted “to move the entire line.” K.G. responded: “We will need to be cautious after what happened with Clonidine. I would rather cover them on a short-term basis where they have an issue and revisit if [it] becomes a more prolonged and extensive event.” The Clonidine incident references a rare and brief incidence of competition between Teva and Mylan in late 2011 and early 2012 for market share of Clonidine-TTS, which ended first with Teva conceding its “McKesson business” and then later CVS, its “largest customer,” to make peace with Mylan, who, as Teva internally lamented, was “trashing the price in pretty much a two-player market.”

749. Determined not to let that happen again, Patel began to investigate Mylan drugs as a potential source for coordinated price increases immediately after she was hired at Teva. Teva and Mylan coordinated price increases on multiple drugs over time, including their drastic price increases on Doxazosin Mesylate in the summer of 2013. During each step in the process, Teva and Mylan executives kept their generic manufacturer co-conspirators apprised of their decisions. Between May and August 2013, for example, Teva and Mylan exchanged 101 phone and text communications. Patel typically initiated Teva’s communication with Nesta of Mylan either directly or through Green, whom she asked to seek “intel” from Nesta on many different drugs.

750. For example, on July 22, 2013, Patel emailed Green a spreadsheet titled “Round 2” increase items, telling him that she was “seeking intel” for a group of drugs, including Doxazosin Mesylate, in the attached spreadsheet with a highlighted yellow “x” and included in a column titled “Follow Mylan/Other:”

Product Family	Initial Comments	PM Related	Follow Mylan/Other
Amiloride	Mylan increase; Teva only has HCTZ		x
Diclofenac Tab	Mylan increase; On historical PI list	x	x
Doxazosin Mesylate Tabs	Mylan increase; On historical PI list		x
Enalapril Tab	Mylan increase; On historical PI list--COMPLETED		x
Ketoprofen	Follow Mylan; Deletion candidate; PM related	x	x
Ketorolac	Follow Mylan; Deletion candidate; PM related	x	x
Metoprolol	Mylan increase (Teva does not have 25mg but small sku)		x
Nystatin	Heritage involved follow Mutual deletion candidate PM related	x	x
Pravastatin	Carried over from round 1		x
Sotalol	Mylan increase; On historical PI list		x
Tolmetin Tab	Mylan increase; Teva has 94 share; On historical PI list		x
Verapamil (Isoptin SR)	Mylan increase (lost Kroger and OneStop--to who?)		x

751. The next day – July 23, 2013 – at 4:30 pm, Green and Nesta spoke for more than six minutes. Immediately after hanging up the phone, Green called Patel to convey the “intel” he had obtained from Mylan. The call lasted more than three minutes.

752. On July 26, 2013, Teva received a bid request from AmerisourceBergen for multiple products, including Doxazosin Mesylate. For many products, AmerisourceBergen described the reason for the bid as a “change in market dynamics.” Patel interpreted this to refer to products, which were “[a]warded to Teva, but put out to bid due to our 7/3 increase” or “[a]warded to Mylan and put out to bid due to their 7/1 increase.” She proposed the following response, designed to support the Fair Share Agreement:

- We may plan to follow and will not bid
- We may not follow and may bid at a higher price than normal (bid new business at higher prices)
- We may plan to take no pricing action and will bid as we normally would.

753. Consistently, when Teva received requests from OptumRx and Rite Aid to bid on Doxazosin Mesylate and other drugs, Teva offered a bid only for the drug that was not subject to price coordination: “Etodolac and Doxazosin are strong increase candidates. We are unable to bid at this time.”

754. Likewise, on July 31, 2013, in response to a request from Walgreens, Teva’s Green analyzed market share before determining Teva’s response.

755. Defendants coordinated the amount and timing of their price increases. For example, Apotex increased its price on July 23, 2013 after a conversation between B.H. of Apotex and Patel of Teva. And similarly, approximately a week before Teva matched Apotex's and Mylan's prices, B.H. and Patel spoke again for almost fifteen minutes


756. The Defendants continued to police the Fair Share Agreement as it applied to Doxazosin Mesylate. For example, Par matched the elevated pricing when it entered the market in late 2013. Additionally, when Greenstone entered the market a year after the dramatic increase in the price of Doxazosin Mesylate Tablets, Patel cautioned against bidding on a supply agreement, and was willing to cede share to keep prices high.

757. The other drug that was discussed along with Doxazosin Mesylate in a document cited above was Etodolac. The market for Etodolac is mature. At all relevant times, there have been multiple manufacturers of Etodolac Capsules and Tablets (including Tablets ER).

758. During the relevant time period, Defendants Apotex, Sandoz, Taro, Teva, and Zydus were the primary manufacturers of Etodolac.

759. For years, the price of Etodolac Capsules was stable. That changed in the spring of 2012. Taro was the dominant seller in the market. Teva was preparing to exit and Apotex was preparing to re-enter.

760. In conjunction with Apotex's entry into the market, Taro and Apotex announced identical and nearly simultaneous list (WAC) price increases. Rather than stimulate price competition, Apotex's entry into the market resulted in much higher prices.



761. Apotex quickly gained market share, all while it and Taro maintained high prices. Their Fair Share Agreement made this possible. For example, in August 2013, [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] Doing so would

have disrupted the Fair Shares of each manufacturer of Etodolac Capsules and Tablets.

762. [REDACTED]



[REDACTED]


763. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

764. The agreement was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Etodolac Capsules.

765. The primary manufacturers of Etodolac Tablets and Tablets ER were Apotex, Sandoz, Taro, Teva, and Zydus. As was the case with Etodolac Capsules, for years the prices of Etodolac Tablets and Tablets ER were relatively low and stable. That changed around the summer of 2013 when Teva, Taro and Sandoz imposed nearly simultaneous price increases of Tablets and Teva and Taro did the same on Tablets ER. Again, the price increases were very large, and very similar in amount.

766. When Apotex re-joined with Tablets in the spring of 2015, it matched Sandoz and Teva's prices. And when Zydus entered with Tablets ER, it matched the prices of Taro and Teva.





767. Throughout this period, Teva, Sandoz, Taro, Apotex and Zydus met at trade conferences and communicated directly with each other,

768. For example, during July of 2013, there were numerous phone calls among Sandoz, Taro and Teva for the express purpose of implementing price increases on Etodolac. Between July 16 and 18, there were a flurry of calls between individuals at all three companies, including C.B., a National Account Executive at Sandoz, Taro's Aprahamian and Teva's Patel. On July 18, 2013, Patel called M.V., the Associate Director of Pricing at Sandoz, during which the companies agreed to raise prices.

769. Before any price increases took effect or were made public, Teva knew that Sandoz planned to increase its price on Etodolac, and that Taro would follow suit and raise its prices as well. During those conversations, Teva agreed to follow both price increases.

770. Leading up to the price increases that were imposed in late July and early August, Sandoz, Teva, and Taro continued to communicate and re-affirm their intentions to raise Etodolac prices. For example, on July 23, 2013, Patel at Teva spoke with her contact at Sandoz, and Aprahamian at Taro spoke with his contact at Sandoz.

771. Between July 29 and August 2, 2013, Patel engaged in a series of thirteen calls with her Sandoz contact and Aprahamian of Taro. Aprahamian also spoke to his contact at Sandoz during this time, including three calls between July 30 and August 2, 2013.

772. When Patel sent the “Price Increase Overview” spreadsheet to her supervisor on August 7, 2013, summarizing Teva’s upcoming August 9 price increases, she again made it clear that the reason Teva was increasing its prices for Etodolac and Etodolac ER was because Teva senior executives knew that Taro would be raising its prices on both drugs “this week.” Patel’s supervisor quickly instructed her to delete those entries. Notably, he did not tell her to stop colluding with Taro or any of Teva’s other ostensible competitors, and so she continued to do so.

773. On August 8, 2013, Patel again spoke to Aprahamian (Taro) numerous times and to her contact at Sandoz. The next day, Teva and Taro announced identical and very large price increases on their Etodolac and Etodolac ER products.

774. Zydus’s entry into the Etodolac ER market in the spring of 2014 spurred another round of communications and coordination aimed at keeping prices high. In the days leading up to the Zydus launch, there were numerous communications between Teva, Zydus and Taro to discuss how customers would be ceded to Zydus without driving prices down.

775. The conversations accomplished their goal. Zydus announced list prices identical to those of Teva and Taro. And Teva and Taro ceded customers to Zydus. For example, when Teva learned on May 14, 2014, that one of its wholesaler customers had received a bid from

Zydus for Etodolac ER, it prompted a series of communications between Teva's Patel, Taro's Aprahamian, and Zydus's Green, as well as direct communications between Maureen Cavanaugh at Teva and K.R., Vice President of Sales at Zydus. The end result: Teva ceded its wholesaler customer to Zydus.

776. In July of 2014, Teva ceded another customer to Zydus to allow it to gain a Fair Share of the market. Patel explained Teva's decision as needed to make room for a new market entrant.

777. Taro, too, worked to ensure that Zydus maintained a Fair Share of the Etodolac market. For example, in August 2015, Taro declined to bid on Etodolac ER at a large customer where Zydus was the incumbent. Taro worried that pursuing Zydus's customer would result in retaliation, possibly on another product that was part of their Fair Share Agreement, Warfarin Sodium Tablets: Zydus "could hit us on Warfarin. Not worth a fight in the sandbox over 300 annual units for Etodolac."

778. No non-collusive market factors (e.g., product shortages) can explain the artificially inflated prices.

779. The agreement between Apotex, Sandoz, Taro, Teva, and Zydus was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Etodolac Tablets, Tablets ER, and Capsules.

45. Drospirenone and Ethinyl Estradiol

780. Drospirenone and Ethinyl Estradiol, commonly known by the brand name Ocella, is an oral contraceptive available as a Tablet. It has been available in the United States in a generic form for many years.

781. The market for Drospirenone and Ethinyl Estradiol is mature. At all relevant times, there have been multiple manufacturers of Drospirenone and Ethinyl Estradiol Tablets.

782. During the relevant time frame, Defendants Teva, Lupin, and Actavis were the primary manufacturers of Drospirenone and Ethinyl Estradiol.

783. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Drospirenone and Ethinyl Estradiol beginning at least as early as April 2013.

784. In early 2013, Lupin was planning to enter the market. Rather than strategize on how to gain market share through competition, Lupin contacted Teva to reach an agreement on pricing and market share. In late April, Berthold (Lupin) and Green (Teva) spoke multiple times. Communications between Teva and Lupin eventually looped in Actavis. For example, Teva's Rekenhaller and Patel each spoke with a senior sales and marketing executive at Actavis on April 30, and the next day Patel exchanged a number of text messages with him as well.

785. Throughout May, intense communications among the competitors continued as they worked out the details of their agreement. On May 6, Patel and Berthold spoke twice by phone. Green and Berthold also spoke that same day. On May 7, Patel and Berthold had yet another call. Patel also placed a call to Rogerson at Actavis. Patel again spoke to Rogerson on May 8. And on May 9, Green again spoke with Berthold twice. On May 10, Patel spoke to Berthold three times, and also spoke to Rogerson again.

786. In the wake of all these communications, Teva agreed to concede business to Actavis in order to maintain higher prices for Drospirenone and Ethinyl Estradiol.

787. Communications continued through the summer 2013. Numerous calls between Patel and Green at Teva and Berthold at Lupin took place, all aimed at orchestrating Lupin's acquisition of a Fair Share of Drospirenone and Ethinyl Estradiol, which they did.

788. The ability of Teva, Lupin, and Actavis to reach agreements on Drospirenone and Ethinyl Estradiol was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

789. The coordinated price increases by Teva, Lupin, and Actavis are consistent with the Fair Share Agreement.

790. The agreement between Defendants Teva, Lupin, and Actavis was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Drospirenone and Ethinyl Estradiol Tablets.

46. Enalapril Maleate

791. Enalapril Maleate is used to treat high blood pressure. It is available in Tablet (2.5, 5, 10, 20 mg) form and has been on the market in the United States for years as a generic medication.

792. The market for Enalapril Maleate is mature. At all relevant times, there have multiple manufacturers of Enalapril Maleate.

793. Defendants Bausch, Mylan, Taro, Teva, and Wockhardt dominate sales of Enalapril Maleate.

794. For years, the prices of Enalapril Maleate Tablets were relatively low and stable. By mid-2013, the market was shared by three Defendants: Mylan, Wockhardt, and Teva. Those

three manufacturers coordinated a significant price increase for Enalapril Maleate in the second half of 2013.


795. Mylan increased its list (WAC) price for Enalapril effective July 2, 2013. Enalapril Maleate was on a list of drugs slated for a price increase that Teva had received from Mylan in June 2013, before those price increases were put into effect.

796. Teva quickly followed Mylan's increase, announcing its own list (WAC) price increases. Wockhardt followed as well, raising its list prices for Enalapril Maleate. Taro, which was in the process of re-entering with Enalapril Maleate in mid-2013, joined the price increases. Rather than offer better prices to gain share, Taro raised its list prices.

797. [REDACTED] at that time.

798. In the spring of 2014, Mylan led another even more extreme round of price increases. In 2013, Mylan increased list prices by approximately 100%. In April 2014, it increased list (WAC) prices again by approximately 300%. Teva followed the increase—announcing identical WAC prices—in August. Taro did exactly the same in October. And Wockhardt raised its list (WAC) prices again in December.

799. After Mylan, Teva, Wockhardt, and Taro had completed their second round of coordinated price increases, Bausch (Oceanside) entered the market. Rather than offer better prices to win new customers, Bausch (Oceanside) matched the list (WAC) prices of the other sellers, and NSP prices that [REDACTED].



800. Throughout this period, Mylan, Teva, Wockhardt, Taro, and Bausch met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreement for Enalapril Maleate and of the Fair Share Agreement

801. For example, in the short window of time after Mylan raised prices in 2013 and before Teva, Taro, and Wockhardt followed the increase, Teva received a request on July 10, 2013, from a customer seeking a lower price on Enalapril. This set off a series of communications, the purpose of which was to ensure that Teva, Taro, and Wockhardt joined Mylan's increase. On July 10, Green of Teva and Nesta of Mylan had two phone calls, and they spoke twice more the following day. During these conversations, Nesta explained to Green that Wockhardt already had agreed to follow the Mylan price increase on Enalapril. Teva's Patel also called Nesta directly on July 12, 2013, and they spoke three times. Not long after, K.K., a senior

national account executive at Wockhardt, spoke to Green of Teva (twice on July 15, 2013), and reported internally the specific price ranges for Enalapril that he had obtained from Green. Soon thereafter, Teva and Wockhardt implemented price increases on their Enalapril Maleate Tablets.

802. Similarly, as Taro evaluated whether to re-enter the Enalapril market, it engaged in a series of communications to shore up the Fair Share Agreement among Defendants. Aprahamian of Taro communicated with Patel of Teva and M.C., Senior Vice President of Sales and Marketing at Wockhardt in July 2013, in the midst of the coordinate price increases by those manufacturers.

803. Aprahamian also coordinated with M.A., a Mylan National Account Director, on how to allocate Enalapril; the two spoke on December 6, 11, and 12, 2013.

804. On December 5, 2013, Aprahamian spoke to Teva's Patel and sought her input before sending a proposal to a Teva customer.

805. On December 31, 2013, Aprahamian spoke with M.C. at Wockhardt, and they agreed that Wockhardt would concede one large customer to Taro so long as Wockhardt was able to retain a different large customer.

806. In early 2014, market share was allocated "fairly" among the four competitors. As Teva was considering whether to bid on an RFP, with regard to Enalapril Patel cautioned: "no bid due to potential market/customer disruption, aka strategic reasons." The same day, Patel spoke to Aprahamian and exchanged 8 text messages with him.

807. As 2014 progressed, Defendants again communicated directly in order to coordinate a second round of price increases. For example, Taro's Aprahamian spoke with his contact at Wockhardt on August 8 and August 14, 2014, and spoke with Teva's Patel on August 27.

808. [REDACTED]

809. The agreement between Defendants Mylan, Taro, Teva, Wockhardt, and Bausch was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Enalapril Maleate Tablets (2.5, 5, 10, 20 mg).

47. Entecavir

810. Entecavir, also known by the brand name Baraclude, among others, is a medication used to treat chronic Hepatitis B. It is available as a Tablet and has been available in the United States in a generic form for many years.

811. The market for Entecavir is mature. At all relevant times, there have been multiple manufacturers of Entecavir.

812. During the relevant time frame, Defendants Teva and Par were the primary manufacturers of Entecavir.

813. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Entecavir Tablets beginning at least as early as the summer of 2014.

814. In the summer of 2014, Teva and Par were preparing to enter the market for Entecavir. Both companies were soliciting new customers before their launch. On August 28, 2014, Teva's Rekenhaller had three phone calls with M.B, a Vice President of National Accounts at Par. The next day, one of Teva's potential customers sought a lower price from Teva, suggesting it could lose the business to Par. Teva, reassured by its discussions with Par, refused to lower its price, and retained the customer's Entecavir business. In light of the successful

coordination internally at Teva, Rekenhaller discussed the possibility of conceding a large customer to Par.

815. Teva and Par both launched their Entecavir on September 4, 2014. Within a few weeks, however, Teva and Par had divided the market according to the Fair Share Agreement.

816. Teva and Par continued to coordinate pricing and allocate customers, with Rekenhaller and the VP at Par speaking twice on October 2. For the entirety of the period in which Par and Teva were the only generic suppliers of Entecavir, market share and prices remained stable and higher than they would have been in a competitive market.

817. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

818. The ability of Teva and Par to reach agreements on Entecavir tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

819. The coordinated price increases by Teva and Par are consistent with the Fair Share Agreement.

820. The agreement between Defendants Teva and Par was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Entecavir Tablets.

48. Estradiol

821. Estradiol is a hormone. It is available in a Tablet (0.5, 1, and 2 mg) formulation. It has been available in the United States in a generic form for many years.

822. The market for Estradiol is mature. At all relevant times, there have been multiple manufacturers of Estradiol.

823. During the relevant time frame, Defendants Actavis, Mylan, and Teva were the primary manufacturers of Estradiol.

824. [REDACTED]

825. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

826. Throughout this period, Teva, Mylan and Actavis met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreements on Estradiol and other drugs.

827. For example, in the summer of 2012, Teva, Mylan and Actavis began coordinated price increases on Estradiol tablets. As they began to roll out increases to customers, the lines of communication were open and frequently utilized. Teva's Green spoke to Mylan's Nesta on August 1, 2, 6, 7, 8, 10, 13, 15, 16, 17, and 28.

828. Teva was also in touch with Actavis. T.C., Teva's Senior Director of Sales, spoke twice (once for 10 minutes and another time for 15 minutes) with L.P., a Senior Director of National Accounts at Actavis, on August 6, 2012. By the end of the year, Actavis, Mylan and Teva had increased their Estradiol prices to customers by double or more.

829. In early 2015, when Actavis, Mylan, and Teva imposed another round of price increases, they again orchestrated these price increases by direct communication. For example, Teva's Rekenhaller spoke to Nesta of Mylan on January 14 (two calls) and 20, 2015. In addition, Rekenhaller spoke to Falkin of Actavis on January 13, 14 (two calls), and 16, 2015. Over the

ensuing months, all three manufacturers were again able to impose Estradiol price increases on their customers.

830. The coordination by Actavis, Mylan, and Teva is consistent with the Fair Share Agreement.

831. The agreement between Defendants Actavis, Mylan, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Estradiol Tablets (0.5, 1, and 2 mg).

49. Estradiol and Norethindrone Acetate

832. Estradiol and Norethindrone Acetate, also known as Mimvey, is an oral contraceptive available as a Tablet. It has been available in the United States in a generic form for many years.

833. The market for Mimvey is mature. At all relevant times, there have been multiple manufacturers of Mimvey.

834. During the relevant time frame, Defendants Teva and Breckenridge were the primary manufacturers of Mimvey.

835. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Mimvey tablets beginning at least as early as October 2013.

836. On November 14, 2013, Breckenridge increased its pricing on Mimvey. Leading up to that increase, Rekenhaller of Teva had several phone calls with the Director of Sales at Breckenridge to coordinate the price increases, including two calls on October 14, 2013 and one on October 24, 2013. After those calls, they did not speak again until mid-January 2014, when Teva began preparing to implement its increase.

837. On April 4, 2014, Teva increased pricing on a number of drugs, including Mimvey. Teva's new list (WAC) price exactly matched Breckenridge's list price. As Patel of Teva planned for Teva's April 4, 2014 price increases, both she and Rekenhaler continued to communicate with their counterparts at Breckenridge. Rekenhaler spoke again to the Director of Sales at Breckenridge on January 15, 2014 and Patel spoke with a Director of National Accounts at Breckenridge two times on February 7, 2014.

838. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

839. The ability of Teva and Breckinridge to reach agreements on Mimvey tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

840. The coordination between Teva and Breckenridge is consistent with the Fair Share Agreement.

841. The agreement between Defendants Teva and Breckinridge was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Estradiol and Norethindrone Acetate [Mimvey] Tablets.

50. Ethinyl Estradiol and Levonorgestrel

842. Ethinyl Estradiol and Levonorgestrel, when used in combination, is an oral contraceptive used to prevent pregnancy, and is available in Tablet form. It has been available in the United States in a generic form for many years.

843. The market for Ethinyl Estradiol and Levonorgestrel is mature. At all relevant times, there have been multiple manufacturers of Ethinyl Estradiol and Levonorgestrel.

844. During the relevant time period, both Teva and Sandoz marketed Ethinyl Estradiol and Levonorgestrel Tablets under multiple names – including both Portia and Jolessa.

845. Plaintiffs allege that as part of Defendants’ Fair Share Agreement, Teva and Sandoz conspired to fix, raise, maintain or stabilize the prices of Ethinyl Estradiol and Levonorgestrel beginning at least as early as the spring of 2012.

846. In May 2012, Teva had much higher market share than Sandoz for both Portia and Jolessa. When Walmart contacted Teva with a right of first refusal and explained that Sandoz made an offer for the sale of drugs including Portia and Jolessa, Teva initially sent a competitive offer. However, after Teva’s Green spoke to a contact at Sandoz, Teva withdrew its offer for Portia and Jolessa the next day and conceded Walmart to Sandoz.

847. Sandoz continued to coordinate with Teva to achieve its Fair Share of the markets for Portia and Jolessa. In July 2013, a key customer contacted Teva stating it had received bids on Portia and Jolessa, and in order for Teva to retain the business, Teva would have to submit its “best bids.” A few days later, Teva’s Patel spoke to a contact at Sandoz, and Teva’s Rekenenthaler spoke to a different Sandoz contact. Ultimately, Teva submitted a cover bid to the customer for Portia and Jolessa, intentionally inflating the bid to ensure that Sandoz obtained the primary award with the customer.

848. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

849. The ability of Teva and Sandoz to reach agreements on Ethinyl Estradiol and Levonorgestrel was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

850. The coordination by Teva and Sandoz is consistent with the Fair Share Agreement.

851. The agreement between Defendants Teva and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Ethinyl Estradiol and Levonorgestrel Tablets.


51. Exemestane

852. Exemestane is used to treat certain types of breast cancer. It is available in Tablet (25mg) form and has been available in the United States for many years as a generic medication.

853. The market for Exemestane is mature. At all relevant times, there have been multiple manufacturers of Exemestane.

854. Defendants Greenstone, West-Ward, and Alvogen dominate sales of Exemestane Tablets with [REDACTED].

855. [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]



856. The ability of Greenstone, West-Ward, and Alvogen to reach agreements on Exemestane was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

857. [REDACTED]

858. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

859. The agreement between Defendants Greenstone, West-Ward, and Alvogen was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise

prices, rig bids, and engage in market and customer allocation for generic drugs, including Exemestane Tablets (25 mg).

52. Fenofibrate

860. Fenofibrate, also known by the brand name Tricor, is a medication used to treat cholesterol conditions. It is available in Tablet (48 mg and 145 mg) form and has been available in the United States in a generic form for many years.

861. The market for Fenofibrate is mature. At all relevant times, there have been multiple manufacturers of Fenofibrate.

862. During the relevant time frame, Defendants Teva, Lupin, Perrigo and Mylan were the primary manufacturers of Fenofibrate. Defendant Zydus joined the Fenofibrate market and the Fenofibrate conspiracy in February 2014.

863. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Fenofibrate Tablets (48 mg and 145 mg) beginning at least as early as the beginning of 2013.

864. Initially, Teva and Lupin were the first major suppliers of generic Fenofibrate. Perrigo and Mylan joined the market not long after. In order to keep prices high, the Fenofibrate manufacturers coordinated pricing and market share.

865. For example, in early 2013, Teva's Green called Mylan's Nesta to find out more about Mylan's plans with Fenofibrate. Green reported back to his Teva colleagues that Mylan planned to launch Fenofibrate sometime around November 2013.

866. A few months later in 2013, however, Teva learned that Mylan was moving up its launch date for Fenofibrate. In advance of this launch, Teva, Lupin, Mylan, and Perrigo conspired to allocate the market for Fenofibrate.

867. For example, executives for Teva, Mylan, and Lupin were in regular contact by phone. Patel (Teva) spoke to Berthold (Lupin) on May 6 and 7, and Green (Teva) spoke to Berthold on May 6 and 9, 2013. Further, Green spoke to Nesta (Mylan) on May 7, 8, and 9, 2013. And Nesta spoke to Berthold on May 7 and 8, 2013. On these calls, Teva, Mylan, and Lupin executives shared information about Mylan's Fenofibrate launch and the plan to allocate market share to Mylan.

868. All of the coordination had real effects. For example, Teva decided to concede one of its largest customers to Mylan so that Mylan could obtain a Fair Share of the market and thus avoid price competition.

869. Similarly, in February 2014, Zydus was preparing to enter the Fenofibrate market. Green, formerly at Teva but now at Zydus, colluded with Teva's Patel and Rekenhaller, Mylan's Nesta, and Lupin's Berthold to share pricing information and allocate market share to his new employer, Zydus. Mylan's Nesta spoke to T.P., Perrigo's Director of National Accounts, on February 6, 2014.

870. In March 2014, when Zydus entered the Fenofibrate market, it announced list prices that matched Teva, Mylan, and Lupin. In the days leading up to the launch, executives from all four competitors were in regular contact with each other to discuss pricing and allocating market share to Zydus. Between March 3 and March 7, 2014, these competitors exchanged at least 26 calls with each other.

871. In the months that followed, Teva "strategically conceded" several customers to Zydus in accordance with the agreement they had reached. Throughout, Teva communicated directly with competitors to keep them apprised of developments and to ensure that Fair Share

was maintained for Fenofibrate. For example, Teva's Patel continued to communicate directly with Berthold (Lupin) and Green (Zydus) in May and June.

872. By coordinating prices and market share, Teva, Mylan, Lupin, Perrigo, and Zydus were able to keep Fenofibrate prices higher than they would have been in a competitive market.

873. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

874. The ability of Teva, Mylan, Lupin, Perrigo, and Zydus to reach agreements on Fenofibrate tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

875. The coordinated price increases by Teva, Mylan, Lupin, Perrigo and Zydus are consistent with the Fair Share Agreement.

876. The agreement between Defendants Teva, Mylan, Lupin, Perrigo and Zydus was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Fenofibrate Tablets (48, 145 mg).


53. Fluconazole

877. Fluconazole is a commonly prescribed antifungal medication that has been available in the United States for decades. The World Health Organization includes Fluconazole on its List of Essential Medicines, *i.e.*, one of the most effective and safe medicines needed in a health system. Fluconazole is available in the United States in several dosage strengths, including 50, 100, 150, and 200 mg Tablets.

878. The market for Fluconazole is mature. At all relevant times, there have been multiple manufacturers of Fluconazole. Defendants Citron, Dr. Reddy's, Glenmark, Greenstone, and Teva dominated sales of Fluconazole in the relevant period.

879. [REDACTED]

[REDACTED], as illustrated by the following example of 100 mg Tablets:



880. The GAO found that all four dosage strengths had “extraordinary price increases” in 2013-2014. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including Citron, Dr. Reddy's, Glenmark, Greenstone, and Teva.

881. Defendants Citron, Dr. Reddy's, Glenmark, Greenstone, and Teva became aware of the potential for coordinating price increases on Fluconazole in early 2013. As explained above, Glenmark was one of Teva's highest-ranked competitors by "quality." Teva also viewed Greenstone as a "high quality" competitor.

882. As discussed previously, Teva's Patel went to great lengths to coordinate Teva's price increases with competitors before sending the list to K.G. on May 24, 2013. She saw potential when Glenmark prepares to increase the price of a large number of drugs, and Teva also sold a number of them.

883. In an email to Patel on May 1, 2013, K.G. identified as Teva's "Main priority" price increases for other drugs, namely "Methotrexate, Nadolol, and Fluocinonides. We need to try to get these done within the next 2-3 weeks if we can get approval." Anticipating Glenmark's price increases (which were not made public before May 16, 2013), Patel responded: "I also expect to have some high priority items to add to this list. I should have them shortly." Fluconazole is one of several drugs Patel identified for price increases. And indeed, she had numerous conversations with various sales and marketing executives at Glenmark over the next five days to discuss raising the price of Fluconazole and other drugs, including:

- May 2, 2013: four calls with a senior executive at Glenmark
- May 3, 2013: two calls and one text with a senior executive at Glenmark
- May 6, 2013: three calls with J.C.
- May 7, 2013 three calls with J.C.

884. Consistent with the Fair Share Agreement, as the Glenmark price increases were approaching, Patel took steps to make sure that Teva did not undermine its competitor's action.

885. For example, on the morning of May 15, 2013, in anticipation of the Glenmark price increases that had not yet been implemented or made public, Patel instructed her Teva colleagues to alert her of any requests by customers for pricing relating to eight different Glenmark drugs, including Fluconazole. Teva planned to “discuss where to price” these drugs “based on market intelligence she has collected.” In the interests of coordinating prices, Teva wanted to be careful to avoid obtaining any market share from Glenmark after the price increases.

886. Patel also spoke to a senior executive at Glenmark for nearly six minutes the next day, May 16, 2013 – the day of the Glenmark price increases. Effective that day, Glenmark increased price on numerous drugs where there was an overlap with Teva, including Fluconazole. Patel also spoke to a senior executive and J.C. at Glenmark multiple times on May 17, 2013. After Glenmark’s price increases, and before Teva had the opportunity to institute them, Teva was approached by several customers looking for a lower price. Teva refused to bid on most of these solicitations in order to maintain market stability. When it did bid, Teva intentionally bid high so that it would not win the business. As Patel stated to a Teva colleague when a large wholesaler approached Teva about bidding on several drugs for which Glenmark had increased its prices: “IF we bid, we need to bid high, or we will disturb the market.”

887. But Patel did not immediately push to increase Teva’s prices on all of the overlapping drugs that Glenmark increased, such as Fluconazole. Instead, Teva waited until July 3, 2013. Teva hesitated because certain overlapping drugs also involved competitors that Patel did not consider at that time to be of the highest “quality.” For these drugs, Patel anticipated that a little more work (and communication) was required before she would feel comfortable moving forward with a price increase.

888. As of Friday, May 17, 2013, Patel had not yet decided whether Teva should institute the Glenmark price increase on Fluconazole, fearing that Greenstone might not be responsive to price coordination. In an internal email that day, Patel indicated to colleagues – including her supervisor, K.G., that she was “[g]athering some revised intel” about Fluconazole in order to determine next steps.

889. The following Monday, May 20, Patel called R.H., a director of national accounts at Greenstone but was unable to connect. Patel was ultimately not able to communicate with R.H. by phone until May 28, 2013 when the two had a twenty-one-minute call. The next day after speaking to R.H. – May 29, 2013 – Patel promptly added Fluconazole to the Teva price increase list.

890. While it was still deciding whether to institute Glenmark’s price increases, Teva declined to capitalize on its competitor’s price increase to gain market share. For example, in a May 17, 2013 email about Fluconazole, Teva’s B.B. expressed concern to his colleagues about the prospect of taking McKesson’s business, which represented all of Greenstone’s or Glenmark’s customers. Patel agreed and advised the group to decline to bid because she had heard that Greenstone was also increasing its price, and because Teva already had 80% share and the lowest price in the market. In another internal Teva email, dated May 22, 2013, a Teva employee reports that Teva declined to bid at One Stop on Fluconazole after a Glenmark price increase and asks “to confirm that we want to follow the same [no-bid] strategy for Rite Aid?” Likewise, when Walgreens asked for a bid on Fluconazole and other items, Teva’s Green forwarded the request to Patel on May 30, 2013, and wondered whether Glenmark’s price increase prompted the inquiry. Anticipating that Teva would join the others and increase its prices shortly, she responded: “We are in a great inventory position, but not sure I want to steal it

on an increase. . . . GS has very little share and no significant customers.” Teva’s patience and persistence was rewarded when each of the Defendants increased their prices on Fluconazole tablets in coordinated fashion.

891. Defendants coordinated prices each step of the way and avoided bidding on business that would disrupt the Fair Share Agreement. Like its competitors, Teva increased its prices significantly. Teva’s WAC prices for Fluconazole, which it announced on July 3, 2013, resulted in a tripling and quadrupling of its former prices. And just as they had done, when Glenmark increased its prices, Patel spoke to R.H. and a senior executive at Glenmark for nearly 16 minutes and almost five minutes, respectively.

892. [REDACTED]

893. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

894. The agreement between Defendants Citron, Dr. Reddy’s, Glenmark, Greenstone, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Fluconazole Tablets.

54. Fluocinolone Acetonide

895. Fluocinolone Acetonide is a commonly prescribed corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching. It has been on the market for decades and is available in several forms, including Fluocinolone Acetonide Ointment (0.025%), Cream (0.01% and 0.025%), and Solution (0.01%).

896. The market for Fluocinolone Acetonide is mature. At all relevant times, there have been multiple manufacturers. Defendants G&W, Sandoz, Taro, and Teligent dominated

sales of these Fluocinolone Acetonide products in the relevant period. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

897. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

898. The GAO reported that Fluocinolone Acetonide experienced “an extraordinary price increase” in 2012-2013.

899. There were no reported shortages of these products in the relevant period. Yet, rather than lowering its prices in anticipation of competition from G&W and Teligent, Defendant Sandoz tripled its WAC prices on December 21, 2011. And instead of competing on price, both G&W and Teligent entered the market with similar, supracompetitive prices. Teligent preceded its entry with the announcement of WACs that matched or slightly exceeded Sandoz's prices.

900. [REDACTED]

901. Pursuant to Defendants' agreement, their price increases did not result in significant market share losses in the relevant period.

902. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers, including G&W, Sandoz, Taro, and Teligent. Co-Defendant Teva considered Sandoz to be a "quality competitor," with whom it was easy to facilitate price coordination.

903. The ability of G&W, Sandoz, Taro, and Teligent to reach agreement regarding Fluocinolone Acetonide was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

904. [REDACTED]

905. The agreement between Defendants G&W, Sandoz, Taro and Teligent was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Fluocinolone Acetonide Ointment (0.025%), Cream (0.01% and 0.025%), and Solution (0.01%).

55. Fluocinonide (Solution 0.05% and Cream 0.1%)

906. Fluocinonide is a corticosteroid used to treat a variety of skin conditions, including eczema, dermatitis, allergies, and rash. It is available in a Solution formulation, among others previously sued on in individual drug complaints.

907. Fluocinonide has been available in the United States in a generic form for many years.

908. The market for Fluocinonide is mature. At all relevant times, there have been multiple manufacturers of Fluocinonide.

909. During the relevant time frame, Actavis, Sandoz, and Taro were the primary manufacturers of Fluocinonide Solution.

910. Plaintiffs allege that as part of Defendants' Fair Share Agreement, Defendants Actavis, Sandoz and Taro conspired to fix, raise, maintain or stabilize the prices of Fluocinonide Solution beginning at least as early as 2011.

911. In early 2011, the competitors in the Fluocinonide Solution market were Sandoz, Taro, and Actavis.

912. In the beginning of April 2011, Sandoz experienced a disruption in its supply of Fluocinonide Solution. W.K., Sandoz's Vice President of Accounts, learned, however, that Actavis planned to leave the market.

913. Despite experiencing supply problems, Sandoz planned to raise prices on Fluocinonide Solution because of Actavis' decision to leave the market. Internally, Sandoz expected [REDACTED] and that the two companies would share the market equally.

914. On May 10, 2011, Sandoz raised its list (WAC) price for Fluocinonide Solution, and within a few days representatives from Sandoz began exchanging phone calls with Taro

representatives. On May 20, 2011, Taro followed Sandoz's lead and increased its prices for Fluocinonide Solution.

915. In accordance with the Fair Share Agreement, Sandoz and Taro took nearly identical shares of the Fluocinonide Solution market following the price increases.

916. In early 2012, Sandoz and Taro coordinated another price raise on Fluocinonide Solution, and the two companies communicated to facilitate the increase.

917. For example, at the end of January 2012, A.T., Sandoz's National Accounts Executive, exchanged numerous phone calls with H.M., Taro's Director of Corporate Accounts, to facilitate the price increase.

918. The day after Sandoz's A.T. spoke with Taro's H.M. by phone again on February 13, 2012, Sandoz raised its prices for Fluocinonide Solution. A.T. and H.M. spoke again on February 15, 2012, and that same day an internal Taro email confirmed that Taro would be following Sandoz's price increase.

919. Following Sandoz's price increase, representatives from Sandoz and Taro continue to exchange phone calls, and coordinated to maintain their respective Fair Shares of the market. For example, Taro declined to bid when two Sandoz customers requested a bid from Taro on Fluocinonide Solution.

920. Taro planned to match Sandoz's price increase for Fluocinonide Solution. In preparation for its price increase, representatives from Taro remained in contact with representatives from Sandoz. For example, in February 2012, D.S., a Taro AVP of National Accounts, exchanged three phone calls with Sandoz's A.T., and A.T. spoke with Taro's H.M. over the phone. On March 7 and March 8, 2012, D.S. exchanged three phone calls with K.K., a senior sales executive at Sandoz.

921. On March 9, 2012, Taro followed Sandoz and raised its prices on Fluocinonide Solution.


922. Beginning in June 2013, Actavis began planning to enter the Fluocinonide Solution market sometime the following month.

923. To facilitate Actavis's entry into the market, and to allow it to gain a Fair Share, Taro and Sandoz began sharing information to divide up the market for Fluocinonide Solution.

924. Because Actavis and Sandoz did not have an independent relationship, Taro representative Aprahamian relayed information between the two companies in preparation for Actavis's launch. Representatives of Actavis exchanged several phone calls with Taro representatives Aprahamian and Perfetto. During the same period, Aprahamian was also communicating with C.B. at Sandoz.

925. On July 22, 2013, Actavis formally launched a Fluocinonide Solution product, and matched Sandoz and Taro's price points.

926. [REDACTED]
[REDACTED]:



927. As was contemplated by the Fair Share Agreement, when Actavis entered the Fluocinonide Solution market and began targeting customers, Sandoz and Taro relinquished those customers to Actavis. Similarly, Actavis did not target large Sandoz and Taro customers so its entry would not upset the market. Sandoz and Taro also did not target each other's customers.

928. Actavis ultimately secured of 24% of the Fluocinonide Solution market—its Fair Share.

929. Plaintiffs also allege that as part of Defendants' overarching conspiracy with respect to the Drugs at Issue, they also conspired to fix, raise, maintain or stabilize the prices of Fluocinonide Cream (0.1%) beginning at least as early as January 2014.

930. During the relevant time frame, Defendants Bausch, Glenmark, Perrigo, Sandoz and Taro were the primary manufacturers of Fluocinonide Cream (0.1%).

931. In January 2014, Perrigo and Bausch launched generic versions. They were the first generics on the market. From day one, Perrigo and Bausch abided by the Fair Share Agreement.

932. For example, although Perrigo had a slight head start on Bausch in getting to market, it was careful not to take more than a Fair Share; even though it was only getting started in the market for Fluocinonide, it ceded customers to Bausch.

933. By the summer of 2014, Taro and Glenmark were preparing to enter the market. Rather than devise a plan to win over customers with better prices, both companies opted to conspire with the incumbent manufacturers, Perrigo and Bausch, to get a Fair Share.

934. For example, on June 3, 2014, Michael Perfetto, Taro Chief Commercial Officer, exchanged multiple calls with Douglas Boothe, Perrigo Executive Vice President. Throughout the rest of June, the ostensible competitors continued to communicate. Perfetto (Taro) communicated by phone multiple additional times with Boothe (Perrigo) and also spoke a number of times with Jim Grauso, Glenmark Executive Vice President.

935. In July, Ara Aprahamian, Taro Vice President of Sales, and Grauso (Glenmark) spoke numerous times by phone, including on the day that each company launched its Fluocinonide 0.1% Cream products. Grauso (Glenmark) also spoke to M.S., Bausch Senior Director of Generics Marketing, numerous times in July 2014.

936. Over the next couple of months, Bausch and Perrigo monitored the market as Glenmark and Taro launched their products. They each ceded customers to Taro and Glenmark so that everyone could obtain a Fair Share of the market.

937. The following year, Sandoz was preparing to enter the market. As was its custom, it reached out to the incumbent manufacturers to coordinate pricing and to figure out which customers to pursue. To that end, on September 24, 2015, C.B., Sandoz National Account Director, called Aprahamian (Taro). The same day, C.B. also called T.P., Perrigo Director of National Accounts. On these calls, C.B. learned confidential and competitively sensitive pricing information and details about specific customers, which Sandoz then used to pursue its Fair Share of Fluocinonide Cream (0.1%).

938. As a result of the agreement and anticompetitive coordination between Actavis, Bausch, Glenmark, Perrigo, Sandoz, and Taro, prices for Fluocinonide (Solution 0.05% and Cream 0.1%) were higher than they would have been in a competitive market.

939. The ability of Actavis, Bausch, Glenmark, Perrigo, Sandoz, and Taro to reach agreements on Fluocinonide was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

940. The coordination by Actavis, Bausch, Glenmark, Perrigo, Sandoz, and Taro on Fluocinonide is consistent with the Fair Share Agreement.

941. The agreements between Defendants Actavis, Bausch, Glenmark, Perrigo, Sandoz, and Taro described above were part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Fluocinonide (Solution 0.05% and Cream 0.1%).

56. Fluoxetine HCL

942. Fluoxetine HCL is a medication used to depression. It is available in a Tablet formulation. It has been available in the United States in a generic form for many years.

943. The market for Fluoxetine HCL is mature. At all relevant times, there have been multiple manufacturers of Fluoxetine HCL.

944. During the relevant time frame, Defendants Mylan, Par, and Teva were the primary manufacturers of Fluoxetine HCL.

945. In late June 2014, Mylan imposed large price increases on Fluoxetine HCL. Around the time of the increases, Mylan, Teva, and Par directly communicated via phone to coordinate.

946. For example, on June 18, 2014, less than a week before Mylan announced its Fluoxetine HCL price increases, a National Account Manager at Mylan spoke to the Vice President of National Accounts at Par.

947. On June 24, the day after Mylan announced its price increases, Mylan's Nesta spoke to Teva's Rekenhaller.

948. Two days later, on June 26, Teva's Patel exchanged a series of text messages with the Chief Commercial Officer at Par.

949. In January 2015, Teva followed Mylan's price increases for Fluoxetine HCL Tablets. Again, the manufacturers of Fluoxetine were in communication to coordinate.

950. On January 5, 14, and 20, Teva's Rekenhaller spoke with Mylan's Nesta.

951. On January 26, Rekenhaller spoke with a Vice President of National Accounts at Par for 14 minutes, and on January 28, he spoke with Par's Vice President of Sales.

952. The ability of Mylan, Par, and Teva to reach agreements on Fluoxetine HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

953. The coordination by Mylan, Par, and Teva is consistent with the Fair Share Agreement.

954. The agreement between Defendants Mylan, Par, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Fluoxetine HCL Tablets.

57. Fluticasone Propionate

955. Fluticasone Propionate is a steroid medication used for the long-term management of asthma and chronic obstructive pulmonary disease. It is available as a 50cg Nasal Spray and has been available in the United States for many years in a generic form.

956. The market for Fluticasone Propionate is mature. At all relevant times, there have been multiple manufacturers.


957. Defendants Akorn, Apotex, West-Ward, and Wockhardt dominate sales of Fluticasone Propionate.

958. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



959. The ability of Akorn, Apotex, West-Ward, and Wockhardt to reach agreements on Fluticasone Propionate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

960. [REDACTED]

[REDACTED]

961. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

962. The agreement between Defendants Akorn, Apotex, West-Ward, and Wockhardt was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and

raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Fluticasone Propionate Nasal Spray.

58. Gabapentin

963. Gabapentin is an anticonvulsant used to treat seizures. It is available in Capsule, Tablet, and Oral Solution formulations. It has been available in the United States for over a decade in a generic form.

964. The market for Gabapentin is mature. At all relevant times, there have been multiple manufacturers of Gabapentin.

965. Defendants Aurobindo, Glenmark, and Teva dominate sales of Gabapentin 600 mg and 800 mg Tablets. Glenmark had a majority of the market share during the relevant time period, while Teva and Aurobindo had smaller but still significant shares.

966. [REDACTED]

967. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers Aurobindo, Glenmark, and Teva.

968. Defendants became aware of the potential for coordinating price increases on Gabapentin in fall 2014. On October 13 and 14, 2014, Nisha Patel of Teva attended the Annual Meeting of the Pharmaceutical Care Management Association (“PCMA”) in Rancho Palos Verdes, California, along with a number of Teva’s competitors. The PCMA described its Annual Meeting as “the . . . ideal venue for senior executives from PBMs, specialty pharmacy, payer organizations and pharmaceutical manufacturers to network, conduct business and learn about the most current strategic issues impacting the industry.”

969. Shortly after returning from that meeting, during the morning of October 15, 2014, Patel informed colleagues at Teva that Glenmark would be taking a price increase on

Gabapentin, and suggested that this would be a great opportunity to pick up some market share. The Glenmark price increase had not yet been made public, and would not be effective until November 13, 2014. Nonetheless, Patel informed her colleagues in an email that same day that there would be a WAC increase by Glenmark effective November 13, and that she had already been able to obtain certain contract price points that Glenmark would be charging to distributors. At around the time she sent the email, Patel exchanged two text messages with Jim Brown of Glenmark.

970. Having relatively little market share for Gabapentin, Teva discussed whether it should use the Glenmark price increase as an opportunity to pick up some market share. Over the next several weeks, Teva did pick up “a bit of share” to be more in line with fair share principles, but cautioned internally that it did not “want to disrupt Glenmark’s business too much.”

971. [REDACTED]

972. The ability of Aurobindo, Glenmark, and Teva to reach agreements on Gabapentin was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

973. [REDACTED]

974. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

975. The agreement between Defendants Aurobindo, Glenmark, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices,

rig bids, and engage in market and customer allocation for generic drugs, including Gabapentin Tablets (600, 800 mg).

59. Glimepiride

976. Glimepiride is a medication used to diabetes. It is available in a Tablet formulation. It has been available in the United States in a generic form for many years.

977. The market for Glimepiride is mature. At all relevant times, there have been multiple manufacturers of Glimepiride.

978. During the relevant time frame, Defendants Dr. Reddy's and Teva were the primary manufacturers of Glimepiride.

979. On August 28, 2014, Dr. Reddy's significantly increased its Glimepiride pricing. The increases were significant—with the Glimepiride WAC going up by approximately 300% across dosage strengths. Dr. Reddy's price increases for Glimepiride were preceded by frequent calls between a Vice President of Sales at Dr. Reddy's, and Teva's Patel. They also exchanged text messages on August 25, 2014, three days before the price increase. The Dr. Reddy's VP and Patel continued to communicate after the price increase as well.

980. Although Teva did not initially follow Dr. Reddy's price increases for Glimepiride, the Dr. Reddy's VP and Patel continued to communicate, and they exchanged four text messages on October 10, 2014.

981. Several months later, on January 25, 2015, Teva raised prices on a number of different drugs, including Glimepiride. Teva raised its list (WAC) prices to match Dr. Reddy's list prices exactly.

982. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

983. The ability of Dr. Reddy's and Teva to reach agreements on Glimepiride was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

984. The coordination by Dr. Reddy's and Teva is consistent with the Fair Share Agreement.

985. The agreement between Defendants Dr. Reddy's and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Glimepiride Tablets.

60. Griseofulvin

986. Griseofulvin is a medication used to treat fungal infections. It is available in a Suspension formulation. It has been available in the United States in a generic form for many years.

987. The market for Griseofulvin is mature. At all relevant times, there have been multiple manufacturers of Griseofulvin.

988. During the relevant time frame, Defendants Actavis and Teva were the primary manufacturers of Griseofulvin.

989. On September 9, 2014, Actavis notified its customers of a price increase on Griseofulvin Suspension (Micro). From September, through the day of the price increase Patel and Rekenhler communicated with Falkin and Rogerson of Actavis to coordinate the increase over the course of at least ten telephone calls.

990. Teva added Griseofulvin to its own price increase list, with the notation “Follow Competitor – Actavis” as the reason for the price increase, and followed the Actavis increase for Griseofulvin during its next price increase event on January 28, 2015.

991. As with the Actavis price increase in September, in the days leading up to the January 2015 price increase, Rekenhler of Teva and Falkin of Actavis coordinated frequently.

992. Teva’s price increase for Griseofulvin matched Actavis’s list (WAC) pricing exactly.

993. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

994. The ability of Actavis and Teva to reach agreements on Griseofulvin was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

995. The coordination by Actavis and Teva is consistent with the Fair Share Agreement.

996. The agreement between Defendants Actavis and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Griseofulvin Suspension (Micro).

61. Halobetasol Propionate

997. Halobetasol Propionate is a corticosteroid used to treat a variety of skin conditions such as eczema, dermatitis, psoriasis, and rash. It is available in Ointment (0.05%) and Cream (0.05%) formulations, and has been available in the United States for decades in a generic form.

998. The market for Halobetasol Propionate is mature. At all relevant times, there have been multiple manufacturers of Halobetasol Propionate.

999. Defendants G&W, Perrigo, Sandoz, and Taro dominate sales of Halobetasol Propionate. During much of the relevant time period, G&W and Perrigo had a roughly 40/60 split of the markets for both Ointment (0.05%) and Cream (0.05%). Defendant Sandoz rejoined the market for Cream in early 2014, growing to a smaller but still sizeable share of the cream. Defendant Taro rejoined the market for Cream and Ointment in summer 2014 and had small shares of both.

1000. [REDACTED]

[REDACTED]


[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1001. The GAO noted that the Halobetasol Propionate 0.05% Ointment and 0.05% Cream had “extraordinary price increases” in the years 2013-2014.



Under the Fair Share Agreement, Sandoz and Taro did not attempt to undercut competitors’ prices in order to gain additional market share. When reentering the market and gaining share, Sandoz and Taro targeted the competitor with the higher market share in order to maintain market share at what they considered to be “fair share.” For example, in December 2013, when Sandoz was planning its relaunch of the 0.05% Cream, Arpad Szechenyi of Sandoz noted in internal Sandoz emails that G&W had 63% of the market and Perrigo had 36% and that Sandoz would seek to “[t]ake most of the share from G&W and one smaller account from Perrigo.” Likewise, when Taro was relaunching the 0.05% Ointment, Taro made an offer at Publix, and Publix reached out to Perrigo to see if Perrigo would match Taro’s price proposal.

Internally, Perrigo employees discussed conceding market share on Halobetasol Propionate to Taro, as it was the new entrant. Tony Polman of Perrigo said, [REDACTED]

[REDACTED]

1003. The ability of G&W, Perrigo, Sandoz, and Taro to reach agreement regarding Halobetasol Propionate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

[REDACTED]

1005. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1006. The agreement between Defendants G&W, Perrigo, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Halobetasol Propionate Ointment (0.05%) and Cream (0.05%).

62. Haloperidol


1007. Haloperidol is an antipsychotic used to treat disorders such as schizophrenia and Tourette syndrome. It is available in a Tablet (0.5, 1, 2, 5, 10, 20 mg) formulation and has been available in the United States for many years in a generic form.

1008. The market for Haloperidol is mature. At all relevant times, there have been multiple manufacturers.

1009. During the relevant time frame, Defendants Mylan, Sandoz, and Zydus were the primary manufacturers of Haloperidol Tablets.

1010. For years, the prices for Haloperidol tablets were relatively low and stable. In the summer of 2013, however, the manufacturers of Haloperidol were determined to raise prices. In the second half of 2013, they did so. For example, on the 5 mg dosage, Mylan first announced a list (WAC) price increase that more than tripled its prices. Sandoz followed the increase, announcing similar list (WAC) prices in January 2014. And Zydus, which entered the market in the fall of 2014, offered virtually identical prices as Mylan and Sandoz instead of trying to win customers through price competition.

1011. The NSP data also shows Mylan, Sandoz, and Zydus pricing:



1012. Throughout this period, Mylan, Sandoz and Zydus met at trade conferences and communicated directly with each other in furtherance of their price fixing agreement on Haloperidol and of their Fair Share Agreement.

1013. For example, in July 2013, Sandoz executives were carefully monitoring the generic market in order to ensure that they adhered to the Fair Share Agreement. Sandoz did not want to accidentally poach customers from its co-conspirators. As part of this effort, D.L., a Sandoz Director of National Accounts, called her contact at Mylan, Jim Nesta, and obtained a list of drugs for which Mylan had increased prices, including Haloperidol, so that Sandoz could follow with its own price increase.

1014. Not long after, Nesta twice called this Director of National Accounts at Sandoz on August 6, a few days before Mylan imposed price increases on Haloperidol. On August 9, 2013, Mylan implemented significant list price increases on Haloperidol.

1015. Nesta also kept Zydus in the loop. On August 15, Nesta and K.R., a Vice President of Sales at Zydus, exchanged text messages, and the next day the two spoke by phone.

1016. After the Mylan price increase, Sandoz and Zydus were careful not to take business and instead endeavored to maintain high prices, as contemplated by the Fair Share Agreement.

1017. For example, on October 2, 2013, M.V., the Associate Director of Pricing at Sandoz, advised a colleague to decline to bid on Haloperidol and Trifluoperazine: “We have been running up against Mylan a lot lately (Nadolol, Benaz/Hctz), and fear blowback if we take on any more products at this moment. Trying to be responsible in the sandbox.” M.V. went on to suggest that a pretextual excuse be offered to the customer: “I recommend you blame supply.” Of course, the real reason for turning down the competitive opportunity was Sandoz’s adherence to the Fair Share Agreement.

1018. On October 3, 2013, the day after this internal discussion at Sandoz in which it reaffirmed its commitment to “be responsible in the sandbox,” D.L. (Sandoz Director of National

Accounts) and Nesta of Mylan spoke by phone. The two spoke again on October 4 and 14, 2013. Nesta also exchanged text messages with the VP of Sales at Zydus on October 9, 2013. Not long after, Sandoz increased its pricing on Haloperidol.

1019. In November and December of 2013, as well as in January, February, March, April, June, July, August, September, and October of 2014, Nesta (Mylan) and Kevin Green (who by then had left Teva and had begun working at Zydus) communicated by phone numerous times. Zydus also joined the Haloperidol price increases during this period.

1020. [REDACTED]

1021. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1022. The agreement between Defendants Mylan, Sandoz, and Zydus was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Haloperidol Tablets (0.5, 1, 2, 5, 10, 20 mg).

63. Hydrocodone Acetaminophen

1023. Hydrocodone Acetaminophen is a pain reliever and is available in tablet form in multiple strengths, including 5-325 mg and 10-325 mg Tablets. It has been available in the United States for over a decade in a generic form.

1024. The market for Hydrocodone Acetaminophen 5-325 mg and 10-325 mg Tablets is mature. At all relevant times, there have been multiple manufacturers.

1025. Amneal, Mallinckrodt, Par, and Teva dominated the sales of Hydrocodone Acetaminophen 5-325 mg and 10-325 mg Tablets in the relevant period with Mallinckrodt, Par, and Teva having roughly equal shares of the 5-325 mg Tablet market, and Amneal having a


smaller share. On the 10-325 mg Tablets, Mallinckrodt and Par had large shares of the market, Teva had a smaller but still significant share, and Amneal had a relatively small share of the market.

1026. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1027. [REDACTED]

1028. The ability of Amneal, Mallinckrodt, Par, and Teva to reach agreements on Hydrocodone Acetaminophen was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1029. [REDACTED]



1030. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1031. The agreement between Defendants Amneal, Mallinckrodt, Par, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise

prices, rig bids, and engage in market and customer allocation for generic drugs, including Hydrocodone Acetaminophen Tablets (5-325, 10-325 mg).

64. Hydrocortisone Valerate

1032. Hydrocortisone Valerate is a corticosteroid used to treat a variety of skin conditions such as eczema, dermatitis, psoriasis, and rash. It is available in a Cream (0.2%) formulation and has been available in the United States for decades in a generic form.

1033. The market for Hydrocortisone Valerate is mature. At all relevant times, there have been multiple manufacturers of Hydrocortisone Valerate.

1034. Defendants G&W, Perrigo, and Taro dominate sales of Hydrocortisone Valerate Cream (0.2%). [REDACTED]

[REDACTED]


[REDACTED]

1035. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1036. The GAO noted that the Hydrocortisone Valerate 0.2% Cream had an “extraordinary price increase” in the years 2013-2014.

1037. [REDACTED]

1038. The ability of G&W, Perrigo, and Taro to reach agreement regarding Hydrocortisone Valerate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).



1040. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1041. The agreement between Defendants G&W, Perrigo, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Hydrocortisone Valerate Cream (0.2%).

65. Irbesartan

1042. Irbesartan, also known by the brand name Avapro, is a medication used in the treatment of hypertension and is available in a Tablet formulation. It has been available in the United States in a generic form for many years.

1043. The market for Irbesartan is mature. At all relevant times, there have been multiple manufacturers of Irbesartan.

1044. During the relevant time frame, Defendants Teva and Lupin were the primary manufacturers of Irbesartan.

1045. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Irbesartan Tablets beginning at least as early as the late winter into spring of 2012.

1046. Teva received approval to manufacture generic Irbesartan in March 2012.

1047. On March 6, 2012, K.G., a Teva senior marketing executive, asked the sales team for information about competitors that were also making offers to supply Irbesartan.

1048. At 11:27 am, J.P., an account manager at Teva, responded: "Lupin is promising offers today." Less than twenty minutes later, Teva's Kevin Green called David Berthold at Lupin. They talked for seventeen (17) minutes. Shortly after the call, Green emailed his Teva colleagues with the information he obtained: "Lupin is looking for a 15% share. They already have ABC. Confirmed Zydus is out."

1049. That same day, Teva's David Rekenhaller informed the group that he still had not received "a call from any other manufacturer on Irbesartan." A senior commercial operations executive at Teva immediately responded: "Then work harder..." Rekenhaller followed that directive.

1050. The next morning, Green called Berthold again. He learned details regarding which competitors were launching or not launching the drug and the identities of customers who received offers. As a result of the coordination with Lupin, Teva was in a position to take up to a 40% market share when it launched Irbesartan without having to engage in price competition.

1051. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1052. The ability of Teva and Lupin to reach agreements on Irbesartan was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1053. The coordination by Teva and Lupin is consistent with the Fair Share Agreement.

1054. The agreement between Defendants Teva and Lupin was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Irbesartan Tablets.

66. Isosorbide Dinitrate

1055. Isosorbide Dinitrate is a commonly prescribed medication used to prevent chest pain (angina) in patients with coronary artery disease. It has been on the market for decades and is available in several dosages, including 5 mg, 10 mg, 20 mg, and 30 mg Tablets.

1056. The market for Isosorbide Dinitrate is mature. At all relevant times, there have been multiple manufacturers. Defendants Sandoz, Par, and West-Ward dominated sales of Isosorbide Dinitrate in the relevant period. Sandoz and West-Ward roughly split the market at

the time of the price increase on the 5 mg, 10 mg, and 20 mg Tablets. Par re-entered the market later and regained a roughly equal share. On the 30 mg Tablets, Par had approximately 90% of the market share, and West-Ward had approximately 10% of the market share during the relevant time period.

1057. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1058. [REDACTED]

[REDACTED]

[REDACTED]

1059. Pursuant to Defendants' agreement, their price increases had no significant impact of their respective market shares.

1060. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including Par, Sandoz, and West-Ward. Co-Defendant Teva identified both Par and Sandoz as competitors willing to coordinate price increases under the Fair Share Agreement. Defendants' coordination included raising Isosorbide Dinitrate prices.

1061. The ability of Par, Sandoz, and West-Ward to reach agreement regarding Isosorbide Dinitrate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1062. [REDACTED]

1063. The agreement between Defendants Par, Sandoz, and West-Ward was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Isosorbide Dinitrate Tablets (5, 10, 20, 30 mg).

67. Ketoconazole

1064. Ketoconazole is a commonly prescribed antifungal medication that has been available in the United States for decades as a generic. It is available as a Tablet to treat certain serious fungal infections in the body and as a Cream to treat fungal infections of the skin.


1065. The market for Ketoconazole is mature. At all relevant times, there have been multiple manufacturers of both Ketoconazole Tablets and Cream. Defendants G&W, Sandoz,

Taro, and Teva dominated sales of Ketoconazole Cream in the relevant period. Defendants Mylan, Taro, and Teva dominated sales of Ketoconazole Tablets in the relevant period.

1066. [REDACTED]

[REDACTED]:

[REDACTED]



1067. The GAO noted that Ketoconazole had “extraordinary price increases” in 2014-2015.

1068. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including G&W, Mylan, Sandoz, Teva, and Taro.

1069. When Defendant Teva increased prices for Ketoconazole on April 4, 2014, it made sure to coordinate with all of its competitors in doing so. Teva’s price increases doubled its WAC price for Ketoconazole Cream and tripled its WAC price for 200 mg Tablets, which would leave it vulnerable to challenges unless it coordinated the price increases with its competitors. In a practice that had now become routine at Teva, leading up to the price increase Patel and Rekenhaller both were communicating frequently with competitors, including in this case, Taro, and Sandoz. For example, Patel called Taro’s Aprahamian twice on March 10, 2014,

before he returned her call at 10:46 am, at which time they spoke for five minutes. On March 17, 2014, she returned a call he had made two minutes earlier and they spoke for nine minutes. Patel also spoke with Sandoz's M.V. on March 31, 2014, for fifteen minutes. On April 4, 2014 – the day of the Ketoconazole increases – Patel spoke separately with both Aprahamian of Taro and M.V. of Sandoz. During each call, she let them know that Teva was increasing the price of its Ketoconazole products. Patel's call with M.V. lasted over twenty-five minutes. Rekenthaler relayed the same message when he spoke to Nesta of Mylan that same day for six minutes.

1070. M.V. at Sandoz immediately told his colleagues not to bid on any new opportunities for the drugs, and instead put the products on "strict allocation" until Sandoz determined how to proceed. That same day, Aprahamian sent a similar internal email to his colleagues at Taro.

1071. Co-conspirators at Taro and Sandoz also communicated directly with each other to coordinate the price increases. On April 4, 2014, for example, Aprahamian spoke to C.B. at Sandoz for nineteen minutes. They discussed Teva's 2% Cream price increase and the fact that Taro would match. C.B. then sent an email internally at Sandoz, alerting colleagues of the price increase and conveying information about Taro's own plans to increase prices.

1072. Four days after Teva increased its Ketoconazole products, on April 8, 2014, Aprahamian called Patel and the two spoke for more than nineteen minutes. Later that same day, Aprahamian initiated a price increase for all of Taro's customers on Ketoconazole. Aprahamian directed that notice letters be sent to customers on April 16, 2014, with an effective date of April 17, 2014. Like Teva, Taro's WAC prices doubled for Ketoconazole Cream and tripled for Tablets.

1073. Previously, in anticipation of its own price increase, on April 7, 2014, Taro turned down an opportunity to bid on Ketoconazole 200 mg Tablets. After reviewing the request, a Taro sales executive sent an internal email stating: “we are not going to bid this product. . . . Taro has 27% share in a 4-player market.” In a follow-up email, E.G., a Director of Corporate Accounts at Taro, confirmed that Taro would decline to bid, but indicated that Taro would need to lie about the reason: “Yes, we are declining, but we need to advise its [sic] due to supply.”

1074. Teva upheld its end of the deal on multiple occasions by not encroaching on its competitors’ market share. For example, on May 14, 2014, Patel directed Teva to decline to bid for Ketoconazole at AmerisourceBergen, citing the same logic Taro used: “unable to bid (strategic reasons, for internal purposes).” Again on August 8, 2014, Teva turned down a Ketoconazole bid request from McKesson, reasoning in an internal email: “we just implemented the increase and we have very high share so whomever is challenging will continue to look elsewhere until they find their piece of the pie.” And again on April 14, 2014, in another internal email, it noted simply: “Ketoconazole. Decline to adjust. We have lead share.”

1075. Although Sandoz immediately understood that it would match Teva and Taro’s price increases for Ketoconazole Cream, it could not implement the price increase until October. Sandoz’s contracts with certain customers contained price protection terms, which would impose substantial penalties if Sandoz increased its prices at that time – and those penalties would have caused Sandoz to miss certain financial targets during the months after April 2014. At Sandoz, senior management held monthly budget meetings where they analyzed whether it made financial sense to implement a particular price increase. In the case of Ketoconazole, the ramifications of the price protection terms did not make sense for Sandoz to follow until October 2014. When Sandoz ultimately matched the Teva and Taro increases for Ketoconazole Cream

on October 10, 2014, Patel and M.V. at Sandoz spoke for more than three minutes. Sandoz's WACs matched Teva and Taro's and doubled its prior price.

1076. [REDACTED]

1077. The agreement between Defendants G&W, Mylan, Sandoz, Taro, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Ketoconazole Cream and Tablets.

68. Ketoprofen

1078. Ketoprofen, also known by the brand name Dolobid, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain, and to relieve symptoms of arthritis, such as inflammation, swelling, stiffness, and joint pain. It is available as a Capsule and has been available in the United States in a generic form for many years.

1079. The market for Ketoprofen Capsules was mature and at all relevant times had multiple manufacturers.

1080. During the relevant time frame, Defendants Teva and Mylan were the primary manufacturers of Ketoprofen Capsules.

1081. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Ketoprofen beginning at least as early as September 2012.

1082. In the summer of 2013, Teva's Patel said she had heard "rumors of activity," *i.e.*, a price increase, on Ketoprofen. "Rumors" was a term consistently used by Patel in emails to as a euphemism for communicating with competitors about future price increases.

1083. On June 28, 2013, Teva's Green and Mylan's Nesta spoke on the phone. Shortly thereafter, Patel sent an email internally at Teva stating that Mylan was announcing price increases that day, including for Ketoprofen. In actuality, Mylan did not announce the price increases until July 1, 2013, with an effective date of July 2, 2013. Teva followed on August 9, 2013.

1084. As Teva prepared to follow the Mylan increase, the companies were in frequent contact. For example, on July 10, 2013, Green and Nesta spoke twice, and the next day, Nesta and Green exchanged several more calls. In addition, Green spoke to Nesta on August 1 (two calls), 2, 6 (three calls), and 8 (three calls), 2013.

1085. The day before Teva officially followed Mylan's price increase – August 8, 2013 – Patel spoke directly to Nesta.

1086. On January 28, 2015, Teva again raised its price on Ketoprofen capsules. Again, Teva's Patel and Rekenhaller communicated with Mylan before doing so. For example, Rekenhaller spoke to Nesta of Mylan on January 14 (2 calls) and January 20, 2015.

1087. The ability of Teva and Mylan to reach agreements on Ketoprofen Capsules was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1088. The coordination by Teva and Mylan is consistent with the Fair Share Agreement.

1089. The agreement between Defendants Teva and Mylan was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Ketoprofen Capsules.


69. Ketorolac Tromethamine

1090. Ketorolac Tromethamine is a medication used to treat pain. It is available in a Tablet formulation. It has been available in the United States in a generic form for many years.

1091. The market for Ketorolac Tromethamine is mature. At all relevant times, there have been multiple manufacturers of Ketorolac Tromethamine.

1092. During the relevant time frame, Defendants Mylan and Teva were the primary manufacturers of Ketorolac Tromethamine.

1093. For years, the prices of Ketorolac Tromethamine Tablets were relatively low and stable. As with numerous other drugs during manufactured by Teva and Mylan, things changed in mid-2012, when those manufacturers began to implement coordinated and sustained price increases.



1094. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1095. The ability of Mylan and Teva to reach agreements on Ketorolac Tromethamine was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1096. Throughout 2012, 2013, and 2014, Teva and Mylan were also in regular communication for the purposes of fixing the prices of generic drugs, including Ketorolac Tromethamine. For example, Teva’s Green and Mylan’s Nesta spoke many times by phone in 2012 and 2013. In 2014, Teva’s Reckenthaler stepped in for Green and communicated directly with Nesta to work out pricing and Fair Share for Ketorolac Tromethamine and other drugs.

1097. The coordination by Mylan and Teva is consistent with the Fair Share Agreement.

1098. The agreement between Defendants Mylan and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Ketorolac Tromethamine.

70. Labetalol HCL

1099. Labetalol HCL is a beta-blocker used to treat high blood pressure. It has been in the United States market for years and is available in, for example, Tablets (100, 200, 300 mg).

1100. [REDACTED]

[REDACTED]

[REDACTED]

1101. [REDACTED]

[REDACTED]. The GAO observed “extraordinary price increases” for Labetalol around that time. [REDACTED].

1102. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including Actavis, Par, Sandoz, and Teva.

1103. Before raising its price on Labetalol, Teva coordinated with its competitors. For example, Teva's Green spoke to a contact at Sandoz twice on July 29, and once on July 31, 2012. Teva's Rekenhaller spoke twice with a senior Actavis sales executive on July 11, 2012.

1104. After Teva increased its pricing on Labetalol in the summer of 2012, it continued to coordinate with its competitors to maintain supracompetitive pricing for the drug. For example, on October 16, 2012, Green again spoke to his Sandoz contact two (2) times. After those calls, Green emailed a Teva colleague: "Sandoz is back in good supply. They took a 500% price increase several months back, and they are holding firm with their prices. Stay the course and maintain our higher price."

1105. Meanwhile, Teva's Rekenhaller worked the phones to confirm that Actavis was also still committed to the Labetalol HCL price-fixing agreement. To that end, on October 18, 2012, Rekenhaller spoke with the senior sales executive at Actavis by phone four (4) times.

1106. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1107. The agreement between Defendants Actavis, Par, Sandoz, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Labetalol HCL (100, 200, 300 mg)

71. Lamivudine/Zidovudine

1108. Lamivudine/Zidovudine, also known by the brand name Combivir, is a combination of medications available in a Tablet and used in the treatment of human

immunodeficiency virus (HIV) infection. It has been available in the United States in a generic form for many years.

1109. The market for generic Combivir is mature. At all relevant times, there have been multiple manufacturers of generic Combivir.

1110. During the relevant time frame, Defendants Teva, Lupin, Aurobindo, and Camber were the primary manufacturers of generic Combivir.

1111. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of generic Combivir Tablets beginning at least as early as April 2012. Teva launched its generic Combivir product in December 2011. In mid-May, 2012, two competitors – Lupin and Aurobindo – received FDA approval for generic Combivir and were preparing to enter the market.

1112. Even before Lupin and Aurobindo obtained FDA approval, Teva was communicating with both about how to divvy up the market. In late April 2014, Teva's Rekenhaller was speaking to the CEO at Aurobindo, who was a former colleague of Rekenhaller's at Teva. Meanwhile, Teva's Green was speaking to David Berthold, an executive at Lupin, and Jim Grauso at Aurobindo.

1113. In early May 2014, with the Lupin and Aurobindo launches just days away, communications among all three competitors accelerated. Between May 7 and 10, 2014, for example, the three companies spoke at least 32 times. Green (Teva), Berthold (Lupin), and Grauso (Aurobindo) discussed the specific customers that Teva would concede in order to ensure that Lupin and Aurobindo gained a Fair Share of the market without eroding prices.

1114. Similarly, when Camber received approval to market a generic form of Combivir, Teva, again, coordinated the entry. Konstantin Ostaficiuk, the President of Camber,

communicated with Rekenhler of Teva and Berthold of Lupin to negotiate Camber's entry into the market. For example, on September 24, 2014, Ostaficiuk spoke to Rekenhler three times and to Berthold twice. That same day, Berthold also spoke to a senior operations executive at Aurobindo, to close the loop on generic Combivir communications.

1115. By coordinating the entry of competitors into the generic Combivir market, Teva, Lupin, Aurobindo and Camber were able to keep prices higher than they would have been in a competitive market.

1116. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1117. The ability of Teva, Lupin, Aurobindo, and Camber to reach agreements on generic Combivir tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1118. The coordination by Teva, Lupin, Aurobindo, and Camber is consistent with the Fair Share Agreement.

1119. The agreement between Defendants Teva, Lupin, Aurobindo, and Camber was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including generic Lamivudine/Zidovudine Tablets.

72. Latanoprost

1120. Latanoprost is used to treat glaucoma and high pressure in the eyes. It has been available in the United States for many years in a generic form.

1121. The market for Latanoprost Ophthalmic Liquid Eye (0.005%) is mature. At all relevant times, there have been multiple manufacturers.

1122. [REDACTED]

[REDACTED]

1123. [REDACTED]

[REDACTED]

[REDACTED]

1124. The ability of Akorn, Bausch, Greenstone, and Sandoz to reach agreements on Latanoprost was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1125. [REDACTED]

[REDACTED]

1126. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1127. The agreement between Defendants Akorn, Bausch, Greenstone, and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Latanoprost Ophthalmic Liquid Eye (0.005%).

73. Lidocaine HCL

1128. Lidocaine HCL is a local anesthetic used on the skin to stop itching and pain from certain skin conditions. Some forms of this medication are also used to decrease discomfort or pain during certain medical procedures. It is available in many forms including Ointment. Lidocaine HCL has been available in the United States for decades in a generic form.

1129. The market for Lidocaine HCL is mature. At all relevant times, there have been multiple manufacturers of Lidocaine HCL.


1130. Defendants Akorn, Sandoz, and Taro dominate sales of Lidocaine HCL 5% Ointment. During much of the relevant time period, Akorn, Sandoz, and Taro roughly split the market for Lidocaine HCL 5% Ointment in equal shares.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1132. [REDACTED].

1133. The ability of Akorn, Sandoz, and Taro to reach agreements regarding Lidocaine HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1134. [REDACTED]

[REDACTED]

1135. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1136. The agreement between Defendants Akorn, Sandoz, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig

bids, and engage in market and customer allocation for generic drugs, including Lidocaine HCL Ointment (5%).

74. Loperamide HCL

1137. Loperamide HCL is a medication used to treat diarrhea. It is available in a Capsule formulation. It has been available in the United States in a generic form for many years.

1138. The market for Loperamide HCL is mature. At all relevant times, there have been multiple manufacturers of Loperamide HCL.

1139. During the relevant time frame, Defendants Mylan and Teva were the primary manufacturers of Loperamide HCL.

1140. [REDACTED]

[REDACTED].

[REDACTED]

1141. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1142. The ability of Mylan and Teva to reach agreements on Loperamide HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1143. Throughout this period, Teva and Mylan also communicated directly with each other in furtherance of their price-fixing agreements on Loperamide HCL capsules and other drugs.

1144. For example, in the weeks leading up to the first price increase for Loperamide, Teva's Green spoke to Nesta of Mylan on July 23, 24 (2 calls), 25, 26, 30 (2 calls), and 31, 2012.

1145. The two companies even went so far as to share internal documents and analyses on some occasions. For example, on April 21, 2014, a national account executive at Teva forwarded to Patel two spreadsheets—that were created by Mylan personnel—that included information about Mylan's Loperamide price increases.

1146. With Mylan's price increase information in hand, Teva began to plan how to follow those increases, and communicated directly with Mylan to work out the details. To that end, Teva's Rekenhaller spoke to Nesta at Mylan a number of times in May 2014 and a number of additional times in August 2014.

1147. [REDACTED]

1148. The agreement between Defendants Mylan and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and

engage in market and customer allocation for generic drugs, including Loperamide HCL Capsules.

75. Metformin ER (F)

1149. Metformin ER (F) is a drug used to treat high blood sugar levels caused by type 2 diabetes, and is available as a Tablet (500 and 1000 mg). It has been available in the United States for over a decade in a generic form. Due to, among other things, its clinical efficacy and safety, Metformin has been designated as a model essential medicine by the World Health Organization.

1150. The market for Metformin ER (F) is mature. At all relevant times, there have been multiple manufacturers of Metformin ER (F).

1151. Defendants Actavis and Lupin dominate sales of Metformin ER (F) Tablets (500, 1000 mg). [REDACTED]



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1153. [REDACTED] Under the Fair Share Agreement, Actavis and Lupin did not attempt to undercut competitors' prices in order to gain additional market share

1154. The ability of Actavis and Lupin to reach agreements regarding Metformin ER (F) was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1155. [REDACTED]
[REDACTED]

1156. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1157. The agreement between Defendants Actavis and Lupin was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Metformin ER (F) Tablets (500, 1000 mg).

76. Methadone HCL

1158. Methadone HCL is an opioid analgesic used to treat addiction to opioids. It is available in Injectable, Tablet, and Oral Liquid formulations. It has been available in the United States for decades in a generic form. Due to, among other things, its clinical efficacy and safety, Methadone HCL has been designated as a model essential medicine by the World Health Organization.

1159. The market for Methadone HCL is mature. At all relevant times, there have been multiple manufacturers of Methadone HCL.

1160. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]


[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1162. The GAO noted that the Methadone HCL 5 mg Tablets had an “extraordinary price increase” in the years 2014-2015.

1163. [REDACTED]

1164. The ability of Mallinckrodt and West-Ward to reach agreement regarding Methadone HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1165. [REDACTED]

[REDACTED]

1166. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1167. The agreement between Defendants Mallinckrodt and West-Ward was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Methadone HCL Tablets (5, 10 mg).

77. Methazolamide

1168. Methazolamide is a drug used to treat ocular conditions, including several types of glaucoma. It is available in Tablet form in 25 mg and 50 mg dosages.

1169. During the relevant time frame, Perrigo and Sandoz were the primary manufacturers of Methazolamide.

1170. Plaintiffs allege that as part of Defendants' Fair Share Agreement, Defendants Perrigo and Sandoz conspired to fix, raise, maintain or stabilize the prices of Methazolamide beginning at least as early as 2014.

1171. In early 2014, Sandoz temporarily withdrew from the Methazolamide market because of supply issues, leaving Perrigo without a major competitor.

1172. As the only manufacturer with the ability to supply Methazolamide, Perrigo instituted a large price increase in the spring of 2014.

1173. By June 2014, Sandoz reentered the Methazolamide market. The day that Perrigo learned of Sandoz's reentry, T.P., Perrigo's Director of National Accounts, and C.B., Sandoz's Director of National Accounts, began communicating about pricing. Through their discussions, T.P. learned that Sandoz reentered only the 25 mg market, and did so at its former, lower price. Internally, Perrigo lamented that Sandoz reentered without "[REDACTED]"


1174. To rectify the price disparity between Perrigo and Sandoz's 25mg Methazolamide Tablets, Perrigo's T.P. spoke with C.B. in October 2014, and provided him with Perrigo's

increased pricing for both Methazolamide 25 mg and 50 mg. C.B. kept notes of his conversation with T.P.

1175. Internally, Sandoz prepared to increase its prices on its 25mg Methazolamide tablets, and reenter the 50mg Methazolamide tablet market at Perrigo's increased price. In November and December 2014, Perrigo's T.P. and Sandoz's C.B. continued to communicate by phone, and C.B. shared with his supervisors at Sandoz the confidential information about Perrigo that he received from T.P.

1176. In December 2014, Sandoz increased its Methazolamide 25 mg Tablet prices to match Perrigo's. On the same day, Sandoz relaunched its Methazolamide 50 mg Tablet and matched Perrigo's increased price.

1177. Perrigo and Sandoz's Methazolamide 25 mg Tablet parallel price increases are illustrated in the chart below. Prices for Perrigo and Sandoz's Methazolamide 25mg Tablets exhibited similar behavior.



1178. [REDACTED]

1179. As a result of the agreement and anticompetitive coordination between Perrigo and Sandoz, prices for Methazolamide were higher than they would have been in a competitive market.

1180. The ability of Perrigo and Sandoz to reach agreement regarding Methazolamide was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1181. [REDACTED]
[REDACTED]

1182. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1183. The agreement between Defendants Perrigo and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Methazolamide Tablets (25 mg and 50 mg).


78. Methotrexate

1184. Methotrexate is an antimetabolite used to treat cancer by slowing the growth of cancer cells. It is available in Tablet and Injection formulations. It has been available in the United States for decades in a generic form. Due to, among other things, its clinical efficacy and safety, Methotrexate has been designated as an essential medicine by the World Health Organization.

1185. The market for Methotrexate is mature. At all relevant times, there have been multiple manufacturers of Methotrexate.

1186. [REDACTED]

1187. [REDACTED]



1188. The GAO noted that Methotrexate 2.5 mg Tablets had an “extraordinary price increase” in the years 2013-2014.

1189. Documentary evidence confirmed that these parallel price increases were the result of collusion among generic drug manufacturers Mylan, Par, Teva, and West-Ward.

1190. Immediately after she began working at Teva, Nisha Patel began to investigate Mylan drugs as a potential source for coordinated price increases. In May 2013, Patel asked Kevin Green of Teva to look into certain drugs, including Methotrexate. The next day, Green spoke to Jim Nesta at Mylan three times and then reported back to Patel. Green and Nesta spoke a number of times over the next several days. On May 29, 2013, after a discussion with Maureen Cavanaugh of Teva, Patel added four Mylan drugs to the Teva price increase list, including Methotrexate. Discussions between Green and Nesta about specific drugs continued into June.

1191. On July 2, 2013 – the day before Teva’s price increases went into effect, including for Methotrexate– a colleague asked Patel how Teva’s competitors’ pricing compared with respect to Methotrexate. Patel responded that Mylan’s pricing was a little low on the drug, “but we are hearing rumors of them taking another increase,” so Teva felt comfortable increasing the price of that drug on July 3, 2013. These “rumors” – which were based on the direct communications between Green and Nesta noted above – again turned out to be accurate: Mylan increased its price of Methotrexate, pursuant to its agreement with Teva, on November 15, 2013.

1192. There are some indications of supply issues on Methotrexate in spring 2013, around the time of the price increases, but the over 600% price increase went far beyond what market conditions required. [REDACTED]

[REDACTED] far longer than what would be expected due to a temporary supply issue.

1193. Under the Fair Share Agreement, Mylan, Par, Teva, and West-Ward did not attempt to undercut competitors’ prices in order to gain additional market share. For example, in May 2014, internal Teva emails show that Teva was seeking share from West-Ward to maintain fair share. J.B. of Teva wrote to Nisha Patel of Teva, suggesting that they should look at Walmart as a possible share pickup because Walmart was with Teva. Nisha Patel wrote back in favor of pursuing a West-Ward customer, noting that “We are trying to be responsible and really need to pick up share.”

1194. The ability of Mylan, Par, Teva, and West-Ward to reach agreements on Methotrexate Tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1195. [REDACTED]

[REDACTED]

1196. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1197. The agreement between Defendants Mylan, Par, Teva, and West-Ward was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Methotrexate Tablets.

79. Methylphenidate

1198. Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD). It is available in Immediate Release (“IR”) Tablet, Chewable Tablet, Long-Acting Extended Release (“ER”) Tablet, and Liquid formulations. It has been available in the United States for decades in a generic form.

1199. The market for Methylphenidate is mature. At all relevant times, there have been multiple manufacturers of Methylphenidate.

1200. Plaintiffs allege that as part of Defendants’ Fair Share Agreement, Defendants Actavis, Impax, Mallinckrodt, Par, Sandoz, and Sun conspired to fix, raise, maintain or stabilize the prices of Methylphenidate beginning at least as early as the March 2013.

1201. Defendants Actavis, Impax, Mallinckrodt, Par, Sandoz, and Sun dominate sales of Methylphenidate IR Tablets. As of November 2012, Defendants Sandoz and Mallinckrodt were the manufacturers of Methylphenidate ER Tablets.

1202. [REDACTED]

[REDACTED]

[REDACTED]

1203. [REDACTED]

[REDACTED]

1204. On February 13, 2013, L.J., a Sandoz sales executive, circulated an internal email asserting that he heard that Mallinckrodt was experiencing Methylphenidate supply disruptions. On the same day, C.B., a Sandoz National Account Executive, called K.K., a senior Mallinckrodt sales executive, and Ara Aprahamian, an Actavis sales executive. After C.B.'s conversations, he informed D.P., a senior Sandoz sales executive, of his discussions.

1205. C.B. also circulated an internal email on February 13, 2013, relaying that Mallinckrodt was temporarily discontinuing most of its IR Tablet line, and its 20mg ER Tablet. In response, [REDACTED]

[REDACTED]

1206. To coordinate the price increase, C.B. began reaching out to representatives at Mallinckrodt. For example, on March 1, 2013, C.B. exchanged nine (9) text messages with W.K., Vice President and General Manager at Mallinckrodt. C.B. took contemporaneous notes of their conversation.

1207. C.B. also exchanged at least twenty-three (23) calls with Mallinckrodt's W.K. and K.K., and six (6) calls with Ara Aprahamian of Actavis, between March 3 and March 8, 2013.

1208. [REDACTED]

[REDACTED]

1209. Between March 13 and April 2, 2013, Sandoz's C.B. and Mallinckrodt's K.K. exchanged numerous text messages. C.B. also had frequent communication with Actavis's Aprahamian.



1210. From April 20 to April 23, 2013, representatives from Sandoz, Mallinckrodt, Actavis, Sun, and Taro attended the NACDS annual meeting in Palm Beach, Florida. Representatives included Sandoz's D.P., Mallinckrodt's K.K., Sun's G.S., and Taro's Perfetto and J.K.


1211. On April 24, 2013, the day after the NACDS annual meeting concluded, Actavis matched Sandoz's Methylphenidate IR Tablet price increase. Shortly thereafter, Sun and Impax entered the IR Tablet market at the elevated price point.

1212. On May 1, 2013, Mallinckrodt reentered the market for both Methylphenidate IR and ER Tablets, and quickly matched competitor price points on both formulations.

1213. [REDACTED]

[REDACTED] The parallel price increases and coordinated market entrances for Methylphenidate IR Tablets are illustrated in the chart below:






1214. [REDACTED]

1215. Under the Fair Share Agreement, Actavis, Impax, Mallinckrodt, Par, Sandoz, and Sun did not attempt to undercut competitors' prices in order to gain additional market share. For example, in an internal Sandoz email regarding a Methylphenidate price increase proposal, D.D. of Sandoz wrote to colleague R.T., "Any incremental supply would look to (best case) maintain our share of the market." Along similar lines, in an internal Sun email, D.V. of Sun wrote to colleague G.S., noting that on Methylphenidate IR Tabs, "We are at 2% market share (versus budget and fair of 17%)."

1216. [REDACTED]



1217. The ability of Actavis, Impax, Mallinckrodt, Par, Sandoz, and Sun to reach agreements regarding Methylphenidate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1218. [REDACTED]

1219. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1220. The agreement between Defendants Actavis, Impax, Mallinckrodt, Par, Sandoz, and Sun was part of an overarching conspiracy between generic drug manufacturers to fix,

stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Methylphenidate IR and ER Tablets.

80. Methylprednisolone

1221. Methylprednisolone is an adrenocortical steroid used to treat inflammatory conditions like arthritis, lupus, psoriasis, and ulcerative colitis. It is available in Tablet, Suspension, and Injection formulations. It has been available in the United States for decades in a generic form.

1222. The market for Methylprednisolone is mature. At all relevant times, there have been multiple manufacturers of Methylprednisolone.

1223. Defendants Breckenridge, Cadista, Greenstone, Par, and Sandoz dominate sales of Methylprednisolone Tablets (4 mg). [REDACTED]

[REDACTED]


[REDACTED]

1224. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1225. The GAO noted that the Methylprednisolone 4 mg Tablets had an “extraordinary price increase” in the years 2011-2012.

1226. [REDACTED]

[REDACTED] Under the Fair Share Agreement, Breckenridge, Greenstone, Par, and Sandoz did not attempt to undercut competitors’ prices in order to gain additional market share. For example, in December 2012, R.T. of Sandoz warned another colleague at Sandoz, “We should not go after Walgreens on Methylprednisolone Tabs” due to a “high risk of market disruption.” Approximately one week later, Armando Kellum of Sandoz reiterated to R.T. that going after Methylprednisolone at Walgreens might “disrupt [the] market.” Then, in September 2013, S.G. of Sandoz wrote to Walgreens about the possibility of picking up additional market share. A few minutes later, Kellum (who was presumably blind carbon copied on the prior email) forwarded the email to S.G., asking “What is the deal here??? We were going to target

one Cadista account?” Greenstein responded, “25% share [of Walgreens] would be the amount to get about 4-5% [market] SHARE.” Kellum replied, “we really need to make sure we are coordinated. I think we can get share on this product in a non-disruptive way. I’m worried that we are just going bombs away.” Greenstein reassures Kellum that they “can manage appropriately.”

1227. The ability of Breckenridge, Greenstone, Par, and Sandoz to reach agreements regarding Methylprednisolone was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1228. [REDACTED]

1229. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1230. The agreement between Defendants Breckenridge, Greenstone, Par, and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Methylprednisolone Tablets (4 mg).

81. Metronidazole Gel (1%)

1231. Metronidazole is a medication used to treat parasitic infections including *Giardia* infections of the small intestine, amebic liver abscess, amebic dysentery, bacterial vaginosis, and trichomonas vaginal infections. It is available in several formulations, including a Gel (1%).

1232. Plaintiffs allege that as part of Defendants’ Fair Share Agreement, Defendants Sandoz and Taro conspired to fix, raise, maintain or stabilize the prices of Metronidazole Gel (1%) beginning at least as early as the summer of 2014.

1233. Before the summer of 2014, Sandoz was the lone manufacturer of Metronidazole. In July 2014, however, Taro entered the market. Before doing so, Sandoz and Taro exchanged communications to coordinate pricing and Fair Shares of the market.

1234. During the summer of 2014, before Taro entered the Metronidazole Gel market, C.B., Sandoz's Director of National Accounts, and Ara Aprahamian, Taro's Vice President of Sales, spoke several times to discuss pricing and which customers Taro should target (and which customers Sandoz would relinquish).

1235. Taro began to approach Sandoz customers in June and July of 2014. Sandoz's C.B. and Taro's Aprahamian remained in contact throughout the summer. [REDACTED]

[REDACTED]

[REDACTED] :

[REDACTED]

1236. As a result of the agreement and anticompetitive coordination between Sandoz and Taro, prices for Metronidazole Gel were higher than they would have been in a competitive market.

1237. The ability of Sandoz and Taro to reach agreement regarding Metronidazole was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1238. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1239. The agreement between Defendants Sandoz and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Metronidazole Gel (1%).

82. Moexipril HCL and Moexipril HCL HCTZ

1240. Moexipril HCL (Moexipril), also known by the brand name Univasc, is part of a class of drugs called angiotensin-converting enzyme (ACE) inhibitors. It is used to treat high blood pressure by reducing the tightening of blood vessels, allowing blood to flow more readily and the heart to pump more efficiently. It is available as a Tablet and has been available in the United States in a generic form for many years.

1241. Moexipril HCL HCTZ (Moexipril HCTZ) is a combination of Moexipril and Hydrochlorothiazide (a diuretic). This combination is used to treat high blood pressure. It also has been available in the United States in a generic form for many years.

1242. The markets for Moexipril and Moexipril HCTZ is mature. At all relevant times, there have been multiple manufacturers of Moexipril and Moexipril HCTZ.

1243. During the relevant time frame, Defendants Teva and Glenmark were the primary manufacturers of Moexipril and Moexipril HCTZ.

1244. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Moexipril and Moexipril HCTZ tablets beginning at least as early as May 2013.

1245. As soon as Patel started at Teva, she began to identify price increase candidates through her conversations with various contacts at other drug manufacturers, including Glenmark. For example, Patel had four calls with an Executive Vice President of Glenmark on May 2, 2013.

1246. Shortly after one of those calls, Patel sent an internal email where she identified six Glenmark drugs to add to the price increase list, including Moexipril and Moexipril HCTZ. Glenmark had not yet increased prices or announced price increases on any of those drugs.

1247. Patel also made efforts to ensure that Teva abided by the Fair Share Agreement. On May 15, 2013, in anticipation of the Glenmark price increases that were not yet public, Patel instructed her Teva colleagues to alert her of any requests by customers for pricing relating to a number of Glenmark drugs, including Moexipril and Moexipril HCTZ. In accordance with the Fair Share Agreement, Patel wanted to be careful to avoid obtaining any market share from Glenmark after the price increases.

1248. Patel also spoke to the same Executive Vice President at Glenmark on May 16, 2013 – the day of the Glenmark price increases. Effective that day, Glenmark increased prices on numerous drugs also sold by Teva, including Moexipril and Moexipril HCTZ. Patel again spoke to the EVP as well as to an Associate Director of Sales and Marketing at Glenmark multiple times on May 17, 2013.

1249. After the Glenmark price increases, Teva was approached by several customers looking for lower prices. Teva declined the invitations in order to maintain Fair Shares and avoid price erosion. On occasions when it did provide a customer with a bid, Teva intentionally bid high so that it would not win the business.

1250. Teva, as agreed, soon followed the Glenmark price increases for Moexipril and Moexipril HCTZ tablets; Teva's increases went into effect on July 3, 2013. Thereafter, Teva and Glenmark monitored the Fair Share Agreement and communicated as necessary to ensure that prices remained high.

1251. For example, on August 5, 2013, Teva learned that it had been underbid by Glenmark at one of its largest wholesaler customers. That same day, Patel called the Executive Vice President at Glenmark, to find out what was going on. They spoke three times that day. The following day – August 6, 2013 – Patel spoke to Jim Brown, the Vice President of Sales at Glenmark, two times. During these calls, Teva and Glenmark reaffirmed their prior agreement to maintain Fair Share and not to poach each other's customers after a price increase, and Glenmark withdrew its offer to Teva's customer.

1252. The ability of Teva and Glenmark to reach agreements on Moexipril and Moexipril HCTZ tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

1253. The coordination by Teva and Glenmark is consistent with the Fair Share Agreement.

1254. The agreement between Defendants Teva and Glenmark was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig

bids, and engage in market and customer allocation for generic drugs, including Moexipril and Moexipril HCTZ Tablets.

83. Nadolol


1255. Nadolol is a commonly prescribed medication for the treatment of high blood pressure, heart pain, and atrial fibrillation (abnormal heart rhythm) that has been available in the United States for decades in a generic form. It is available in the United States in several dosage strengths, including 20mg, 40mg, and 80mg Tablets.

1256. The market for Nadolol is mature. At all relevant times, there have been multiple manufacturers. Defendants Greenstone, Mylan, Sandoz, and Teva dominated sales of Nadolol in the relevant period.

1257. [REDACTED]

[REDACTED]

[REDACTED]



1258. The GAO found that all four dosage strengths had “extraordinary price increases” in 2012-2013 or 2013-2014.

1259. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers, including Greenstone, Mylan, Sandoz, and Teva.

1260. Beginning in the summer of 2012, Defendants Greenstone, Mylan, Sandoz, and Teva became aware of the potential for coordinating price increases on Nadolol. As explained above, an anticompetitive understanding among these companies was firmly entrenched. Teva considered Mylan its highest-ranked competitor by “quality.” Teva also viewed Sandoz and Greenstone as “high quality” competitors.

1261. In 2012 and 2013, Mylan, Sandoz, and Teva were the only manufacturers of Nadolol. All three companies experienced supply problems of some sort during that time period,

but they remained in continuous communication to coordinate pricing and market allocation to maintain market stability. Nadolol was a high-volume drug and one of the most profitable drugs where Teva, Mylan, and Sandoz overlapped, so it was very important that they maintain their coordination.

1262. Defendants coordinated their price increases at every step. The day before the August 27, 2012 Sandoz increase, Armando Kellum, then the Senior Director of Pricing and Contracts at Sandoz, called Teva's Green. They had also spoken once earlier in the month. P.K., then at Sandoz, also called Green twice on August 21, 2012 – the same day that Sandoz requested approval from its Pricing Committee to raise the Nadolol price. Sandoz's price increases for Nadolol resulted in a staggering 700% increase. The day after the Sandoz increase, Green – acting as the conduit of information between Sandoz and Mylan – called Nesta of Mylan twice, with one call lasting fourteen minutes.

1263. Mylan, which returned to the market after a brief supply disruption, increased its prices on January 4, 2013. In what had become a routine component of the scheme, the day before the Mylan increase Nesta spoke to Green four times. The next day, Teva's Green conveyed the information he had learned from Nesta directly to Kellum, his counterpart at Sandoz. On January 4, 2013 – the day of the Mylan increase – Green called Kellum twice in the morning, including a six-minute call at 9:43 am. Shortly after hanging up with Green, Kellum reported internally on what he had learned – but concealing the true source of the information, a convention that was frequently employed by many Sandoz executives to avoid documentation of their covert communications with competitors:

From: Kellum, Armando
Sent: Friday, January 04, 2013 11:28 AM
To: [REDACTED]
Subject: Levothyroxine and nadolol

Just heard from a customer that

- Teva and Mylan raised have now raised price on Nadolol to our levels

and

Mylan took a significant price increase on Levothyroxine

Let's please be cautious on both of these products.

Thanks

1264. Being “cautious” on those products meant that Sandoz did not want to steal business away from its competitors by offering a lower price and taking their market share.

1265. Kellum’s phone records demonstrate that he did not speak with any customers during the morning of January 4, 2013. At 11:50 am the same morning, Teva’s Green also called P.K. at Sandoz and they spoke for fifteen (15) minutes.

1266. Defendants Teva, Mylan, and Sandoz continued to conspire about Nadolol and many other drugs throughout 2013 and thereafter. On May 14, 2013, Teva’s Patel asked Green and others at Teva to obtain “price points” on certain Mylan drugs including Nadolol in preparation for a potential price increase. While Patel was waiting for their responses, she indicated internally to another Teva colleague that she was expecting “additional Mylan intel” and that she was expecting Mylan “to take an additional increase” on those items. On May 17, 2013, Teva’s Green spoke to Mylan’s Nesta six times, including calls lasting 11:50, 2:23, 4:25, and 16:02.

1267. On May 29, 2013, after a discussion with Cavanaugh, Patel added four Mylan drugs, including Nadolol, to the Teva price increase list. A month later, on July 2, 2013 and July 3, 2013 respectively, both Mylan and Teva increased the price of Nadolol to the point where

their prices reached parity with Sandoz's prices. Shortly after the increases, Sandoz's M.V. sent Patel a congratulatory message regarding the increase. Internally, Sandoz calculated that the price increases justified Sandoz taking on an additional account at this "good price level," and explaining: "We want to target a Mylan account since they have 60% of the share."

1268. Teva, which split the remaining 40% of the market with Sandoz viewed the matter in the same light. When a large retail pharmacy asked Teva to bid on several drugs, Patel sent an internal email with "commentary" about the customer request, on July 31, 2013, stressing the need to take market share into consideration when considering adding to Teva's existing business, for example, "Nadolol: can pursue additional share (Mylan) for 3-player market."

1269. Defendants were careful not to overstep. In October 2013, M.V., a senior pricing executive at Sandoz, sent an internal email, including to Kellum, stating that Sandoz had decided not to bid on [REDACTED] at a large retail customer. M.V. explained his reasoning as follows: "We have been running up against Mylan a lot lately (Nadolol/Benaz/Hctz), and fear blowback if we take any more products at this moment. Trying to be responsible in the sandbox." These decisions were made by Sandoz executives as a direct result of communications between the companies, and in the context of an ongoing understanding among Defendants Sandoz, Mylan, and others to fix prices and avoid competition on a number of different drugs, including Nadolol.

1270. Similarly, when Greenstone entered the Nadolol market in mid-2014, rather than competing for market share, it priced its Nadolol Tablets at supracompetitive prices in coordinated fashion with Defendants Mylan, Teva, and Sandoz.

1271. [REDACTED]

1272. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1273. The agreement between Defendants Greenstone, Mylan, Sandoz, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Nadolol Tablets.

84. Naproxen Sodium

1274. Naproxen Sodium is a nonsteroidal anti-inflammatory drug used to relieve pain from various conditions and is available in a Tablet (275 mg and 550 mg). It has been available in the United States for decades in a generic form.

1275. The market for Naproxen Sodium is mature. At all relevant times, there have been multiple manufacturers of Naproxen Sodium.

1276. Defendants Amneal and Glenmark dominate sales of Naproxen Sodium Tablets (275 mg and 550 mg). [REDACTED]

[REDACTED]

[REDACTED]



[REDACTED]

[REDACTED]

1277. [REDACTED]

[REDACTED]

[REDACTED]



1278. [REDACTED]

1279. The ability of Amneal and Glenmark to reach agreement regarding Naproxen Sodium was aided by the prevalence of trade association meetings and conferences where the

parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

[REDACTED]

[REDACTED].

1281. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1282. The agreement between Defendants Amneal and Glenmark was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Naproxen Sodium Tablets (275 and 550 mg).

85. Niacin

1283. Niacin is a medication used to treat high cholesterol and is available as a Tablet ER. It has been available in the United States in a generic form for many years.

1284. The market for Niacin is mature. At all relevant times, there have been multiple manufacturers of Niacin.

1285. During the relevant time frame, Defendants Teva, Lupin, and Zydus were the primary manufacturers of Niacin Tablets ER.

1286. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Niacin Tablets ER beginning at least as early as March 2014.

1287. Teva entered the market for Niacin ER on September 20, 2013 as the first-to-file generic manufacturer and was awarded 180 days of exclusivity.

1288. Teva's exclusivity was set to expire on March 20, 2014. Teva learned that Lupin planned to enter that day, and that Zydus planned to enter on June 28, 2014.

1289. In order to facilitate the entry of Lupin and Zydus, and to maintain dollar revenue while ceding share to those new entrants, Teva increased prices on Niacin ER on March 7, 2014, before the new generics entered the market. Yet again, the entrance of additional suppliers had the perverse effect of increasing prices, which was a hallmark feature of the Fair Share Agreement.

1290. Prior to Teva's price increase, Teva, Lupin, and Zydus exchanged calls during which they discussed the pricing of Niacin ER and ensuring that Fair Share principles would be followed. The calls were between Green of Zydus, Patel and Rekenthaler of Teva, and Berthold of Lupin.

1291. Similarly, in the days leading up to the Lupin launch on March 20, 2014, all three competitors spoke again to discuss their plans for Niacin ER, with Teva agreeing to concede a Fair Share of the market to Lupin upon entry.

1292. When Lupin entered the market for Niacin ER on March 20, 2014, it entered at the exact same list (WAC) prices as Teva. [REDACTED], suggesting that it was not trying to lure away Teva's customers with better prices.

1293. After Lupin's launch, Patel and Berthold continued to coordinate to make sure Lupin obtained the agreed-upon customers. They coordinated a number of concessions by Teva that allowed Lupin to acquire large customers and its Fair Share without resorting to unfettered price competition.

1294. In May 2014, Zydus was preparing to enter the Niacin ER market. On May 6, 2014, Teva's Rekenthaler and Patel exchanged calls with Zydus's Green, after which Teva internally agreed to concede a large wholesaler customer, though it required a number of follow-up conversations with Zydus to hammer out the details. On May 29, 2014, Rekenthaler again

called Green, and they spoke twice that day. Patel also called Green that day, and there were additional phone calls between Green and Rekenhler and Patel on June 2, 2014. After these communications, Teva committed to conceding a large wholesale customer to Zydus.

1295. On June 28, 2014, Zydus launched Niacin ER and announced list (WAC) prices that matched Teva and Lupin. [REDACTED]

1296. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1297. The ability of Teva, Lupin, and Zydus to reach agreements on Niacin Tablets ER was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1298. The coordination by Teva, Lupin, and Zydus is consistent with the Fair Share Agreement.

1299. The agreement between Defendants Teva, Lupin, and Zydus was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Niacin Tablets ER.

86. Nitrofurantoin

1300. Nitrofurantoin is an antibiotic. It is available in several forms, including Macrocrystal (MAC) Capsules, and has been available in the United States for over a decade in a generic form.


1301. The market for Nitrofurantoin is mature. At all relevant times, there have been multiple manufacturers.

1302. Defendants Alvogen, Mylan, and Teva dominate sales of Nitrofurantoin MAC Capsules.

1303. In late 2010, [REDACTED]
[REDACTED]
[REDACTED].

1304. As summer 2011 approached, a new manufacturer, Alvogen, was planning to enter the market. In anticipation of Alvogen's entry, Teva began to raise its NSP prices more aggressively. And when Alvogen finally entered, it announced list (WAC) prices close to Mylan's already high prices, and its NSP prices were high as well. Mylan responded by raising its list (WAC) prices again, even higher than Alvogen's. Instead of driving prices down, Alvogen's entry into the market had the perverse effect of causing all manufacturers to raise prices, which was exactly what the Fair Share Agreement was supposed to do.

1305. Alvogen quickly gained market share, even with higher prices than Teva. Teva, for its part, continued to steadily raise prices. In July 2012, Teva announced a list (WAC) price increase that made its prices the highest in the market. Before implementing this large price increase, Teva coordinated with Mylan and Alvogen to ensure that Fair Share would be maintained. The NSP price chart below shows the large price increases imposed on Nitrofurantoin by Mylan and Teva, which were then matched by Alvogen when it entered the market.



1306. Throughout the relevant period, Mylan, Teva, and Alvogen met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreement on Nitrofurantoin and of the Fair Share Agreement.

1307. For example, in the weeks before Teva raised its list (WAC) prices in 2012 to bring them more in line with Mylan's list prices, Teva's Green spoke to Nesta of Mylan on July 23, 24 (2 calls), 25, 26, 30 (2 calls), and 31 (5 calls), 2012.

1308. After some of the calls between Green and Nesta on July 31, 2012, Nesta called B.H., the Executive Vice President of Commercial Sales at Alvogen.

1309. Teva, Mylan, and Alvogen continued to coordinate and communicate in order to maintain Fair Shares. For example, on October 10, 2012, a distributor customer approached Teva requesting a lower price for Nitrofurantoin MAC. This prompted Teva's Green to reach

out to both Nesta at Mylan and again to B.H. at Alvogen. Nesta separately spoke to the same contact at Alvogen. After coordinating with Mylan and Alvogen and re-confirming their price-fixing agreement on Nitrofurantoin MAC capsules, Teva did not lower its price.

1310. [REDACTED]

1311. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1312. The agreement between Defendants Teva, Mylan, and Alvogen was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Nitrofurantoin Macrocrystal Capsules.


87. Neomycin Polymyxin Hydrocortisone

1313. Neomycin Polymyxin Hydrocortisone is a topical antibiotic used to treat outer ear infections caused by bacteria. It is available in several forms, including a Solution and has been available in the United States for over a decade in a generic form.

1314. The market for Neomycin Polymyxin Hydrocortisone Solution (3.5mg-10MU 1%) is mature. At all relevant times, there have been multiple manufacturers.

1315. Defendants Bausch and Sandoz dominate sales of Neomycin Polymyxin Hydrocortisone [REDACTED]

1316. [REDACTED]



1317. The ability of Bausch and Sandoz to reach agreements on Neomycin Polymyxin Hydrocortisone was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1318. [REDACTED]



1319. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1320. The agreement between Defendants Bausch and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Neomycin Polymyxin Hydrocortisone Solution (3.5mg-10MU 1%).

88. Norethindrone/Ethinyl Estradiol

1321. Norethindrone/Ethinyl Estradiol is an oral contraceptive available as a Tablet. Teva markets its generic of this medication under the name Balziva. Norethindrone/Ethinyl Estradiol has been available in the United States in a generic form for many years.

1322. The market for Norethindrone/Ethinyl Estradiol is mature. At all relevant times, there have been multiple manufacturers of Norethindrone/Ethinyl Estradiol.

1323. During the relevant time frame, Teva and Lupin were the primary manufacturers of Norethindrone/Ethinyl Estradiol.

1324. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Norethindrone/Ethinyl Estradiol tablets beginning at least as early as January 2014.

1325. On January 23, 2014, a customer informed Teva that a new market entrant was seeking a share of its business on Norethindrone/Ethinyl Estradiol. Teva employees surmised that the entrant was Lupin, as it had recently obtained approval to begin marketing the generic drug.

1326. Teva employees discussed internally how to respond to the entrant, with at least one expressing concern that conceding business would cause Teva to lose its position as the Norethindrone/Ethinyl Estradiol market leader.

1327. On January 24, 2014, Teva's Patel spoke to Berthold at Lupin twice by phone. Several days after that call, on January 29, 2014, Patel internally recommended conceding "part of the business" with the customer at issue to Lupin, in order "to be responsible in the market." Patel and Berthold spoke again on February 4, 2014, to further coordinate Lupin's entry into the market.

1328. As a result of the agreement and anticompetitive coordination between Teva and Lupin, prices for Norethindrone/Ethinyl Estradiol tablets were higher than they would have been in a competitive market.

1329. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1330. The ability of Teva and Lupin to reach agreements on Norethindrone/Ethinyl Estradiol tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1331. The coordination by Teva and Lupin is consistent with the Fair Share Agreement.

1332. The agreement between Defendants Teva and Lupin was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Norethindrone/Ethinyl Estradiol Tablets.

89. Nortriptyline HCL

1333. Nortriptyline HCL, also known by the brand name Pamelor, is a medication used to treat depression. It is available as a Capsule and has been available in the United States in a generic form for many years.

1334. The market for Nortriptyline HCL was mature and at all relevant times had multiple manufacturers.

1335. During the relevant time frame, Defendants Teva, Taro, and Actavis were the primary manufacturers of Nortriptyline HCL Capsules.

1336. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Nortriptyline Hydrochloride capsules beginning at least as early as January 2011.

1337. For years, the prices for Nortriptyline HCL capsules were low and relatively stable. In the spring and summer of 2011, however, Teva and Actavis reached an agreement to impose significant price increases on all doses of Nortriptyline HCL capsules. Both manufacturers approximately [REDACTED] their prices. In late 2013, when Taro was preparing to enter the market, Teva and Actavis brought it into their price-fixing agreement and Taro entered the market at elevated prices.

1338. [REDACTED]

[REDACTED]

[REDACTED]

1339. Throughout this period, Actavis, Teva, and Taro met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreements on Nortriptyline HCL and their Fair Share Agreement.

1340. For example, in late 2013, Teva, Actavis and Taro carefully orchestrated Taro's entry into the Nortriptyline HCL market. In order to accommodate Taro's entry without disrupting prices, David Rekenhaller of Teva and Marc Falkin of Actavis spoke by phone on November 10, 14, 15, and 18, 2013. Falkin also exchanged text messages with Maureen Cavanaugh of Teva on November 17 and 18. Also during November, Ara Aprahamian of Taro spoke by telephone with Teva's Patel and Actavis's M.D. to hammer out their agreement. Teva and Actavis both agreed to cede customers to Taro, and Taro was careful not to pursue more than its "fair share" from Teva or Actavis. Thereafter, Aprahamian (Taro), Falkin (Actavis), and Rekenhaller and Patel (Teva) continued to coordinate the pricing of Nortriptyline HCL, with numerous direct communications between them in 2014 and 2015.

1341. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1342. The ability of Actavis, Teva and Taro to reach agreements on Nortriptyline HCL Capsules was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1343. [REDACTED]

[REDACTED].

1344. The agreement between Defendants Actavis, Teva and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig

bids, and engage in market and customer allocation for generic drugs, including Nortriptyline HCL Capsules.

90. Nystatin Triamcinolone

1345. Nystatin Triamcinolone is a steroid medication used to treat fungal infections. It comes in a Cream and Ointment formulation, among others. It has been available in the United States in a generic form for several years.

1346. During the relevant time frame, Defendants Taro and Sandoz were the only manufacturers of Nystatin Triamcinolone.

1347. Prior to certain Defendants launching Nystatin Triamcinolone, Defendants Taro and Sandoz engaged in conversations about their launch. These conversations involved discussions of market and customer allocations.

1348. The ability of Taro and Sandoz to reach agreements on Nystatin Triamcinolone was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

1349. The coordination by Taro and Sandoz is consistent with the Fair Share Agreement.

1350. The agreement between Defendants Taro and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Nystatin Triamcinolone Cream and Ointment.

91. Omega-3-Acid Ethyl Esters

1351. Omega-3-Acid Ethyl Esters, also known by the brand name Lovaza, is a medication used to lower high triglyceride levels in the blood and is available in a Tablet (600 mg). It has been available in the United States in a generic form for many years.

1352. The market for Omega-3 Acid Ethyl Esters is mature. At all relevant times, there have been multiple manufacturers of Omega-3 Acid Ethyl Esters.

1353. During the relevant time frame, Teva, Par, and Apotex were the primary manufacturers of Omega-3-Acid Ethyl Esters Capsules.

1354. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Omega-3-Acid Ethyl Esters capsules beginning at least as early as the spring of 2014.

1355. On April 8, 2014, Teva launched Omega-3 Acid Ethyl Esters.

1356. On the morning of June 26, 2014, Patel emailed a colleague at Teva relaying that Par had recently received FDA approval for this drug. Patel said that she would "snoop around" to see if Par had begun shipping product. That morning, Patel sent a message to T.P., Chief Commercial Officer at Par through LinkedIn. Later that day, they exchanged a number of text messages.

1357. The next morning, Par's Chief Commercial Officer called Patel and they spoke for nearly 30 minutes. That same morning, Patel told colleagues that she now had "some more color" on Par's launch of Omega-3-Acid Ethyl Esters. Internally, Teva documents evidence a clear understanding of Par's confidential bidding and pricing plans.

1358. Par launched on June 30, 2014. Teva proceeded to concede business to Par to ensure Par's smooth entry into the market.

1359. As new competitors entered the market, Teva coordinated with them to avoid competition and keep prices high, including through phone calls between Teva's Rekenhaller and a Senior Vice President and General Manager of U.S. Sales at Apotex on September 25 and 27, 2014.

1360. Due to supply limitations, Par was not able to pursue a full Fair Share of the Omega-3-Acid Ethyl Esters Capsule market until late November 2014. On November 10, 2014, Patel and Par's Chief Commercial Officer exchanged five (5) text messages.

1361. By mid-February 2015, Teva had conceded several large customers to Par. During this time, Rekenhaller was speaking frequently with M.B., a senior national account executive at Par, to coordinate.

1362. By April 2015, Apotex had officially entered the market, and consistent with the Fair Share Agreement, Teva conceded customers to accommodate the new entrant. During this period, Rekenhaller spoke multiple times with J.H., Senior VP at Apotex.

1363. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1364. The ability of Teva, Par, and Apotex to reach agreements on Omega-3-Acid Ethyl Esters Capsules was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1365. The coordination by Teva, Par, and Apotex is consistent with the Fair Share Agreement.

1366. The agreement between Defendants Teva, Par and, Apotex was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig

bids, and engage in market and customer allocation for generic drugs, including Omega-3 Acid Ethyl Esters Capsules.

92. Oxaprozin

1367. Oxaprozin is a commonly prescribed nonsteroidal anti-inflammatory drug (NSAID) to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. It has been in the United States market for decades and is available in Tablets (600 mg).

1368. [REDACTED]

[REDACTED]

[REDACTED].

1369. [REDACTED]

[REDACTED]

[REDACTED]

1370. The GAO observed “extraordinary price increases” for Oxaprozin in 2012-13. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including Dr. Reddy’s, Greenstone, Sandoz, and Teva.

1371. Defendants coordinated their price increases. Teva initiated the price increase on July 31, 2012, resulting in an increase of more than six times its prior WAC price for Oxaprozin. Sandoz matched on November 5, 2012 with WAC prices that also were severalfold increase in its prior WAC price. Following a routine and systematic pattern, Teva’s Green was in frequent communication with executives at Sandoz and other Teva competitors to implement these and other drug price increases. For example, communications between Teva’s Green and Sandoz executives include 84 texts and calls with P.K. from April 26, 2010 to January 14, 2013, 14 calls with Kellum from March 21, 2012 to August 14, 2013, and four calls or texts with R.T. from May 23, 2010 to May 15, 2013.

1372. Sandoz observed its agreement with Teva and did not bid when Teva’s customer, Walgreens, requested a bid on Oxaprozin. Kellum responded internally: “Let’s hold tight. Teva did the right thing here, our supply is tight and we are making good money on it.”

1373. Defendants also coordinated Greenstone’s entry into the market on March 27, 2013, where Greenstone entered with the same WACs as Teva and Sandoz. For example, when Sandoz’s customer, Optisource, informed it in early March 2013 that it had received a much lower offer from Greenstone on Oxaprozin, Sandoz decided to concede its business, rather than risk lower market prices. As one Sandoz executive put it: “My hope is Greenstone understands the market, stays away from RAD and ABC, and goes after Teva. Also, we do not need ABC seeing Opti with Sandoz product so low in the market.”

1374. In the days and weeks leading up to Greenstone's entry into the market, Green of Teva and R.H. of Greenstone were in frequent communication by phone and text to coordinate the entry, including one call for almost eleven minutes on March 6, 2013; two calls on March 11, 2013; three calls on the evening of March 18, 2013, and seven calls and a text message between March 20, 2013 and March 22, 2013. During these communications, Teva agreed to concede specific customers to Greenstone in order to avoid competition and price erosion resulting from Greenstone's entry.

1375. Part of their understanding required Teva to cede two large customers — CVS and Cardinal Health — to Greenstone, while Teva would retain Walmart. However, on March 27, 2013, Teva learned from Walmart that Greenstone had also bid on Walmart's business. This infuriated Teva. In an internal email, Rekenhaller lamented: "They should not have gone to WalMart. Poor strategy on their part for sure." Another Teva executive agreed that Greenstone was not keeping its part of the bargain: "I thought they said they were done after cardainl [sic].. I am pissed."

1376. Teva took immediate steps to enforce the agreement. On March 27, 2013, Green called R.H. at Greenstone at 5:25 pm, but she did not answer. The next day there were seven calls, and nine text messages between Green and R.H. During those conversations, Greenstone agreed to withdraw the offer to Walmart and honor the agreement with Teva. True to its word, Greenstone withdrew its offer to Walmart by that afternoon. Walmart informed Teva: "I just received word from Greenstone that they have met their market share and the proposal has expired. Please see what you can do with pricing." Teva's internal response ("Funny") indicated that it had no intention of lowering its price for Walmart, now that Greenstone had stepped down.

1377. The Defendants were also ready when Dr. Reddy's re-launched its Oxaprozin Tablets on June 27, 2013. Indeed, Dr. Reddy's had advance knowledge of Teva's concessions to Greenstone, as reflected by a May 10, 2013 internal email, remarking: "Cardinal switched to Greenstone. Teva was 'fine' with it! Pricing still high."

1378. Consistent with their agreement, Dr. Reddy's entered the market with the same WAC prices as the other Defendants and almost immediately got two customers, Keysource and Premier. But when Dr. Reddy's competed for Teva's Oxaprozin business at Walgreens, that triggered a nearly five-minute call between Teva's Green and J.A. of Dr. Reddy's – the only one ever between these two individuals that is identified in the phone records. Eager to avoid price erosion, Teva considered the possibility of keeping the Walgreens business, but conceding Teva's next largest customer for Oxaprozin – Econdisc – to Dr. Reddy's.

1379. Patel asked a colleague to "run the customer volume and profitability analysis for Oxaprozin." It was typical at Teva to run this type of report before negotiating market share with a competitor. At 2:20 pm, that colleague provided the information to Patel, copying Rekenenthaler and K.G. of Teva. With this information in hand, less than an hour later Rekenenthaler placed a call to T.W., a Senior Director of National Accounts at Dr. Reddy's. The call lasted two minutes and was their only telephone conversation in 2013.

1380. After this conversation, Teva decided to maintain the Walgreens business, but concede the Econdisc business to Dr. Reddy's, which Teva conceded on August 7, 2013. Green listed "Strategic Market Conditions" in Teva's Delphi database as the reason for conceding the business to Dr. Reddy's. By September 10, 2013, Dr. Reddy's had achieved its goal of obtaining a 20% market share.

1381. [REDACTED]

[REDACTED]

1382. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1383. The agreement between Defendants Dr. Reddy's, Greenstone, Sandoz, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Oxaprozin Tablets (600 mg).

93. Oxybutynin Chloride

1384. Oxybutynin Chloride is a commonly prescribed antispasmodic and anticholinergic agent used to treat symptoms of overactive bladder. It has been in the United States market for years and is available in Tablets.


1385. [REDACTED]

[REDACTED]

[REDACTED].

1386. [REDACTED]

[REDACTED]:



1387. The GAO observed “extraordinary price increases” for Oxybutynin Chloride in 2013-14. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers including Par, Teva, and Upsher-Smith.

1388. In 2013, Teva, Par, and Upsher-Smith coordinated their pricing actions. For example, Teva’s Patel spoke to B.L. at Upsher-Smtih on April 29, 2013 for nearly twenty (20) minutes reached an understanding that Teva and Upsher-Smith would follow each other’s price increases. On June 15, 2013, after Teva, Upsher-Smith, and Par had begun to radically raise prices, Patel exchanged six (6) text messages with B.L. Also in June, K.O, VP of National Accounts at Par, spoke multiple times to B.P., National Account Manager at Upsher-Smith.

1389. [REDACTED]

1390. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1391. The agreement between Defendants Par, Teva, and Upsher-Smith was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Oxybutynin Chloride Tablets.

94. Oxycodone Acetaminophen

1392. Oxycodone Acetaminophen is a pain reliever that has been available in the United States for decades. It is available in Capsule, Tablet, and Oral Solution formulations.

1393. The market for Oxycodone Acetaminophen is mature. At all relevant times, there have been multiple manufacturers of Oxycodone Acetaminophen.

1394. Defendants Actavis, Alvogen, Amneal, Aurobindo, Mallinckrodt, and Par dominate the sale of Oxycodone Acetaminophen, which comes in several dosage strengths including 5-325, 7.5-325, 10-325 mg Tablets.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1398. The ability of Actavis, Alvogen, Amneal, Aurobindo, Mallinckrodt, and Par to reach agreement regarding Oxycodone Acetaminophen was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1399. [REDACTED]

[REDACTED]

[REDACTED]

1400. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1401. The agreement between Defendants Actavis, Alvogen, Amneal, Aurobindo, Mallinckrodt, and Par was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Oxycodone Acetaminophen Tablets (5-325, 7.5-325, 10-325 mg).

95. Oxycodone HCL


1402. Oxycodone HCL is an opioid agonist indicated for the management of moderate to severe acute and chronic pain where the use of an opioid analgesic is appropriate. It is available in several forms, including Tablet and Oral Solution, and has been available in the United States for over a decade in generic form.

1403. The market for Oxycodone HCL is mature. At all relevant times, there have been multiple manufacturers of Oxycodone HCL. [REDACTED]

[REDACTED]

1404. [REDACTED]

[REDACTED]



1405. The GAO noted that Oxycodone HCL had “extraordinary price increases” in the years 2010-2011.

1406. [REDACTED]

1407. The ability of Glenmark and Lannett to reach agreements on Oxycodone HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1408. [REDACTED]



1409. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1410. The agreement between Defendants Glenmark and Lannett was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Oxycodone HCL Oral Solution (20mg/ml).


1411. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1412. The ability of Actavis, Mallinckrodt, Par, and Sun to reach agreements on Oxycodone HCL Tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1413. [REDACTED]



1414. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1415. The agreement between Defendants Actavis, Mallinckrodt, Par, and Sun was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise

prices, rig bids, and engage in market and customer allocation for generic drugs, including Oxycodone HCL Tablets (15 mg and 30 mg).

96. Paricalcitol

1416. Paricalcitol, also known by the brand name Zemplar, is a medication used to treat and prevent high levels of parathyroid hormone in patients with chronic kidney disease. It is available as a Capsule and has been available in the United States in a generic form for many years.

1417. The market for Paricalcitol is mature. At all relevant times, there have been multiple manufacturers of Paricalcitol.

1418. During the relevant time frame, Defendants Teva, Dr. Reddy's, and Zydus were the primary manufacturers of Paricalcitol Capsules.

1419. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Paricalcitol Capsules beginning at least as early as the beginning of 2014.

1420. Teva was the first generic manufacturer to enter the market for Paricalcitol and thus had 180 days of exclusivity. In March 2014, as the end of the exclusivity period was approaching, Teva began to plan for the ceding of Fair Shares to new market entrants.

1421. Zydus was one of the new market entrants. Before Zydus launched its product, Patel and Rekenthaler of Teva spoke with Green of Zydus and discussed which Paricalcitol customers Teva would retain and which customers it would concede to Zydus. Rekenthaler and Green spoke on February 28 and March 3, 2014, and Green and Patel spoke at least five times over the course of two days (March 3 and March 4, 2014).

1422. Throughout March and April, Patel, Rekenthaler, and Green continued to coordinate closely about divvying up the market. Representatives of the two companies spoke on

March 14 (Patel called Green, and Rekenhaller called Patel), March 17 (three calls between Patel and Green), March 27 (Patel to Green), April 1-2 (voicemail and call between Patel and Green), and April 17, 2014 (Green and Patel spoke). In close proximity to these communications, Teva strategically conceded several Paricalcitol customers to Zydus.

1423. By May 2014, Dr. Reddy's was preparing to enter the Paricalcitol market.

1424. On May 1, 2014, a Senior Director of National Accounts at Dr. Reddy's spoke with Rekenhaller of Teva. On June 10, 2014, Patel spoke with the Vice President of Sales for North American Generics at Dr. Reddy's.

1425. As Dr. Reddy's solicited business from Teva customers, Teva conceded them to Dr. Reddy's as agreed. For example, a large grocery chain informed Teva that it had received a competing offer for Paricalcitol from Dr. Reddy's. Internally, Patel recommended that Teva concede the business, and it did.

1426. On July 10, 2014, another grocery chain informed Teva that it had received a Paricalcitol offer. That day, the Head of National Accounts at Dr. Reddy's called Patel. The next day, Teva conceded the customer to Dr. Reddy's.

1427. In July, after Teva conceded yet another grocery customer to Dr. Reddy's, a large wholesaler informed Teva that it had received a competing bid for Paricalcitol. On July 18, 2014, Patel called the Head of National Accounts at Dr. Reddy's and left a message. On July 21, they spoke, and again on the following day. During these calls, Patel and the Head of National Accounts at Dr. Reddy's agreed that Dr. Reddy's would stop soliciting Teva customers if Teva conceded the large wholesaler to Dr. Reddy's. Dr. Reddy's confirmed to Teva that it "would be done after this." The next day, Teva conceded the wholesale customer to Dr. Reddy's.

1428. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1429. The ability of Teva, Dr. Reddy's, and Zydus to reach agreements on Paricalcitol capsules was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1430. The coordination by Teva, Dr. Reddy's, and Zydus is consistent with the Fair Share Agreement.

1431. The agreement between Defendants Teva, Dr. Reddy's, and Zydus was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Paricalcitol Capsules.

97. Permethrin

1432. Permethrin is a medication used to treat scabies and is available as a Cream (5%). It has been available in the United States for decades in a generic form. Due to, among other things, its clinical efficacy and safety, Permethrin has been designated as a model essential medicine by the World Health Organization.

1433. The market for Permethrin is mature. At all relevant times, there have been multiple manufacturers of Permethrin.

1434. Defendants Actavis, Mylan, and Perrigo dominate sales of Permethrin 5% Cream.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1435. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1436. The GAO noted that the Permethrin 5% Cream had an “extraordinary price increase” in the years 2011-2012.

1437. [REDACTED]

[REDACTED].

1438. The ability of Actavis, Mylan, and Perrigo to reach agreement regarding Permethrin was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1439. [REDACTED]

[REDACTED].

1440. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1441. The agreement between Defendants Actavis, Mylan, and Perrigo was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Permethrin Cream (5%).



98. Perphenazine



1442. Perphenazine is a psychiatric medication used to treat mental or mood disorders such as schizophrenia. It is available in Tablets (2, 4, 8, and 16 mg) and has been available in the United States for decades in a generic form.

1443. The market for Perphenazine is mature. At all relevant times, there have been multiple manufacturers of Perphenazine.

1444. Defendants Par and Sandoz dominate sales of Perphenazine 2 mg, 4 mg, 8 mg, and 16 mg Tablets. During the early part of the relevant time period, Par and Sandoz divided the market for Perphenazine Tablets in a roughly 10/90 split. Over the course of the time period, the market share grew closer to a 30/70 split.

1445. [REDACTED]





1446. [REDACTED]

[REDACTED]

1447. The ability of Par and Sandoz to reach agreement regarding Perphenazine was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1448. [REDACTED]

1449. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1450. The agreement between Defendants Par and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Perphenazine Tablets (2, 4, 8, and 16 mg).

99. Phenytoin Sodium

1451. Phenytoin Sodium is an antiepileptic drug used to prevent and treat seizures. It is available as Capsules (100 mg) and has been available in the United States for decades in a generic form. Due to, among other things, its clinical efficacy and safety, Phenytoin Sodium has been designated as an essential medicine by the World Health Organization.

1452. The market for Phenytoin Sodium is mature. At all relevant times, there have been multiple manufacturers of Phenytoin Sodium.

1453. Defendants Amneal, Mylan, Sun, and Taro dominate sales of Phenytoin Sodium 100 mg Capsules.²⁹ During the relevant time period, Taro held about 50% of the market share, while Amneal, Mylan, and Sun split the rest of the market.

1454. [REDACTED]

[REDACTED]

[REDACTED]

1455. The GAO noted that Phenytoin Sodium 100 mg Capsules had an “extraordinary price increase” around this time.

1456. Documentary evidence confirms that these parallel price increases were the result of collusion among Amneal, Mylan, Sun, and Taro.

²⁹ Although Phenytoin Sodium extended release is also sold in dosage strengths of 200 mg and 300 mg, only Sun sells those dosage strengths.

1457. By early-2014, Amneal, Mylan, Sun, and Taro became aware of the potential for price increases on Phenytoin Sodium. For example, on April 21, 2014, R.C. of Sun sent an internal email to colleagues asking about multiple drugs including Phenytoin Sodium stating, “I am starting to hear some rumblings in the marketplace about potential price increases on Phenytoin 100mg caps. . . . Could you please let me know what you are hearing on these products?” W.F. of Sun responded, “No price increase yet on Phenytoin but I have heard one might be coming.”

1458. By mid-summer of 2014, prices on Phenytoin Sodium had begun to rise.

1459. On July 11, 2014, C.W. of Mylan wrote to her Mylan colleagues, “Walmart has submitted an opportunity for Ext Phenytoin due to a price increase from their incumbent. This is a future price increase item. Taro increased in June, Amneal increase is rumored but not confirmed, and Upsher Smith posted pricing 6/26/14. Walgreens and CVS both approached us for a bid last month and we did not pursue. . . . P&C is suggested NOT to give Walmart an offer but need management’s weigh in.” C.W.’s email also included relative market share for each of the manufacturers on Phenytoin Sodium and a spreadsheet attachment noting that it was an upcoming price increase product for Mylan. Based on the foregoing, Mylan declined to bid for the Walmart business as to not disrupt the Phenytoin Sodium pricing and market shares that were in place.

1460. After Mylan’s refusal, Walmart turned to Taro for a bid. Taro also refused to bid due to their high market share, in consideration of the existing market shares and elevated pricing that was being put in place among the manufacturers. On August 4, 2014, T.I. of Taro wrote to colleagues, “Base[d] on current market share, not sure this is something we want.” A.L. of Taro

agreed, saying, “While we would be happy to give them a one time buy to get them to full stock level we are not currently in position to pick up additional share.”

1461. [REDACTED] Because of the ongoing understanding of the Fair Share Agreement between the companies, they did not worry about their ostensible competitors cutting prices to gain market share. They also did not attempt to undercut their ostensible competitors’ prices in order to gain additional market share. For example, in July 2015, roughly one year after the dramatic price increases, D.S. of Taro reported to colleagues about a response to a request for a bid from Meijer. D.S. stated, “I chose not to bid on Extended Phenytoin Sodium Capsules, USP 100 mg 100, due to Taro having enough market share...64% in 5 player market.” Similarly, by way of another example, on August 6, 2015, M.L. of Taro wrote to colleague A.L., “Spoke to Lisa yesterday and she is still looking for an offer to be sent to R&S for the phenytoin 1000’s. When we first took a look at this product we said no since we had enough Market Share.” A.L. responded, “The answer on Phenytoin is still the same, we have our share. We don’t need anymore.”

1462. [REDACTED]
[REDACTED]
[REDACTED]

1463. The ability of Amneal, Mylan, Sun, and Taro to reach agreement regarding Phenytoin Sodium was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

1464. [REDACTED]
[REDACTED].

1465. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1466. The agreement between Defendants Amneal, Mylan, Sun, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Phenytoin Sodium Capsules (100 mg).

100. Pilocarpine HCL


1467. Pilocarpine HCL is a drug used to reduce pressure inside the eye and treat dry mouth. It is available in Tablet (5 mg) and Oral Liquid formulations. It has been available in the United States for over a decade in a generic form.

1468. The market for Pilocarpine HCL is mature. At all relevant times, there have been multiple manufacturers of Pilocarpine HCL.

1469. Defendants Actavis, Impax, and Lannett dominate sales of Pilocarpine HCL Tablets (5 mg). During much of the relevant time period, Lannett held approximately 80% of the market share and Actavis held most of the remaining 20%. Impax had a relatively small market share.

[REDACTED]

[REDACTED]



1471. [REDACTED].

1472. The ability of Actavis, Impax, and Lannett to reach agreement regarding Pilocarpine HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1473. [REDACTED]



1474. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1475. The agreement between Defendants Actavis, Impax, and Lannett was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig

bids, and engage in market and customer allocation for generic drugs, including Pilocarpine HCL Tablets (5 mg).

101. Piroxicam

1476. Piroxicam, also known by the brand name Feldene, is a nonsteroidal anti-inflammatory drug (NSAID) available in Capsule (10 and 20 mg) form. Piroxicam is used to treat rheumatoid arthritis, osteoarthritis, and juvenile rheumatoid arthritis. It has been available in the United States in a generic form for many years.

1477. The market for Piroxicam was mature and at all relevant times had multiple manufacturers.

1478. During the relevant time frame, Defendants Teva and Mylan were the primary manufacturers of Piroxicam Capsules (10 and 20 mg). Defendant Greenstone joined the Piroxicam market and the Piroxicam conspiracy in 2014.

1479. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Piroxicam capsules beginning at least as early as the spring of 2010.

1480. Piroxicam Capsule prices were relatively low and stable for years, but in the spring of 2010, prices skyrocketed and have remained elevated above competitive levels ever since. Teva and Mylan announced identical list (WAC) prices that were more than 30 times higher than the former list prices. NSP prices [REDACTED]. When Greenstone later joined the market, it matched those inflated WAC prices and its NSP prices [REDACTED]

1481. The list (WAC) price and [REDACTED] in the spring of 2010, and Greenstone matched Teva and Mylan's high prices when it joined the market in 2014.

1482. Throughout this period, Teva, Mylan, and Greenstone met at trade conferences and communicated directly with each other in furtherance of their price-fixing agreement on Piroxicam and of their Fair Share Agreement.

1483. For example, in the period immediately preceding Teva's announcement of list (WAC) price increases on May 12, 2010, Teva's Rekenthaler communicated directly with Mylan via telephone. He spoke with J.K., Mylan's Vice President and Executive Director of Sales shortly before the increase, on April 27, 2010, and then again right after the increase, on May 14, 2010.

1484. When Teva and Mylan learned that Greenstone would be entering the Piroxicam market in the spring of 2014, they quickly moved to bring Greenstone into their Piroxicam price-fixing agreement and the broader Fair Share Agreement. First, on March 3, 2014, Teva's Rekenthaler and Nesta connected by phone for nearly 10 minutes. Then, over the ensuing days, Teva's Patel reached out to Greenstone. On March 5, 6, 12, and 17, 2014—within days of Greenstone's entrance to the market—Teva's Nisha Patel had multiple phone conversations with Jill Nailor, the Senior Director of Sales and National Accounts at Greenstone, and R.H., the Director of National Accounts at Greenstone, during which Teva and Greenstone reached agreement that Teva would cede a Fair Share of the Piroxicam market to Greenstone.

1485. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1486. The ability of Teva, Mylan and Greenstone to reach agreements on Piroxicam Capsules was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1487. [REDACTED]

[REDACTED].

1488. The agreement between Defendants Teva, Mylan and Greenstone was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Piroxicam Capsules (10 and 20 mg).

102. Potassium Chloride

1489. Potassium Chloride is a metal halide salt used to treat low levels of potassium. It is available in different formulations including Long-Acting Tablets (8MEQ, 10MEQ, and 20MEQ). It has been available in the United States for decades in a generic form. Due to, among other things, its clinical efficacy and safety, Potassium Chloride has been designated as an essential medicine by the World Health Organization.

1490. The market for Potassium Chloride is mature. At all relevant times, there have been multiple manufacturers of Potassium Chloride.

1491. Defendants Actavis, Mylan, Sandoz, Upsher-Smith, and Zydus dominate sales of Potassium Chloride 8MEQ, 10MEQ, and 20MEQ Long-Acting Tablets. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



[REDACTED]


[REDACTED]

1492. [REDACTED]

[REDACTED]

[REDACTED]





1493. The GAO noted that Potassium Chloride had an “extraordinary price increase” in the years 2010-2011.

1494. Actavis, Mylan, Sandoz, Upsher-Smith, and Zydus’s Potassium Chloride prices remained elevated.

1495. The ability of Actavis, Mylan, Sandoz, Upsher-Smith, and Zydus to reach agreements regarding Potassium Chloride was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1496. [REDACTED]



1497. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1498. The agreement between Defendants Actavis, Mylan, Sandoz, Upsher-Smith, and Zydus was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Potassium Chloride Long-Acting Tablets (8MEQ, 10MEQ, and 20MEQ).

103. Prazosin HCL

1499. Prazosin HCL is a widely prescribed medication to treat high blood pressure and prostate enlargement. It has been available in the United States for decades. It is available in the United States in 1 mg, 2 mg, and 5 mg Capsules.


1500. The market for Prazosin HCL Capsules is mature. At all relevant times, there have been multiple manufacturers. [REDACTED]


[REDACTED].

1501. [REDACTED]

[REDACTED]

[REDACTED]





1502. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers, including Mylan, and Teva.

1503. Effective July 3, 2013, Teva increased pricing on a number of drugs, including roughly doubling its WAC prices for Prazosin HCL. The day before the price increases, Patel scheduled an internal conference call to discuss those increases with members of Teva's sales and pricing departments.

1504. In the days and weeks leading up to its announced price increases, Teva privately spoke with every important competitor to coordinate its increases and reiterate the understanding already in place with those competitors. To coordinate the prices of Prazosin HCL and other drugs that overlapped with Mylan, Teva's Green and Mylan's Nesta spoke on June 26, 2013, for one hour, and again on June 27, 2013, when they had one-minute and four-minute calls. After the second call, Green immediately called his colleague Patel and spoke with her for eight

minutes. In furtherance of the conspiracy, on June 28, 2013, Green again attempted to reach Nesta, who returned his call on July 3, the day of the price increase, when they spoke for fourteen minutes.

1505. Consistent with their Fair Share Agreement, Defendants' agreed market share limited their willingness to compete for customers. For example, in July 31, 2013, when Teva received a request from Walgreens to bid on drugs that Mylan and others supplied, Teva circulated "the most recent market share reports for each [drug] family." Within that list, Patel identified Prazosin HCL as a market that Teva "shared with Mylan," but Teva could bid on it because "[we] do not have our fair share."

1506. Mylan matched Teva by roughly doubling its own WACs for Prazosin HCL and raising prices on many other drugs. Mylan's increase lead to slightly higher WAC prices for Prazosin HCL than Teva's. Rather than competing for market share, Teva quickly determined to adjust its WAC.

1507. In furtherance of Defendants' price coordination scheme, T.S., Patel's colleague at Teva, sent her spreadsheets, which Mylan personnel had created, that listed all the price increases Mylan had taken. After reviewing the spreadsheets, Patel forwarded the list to the Teva sales team, informing them: "Our intention is to follow Mylan on this increase. Below, you will see the list of increase items where Teva overlaps with Mylan. Please share any pricing intelligence you are able to obtain. Thank you in advance!" The list included Prazosin HCL.

1508. Within days, Teva began receiving requests from potential customers for bids due to the Mylan price increases. On April 24, 2014, Patel began to formulate a "Mylan Increase Strategy" in order to respond to those requests, but noted that Teva was "still awaiting intel" about the Mylan customer contract price points, which were not publicly available. The delay in

Teva's collection of "intel," *i.e.*, its active coordination with Mylan, placed pressure on Teva, which was trying to gain market share for Prazosin HCL—within the Defendants' agreed limits. Patel continued to push Teva employees for specific contract price points from Mylan. For example, on April 28, 2014, she emailed the Teva sales team: "To date, we have no intel on Mylan's recent increases. I realize there is a lot of travel going on, but whatever you can gather and share would be greatly appreciated." And again on May 9, 2014, she reiterated: "Sorry to be so persistent, but we have not received any Mylan price increase intelligence yet In fact, I cannot see Teva being able to follow in the next round of mass price changes (without any price points) at this point. Of course we can always follow by guessing, but it could cause needless price disruption in the market." In other words, to eliminate uncertainty, Teva wanted direct coordination with other manufacturers before raising its prices. After receiving Patel's email – at 11:15 am that morning – Rekenthaler immediately called Nesta at Mylan and left a message. Nesta returned the call moments later at 11:23 am, and the two spoke for nearly eight minutes.

1509. Separately, and before Rekenthaler was able to convey any information he had obtained, Patel forwarded a bid request from AmerisourceBergen to a Teva accounts manager and again requested intel on Mylan's contract prices:

I am in a really tough spot on these. Please help! There are several requests open for offers, but I have ZERO intel. A little frustrating/discouraging, as we are bound to hear complaints on how long it took to close the Delphi request. Is there anything you are able to get to help when you are back? (I know you're in the process of transitioning accounts, but I figured I would give it a shot. At some point, I know I'll have to find another source of magic :)).

1510. Teva ultimately matched Mylan's WAC increases on Prazosin HCL on August 28, 2014, when it raised prices on Prazosin HCL and numerous other overlapping drugs. Following the normal pattern, Teva's Rekenthaler and Mylan's Nesta had numerous calls leading

up to and in furtherance of coordinating the August 28, 2014 increases: three calls on August 11, two calls on August 18, and a final call on August 21, 2014.

1511. On March 4, 2015, Mylan again increased Prazosin HCL WAC prices in coordination with Teva, who would match its WACs a few months later. Again, Nesta and Rekenhtaler engaged in multiple phone calls to coordinate the increase of Prazosin HCL capsules prices—along with other drugs that overlapped with Teva’s: two calls on February 18, 2015 and one call on February 19, 2015.

1512. In furtherance of the scheme, Teva matched Mylan’s WAC prices in July 2015. In the interim, Teva “strategically concede[d]” an “opportunity in April” 2015 to bid on a contract to supply Walgreens with Prazosin HCL capsules and other drugs “because we were waiting to follow[] a Mylan price increase.” Although Teva initially planned to announce price increases in the fall of 2015, Teva fast-tracked its WAC price increases for Prazosin HCL capsules because its supply contracts closely tracked its existing WAC prices and “[i]t might” have been “a challenge to follow Mylan’s price increase without implementing a price increase on [Teva’s] end.”

1513. [REDACTED]

1514. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1515. The agreement between Defendants Mylan and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Prazosin HCL Capsules (1, 2, and 5 mg).

104. Prednisolone Acetate

1516. Prednisolone Acetate is a corticosteroid used to treat certain eye conditions due to inflammation or injury. It has been available in the United States for decades in a generic form. It is available in an Ophthalmic Solution and in Ophthalmic Liquid Eye formulations. Due to, among other things, its clinical efficacy and safety, Prednisolone has been designated as an essential medicine by the World Health Organization.


1517. The market for Prednisolone Acetate Ophthalmic Liquid Eye is mature. At all relevant times, there have been multiple manufacturers of Prednisolone Acetate Ophthalmic Liquid Eye.

1518. Defendants Greenstone and Sandoz dominate sales of Prednisolone Acetate Ophthalmic Liquid Eye (1%). For much of the relevant time period, Sandoz had approximately two thirds of the market, and Greenstone had approximately one third of the market.

1519. [REDACTED]

[REDACTED]

[REDACTED]



1520. The GAO noted that Prednisolone Acetate Ophthalmic Liquid Eye had “extraordinary price increases” in the years 2013-2014.

1521. Documentary evidence confirms that these parallel price increases were the result of collusion among Greenstone and Sandoz.

1522. [REDACTED]

[REDACTED] Because of the ongoing understanding of the Fair Share Agreement between the companies, they did not worry about their ostensible competitors cutting prices to gain market share. They also did not attempt to undercut their ostensible competitors’ prices in order to gain additional market share. For example, in January 2014, several months after the dramatic price increase, C.B. of Sandoz reported to colleagues that OptiSource was looking for a bid on Prednisolone Acetate. Kellum of Sandoz responded, “Why are they asking??? I think we should leave this alone as Pacific raised price etc... to match ours.” D.H. of Sandoz wrote back, “I have

a suspicion that Pacific cannot supply or at least cannot supply consistently. Also, Pacific has likely raised contract pricing in-line with Sandoz contract pricing; so [OptiSource] is likely seeking a better deal. I could be wrong, but based on market intelligence & knowing Rick [Meehan, President of OptiSource] this is likely the situation.” Kellum confirmed, “Agree- I don’t want to bid right now and I think we just blame supply for now.” By way of another example, a Sandoz November 2015 “Key Customers Monthly Business Review” states that Sandoz “lost” \$29,000,000 worth of sales of Prednisolone Acetate because Sandoz “[r]elinquish[ed] [it] to Pacific.”

1523. The ability of Greenstone and Sandoz to reach agreement regarding Prednisolone Acetate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1524. [REDACTED]

1525. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1526. The agreement between Defendants Greenstone and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Prednisolone Acetate Ophthalmic Liquid Eye (1%).

105. Prednisone

1527. Prednisone is a corticosteroid used to treat conditions such as arthritis, blood disorders, breathing problems, and immune system disorders. It is available in Tablet (1, 2.5, 5,

10, and 20 mg) and Oral Solution formulations. It has been available in the United States for over a decade in a generic form.

1528. The market for Prednisone is mature. At all relevant times, there have been multiple manufacturers of Prednisone.

1529. Defendants Actavis, Cadista, Par, and West-Ward dominate sales of Prednisone Tablets. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



1530. [REDACTED]


[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]





1531. The GAO noted that Prednisone had “extraordinary price increases” in the years 2013-2014.

1532. 

1533. The ability of Actavis, Cadista, Par, and West-Ward to reach agreements on Prednisone was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1534. [REDACTED]

1535. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1536. The agreement between Defendants Actavis, Cadista, Par, and West-Ward was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Prednisone Tablets (1, 2.5, 5, 10, and 20 mg).

106. Prochlorperazine Maleate

1537. Prochlorperazine Maleate is a medication used to treat psychotic disorders such as schizophrenia, as well as control severe nausea. It is available in several forms, including a Suppository (25 mg). Prochlorperazine Maleate has been available in the United States in a generic form for many years.

1538. The market for Prochlorperazine Maleate is mature. At all relevant times, there were multiple manufacturers of Prochlorperazine Maleate.

1539. During the relevant time frame, Defendants G&W and Perrigo were the primary manufacturers of Prochlorperazine Maleate Suppositories.


1540. Plaintiffs allege that as part of Defendants' Fair Share Agreement, Defendants G&W and Perrigo conspired to fix, raise, maintain or stabilize the prices of Prochlorperazine Maleate Suppositories beginning at least as early as the January 2012.

1541. For years, the prices for Prochlorperazine Maleate Suppositories were relatively low and stable. [REDACTED]

[REDACTED]

[REDACTED]

1542. G&W and Perrigo's price increases are illustrated in the chart below:



1543. Throughout this period, G&W and Perrigo met at trade conferences and communicated with each other directly in furtherance of their price-fixing agreement on Prochlorperazine Maleate Suppositories and the Fair Share Agreement.

1544. For example, shortly after G&W's January 2012 price increase, Kurt Orlofski, G&W's President, communicated multiple times by phone with S.K., Perrigo's Executive Vice

President and General Manager. The two communicated multiple times in February and April 2012.

1545. On April 19, 2012, Perrigo announced a list (WAC) price increase for Prochlorperazine Maleate 25mg Suppositories that essentially matched G&W's January 2012 price increase. On the same day, G&W's Orlofski and Perrigo's S.K. communicated multiple times by text message.

1546. In January 2013, Perrigo hired Douglas Boothe to serve as Executive Vice President. Almost immediately, Boothe began to communicate directly with competitors. For example, on January 25, 2013, Boothe communicated by phone with G&W's Orlofski, and met with Orlofski for lunch in New Jersey on March 1, 2013.

1547. Within one week of Orlofski and Boothe's lunch meeting, G&W and Perrigo began preparing to institute price increases on Prochlorperazine Maleate Suppositories.

1548. By the third week of March 2013, G&W had announced a large price increase on Prochlorperazine Maleate Suppositories. Around the same time, G&W's Orlofski called Perrigo's Boothe, and within a few weeks Perrigo announced its own price increase on Prochlorperazine 25mg Suppositories.

1549. Over the ensuing months, G&W and Perrigo adhered to the Fair Share Agreement, and declined to seek more than their agreed upon share of the Prochlorperazine Maleate Suppository market.

1550. As a result of the agreement and anticompetitive coordination between G&W and Perrigo, prices for Prochlorperazine Maleate Suppositories were higher than they would have been in a competitive market.

1551. [REDACTED]

1552. The ability of G&W and Perrigo to reach agreement regarding Prochlorperazine Maleate Suppositories was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1553. [REDACTED]

1554. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1555. The agreement between Defendants G&W and Perrigo was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Prochlorperazine Maleate Suppositories (25 mg).

107. Promethazine HCL

1556. Promethazine HCL is an antihistamine used to treat some allergies, nausea, and vomiting. It is available in several forms, including Suppositories (12.5mg and 25mg). Promethazine HCL has been available in the United States in a generic form for many years.

1557. The market for Promethazine HCL is mature. At all relevant times there were multiple manufacturers of Promethazine HCL.

1558. During the relevant timeframe, the primary manufacturers of Promethazine HCL were Actavis, G&W, Mylan, Perrigo, and Taro.

1559. Plaintiffs allege that as part of Defendants' Fair Share Agreement, Defendants Actavis, G&W, Mylan, Perrigo, and Taro conspired to fix, raise, maintain or stabilize the prices of Promethazine HCL Suppositories beginning at least as early as the August of 2012.

1560. For years, the prices for Promethazine HCL Suppositories were relatively low and stable. Beginning in August 2012, however, Actavis, G&W, and Perrigo coordinated large price increases—one in October 2012, and another in April 2013.

1561. In September 2014, Mylan joined the market and rather than offer lower prices to gain market share, it imposed prices even higher than Actavis, G&W, and Perrigo.

1562. In the summer of 2015, Taro entered the market, and it too offered inflated prices.

1563. In preparation for the 2012 price increase, G&W began to reach out to competitors to coordinate.

1564. For example, in September 2012, Vogel-Baylor, G&W's Vice President of Sales and Marketing, communicated by phone numerous times with Rick Rogerson, Actavis's Senior Director of Pricing. Vogel-Baylor also communicated with T.P., Perrigo's Director of National Accounts, using A.T., Aurobindo's Director of National Accounts, as a conduit. Perrigo's T.P. also communicated by phone with M.D., Actavis's Director of National Accounts, during this same period.

1565. In October 2012, after solidifying an agreement with Perrigo and Actavis to raise prices, G&W announced a price increase for Promethazine HCL.


1566. In December 2012, Perrigo announced its own price increase, which took effect the following month. Actavis announced its price increase shortly afterwards.

1567. In March 2013, Orlofski, G&W's President, and Douglas Boothe, Perrigo's Executive Vice President and General Manager, communicated by phone multiple times in preparation for another price increase.

1568. In March and April 2013, G&W's Vogel-Baylor continued to communicate with Actavis's Rogerson and Perrigo's T.P., using Aurobindo's A.T. as a conduit to communicate with T.P. Actavis's M.D. also resumed communications with T.P.

1569. All three companies came to an agreement on a second price increase for Promethazine HCL. In April 2013, G&W announced a large price increase for Promethazine HCL. Actavis matched G&W's prices in June 2013, and Perrigo followed suit in August of 2013. The companies continued to communicate by phone leading up to the price increases.

1570. The parallel price increases for Promethazine HCL Suppositories is illustrated in the chart below:



1571. As each manufacturer raised prices, customers requested bids from competitors. But, in accordance with the Fair Share Agreement, each company refused to make competitive bids to gain market share. For example, when G&W was approached by a large Actavis customer seeking a new supplier for Promethazine HCL, G&W declined the opportunity by saying that it did not have the capacity to take on the account. In fact, G&W simply did not want to upset the market share equilibrium.

1572. [REDACTED]

1573. As a result of the agreement and anticompetitive coordination between Actavis, G&W, Mylan, Perrigo, and Taro, prices for Promethazine HCL were higher than they would have been in a competitive market.

1574. The ability of Actavis, G&W, Mylan, Perrigo, and Taro to reach agreement regarding Promethazine HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1575. [REDACTED]

1576. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1577. The agreement between Defendants Actavis, G&W, Mylan, Perrigo, and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Promethazine HCL Suppositories (12.5 and 25 mg).

108. Raloxifene HCL

1578. Raloxifene HCL, also known by the brand name Evista, is a medication used to combat the effects of osteoporosis in postmenopausal women. It is available in a Tablet formulation.

1579. During the relevant time frame, Defendants Teva and Camber were the primary manufacturers of Raloxifene HCL Tablets.

1580. In March 2014, Teva began marketing Raloxifene HCL. Actavis had received approval to begin marketing Raloxifene HCL in 2014 as well, but, by September 2014, had not entered the market. Camber entered the market in September 2014.

1581. With anticipated product launches approaching, the market entrants discussed an allocation scheme in September 2014: On September 9, 2014, Teva's Rekenthaler had a twenty-six (26) minute phone call with the Senior Vice President of U.S. Sales at Actavis, and, over the course of the following week, Rekenthaler spoke with multiple Actavis employees, including the SVP of U.S. Sales again, on September 16, 2014, for over half an hour.

1582. On September 17, 2014, Camber sent an offer for Raloxifene HCL to a large Teva customer. That day, Rekenthaler shared internally the information he had gathered from other manufacturers, including that Actavis would be "late" to the market, and that he would learn more about Camber's plan following an upcoming trip.

1583. Rekenthaler and Kon Ostaficiuk, the President of Camber Pharmaceuticals, spent the next three days playing golf during the day and socializing at night at an industry outing in Kentucky. On September 21 and 22, 2014, Ostaficiuk had a series of five phone calls with Rekenthaler. After those calls, Camber sent a revised offer to a potential customer that same afternoon, containing modified prices for Raloxifene HCL.

1584. On September 24, Patel discussed a Raloxifene HCL market strategy with her Teva colleagues in light of Camber's offer to the large Teva customer. Later that morning, Rekenhaller called Ostaficiuk and the two spoke for 2 minutes. They spoke two more times that day.

1585. On September 25, after discussing with his colleagues which customers Teva should concede to give Camber its Fair Share of the Raloxifene HCL market, and armed with the information Rekenhaller had gathered from Ostaficiuk, Teva decided to concede certain additional, smaller customers. Rekenhaller and Ostaficiuk spoke again twice that day.

1586. On Friday, September 26, 2014, Camber announced that it was launching Raloxifene HCL. Rekenhaller called Ostaficiuk that day to convey that Teva did not want Camber taking any more of its Raloxifene HCL customers. Camber agreed, and on September 29, 2014, Ostaficiuk sent an email to colleagues at Camber warning them not to "offer anything to any Teva customers...Not even a 'bad price'! Please acknowledge....We do not want to upset them more!" The Director of Sales and Operations at Camber, replied, "We have not made any offers to any Teva Raloxifene accounts.... Both Sales and Contracts are aware, & requesting incumbent detail for all offers, if Teva, no offer."

1587. About a week later, on October 7, 2014, a large Teva customer informed a Teva sales representative that Camber had made an unsolicited bid for its Raloxifene HCL business. A Director of National Accounts at Teva sent an internal email at Teva, expressing surprise given the agreement that Teva had previously reached with Camber: "I thought they were done after securing [our large customer]?" Rekenhaller doubted that Camber made an offer to another Teva customer, stating, "You're positive they sent them an offer?" The Teva Director of National Accounts then "relayed 'the message'" to the customer that "the market should be

stable at this point” and Teva doubted that Camber intended to make an offer on Raloxifene HCL. After further discussion with the customer, Teva learned that it was a misunderstanding. Camber never actually made the offer; it complied with the Fair Share Agreement with Teva.

1588. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1589. The ability of Teva and Camber reach agreements on Raloxifene HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1590. The coordination by Teva and Camber is consistent with the Fair Share Agreement.

1591. The agreement between Defendants Teva and Camber was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Raloxifene HCL Tablets.

109. Ranitidine HCL

1592. Ranitidine HCL is a commonly prescribed medication used to prevent and treat heartburn and other symptoms caused by too much acid in the stomach. It has been designated as an essential medicine by the World Health Organization and has been available in the United States for decades. Ranitidine HCL comes in many forms, including 75 mg, 150 mg, 300 mg Tablets, and 150 mg and 300 mg Capsules.

1593. The market for Ranitidine HCL Capsules and Tablets is mature. At all relevant times, there have been multiple manufacturers. Defendants Dr. Reddy’s and Sandoz dominated the sales of Ranitidine HCL Capsules and Defendants Amneal, Glenmark, and Teva dominated the sales of Ranitidine HCL Tablets in the relevant period.

1594. [REDACTED]

[REDACTED]

[REDACTED]


[REDACTED]

1595. WAC pricing also rose in a coordinated fashion. Sandoz substantially raised its WAC prices for Ranitidine HCL on January 13, 2012, a decision it would not have made unless it had pre-existing knowledge that Dr. Reddy's would quickly match its prices, as it did on February 1, 2012.

1596. The GAO reported that 300 mg Ranitidine HCL Capsules experienced "an extraordinary price increase" in 2012-2013.

1597. [REDACTED]

[REDACTED]:



1598. WAC pricing also rose in a coordinated fashion. Glenmark introduced WAC prices on May 16, 2013, which approximately doubled existing prices, a decision it would not have made unless it had pre-existing knowledge that Teva would quickly match its prices, as it did on July 3, 2013, even though it doubled its prior WAC prices. Defendant Amneal benefited from these increases.

1599. 

1600. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers. Teva considered all of these companies to be “quality competitors,” with whom it was easy to facilitate price coordination.

1601. For example, in a June 7, 2013 email, Dr. Reddy’s internally discussed its strategy of supporting Sandoz’s price increase and not exploiting Sandoz’s temporary absence to gain market share: “Sandoz did a price adjustment (Jan’12) and we followed. Then they went on

back order. As a result, we picked up their business temporarily (May'12 – July'12 qtr) from them since we did not want to upset the market post this price adjustment.”

1602. Teva and Glenmark's coordination is also well documented. As soon as she arrived at Teva, Patel began identifying price increase candidates, including drugs, where it ostensibly competed with Glenmark. On May 2, 2013, in a 6:49 am email, Patel informed a colleague that she expected to have some new drugs to add to the price increase list imminently. Not fifteen minutes later, she received a call from a senior executive at Glenmark, with whom she spoke for five minutes. At 7:44 am that day, Patel sent a follow-up email to her subordinate, directing him to add six different “high priority” Glenmark drugs to the price increase list, including Ranitidine HCL. Glenmark increased its WAC prices on all of these drugs two weeks later, on May 16, 2013, and Teva initiated price increases in July, when Teva and Glenmark exchanged six more telephone calls or texts to coordinate Teva's price increases. Although Glenmark increased its prices first, on May 6, 2013, Teva internally considered itself to be the leader on the Defendants' price increase.

1603. The ability of Amneal, Glenmark, Teva, Dr. Reddy's and Sandoz to reach agreement regarding Ranitidine HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1604. [REDACTED]

1605. The agreement between Defendants Amneal, Glenmark, Teva, Dr. Reddy's and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix,

stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including for Ranitidine HCL Capsules and Tablets.

110. Silver Sulfadiazine

1606. Silver Sulfadiazine is an antibiotic used to treat second and third-degree burns. It has been available in the United States for many years in a generic form. It is available in a Cream formulation.


1607. The market for Silver Sulfadiazine 1% Cream is mature. At all relevant times there have been multiple manufacturers.

1608. Defendants Ascend and Actavis dominate sales of Silver Sulfadiazine Cream (1%) [REDACTED]

1609. [REDACTED]

[REDACTED]

[REDACTED]



1610. The ability of Ascend and Actavis to reach agreements on Silver Sulfadiazine was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1611. [REDACTED]

[REDACTED]

1612. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1613. The agreement between Defendants Ascend and Actavis was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig

bids, and engage in market and customer allocation for generic drugs, including Silver Sulfadiazine Cream (1%).

111. Spironolactone HCTZ

1614. Spironolactone Hydrochlorothiazide (HCTZ) is a commonly prescribed medication used to treat high blood pressure. It has been on the market in the United States for decades in a generic form and is available in 25-25mg Tablets.

1615. The market for Spironolactone HCTZ Tablets is mature. At all relevant times, there have been multiple manufacturers. Defendants Greenstone, Mylan, and Sun dominated sales of for 25-25mg Spironolactone HCTZ Tablets in the relevant period.

1616. [REDACTED]

[REDACTED]

[REDACTED]

1617. The GAO reported that 25-25mg Spironolactone HCTZ Tablets experienced “an extraordinary price increase” in 2013-2014. There were no reported shortages of these products in the relevant period.

1618. WAC pricing also rose in a coordinated fashion. Mylan raised its prices on March 6, 2013, roughly five times its prior WAC price, a decision it would not have made unless it had pre-existing knowledge that the others would quickly match, as they did. Greenstone and Sun essentially matched Mylan’s price on April 2, 2013 and April 15, 2013 respectively, causing a more than fourfold increase of their prior WAC prices.

1619. [REDACTED]

1620. Pursuant to Defendants’ agreement, their price increases did not result in significant market share losses in the relevant period. Mylan held the dominant share, while Greenstone and Sun maintained small, but steady market shares.

1621. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers, including Greenstone, Mylan, and Sun. Co-Defendant Teva considered Mylan and Greenstone to be “quality competitors,” with whom it was easy to facilitate price coordination. Greenstone’s R.H. and Mylan’s Nesta exchanged 2,310 telephone calls or texts from 2011 through 2015, through which their companies facilitated price coordination on many products, including Spironolactone HCTZ. Nesta also exchanged 40 phone calls or texts with Greenstone’s Nailor between December 2012 and November 2015 to coordinate prices.

1622. The ability of Greenstone, Mylan, and Sun to reach agreement regarding for Spironolactone HCTZ was aided by the prevalence of trade association meetings and

conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1623. [REDACTED]

1624. The agreement between Defendants Greenstone, Mylan, and Sun was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including for Spironolactone HCTZ Tablets (25-25mg).

112. Tacrolimus

1625. Tacrolimus Ointment is a secondary treatment option for moderate to severe eczema. It is available in several forms, including an Ointment (0.03% and 0.1%).

1626. During the relevant timeframes, Perrigo and Sandoz were the primary manufacturers of Tacrolimus.

1627. Plaintiffs allege that as part of Defendants' Fair Share Agreement, Defendants Perrigo and Sandoz conspired to fix, raise, maintain or stabilize the prices of Tacrolimus beginning at least as early as the fall of 2014.

1628. In August 2014, Perrigo and Sandoz were both preparing to launch Tacrolimus, with Sandoz to be the first-to-file generic, and Perrigo to be the authorized generic.

1629. In August 2014, as Sandoz assessed the market, C.B., Sandoz's Director of National Accounts, communicated by phone with T.P., Perrigo's Director of National Accounts to learn whether Perrigo would be launching, and on what timeframe. Through that communication, C.B. learned that Perrigo would be launching Tacrolimus.

1630. In September 2014, as both companies prepared for the Tacrolimus launch, C.B. and T.P. communicated multiple times to keep each other apprised of developments, and to

coordinate pricing and customer allocation. T.P. shared Perrigo's pricing plans for Tacrolimus, and the companies agreed to an equal split of the market. C.B. kept contemporaneous notes his conversations with T.P.

1631. As November 2014 approached, C.B. and T.P. continued to communicate in anticipation for their respective launches. For example, when Perrigo heard rumors that Sandoz had already launched its Tacrolimus products, T.P. communicated multiple times with C.B. and received direct confirmation that Sandoz had not yet launched. T.P. reported his findings back to his Perrigo supervisor, Wesolowski: "[REDACTED] Likely recognizing that it would be unwise to memorialize in writing that he was illegally coordinating with C.B., a competitor, T.P. instead ascribed the source of the information as a "customer."

1632. Perrigo and Sandoz both launched Tacrolimus in the second half of November 2014 at similar prices, as illustrated below. Perrigo and Sandoz launched Tacrolimus 0.03% and 0.1% Ointments at similar prices.

1633. Perrigo and Sandoz stuck to the plan and pursued only those customers that they had previously agreed to target. Each company successfully retained its agreed-upon customers and achieved its Fair Share.

1634. As a result of the agreement and anticompetitive coordination between Perrigo and Sandoz, prices for Tacrolimus were higher than they would have been in a competitive market.

1635. The ability of Perrigo and Sandoz to reach agreement regarding for Tacrolimus was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1636. The coordinated price increases by Perrigo and Sandoz are consistent with the Fair Share Agreement.

1637. The agreement between Defendants Perrigo and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including for Tacrolimus Ointment (0.03% and 0.1%).

113. Tamoxifen Citrate



1638. Tamoxifen Citrate Tablets are commonly prescribed to treat breast cancer and have been available in the United States for decades. The World Health Organization includes Tamoxifen on its List of Essential Medicines. It is available in the United States in 10 mg and 20 mg Tablets.

1639. The market for Tamoxifen Citrate Tablets is mature. At all relevant times, there have been multiple manufacturers. Defendants Actavis, Mylan, and Teva dominated sales of Tamoxifen Citrate 10 mg and 20 mg Tablets in the relevant period.

1640. [REDACTED]

[REDACTED]

[REDACTED]



1641. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers, including Actavis, Mylan, and Teva.

1642. Effective July 31, 2012, Teva increased pricing on a number of drugs, including Tamoxifen Citrate, where it had the dominant share, followed by “Mylan (22.2%); Watson [Actavis] (10.3%).” Teva coordinated each of these price increases with other manufacturers through numerous calls in July 2012 in the days and weeks leading up to the price increase. For example, Teva’s Green spoke to Mylan’s Nesta on July 23 (seven minutes), 24 (four minute and eight minute calls), 25 (four minutes), 26 (four minutes), 30 (two calls, one for eight minutes), and 31 (six minute, two minute, four minute, seven minute and two minute calls), 2012. Meanwhile, Teva’s Rekenhler spoke to A.S. at Actavis on July 11, 2012 (one minute and nine minute calls).

1643. Defendants orchestrated a second price increase in April 2014. The plan originated with Teva’s advance knowledge that Actavis would increase its price, an increase ultimately implemented on April 15, 2014. Following a now very familiar pattern, at 9:54 am on March 14, 2014, Actavis’s Rogerson called Teva’s Patel and left a message. Patel called Rogerson back at 10:31 am, and the two spoke for more than twelve minutes. Within minutes after hanging up with Rogerson, Patel informed others at Teva about the Actavis increase. Within half an hour of sending that email, Patel instructed colleagues to add the Actavis drugs to the Teva price increase list. She added: “We intend to follow where we can.” Less than two hours later, at 12:37 pm, Patel called Rogerson again. They spoke for more than five minutes. Shortly after hanging up the phone, at 12:51 pm, Patel wrote another email to her colleagues at Teva, stating: “Actavis took an increase. We will follow. We need to review price per my alert list. Let’s wait to see what intel we can get and discuss Monday.”

1644. That Monday, March 17, 2014, Patel forwarded the “PI Candidates” list to K.G. at Teva. The list included both Tamoxifen Citrate. Later that morning, Patel called Actavis’s

Rogerson. After quickly exchanging voicemails, they spoke for more than nineteen minutes. Rekenthaler of Teva and Falkin of Actavis also exchanged four text messages that day and had one call lasting more than six minutes.

1645. In the days leading up to Teva's price increase for Tamoxifen Citrate, Rekenthaler asked Patel for a list of drugs and competitors associated with each of the increase items so that he could confirm that Teva had successfully coordinated increases with everyone. On April 1, 2014, Patel responded by providing a list of only those drugs where Teva was leading the price increase – *i.e.*, the drugs with the most risk if Teva did not secure an agreement with other manufacturers before raising its own price. Again, on April 4, 2014, the day of Teva's price increase, Patel and Rogerson spoke twice by phone, and Rekenthaler and Falkin also spoke by phone that day. Satisfied that Patel and Rekenthaler had confirmed agreement with all the appropriate competitors, Teva announced the price increase on Tamoxifen Citrate and other drugs. Because Teva was able to institute Actavis's planned price increase so quickly, Teva's increase became effective even before Actavis implemented its increases.

1646. After their price increases became effective, Teva took consistent steps not to disrupt the market or steal market share from Actavis. For example, on May 14, Patel declined to bid at AmerisourceBergen on both Tamoxifen Citrate and Estazolam, stating: "unable to bid (strategic reasons, for internal purposes)." When Patel and her other conspirators at Teva used the term "strategic" in this context, it was code for the fact that there was an understanding in place with a supposed competitor.

1647. Similarly, on May 21, 2014, Teva received a request from Wal-Mart for a bid on Tamoxifen Citrate. As of that date, Teva had 58.4% of the market, and Actavis had 40.7%. A Teva analyst forwarded the request to Patel and others, recommending (pursuant to the Fair

Share understanding in the industry) that Teva not bid “as we are first in a two-player market with good share already.” Patel responded: “Agree. We should decline to bid.”

1648. Meanwhile Mylan’s internal emails show that it temporarily discontinued Tamoxifen Citrate sales on October 15, 2013, due to “technical issues” and that it planned to relaunch in June 2014. Mylan listed its target market share as 25%. Under the Fair Share Agreement, Defendants willingly conceded market share to Mylan in order to maintain supracompetitive prices for Tamoxifen Citrate. For example, on June 6, 2014, a Teva employee emailed Patel and K.G.: “Since Mylan is coming into the market and we will need to give up some share, I propose conceding Cardinal.” K.G. countered that Teva had considered giving up CVS instead in order to keep Cardinal Health and Econdisc: “Let’s match Cardinal for now. Hopefully they go to CVS.” In another email, Teva employees considered holding off on bidding on Walmart because Mylan was reentering the market: “My assumption is that we will not want to pick up Wal-Mart, as we will most likely have to concede some of our current business with Mylan re-entering.”

1649. [REDACTED]

1650. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1651. The agreement between Defendants Actavis, Mylan, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Tamoxifen Citrate Tablets.

114. Temozolomide

1652. Temozolomide, also known by the brand name Temodar, is a medication used to treat glioblastoma multiforme and refractory anaplastic astrocytoma, both cancers of the brain. It is available as a Capsule and has been available in the United States in a generic form for many years.

1653. The market for Temozolomide is mature. At all relevant times, there have been multiple manufacturers of Temozolomide.

1654. During the relevant time frame, Defendants Teva and Sandoz were the primary manufacturers of Temozolomide Capsules.

1655. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Temozolomide capsules beginning at least as early as the summer of 2013

1656. Teva and Sandoz had each gained the right to launch on Temozolomide in August 2013. In preparation for the launch, Teva coordinated with Sandoz to divide up the market. For example, when Sandoz received an RFP from a large retail pharmacy customer on July 18, 2013, and after another large customer contacted Teva asking for an offer on Temozolomide on July 30, 2013, Teva and Sandoz communicated with each other to coordinate responses.

1657. For example, Patel of Teva called the Associate Director of Pricing at Sandoz on July 29. Also on July 29, 2013, Green of Teva spoke to Director of National Accounts at Sandoz twice, and then again on July 31, 2013. A different Sandoz Director of National Accounts also coordinated with a National Account Manager at Teva via phone.

1658. Sandoz and Teva continued to monitor and coordinate the price fixing and Fair Share Agreement on Temozolomide. For example, on August 12, 2013, the day of Teva's launch, a Sandoz Director of National Accounts met in person with Rekenhaller at the Grand

Lux Cafe in Las Vegas during the NACDS Total Store Expo Conference. There, Rekenthaler discussed, among other things, Temozolomide and informed the Sandoz Director that Teva had officially launched and shipped all formulations of the drug.

1659. The Sandoz Associate Director of Pricing spoke to Patel both before and after Sandoz sent out offers regarding Temozolomide to ensure that each had a Fair Share of the market.

1660. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1661. The ability of Teva and Sandoz to reach agreements on Temozolomide capsules was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1662. The coordination by Teva and Sandoz is consistent with the Fair Share Agreement.

1663. The agreement between Defendants Teva and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Temozolomide Capsules.

115. Terconazole

1664. Terconazole is a medication used to treat vaginal fungus or yeast infections. It is available in 0.4% and 0.8% Vaginal Cream formulations. Terconazole has been available in the United States in a generic form for many years.


1665. The market for Terconazole was mature, and at all relevant times had multiple manufacturers.

1666. During the relevant timeframe, Actavis and Taro were the primary manufacturers of Terconazole.

1667. Plaintiffs allege that as part of Defendants' Fair Share Agreement, Defendants Actavis and Taro conspired to fix, raise, maintain or stabilize the prices of Terconazole beginning at least as early as the spring of 2013.

1668. For years, the prices for Terconazole were relatively low and stable. By 2013, Sandoz exited the market for 0.8% Terconazole Vaginal Cream, and had a small market share and low capacity for 0.4% Terconazole Vaginal Cream. That left Actavis and Taro as the major manufacturers of the product.

1669. In the spring of 2013, Actavis had higher list (WAC) prices than Taro, but the prices it charged customers (NSP prices) were lower than Taro's. Taro increased its list (WAC) prices to match Actavis's, and Actavis more than tripled NSP prices. Taro quickly followed Actavis's price increase, as illustrated in the Terconazole 0.8% Vaginal Cream chart below. Actavis and Taro instituted similar price increases on Terconazole 0.4% Vaginal Cream.



1670. During this period, Actavis and Taro communicated directly with each other in furtherance of their price-fixing agreements on Terconazole, and their Fair Share Agreement. For example, in late April and May 2013, Taro's Aprahamian and Perfetto communicated by phone multiple times with several Actavis representatives.

1671. During the same period, when Taro customers approached Actavis seeking a competitive bid for Terconazole, Actavis declined to pursue those opportunities, as contemplated by the Fair Share Agreement. Instead, Actavis raised its Terconazole prices.

1672. As a result of the agreement and anticompetitive coordination between Actavis and Taro, prices for Terconazole were higher than they would have been in a competitive market.

1673. The ability of Actavis and Taro to reach agreement regarding for Terconazole was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1674. The coordinated price increases by Actavis and Taro are consistent with the Fair Share Agreement.

1675. The agreement between Defendants Actavis and Taro was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including for Terconazole 0.4% and 0.8% Vaginal Cream.

116. Timolol Maleate

1676. Timolol Maleate is a beta blocker drug, which is used to treat, for example, high pressure inside the eye due to glaucoma or other eye diseases. It has been available in the United States for decades in a generic form. It is available in Ophthalmic Gel, Ophthalmic Liquid Eye, and Tablet formulations. Due to, among other things, its clinical efficacy and safety, it has been designated as an essential medicine by the World Health Organization.

1677. The market for Timolol Maleate is mature. At all relevant times, there have been multiple manufacturers of Timolol Maleate.

1678. Defendants Bausch and Sandoz dominate sales of Timolol Maleate Ophthalmic Gel, which is available in dosage strengths of 0.25% and 0.5%. For much of the relevant time period, Bausch and Sandoz divided the market for Timolol Maleate Ophthalmic Gel in close to a 50/50 split.


1679. [REDACTED]

1680. Documentary evidence confirms that this [REDACTED] was the result of collusion among Bausch and Sandoz.

1681. A product sales and market share performance spreadsheet from Sandoz from May 2013 asks, “Do we want more share on this product?” for Timolol Maleate Ophthalmic Gel. The spreadsheet indicates that the response is “No” because “Sandoz has fair share.” Several months after this spreadsheet was circulated, Sandoz and Bausch engaged in a parallel price increase on Timolol Maleate.

1682. [REDACTED]





1683. The GAO noted that Timolol Maleate Ophthalmic Gel had an “extraordinary price increase” in the years 2014-15.

1684. Bausch and Sandoz’s Timolol Maleate Ophthalmic Gel prices remained elevated and parallel. As shown above, their [REDACTED]

1685. The ability of Bausch and Sandoz to reach agreement regarding Timolol Maleate was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See Exhibit E (Trade Association Contacts as to the Named Generic Drugs).*

1686. [REDACTED]
[REDACTED]

1687. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.


1688. The agreement between Defendants Bausch and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Timolol Maleate Ophthalmic Gel (0.25%, 0.5%).

117. Tizanidine HCL

1689. Tizanidine HCL is a commonly prescribed muscle relaxer that has been available in the United States for decades and is one of the top 200 most prescribed drugs in the United States. It is available in the United States in 2 mg and 4 mg Tablets.

1690. The market for Tizanidine Tablets is mature. At all relevant times, there have been multiple manufacturers. Defendants Apotex, Dr. Reddy's, Mylan, Sandoz, and Sun dominated sales of Tizanidine 2 mg and 4 mg Tablets in the relevant period.

1691. [REDACTED]
[REDACTED], as illustrated by the following example of 2 mg Tablets:



1692. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers, including Apotex, Dr. Reddy's, Mylan, Sandoz, and Sun.

1693. In May 2013, Dr. Reddy's estimated that it had 59% market share and Mylan and Sandoz had 24% and 17% respectively. Tizanidine had been on the market for many years and its price had eroded as many competitors entered and exited the market depending on the profitability of the drug. As Dr. Reddy's explained in an internal presentation, "Price needs to be adjusted to incentivize current manufacturers to stay in this product" and stated that Dr. Reddy's assumes "Mylan and Sandoz are responsible players, and they may not be able to pick up the large volumes we currently service."

1694. Sandoz was thrilled when it learned about Dr. Reddy's anticipated price increase. For example, on May 10, 2013, S.G., a national account executive at Sandoz, sent an internal

email stating that “Giant Eagle just let me know that Dr. Reddy just took a price increase on Tizanidine! Pricing on the 2 & 4mg 150ct went from \$4.50 to \$45.00. . . . We should secure confirmation but if this is true it would be very positive . . .” Kellum responded, “Wow! Thank you.” Kellum then quickly sent out a directive to the team to “[p]lease put the product on strict allocation to forecast. Pricing Team – no new offers.”

1695. Defendants coordinated their price increases at every step. For example, on May 13, 2013, when Dr. Reddy’s published its new WAC pricing for Tizanidine, Mylan’s Jim Nesta called D.L. at Sandoz and they spoke for 4 minutes. Two days later in an internal Sandoz email, M.V. at Sandoz emailed Kellum, “Let’s discuss” regarding “Tizanidine.”

1696. Sandoz raised its WAC pricing on par with Dr. Reddy’s on May 24, 2013, causing Sandoz’s WAC prices for Tizanidine Tablets to triple. In the days leading up to the Sandoz increase, Nesta of Mylan exchanged phone calls with both D.L. of Sandoz and J.A., a national account executive at Dr. Reddy’s, to coordinate the Tizanidine price increases. At least some of those calls are set forth in the table below:

Date	Call Type	Target Name	Direction	Contact Name	Duration
5/20/2013	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)	0:00:06
5/21/2013	Voice	Nesta, Jim (Mylan)	Incoming	J.A. (Dr. Reddy's)	0:00:00
5/21/2013	Voice	Nesta, Jim (Mylan)	Incoming	J.A. (Dr. Reddy's)	0:00:42
5/23/2013	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)	0:00:37
5/23/2013	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)	0:01:25
5/23/2013	Text	Nesta, Jim (Mylan)	Outgoing	J.A. (Dr. Reddy's)	0:00:00
5/23/2013	Text	Nesta, Jim (Mylan)	Outgoing	J.A. (Dr. Reddy's)	0:00:00
5/24/2013	Voice	Nesta, Jim (Mylan)	Outgoing	J.A. (Dr. Reddy's)	0:00:20

1697. The frequent calls and texts between Mylan’s Nesta and Sandoz’s J.A. in the four-day period on or before Sandoz’s price increase are notable because the two did not call or text each other again for the next three months.

1698. Consistent with the Defendants' price scheme, both Apotex and Sun raised their WAC prices in May and June of 2013 despite having largely abandoned the Tizanidine Tablet market at that time. And upon return both maintained high prices so as not to disrupt the Tizanidine price coordination scheme.

1699. Defendants maintained this price scheme in part by raising WACs and in part by refusing to bid on their competitors' customers if it would noticeably disrupt the Defendants' market allocation. For example, on May 29, 2013, customer Omnicare emailed Sandoz and asked whether it wanted to submit a bid for Tizanidine. C.B. of Sandoz forwarded the request internally to M.V. and Kellum asking "[a]re we considering additional Tizanidine market share? I'm assuming are[sic] intent is not to be disruptive at this time." A few minutes later, Nesta called D.L. at Sandoz and they spoke for nearly thirteen minutes. Later that day, M.V. replied to C.B.'s email stating, "[w]e will sit tight for now." C.B. then responded to Omnicare, stating that "[a]lthough we are not in a back order situation we cannot assume additional usage at this time. If this were to change I will let you know."

1700. On June 14, 2013, Anda, Inc.—now a subsidiary of Teva³⁰—emailed J.A. of Dr. Reddy's asking "[d]id mylan follow your increase?" J.A. responded, "We've heard they did." J.A. had learned of Mylan's intent to follow the price increase through his prior communications with Nesta. [REDACTED]

1701. On June 26, 2013, Meijer, a supermarket chain customer, emailed Dr. Reddy's requesting a bid for Tizanidine. J.A. forwarded the request to N.M., a marketing executive at Dr.

³⁰ Anda, Inc. was acquired by Teva from Allergan around the same time as the larger Allergan/Actavis acquisition in August 2016.

Reddy's, stating: "I'm assuming they got a price increase." N.M. responded: "I think, given the market situation and us leading the price adjustment, I think, we should not go behind additional market share since it will erode the market even further." J.A. replied, "[y]eah, I was just sending it as an FYI, no intention to bid." A few weeks later, Meijer forwarded the same request to Sandoz. Sandoz's response was similar: "[w]e cannot supply unfortunately."

1702. [REDACTED]

1703. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1704. The agreement between Defendants Apotex, Dr. Reddy's, Mylan, Sandoz, and Sun was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Tizanidine HCL Tablets (2 and 4 mg)

118. Tobramycin

1705. Tobramycin, also known by the brand name Tobi, is a medication used to treat eye infections. It is available as an Inhalation and has been available in the United States in a generic form for many years.

1706. The market for Tobramycin is mature. At all relevant times, there have been multiple manufacturers of Tobramycin Inhalation.

1707. During the relevant time frame, Defendants Teva and Sandoz were the primary manufacturers of Tobramycin Inhalation.

1708. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Tobramycin Inhalation beginning at least as early as the fall of 2013.

1709. Beginning in October 2013, Sandoz began making plans to enter the Tobramycin market, where Teva was the sole supplier. To facilitate Sandoz's entry into the market, and to allow it to gain a Fair Share, Teva and Sandoz began sharing information and coordinating to divide up the market for Tobramycin.

1710. Patel of Teva exchanged seven calls with the Associate Director of Pricing at Sandoz on July 1, 2014, five calls on July 7, 2014, and one call on July 9, 2014. During these calls, Sandoz and Teva discussed how to coordinate Fair Shares of the market for Tobramycin, including specific accounts that each would maintain or concede.

1711. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1712. The ability of Teva and Sandoz to reach agreements on Tobramycin Inhalation was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1713. The coordination by Teva and Sandoz are consistent with the Fair Share Agreement.

1714. The agreement between Defendants Teva and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Tobramycin Inhalation.

119. Tobramycin Dexamethasone

1715. Tobramycin Dexamethasone is an antibiotic used to treat bacterial eye infections and is available as an Ophthalmic Liquid (0.3-0.1%). It has been available in the United States for over a decade in a generic form.

1716. The market for Tobramycin Dexamethasone is mature. At all relevant times, there have been multiple manufacturers.

1717. Defendants Bausch and Sandoz dominate sales of Tobramycin Dexamethasone Ophthalmic Liquid (0.3-0.1%) [REDACTED].

1718. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1719. The ability of Bausch and Sandoz to reach agreements on Tobramycin Dexamethasone was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1720. [REDACTED]

[REDACTED]

1721. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1722. The agreement between Defendants Bausch and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Tobramycin Dexamethasone Ophthalmic Liquid (0.3-0.1%).

120. Tolmetin Sodium

1723. Tolmetin Sodium, also known by the brand name Tolectin, is a medication used to reduce pain, swelling, and joint stiffness from rheumatoid arthritis and osteoarthritis. It is available as a Capsule and has been available in the United States in a generic form for many years.

1724. The market for Tolmetin Sodium is mature. At all relevant times, there have been multiple manufacturers of Tolmetin Sodium.

1725. During the relevant time frame, Defendants Teva and Mylan were the primary manufacturers of Tolmetin Sodium Capsules.

1726. On August 9, 2013, Teva raised prices on a number of drugs, including Tolmetin Sodium. Leading up to these price increases, Teva coordinated via direct communication with other drug manufacturers, including Mylan.

1727. For example, on July 10, 2013, Teva's Green and Mylan's Nesta spoke twice. The next day, July 11, Nesta and Green exchanged several more calls.

1728. On August 1, 2013, Green again spoke to Nesta (Mylan) 2 times; shortly after the second call, Green called Patel to update her. On August 2, 2013, Patel called Green, after which

Green immediately called Nesta. Green spoke to Nesta three more times on August 6 and three times on August 8, 2013. Patel also spoke to Nesta twice on August 8, 2013.

1729. The day before the price increase went into effect – August 8, 2013 –Patel and Nesta spoke again. Price increases followed the next day.

1730. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1731. The ability of Teva and Mylan to reach agreements on Tolmetin Sodium was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1732. The coordination by Teva and Mylan is consistent with the Fair Share Agreement.

1733. The agreement between Defendants Teva and Mylan was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Tolmetin Sodium Capsules.

121. Tolterodine

1734. Tolterodine, also known by the brand name Detrol, is a medication used for the treatment of an overactive bladder. It is available in Tablets and Tablets ER formulations. It has been available in the United States in a generic form for many years.

1735. The market for Tolterodine is mature. At all relevant times, there have been multiple manufacturers of Tolterodine.

1736. During the relevant time frame, Defendants Teva, Mylan and Greenstone were the primary manufacturers of Tolterodine Tablets and Tablets ER.

1737. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Tolterodine Tartrate Tablets and Tablets ER beginning at least as early as June 2012.

1738. Between June 2012 and January 2013, Teva and Mylan were among the first manufacturers to enter the market for generic Tolterodine Tablets. Greenstone joined the tablet market in January 2014. Around the same time that Greenstone entered the Tablet market in January 2014, Teva and Mylan were the first manufacturers to launch Tolterodine.

1739. Throughout this period, Teva, Mylan, and Greenstone met at trade events and communicated directly in order to keep Tolterodine prices higher than they would have been in a competitive market.

1740. For example, in the second half of 2012, Teva and Mylan regularly communicated on the telephone. Teva's Green spoke to Mylan's Nesta numerous times between May and July of 2012, the period during which Teva was launching Tolterodine Tablets. Green and Nesta spoke again in January 2013, around the time that Mylan was launching its Tolterodine.

1741. Similarly, in the days leading up to Greenstone's entry to the Tolterodine Tablet market, Jill Nailor and a colleague at Greenstone were speaking frequently to Teva's Patel and Rekenhaller to coordinate. For example, on January 21, 2014, Nailor called Patel twice, and on January 22, 2014, Patel called Nailor twice, Nailor called Patel once, and the two exchanged multiple text messages. During these communications, Teva and Greenstone agreed that Teva would concede business to Greenstone in order to avoid significant price erosion in the market. And when Greenstone finally entered the market, it announced the exact same list (WAC) prices as Teva.

1742. Teva and Greenstone continued to communicate over the following months to ensure that Greenstone was able to obtain a Fair Share of the market. For example, in late January and early February, Teva's Patel and a contact at Greenstone communicated a number of times to coordinate Teva's concession of a large pharmacy customer to Greenstone on Tolterodine Tablets.

1743. During this period, Teva and Mylan planned to launch generic Tolterodine ER Tablets. In order to coordinate market share and pricing, Teva and Mylan were in regular contact. For example, on December 23 and 24, 2013, Teva's Rekenhler and Mylan's Nesta had a series of calls during which they agreed to allocate Tolterodine on launch day so that Teva and Mylan could each get a Fair Share without eroding pricing.

1744. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1745. The ability of Teva, Greenstone, and Mylan to reach agreements on Tolterodine Tablets and ER Tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1746. The coordination by Teva, Greenstone, and Mylan is consistent with the Fair Share Agreement.

1747. The agreement between Defendants Teva, Mylan and Greenstone was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Tolterodine Tablets and Tablets ER.

122. Trazodone HCL

1748. Trazodone HCL is a serotonin uptake inhibitor that is used to treat depression. It is available in tablet form in several strengths, including 100 mg Tablets. It has been available in the United States for over a decade in a generic form.

1749. The market for Trazodone HCL is mature. At all relevant times, there have been multiple manufacturers of Trazodone HCL. Defendants Teva and Par dominated the market for Trazodone HCL 100 mg Tablets, with Teva holding about 70% of the market and Par holding about 15% within that timeframe. Apotex and Sun each held smaller shares.

1750. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1751. The ability of Apotex, Par, Sun, and Teva to reach agreements on Trazodone HCL was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1752. [REDACTED]

1753. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1754. The agreement between Defendants Apotex, Par, Sun, and Teva was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Trazodone HCL Tablets (100 mg).

123. Triamcinolone Acetonide

1755. Triamcinolone Acetonide is a corticosteroid used to treat a variety of skin conditions such as eczema, dermatitis, allergies, and rashes. It has been available in the United States for decades in a generic form. It is available in, for example, Cream and Ointment.

1756. The market for Triamcinolone Acetonide is mature. At all relevant times, there have been multiple manufacturers of Triamcinolone Acetonide.

1757. Defendants Ascend, Par, Perrigo, Sandoz, and Taro dominate sales of Triamcinolone Acetonide Cream and Ointment. For much of the relevant period, Sandoz and Perrigo held most of the market share for the 0.025% Ointment, 0.025% Cream, 0.5% Cream, 0.1% Cream, 0.1% Ointment, and 0.5% Ointment with other defendants (Ascend, Par, and Taro) having a small share at certain times.

1758.

[REDACTED]



[REDACTED]



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]





1759. The GAO noted that Triamcinolone Acetonide 0.025% Cream, 0.025% Cream, 0.1% Ointment, 0.1% Cream, and 0.5% Cream had “extraordinary price increases” in the years 2010-2011.

1760. Documentary evidence confirms that these parallel price increases were the result of collusion among Ascend, Par, Perrigo, Sandoz, and Taro.

1761. [REDACTED]

[REDACTED] Under the Fair Share Agreement, they expected that their ostensible competitors would not undercut their prices in order to gain additional market share. When ostensible competitors did seek additional market share, defendants showed surprise and dismay that one would not expect in a competitive market. For instance, in September 2012, Sandoz received a rebid request from Rite Aid on Triamcinolone Acetonide 0.1% Lotion due to a bid from a competitor. R.T. of Sandoz asked colleague D.L. to find out if this was Par (Qualitest) or another competitor. D.L. confirmed that it was Par. R.T. asked, “Why in the heck would they be coming after our share?” C.B. of Sandoz responded, “Low IQ and a lack of understanding the market.”

1762. The ability of Ascend, Par, Perrigo, Sandoz, and Taro to reach agreement regarding Triamcinolone Acetonide was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1763. [REDACTED]

1764. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1765. The agreement between Defendants Ascend, Par, Perrigo, Sandoz, and Taro, was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Triamcinolone Acetonide Cream and Ointment.

124. Triamterene HCTZ



1766. Triamterene HCTZ is a commonly prescribed medication used to treat fluid retention and high blood pressure. It has been on the market for decades and is available in multiple forms and dosages, including Capsules (37.5-25 mg) and Tablets (37.5-25 mg and 75-50 mg).


1767. The market for Triamterene HCTZ Capsules and Tablets is mature. At all relevant times, there have been multiple manufacturers: Defendants Lannett, Mylan, and Sandoz dominated the sales of Capsules and Defendants Actavis, Apotex, Mylan, and Sandoz dominated the sales of Tablets.

1768. For many years the price of Triamterene HCTZ remained stable. However, prices began to rise dramatically [REDACTED]

[REDACTED]

[REDACTED]





1769. The GAO reported that Triamterene HCTZ Tablets experienced “an extraordinary price increase” in 2013-2014.

1770. WAC pricing also rose in a coordinated fashion. Mylan substantially raised its WAC prices on November 18, 2011, a decision it would not have made unless it had pre-existing knowledge that the others would soon match, as they did. Sandoz matched Mylan’s WAC prices on January 13, 2012, even though it meant increasing its prior WAC prices sevenfold. Actavis and Apotex also matched Mylan and Sandoz’s prices on March 9, 2012 and August 28, 2012 respectively, thereby significantly increasing their prior WAC prices.

1771. [REDACTED]

1772. [REDACTED]

1773. Documentary evidence confirms that these parallel price increases were the result of collusion among generic drug manufacturers, including Actavis, Apotex, Lannett, Mylan, and Sandoz. Co-Defendant Teva considered all four to be “quality competitors,” with whom it was easy to facilitate price coordination.

1774. The ability of Actavis, Apotex, Lannett, Mylan, and Sandoz to reach agreements regarding Triamterene HCTZ prices was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1775. [REDACTED]

1776. The agreement between Defendants Actavis, Apotex, Lannett, Mylan, and Sandoz was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including for Triamterene HCTZ Capsules (37.5-25 mg) and Tablets (37.5-25 mg and 75-50 mg).

125. Trifluoperazine HCL

1777. Trifluoperazine HCL, also known by the brand name Stelazine, is a medication used to treat disorders such as schizophrenia and Tourette syndrome. It is available in a Tablet (1, 2, 5, and 10 mg) and has been available in the United States in a generic form for many years.

1778. The market for Trifluoperazine HCL was mature and at all relevant times had multiple manufacturers.



1779. During the relevant time frame, Defendants Mylan and Sandoz were the primary manufacturers of Trifluoperazine HCL Tablets. Defendant Upsher-Smith joined the Trifluoperazine HCL market and the conspiracy in March 2015.

1780. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Trifluoperazine HCL Tablets (1, 2, 5 and 10 mg) beginning at least as early as July, 2013.

1781. For years, the prices for Trifluoperazine HCL tablets were relatively low and stable. In the summer of 2013, Mylan and Sandoz coordinated large price increases for their Trifluoperazine Tablets. Within a small window of time, Mylan and Sandoz approximately doubled their list (WAC) prices to identical levels, [REDACTED]

1782. When Upsher-Smith joined the market in spring of 2015, rather than offer better pricing to win customers, it announced identical list (WAC) prices to Mylan and Sandoz. [REDACTED]

1783. The list (WAC) price chart and the NSP price chart below highlight the abrupt and parallel price increases by Mylan and Sandoz, and the elevated prices at which Upsher-Smith joined the market for Trifluoperazine HCL Tablets.



1784. Throughout this period, Mylan, Sandoz and Upsher-Smith met at trade conferences and communicated directly with each other in furtherance of their price fixing agreement on Trifluoperazine HCL tablets and of the Fair Share Agreement.

1785. For example, on August 6, 2013—just a few days prior to Mylan’s price increases—Nesta (Mylan) was in phone contact with a Sandoz Director of National Accounts.

1786. Once the Mylan price increases were imposed, Sandoz was careful not to take Mylan’s customers and to maintain Fair Shares.

1787. Sandoz and Mylan were in contact by phone on numerous occasions in October, and on October 25, 2013, Sandoz announced identical list (WAC) prices to Mylan.

1788. In January, February and March of 2015, Sandoz’s Kellum was in phone contact with S.H., Senior VP of Global Sales, and J.H., Senior Director of Marketing, at Upsher-Smith. In February 2015, M.A., National Account Director at Mylan, communicated by text message with D.Z., National Accounts Senior Director at Upsher-Smith. On March 17, Upsher-Smith announced identical list prices to Sandoz and Mylan.

1789. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1790. The ability of Mylan, Sandoz and Upsher-Smith to reach agreements on Trifluoperazine tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1791. The coordination by Mylan, Sandoz, and Upsher-Smith is consistent with the Fair Share Agreement.

1792. The agreement between Defendants Mylan, Sandoz and Upsher-Smith was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Trifluoperazine Tablets (1, 2, 5, and 10 mg).

126. Valsartan HCTZ

1793. Valsartan HCTZ, also known by the brand name Diovan, is a medication used to treat high blood pressure. It is available as a Tablet and has been available in the United States in a generic form for many years.

1794. The market for Valsartan HCTZ Tablets was mature and at all relevant times had multiple manufacturers.

1795. During the relevant time frame, Defendants Sandoz and Mylan were the primary manufacturers of Valsartan HCTZ Tablets.

1796. Plaintiffs allege that as part of Defendants' Fair Share Agreement, they conspired to fix, raise, maintain or stabilize the prices of Valsartan HCTZ Tablets beginning at least as early as September 2012

1797. Mylan was the first to file an ANDA to market the generic Valsartan HCTZ, which, if approved, would give Mylan 180 days of generic exclusivity. Sandoz manufactured the authorized generic. This meant that Sandoz and Mylan would be the only two manufacturers of the generic version of the drug for six months.

1798. Mylan and Sandoz both launched Valsartan HCTZ on September 21, 2012. Prior to the launch, D.L., a Director of National Accounts at Sandoz, and Nesta of Mylan spoke numerous times by phone and discussed, among other things, avoiding price competition for customers in the Valsartan HCTZ market. They agreed to split the market 50/50.

1799. Sandoz's Kellum was kept in the loop about the agreement with Nesta.

1800. On September 21, 2012, a Sandoz employee remarked in an email on news of Mylan's FDA approval for Valsartan HCTZ: "Fyi, good news, Mylan has 180 days as expected." A Sandoz executive in Germany responded, ". . . sometimes a little help from our competition is welcome as well." D.D., the President and CEO of Sandoz North America replied: **"I guess this what they call co-opetition."**

1801. Shortly after Mylan entered the market, a large wholesaler contacted Sandoz to ask for better prices on Valsartan HCTZ. Sandoz refused. Kellum at Sandoz continued to monitor the agreement and to make sure that Sandoz was not taking more than its Fair Share. He explained to colleagues: "I'm concerned we are going to disrupt the market. I understand the need for additional sales but we need to be thoughtful here." A directive went out to the Sandoz sales personnel: "Do not approach new customers" without prior approval from the executives.

1802. No non-collusive market factors (*e.g.*, product shortages) can explain the artificially inflated prices.

1803. The ability of Sandoz and Mylan to reach agreements on Valsartan HCTZ tablets was aided by the prevalence of trade association meetings and conferences where the parties were able to meet in person. *See* Exhibit E (Trade Association Contacts as to the Named Generic Drugs).

1804. The coordination by Sandoz and Mylan is consistent with the Fair Share Agreement.

1805. The agreement between Defendants Sandoz and Mylan was part of an overarching conspiracy between generic drug manufacturers to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation for generic drugs, including Valsartan HCTZ Tablets.

D. Defendants' Anticompetitive Conduct Relating to the Other Named Generic Drugs Further Demonstrates Defendants' Overarching Fair Share Agreement

1806. All the individual drug allegations set forth above are in addition to the individual drug allegations and overarching conspiracy allegations described in DPPs' individual drug complaints and the DPPs' previous multi-drug complaint. *See* Exhibit A (DPP Named Generic Drugs in MDL 2724 as of October 2020); Exhibit B (Timeline of DPP Named Generic Drugs in MDL 2724).

E. The Existence of the Fair Share Agreement within the Generic Drug Industry and as to All of the Named Generic Drugs Is Supported by Other Factors.

1807. In addition to the data analysis and conspiracy evidence set forth herein, the existence of the Fair Share Agreement is supported by other factors:

- The many generic drugs that DPP have sued on in MDL 2724. *See* Exhibit A (DPP Named Generic Drugs in MDL 2724 as of October 2020); Exhibit B (Timeline of DPP Named Generic Drugs in MDL 2724).
- Public revelations to date in the ongoing government investigations and other public reports indicating collusion. *See* Exhibit C (History of Government Investigations and Other Public Reports Concerning Anticompetitive Conduct in the Generic Drug Industry); Exhibit D (List of Generic Drug Manufacturers Known to Have Received a DOJ Subpoena and/or CID Relating to Anticompetitive Conduct in the Generic Drug Industry).
- The extensive contacts among generic drug manufacturers including almost constant trade association meetings. *See, e.g.*, Exhibit E (Trade Association Contacts as to the Named Generic Drugs); Exhibit F (Generic Pharmaceutical Association Board of Directors 2010 to 2017); Exhibit I (Sample Telephone Record Summary).
- Economic factors relating to the generic drug industry. Exhibit G (Summary of Economic Factors Indicating Collusion in the Generic Drug Industry).
- Defendants' public communications to investors. Exhibit H (Sample of Defendants' Investor Communications).

VI. CLASS ACTION ALLEGATIONS

1808. Pursuant to Federal Rules of Civil Procedure 23(a) and (b)(3), Plaintiffs bring this action on behalf of a Class defined as:

All persons or entities that directly purchased one or more of the Named Generic Drugs from one or more Defendants in the United States and its territories and possessions, at any time during the period from July 2009 until the effects of the conspiracy cease (the Class Period).

Excluded from the Class are Defendants and their officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities.

1809. Members of the Class are so numerous that joinder is impracticable. There are scores of Class members, geographically dispersed throughout the United States, such that joinder of all Class members is impracticable. Further, the Class members are readily identifiable from information and records maintained by Defendants.

1810. Plaintiffs' claims are typical of, and not antagonistic to, the claims of the other Class members, and there are no material conflicts with any other member of the Class that would make class certification inappropriate. Plaintiffs and all members of the Class were damaged by the same wrongful conduct of Defendants.

1811. Plaintiffs will fairly and adequately protect and represent the interests of the Class and Plaintiffs' interests are coincident with, and not antagonistic to, those of the Class.

1812. Plaintiffs are represented by counsel who are experienced and competent in the prosecution of class action antitrust litigation.

1813. Questions of law and fact common to the members of the Class predominate over questions that may affect only individual Class members because Defendants have acted on grounds generally applicable to the Class. Thus, determining damages with respect to the Class as a whole is appropriate. The common applicability of the relevant facts to claims of Plaintiffs

and the proposed Class is inherent in Defendants' wrongful conduct, because the overcharge injuries incurred by Plaintiffs and each member of the proposed Class arose from the same collusive conduct alleged herein.

1814. The common legal and factual questions do not vary among Class members and may be determined without reference to individual circumstances, and include, but are not limited to, the following:

- (a) Whether Defendants and their generic manufacturer co-conspirators engaged in a contract, combination, or conspiracy to eliminate competition and thereby increase prices of the drugs identified in the DPPs' Amended Complaint and previous complaints in the United States and in its territories and possessions;
- (b) The duration and extent of the alleged contract, combination, or conspiracy between and among Defendants and their generic manufacturer co-conspirators;
- (c) Whether Defendants and their generic manufacturer co-conspirators were participants in the contract, combination, or conspiracy alleged herein;
- (d) The effect of the contract, combination, or conspiracy on prices of the drugs identified in the DPPs' Amended Complaint and previous complaints in the United States and in its territories and possessions during the Class Period;
- (e) Whether Defendants' conduct caused supracompetitive prices for the generic drugs named in this case;
- (f) Whether, and to what extent, the conduct of Defendants and their generic manufacturer co-conspirators caused injury to Plaintiffs and other members of the Class; and
- (g) Whether the alleged contract, combination, or conspiracy violated Sections 1 and 3 of the Sherman Act, 15 U.S.C. §§ 1 and 3.

1815. Treatment as a class action is the superior method for the fair and efficient adjudication of this controversy, as it will permit numerous similarly situated persons or entities to prosecute their common claims in a single forum simultaneously, avoiding unnecessary duplication of evidence, effort, or expense that numerous individual actions would engender. The benefits of proceeding as a class action, including providing injured persons or entities a

method for obtaining redress on claims that could not practicably be pursued individually, substantially outweighs any potential difficulties in management of this class action.

1816. Plaintiffs know of no special difficulty to be encountered in the maintenance of this action that would preclude its maintenance as a class action.

VII. ANTITRUST INJURY

1817. During the Class Period, DPPs and Class members directly purchased the drugs identified in the DPPs' Complaint from Defendants. Because of Defendants' anticompetitive conduct, Plaintiffs and Class members were forced to pay more for these drugs than they otherwise would have, and thus have suffered substantial overcharge damages at the hands of Defendants. This is a cognizable antitrust injury and constitutes harm to competition under the federal antitrust laws.

1818. Defendants' unlawful conduct has successfully eliminated or suppressed competition in the market, and Plaintiffs and Class members have sustained, and continue to sustain, significant losses in the form of artificially inflated prices paid to Defendants. The full amount of such overcharge damages will be calculated after discovery and upon proof at trial.

1819. Defendants, through their unlawful conduct alleged herein, reduced competition in the generic drug market, increased prices, reduced choice for purchasers, and caused antitrust injury to purchasers in the form of overcharges.

1820. Because Defendants' anticompetitive conduct is ongoing, DPPs and the proposed Class continue to pay supracompetitive prices for the drugs named in this case through the present.

VIII. TOLLING OF THE STATUTE OF LIMITATIONS

1821. The statute of limitations, as it applies to the alleged Sherman Act Sections 1 and 3 antitrust violations carried out by Defendants and any generic manufacturer co-conspirators,

were tolled due to one or more events. These include, but are not limited to, the following reasons.

1822. Plaintiffs had no knowledge of the combination or conspiracy alleged herein, or of facts sufficient to place them on inquiry notice of the claims set forth herein, until (at the earliest) Defendants' disclosures of the existence of the government investigations and subpoenas.³¹ Prior to that time, no information in the public domain or available to Plaintiffs suggested that any Defendant was involved in a large criminal conspiracy to fix prices for generic drugs.

1823. Plaintiffs had no knowledge of the combination or conspiracy alleged herein, or of facts sufficient to place them on inquiry notice of the claims set forth against these Defendants, until (at the earliest) the filing of the States' May 2019 Complaint.

1824. No information evidencing antitrust violations was available in the public domain prior to the public announcements of the government investigations that revealed sufficient information to suggest that any of the Defendants was involved in a criminal conspiracy to fix prices for generic drugs.

1825. Many of the Defendants and their generic manufacturer co-conspirators repeatedly and expressly stated throughout the Class Period, including on their public Internet websites, that they maintained antitrust/fair competition policies, which prohibited the type of

³¹ On December 12, 2016, the United States DOJ charged Glazer with a criminal violation of U.S. Antitrust laws. The resulting criminal proceedings against Glazer toll the statute of limitations on Plaintiffs' claims, according to 15 U.S.C. § 16(i). However, the charges against Glazer related to only Doxycycline and Glyburide. The DOJ publicly stated that the charges against Glazer were part of an ongoing federal antitrust investigation into price fixing, bid rigging, and other anticompetitive conduct in the generic pharmaceutical industry. In other words, the charges against Glazer only put plaintiffs on notice as to a small portion of the larger overarching conspiracy.

collusion alleged herein. It was reasonable for members of the Class to believe that Defendants were complying with their own antitrust policies.

1826. In the alternative, application of the doctrine of fraudulent concealment tolled the statutes of limitations on the claims asserted by Plaintiffs.

1827. Conspiracies, by their nature, must be concealed. Defendants and their generic manufacturer co-conspirators maintained their conspiracy through surreptitious meetings and communications. Defendants' and generic manufacturer co-conspirators' affirmative and fraudulent concealment of their conspiratorial acts prevented Plaintiffs from discovering their causes of action and thereby tolled the statute of limitations on Plaintiffs' claims. Such acts included, without limitation:

- (i) Defendants made consistent efforts to avoid communicating with each other in writing, or to delete written electronic communications after they were made, because they were aware that their conduct was illegal;
- (ii) Instructions were communicated among Defendants that they should not communicate through email, but should instead call or meet in person if they had information to convey;
- (iii) The Defendants destroyed emails, text messages, and other documents to avoid detection of their collusive conduct.
- (iv) Defendants made materially false and/or misleading public statements, including financial results, during earnings calls with shareholders and in SEC filings which had the effect of concealing, and/or failed to disclose, that they colluded to fix, stabilize, and raise prices, rig bids, and engage in market and customer allocation of generic drugs, and, consequently, their revenues during the Class Period were in part the result of anti-competitive conduct; and
- (v) As Defendants became more aware that they were under state and federal investigation, they failed to produce certain documents, including emails, in response to, for example, Connecticut's subpoena, even though the subpoena sought all such documents.

1828. The coordinated nature of Defendants' pricing, bids and market allocation was hidden and not easily discernable to Plaintiffs and members of the class, acting with reasonable

diligence. For example, Defendants' supply agreements with Plaintiffs and class members for the Named Generic Drugs are confidential and a review of Plaintiffs' own, individual contracts for Named Generic Drugs would not in themselves or in connection with publicly available information have given them reason to suspect an antitrust conspiracy. To the extent Defendants provided public pretextual reasons for their price increases, *e.g.*, shortages or increased costs of raw materials, Plaintiffs and class members had limited access to information that would have revealed the fraud. Because of Defendants' affirmative concealment, and the fact that antitrust conspiracies such as this one are inherently self-concealing, Plaintiffs could not have learned about the conspiracy any earlier, despite the exercise of reasonable diligence.

1829. The filing and pendency of DPPs' class action complaints against Defendants and generic manufacturer co-conspirators tolled the statute of limitations on Plaintiffs' claims.

1830. For these reasons, DPPs' claims are timely.

1831. Further, even if the Court were to find that a statute of limitations had been triggered, at a minimum, DPPs can still recover at least four years of overcharges. This Complaint alleges a continuing course of conduct. Thus, Plaintiffs and the members of the Class can recover for damages they suffered during any applicable limitations period.

IX. CLAIM FOR RELIEF
Conspiracy in Restraint of Trade in Violation of Sherman Act Sections 1 and 3

1832. Plaintiffs incorporate by reference the allegations set forth above as if fully set forth herein.

1833. This count is brought against all Defendants for their participation in an overarching conspiracy to fix, raise and/or stabilize the prices of Named Generic Drugs.

1834. Defendants and their unnamed generic manufacturer co-conspirators entered into and engaged in a contract, combination, or conspiracy in unreasonable restraint of trade in violation of Sections 1 and 3 of the Sherman Act (15 U.S.C. §§ 1, 3).

1835. During the Class Period, Defendants and their generic manufacturer co-conspirators entered into a continuing agreement, understanding and conspiracy in restraint of trade to artificially allocate customers, rig bids and raise, maintain and fix prices for Named Generic Drugs, thereby creating anticompetitive effects.

1836. This count is also brought against Defendant-participants in each of the drug specific conspiracies alleged above, which include the following:

- (1) Adapalene: Glenmark, Perrigo, Sandoz, Taro, Teva
- (2) Alclometasone Dipropionate: Glenmark, Sandoz, Taro
- (3) Allopurinol: Actavis, Dr. Reddy's, Mylan, Par
- (4) Amantadine HCL: Lannett, Sandoz, Upsher-Smith
- (5) Amiloride HCL/HCTZ: Mylan, Teva
- (6) Ammonium Lactate: Actavis, Perrigo, Taro
- (7) Amoxicillin/Clavulanate: Sandoz, Teva
- (8) Amphetamine/Dextroamphetamine (MAS) [Adderall]: Actavis, Aurobindo, Impax, Mallinckrodt, Sandoz, Teva
- (9) Atenolol Chlorthalidole: Actavis, Mylan
- (10) Atropine Sulfate: Bausch, Sandoz
- (11) Balsalazide Disodium: Apotex, West-Ward
- (12) Betamethasone Dipropionate: Actavis, Perrigo, Sandoz, Taro
- (13) Betamethasone Dipropionate Augmented: Sandoz, Taro
- (14) Betamethasone Dipropionate Clotrimazole: Actavis, Sandoz, Taro

- (15) Betamethasone Valerate: Actavis, G&W, Sandoz, Taro
- (16) Bethanechol Chloride: Amneal, Teva, Upsher-Smith
- (17) Bromocriptine Mesylate: Mylan, Perrigo, Sandoz
- (18) Budesonide: Actavis, Mylan, Par, Sandoz, Teva
- (19) Buspirone HCL: Actavis, Mylan, Teva
- (20) Butorphanol Tartrate: Apotex, Mylan, West-Ward
- (21) Capecitabine: Mylan, Teva
- (22) Captopril: Mylan, West-Ward, Wockhardt
- (23) Carbamazepine: Apotex, Sandoz, Taro, Teva, Torrent
- (24) Carisoprodol: Actavis, Par
- (25) Cefdinir: Lupin, Sandoz, Teva
- (26) Cefprozil: Lupin, Sandoz, Teva
- (27) Cefuroxime Axetil: Aurobindo, Citron, Lupin
- (28) Celecoxib: Actavis, Teva
- (29) Cephalexin (Cefalexin): Lupin, Teva
- (30) Chlorpromazine HCL: Sandoz, Upsher-Smith
- (31) Cholestyramine: Par, Sandoz, Upsher-Smith
- (32) Ciclopirox: Actavis, Akorn, Glenmark, G&W, Perrigo, Sandoz, Taro
- (33) Cimetidine: Mylan, Teva
- (34) Clarithromycin: Actavis, Teva
- (35) Clindamycin Phosphate: Actavis, Greenstone, Perrigo, Sandoz, Taro
- (36) Clonidine TTS: Actavis, Mylan, Teva
- (37) Clotrimazole: Taro, Teva
- (38) Desmopressin Acetate: Actavis, Teva
- (39) Desonide Lotion: Actavis, Sandoz, Taro

- (40) Desoximetasone: Glenmark, Sandoz, Taro
- (41) Dexmethylphenidate HCL [Focalin]: Par, Sandoz, Teva
- (42) Dextroamphetamine Sulfate (Dex Sulfate): Actavis, Aurobindo, Impax, Mallinckrodt, Teva
- (43) Diclofenac Potassium: Mylan, Sandoz, Teva
- (44) Diltiazem HCL: Mylan, Teva
- (45) Diphenoxylate Atropine HCL: Greenstone, Mylan
- (46) Doxazosin Mesylate: Apotex, Greenstone, Mylan, Par, Teva
- (47) Drospirenone and Ethinyl Estradiol: Actavis, Lupin, Teva
- (48) Enalapril Maleate: Bausch, Mylan, Taro, Teva, Wockhardt
- (49) Entecavir: Par, Teva
- (50) Estradiol: Actavis, Mylan, Teva
- (51) Estradiol and Norethindrone Acetate [Mimvey]: Breckenridge, Teva
- (52) Ethinyl Estradiol and Levonorgestrel [Portia and Jolessa]: Sandoz, Teva
- (53) Etodolac: Apotex, Sandoz, Taro, Teva, Zydus
- (54) Exemestane: Alvogen, Greenstone, West-Ward
- (55) Fenofibrate: Lupin, Mylan, Perrigo, Teva, Zydus
- (56) Fluconazole: Citron, Dr. Reddy's, Glenmark, Greenstone, Teva
- (57) Fluocinolone Acetonide: G&W, Sandoz, Taro, Teligent
- (58) Fluocinonide Cream and Solution: Actavis, Bausch, Glenmark, Perrigo, Sandoz, Taro
- (59) Fluoxetine HCL: Mylan, Par, Teva
- (60) Fluticasone Propionate: Akorn, Apotex, West-Ward, Wockhardt
- (61) Gabapentin: Aurobindo, Glenmark, Teva
- (62) Glimepiride: Dr. Reddy's, Teva
- (63) Griseofulvin: Actavis, Teva

- (64) Halobetasol Propionate: G&W, Perrigo, Sandoz, Taro
- (65) Haloperidol: Sandoz, Mylan, Zydus
- (66) Hydrocodone Acetaminophen: Amneal, Mallinckrodt, Par, Teva
- (67) Hydrocortisone Valerate: G&W, Perrigo, Taro
- (68) Irbesartan: Lupin, Teva
- (69) Isosorbide Dinitrate: Sandoz, Par, West-Ward
- (70) Ketoconazole: G&W, Mylan, Sandoz, Taro, Teva
- (71) Ketoprofen: Mylan, Teva
- (72) Ketorolac Tromethamine: Mylan, Teva
- (73) Labetalol HCL: Actavis, Par, Sandoz, Teva
- (74) Lamivudine/Zidovudine [Combivir]: Aurobindo, Camber, Lupin, Teva
- (75) Latanoprost: Akorn, Bausch, Greenstone, Sandoz
- (76) Lidocaine HCL: Akorn, Sandoz, Taro
- (77) Loperamide HCL: Mylan, Teva
- (78) Metformin ER (F): Actavis, Lupin
- (79) Methadone HCL: Mallinckrodt, West-Ward
- (80) Methazolamide: Sandoz, Perrigo
- (81) Methotrexate: Mylan, Par, Teva, West-Ward
- (82) Methylphenidate: Actavis, Impax, Mallinckrodt, Par, Sandoz, Sun
- (83) Methylprednisolone: Breckenridge, Cadista, Greenstone, Par, Sandoz
- (84) Metronidazole Gel 1%: Sandoz, Taro
- (85) Moexipril HCL: Glenmark, Teva
- (86) Moexipril HCL HCTZ: Glenmark, Teva
- (87) Nadolol: Greenstone, Mylan, Sandoz, Teva

- (88) Naproxen Sodium: Amneal, Glenmark
- (89) Neomycin Polymyxin Hydrocortisone: Bausch, Sandoz
- (90) Niacin: Lupin, Teva, Zydus
- (91) Nitrofurantoin: Alvogen, Mylan, Teva
- (92) Norethindrone/Ethinyl Estradiol [Balziva]: Lupin, Teva
- (93) Nortriptyline HCL: Actavis, Taro, Teva
- (94) Nystatin Triamcinolone: Sandoz, Taro
- (95) Omega-3-Acid Ethyl Esters: Apotex, Par, Teva
- (96) Oxaprozin: Dr. Reddy's, Greenstone, Sandoz, Teva
- (97) Oxybutynin Chloride: Par, Teva, Upsher-Smith
- (98) Oxycodone Acetaminophen: Actavis, Alvogen, Amneal, Aurobindo, Mallinckrodt, Par
- (99) Oxycodone HCL: Actavis, Glenmark, Lannett, Mallinckrodt, Par, Sun
- (100) Paricalcitol: Dr. Reddy's, Teva, Zydus
- (101) Permethrin: Actavis, Mylan, Perrigo
- (102) Perphenazine: Par, Sandoz
- (103) Phenytoin Sodium: Amneal, Mylan, Sun, Taro
- (104) Pilocarpine HCL: Actavis, Impax, Lannett
- (105) Piroxicam: Greenstone, Mylan, Teva
- (106) Potassium Chloride: Actavis, Mylan, Sandoz, Upsher-Smith, Zydus
- (107) Prazosin HCL: Mylan, Teva
- (108) Prednisolone Acetate: Greenstone, Sandoz
- (109) Prednisone: Actavis, Cadista, Par, West-Ward
- (110) Prochlorperazine Maleate: G&W, Perrigo
- (111) Promethazine HCL: Actavis, G&W, Mylan, Perrigo, Taro

- (112) Raloxifene HCL: Camber, Teva
- (113) Ranitidine HCL: Amneal, Dr. Reddy's, Glenmark, Sandoz, Teva
- (114) Silver Sulfadiazine: Actavis, Ascend
- (115) Spiro lactone HCTZ: Greenstone, Mylan, Sun
- (116) Tacrolimus: Perrigo, Sandoz
- (117) Tamoxifen Citrate: Actavis, Mylan, Teva
- (118) Temozolomide: Sandoz, Teva
- (119) Terconazole: Actavis, Taro
- (120) Timolol Maleate: Bausch, Sandoz
- (121) Tizanidine HCL: Apotex, Dr. Reddy's, Mylan, Sandoz, Sun
- (122) Tobramycin: Sandoz, Teva
- (123) Tobramycin Dexamethasone: Bausch, Sandoz
- (124) Tolmetin Sodium: Mylan, Teva
- (125) Tolterodine: Greenstone, Mylan, Teva
- (126) Trazodone HCL: Apotex, Par, Sun, Teva
- (127) Triamcinolone Acetonide: Ascend, Par, Perrigo, Sandoz, Taro
- (128) Triamterene HCTZ: Actavis, Apotex, Lannett, Mylan, Sandoz
- (129) Trifluoperazine HCL: Mylan, Sandoz, Upsher-Smith
- (130) Valsartan HCTZ: Mylan, Sandoz
- (131) Warfarin Sodium: Amneal, Taro, Teva, Zydus

1837. The conspiratorial acts and combinations have caused unreasonable restraints in the market for Named Generic Drugs.

1838. As a result of Defendants' unlawful conduct, Plaintiffs and members of the proposed Class who purchased Named Generic Drugs have been harmed by being forced to pay inflated, supracompetitive prices for Named Generic Drugs.

1839. In formulating and carrying out the alleged agreement, understanding and conspiracy, Defendants and their generic manufacturer co-conspirators did those things that they combined and conspired to do, including, but not limited to, the acts, practices and course of conduct set forth herein.

1840. Defendants' conspiracy had the following effects, among others:

(a) Price competition in the market for Named Generic Drugs has been restrained, suppressed, and/or eliminated in the United States;

(b) Prices for Named Generic Drugs provided by Defendants and their generic manufacturer co-conspirators have been fixed, raised, maintained, and stabilized at artificially high, non-competitive levels throughout the United States; and

(c) Plaintiffs and members of the proposed Class who purchased Named Generic Drugs directly from Defendants and their generic manufacturer co-conspirators have been deprived of the benefits of free and open competition.

1841. As a direct and proximate result of Defendants' and generic manufacturer co-conspirators' unlawful conduct, Plaintiffs and members of the proposed Class have been injured in their business and property in that they have paid more for these drugs than they otherwise would have paid in the absence of Defendants' and generic manufacturer co-conspirators' unlawful conduct. The full amount of such damages is presently unknown and will be determined after discovery and upon proof at trial.

1842. All Defendants and generic manufacturer co-conspirators are *per se* liable under Sections 1 and 3 of the Sherman Act, 15 U.S.C. §§ 1 and 3, for the injuries and damages caused by their contract, combination, and conspiracy in restraint of trade as alleged herein.

1843. There is no legitimate, non-pretextual, procompetitive business justification for Defendants' and generic manufacturer co-conspirators' conspiracy that outweighs its harmful effect. Even if there were some conceivable justification, the conspiracy is broader than necessary to achieve such a purpose.

1844. Defendants' and generic manufacturer co-conspirators' unlawful conduct as alleged herein poses a significant and continuing threat of antitrust injury.

X. PRAYER FOR RELIEF

WHEREFORE, DPPs and members of the proposed Class pray for relief from this Court and request:

A. Certification as a class action pursuant to Federal Rule of Civil Procedure 23, and appointment of DPPs as Class representatives and their counsel of record as Class counsel;

B. Adjudication that the acts alleged herein constitute unlawful restraints of trade in violation of the Sherman Act;

C. A judgment against Defendants and generic manufacturer co-conspirators, jointly and severally, for the damages sustained by DPPs and the Class defined herein, and for any additional damages, penalties, and other monetary relief provided by applicable law, including treble damages;

D. An award to DPPs and Class members of pre-judgment and post-judgment interest at the highest legal rate provided by law from and after the date of service of the first-filed complaint in this action;

E. An award to DPPs and Class members of the costs of this suit, including reasonable attorney fees; and

F. An award of any further relief as the Court deems just and proper.

XI. JURY TRIAL DEMANDED

DPPs hereby request a jury trial on all claims so triable.

Dated: October 21, 2020

NASTLAW LLC



Dianne M. Nast
Joseph N. Roda
Michael D. Ford
1101 Market Street, Suite 2801
Philadelphia, Pennsylvania 19107
(215) 923-9300
(215) 923-9302 (fax)
dnast@nastlaw.com
jnroda@nastlaw.com
mford@nastlaw.com

***Lead and Liaison Counsel for Direct
Purchaser Plaintiffs***

BERGER MONTAGUE PC
David F. Sorensen
Candice J. Enders
Zachary D. Caplan
Christina M. Black
1818 Market Street, Suite 3600
Philadelphia, Pennsylvania 19103
(215) 875-3000
dsorensen@bm.net
cenders@bm.net
zcaplan@bm.net
cblack@bm.net

HAGENS BERMAN SOBOL SHAPIRO LLP
Thomas M. Sobol
David S. Nalven
55 Cambridge Parkway, Suite 301
Cambridge, Massachusetts 02142
(617) 482-3700
tom@hbsslw.com
davidn@hbsslw.com

Barbara A. Mahoney
1918 8th Avenue, Suite 3300
Seattle, Washington 98101
(206) 623-7292
barbaram@habsslw.com

KAPLAN FOX & KILSHEIMER LLP

Robert N. Kaplan
Elana Katcher
850 Third Avenue
New York, New York 10022
(212) 687-1980
rkaplan@kaplanfox.com
ekatcher@kaplanfox.com

NUSSBAUM LAW GROUP, PC

Linda P. Nussbaum
1211 Avenue of the Americas, 40th Floor
New York, New York 10036
(917) 438-9189
lnussbaum@nussbaumpc.com

ROBERTS LAW FIRM P.A.

Michael L. Roberts
20 Rahling Circle
Little Rock, Arkansas 72223
(501) 821-5575
mikeroberts@robertslawfirm.us

Direct Purchaser Plaintiffs' Steering Committee

EXHIBIT A

EXHIBIT A – DPP NAMED GENERIC DRUGS IN MDL 2724 AS OF OCTOBER 2020

DPP Bellwether Drugs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
1. Clobetasol	Skin conditions	Cream (0.05%) Ointment (0.05%) Gel (0.05%) Emollient Cream (0.05%) Solution (0.05%)	Actavis, Akorn, Perrigo, Sandoz, Taro, Wockhardt
2. Clomipramine	Antidepressant	Capsules (25, 50, 75 mg)	Mylan, Sandoz, Taro
3. Pravastatin	Anticholesterol	Tablets (10, 20, 40, 80 mg)	Apotex, Glenmark, Lupin, Sandoz, Teva, Zydus

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
4. Acetazolamide	Glaucoma, epilepsy, and edema diuretic	Capsules (500 mg) Tablets (125, 250 mg)	Heritage, Lannett, Taro, Teva, Zydus
5. Adapalene	Acne	Gel (0.1%, 0.3%) Cream (0.1%)	Glenmark, Perrigo, Sandoz, Taro, Teva
6. Albuterol	Bronchodilator	Tablets (2, 4 mg)	Mylan, Sun
7. Alclometasone Dipropionate	Skin conditions	Cream (0.05%) Ointment (0.05%)	Glenmark, Sandoz, Taro
8. Allopurinol	Uric acid reducer	Tablets (100, 300 mg)	Actavis, Dr. Reddy's, Mylan, Par
9. Amantadine HCL	Antiviral	Capsules (100 mg)	Lannett, Sandoz, Upsher-Smith
10. Amiloride HCL/HCTZ	High blood pressure	Tablets (5-50 mg)	Mylan, Teva
11. Amitriptyline	Antidepressant	Tablets (10, 25, 50, 75, 100, 150 mg)	Mylan, Par, Sandoz
12. Ammonium Lactate	Skin conditions	Cream (12%) Lotion (12%)	Actavis, Perrigo, Taro
13. Amoxicillin/Clavulanate	Bacterial infection	Tablets Chewable (200-28.5, 400-57 mg)	Sandoz, Teva

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
14. Amphetamine/Dextroamphetamine (MAS) [Adderall]	ADHD	Capsules ER (5, 10, 15, 20, 25, 30 mg) Tablets IR (5, 10, 20, 30 mg)	Actavis, Aurobindo, Impax, Mallinckrodt, Sandoz, Teva
15. Atenolol Chlorthalidone	High blood pressure	Tablets (50-25, 100-25 mg)	Actavis, Mylan
16. Atropine Sulfate	Eye conditions	1% Ophthalmic Liquid Eye/Solution	Bausch, Sandoz
17. Baclofen	MS muscle relaxant	Tablets (10, 20 mg)	Lannett, Par, Teva, Upsher-Smith
18. Balsalazide Disodium	Anti-inflammatory	Capsules (750 mg)	Apotex, West-Ward
19. Benazepril HCTZ	HBP/kidney disease ACE inhibitor	Tablets (10-12.5, 20-12.5, 20-25 mg)	Mylan, Sandoz
20. Betamethasone Dipropionate	Skin conditions	Ointment (0.05%) Cream (0.05%) Lotion (0.05%)	Actavis, Perrigo, Sandoz, Taro
21. Betamethasone Dipropionate Augmented	Skin conditions	Lotion (0.05%)	Sandoz, Taro
22. Betamethasone Dipropionate Clotrimazole	Skin conditions	Cream (0.05%) Lotion (0.05%)	Actavis, Sandoz, Taro
23. Betamethasone Valerate	Skin conditions	Cream (0.1%) Ointment (0.1%) Lotion (0.1%)	Actavis, G&W, Sandoz, Taro
24. Bethanechol Chloride	Bladder problems	Tablets (5, 10, 25, 50 mg)	Amneal, Teva, Upsher-Smith
25. Bromocriptine Mesylate	Dopamine promoter	Tablets (2.5 mg)	Mylan, Perrigo, Sandoz
26. Budesonide	Steroid	Inhalation (0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/ 2 ml) Capsules DR (3 mg)	Actavis, Mylan, Par, Sandoz, Teva
27. Buspirone HCL	Anxiety disorders	Tablets	Actavis, Mylan, Teva
28. Butorphanol Tartrate	Pain	Nasal Spray (10 mg/ml)	Apotex, Mylan, West-Ward
29. Capecitabine	Chemotherapy	Tablets (150, 500 mg)	Mylan, Teva

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
30. Captopril	High blood pressure	Tablets (12.5, 25 50, 100 mg)	Mylan, West-Ward, Wockhardt
31. Carbamazepine	Anticonvulsant	Tablets (200 mg) Tablets ER (100, 200, 400 mg) Chewable Tablets (100 mg)	Apotex, Sandoz, Taro, Teva, Torrent
32. Carisoprodol	Muscle relaxant	Tablets (350 mg)	Actavis, Par
33. Cefdinir	Bacterial infection	Capsules (300 mg) Suspension (125 mg/5 ml, 250 mg/5 ml)	Lupin, Sandoz, Teva
34. Cefprozil	Bacterial infection	Tablets (250, 500 mg)	Lupin, Sandoz, Teva
35. Cefuroxime Axetil	Antibiotic	Tablets (250, 500 mg)	Aurobindo, Citron, Lupin
36. Celecoxib	NSAID	Capsules (50, 100, 200, 400 mg)	Actavis, Teva
37. Cephalexin (Cefalexin)	Antibiotic	Suspension (125 mg /5 ml, 250 mg/5 ml)	Lupin, Teva
38. Chlorpromazine HCL	Antipsychotic	Tablets (10, 25, 50, 100, 200 mg)	Sandoz, Upsher-Smith
39. Cholestyramine	High cholesterol	Powder (4 gm) Oral Solid (4 gm)	Par, Sandoz, Upsher-Smith
40. Ciclopirox	Skin conditions	Cream (0.77%) Shampoo/Liquid/Solution (1%, 8%)	Actavis, Akorn, G&W, Glenmark, Perrigo, Sandoz, Taro
41. Cimetidine	Ulcers	Tablets (200, 300, 400, 800 mg)	Mylan, Teva
42. Clarithromycin	Anbiotic	Tablets ER (500 mg)	Actavis, Teva
43. Clindamycin Phosphate	Skin conditions	Gel (1%) Lotion (1%) Solution (1%) Vaginal Cream (2%)	Actavis, Greenstone, Perrigo, Sandoz, Taro
44. Clonidine	High blood pressure	Patch (0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr)	Actavis, Mylan, Teva
45. Clotrimazole	Skin infections	Solution/Liquid Emulsion (1%)	Taro, Teva
46. Desmopressin Acetate	Antidiuretic	Tablets (0.1, 0.2 mg)	Actavis, Teva

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
47. Desonide	Skin conditions	Cream (0.05%) Ointment (0.05%) Lotion (0.05%)	Actavis, Perrigo, Sandoz, Taro
48. Desoximetasone	Skin conditions	Ointment (0.25%)	Glenmark, Sandoz, Taro
49. Dexmethylphenidate HCL (Dexmeth ER) [Focalin]	ADHD	ER Capsules (5, 15, 20, 40 mg)	Par, Sandoz, Teva
50. Dextroamphetamine Sulfate (Dex Sulfate)	ADHD	ER Tablets (2.5, 5, 7.5, 10, 15, 20, 30 mg) ER Capsules (5, 10, 15 mg)	Actavis, Aurobindo, Impax, Mallinckrodt, Teva
51. Diclofenac Potassium	NSAID	Tablets (50 mg)	Mylan, Sandoz, Teva
52. Digoxin	Cardiac glycoside	Tablets (0.125, 0.25 mg)	Impax, Lannett, Mylan, Par, West-Ward
53. Diltiazem HCL	High blood pressure	Tablets (30, 60, 90, 120 mg)	Mylan, Teva
54. Diphenoxylate Atropine HCL	Diarrhea	Tablets (2.5-0.025mg)	Greenstone, Mylan
55. Divalproex	Anticonvulsant	Tablets ER (250, 500 mg)	Dr. Reddy's, Mylan, Par, Zydus
56. Doxazosin Mesylate	High blood pressure	Tablets (1, 2, 4, 8 mg)	Apotex, Greenstone, Mylan, Par, Teva
57. Doxycycline	Antibiotic	Capsules RR (50, 100 mg) Tablets RR (100 mg) Tablets DR (75, 100, 150 mg) Tablets Monohydrate (mono) (50, 75, 100, 150 mg)	Actavis, Heritage, Lannett, Mayne, Mylan, Par, Sun, West-Ward
58. Drospirenone and Ethinyl Estradiol [Ocella]	Oral contraceptive	Tablets (0.02-3 mg, 0.03-3 mg)	Actavis, Lupin, Teva
59. Econazole	Antifungal	Cream (1%)	Perrigo, Taro, Teligent
60. Enalapril Maleate	High blood pressure	Tablets (2.5, 5, 10, 20 mg)	Bausch, Mylan, Taro, Teva, Wockhardt
61. Entecavir	Hepatitis B	Tablets (0.5, 1 mg)	Par, Teva
62. Estradiol	Hormone	Tablets (0.5, 1, 2 mg)	Actavis, Mylan, Teva
63. Estradiol and Norethindrone Acetate [Mimvey]	Oral contraceptive	Tablets (1-0.5 mg)	Breckenridge, Teva

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
64. Ethinyl Estradiol and Levonorgestrel [Portia and Jolessa]	Oral contraceptive	Tablets (0.1-0.02-0.01, 0.1-0.02, 0.15-0.02-0.01, 0.15-0.03, 0.15-0.03-0.01, 6-5-10 mg)	Sandoz, Teva
65. Etodolac	NSAID	Capsules (200, 300 mg) Tablets (400, 500 mg) Tablets ER (400, 500, 600 mg)	Apotex, Sandoz, Taro, Teva, Zydus
66. Exemestane	Estrogen modulator	Tablets (25 mg)	Alvogen, Greenstone, West-Ward
67. Fenofibrate	High cholesterol	Tablets (48, 145 mg)	Lupin, Mylan, Perrigo, Teva, Zydus
68. Fluconazole	Antifungal	Tablets (50, 100, 150, 200 mg)	Citron, Dr. Reddy's, Glenmark, Greenstone, Teva
69. Fluocinolone Acetonide	Skin conditions	Cream (0.01%, 0.025%) Ointment (0.025%) Solution (0.01%)	G&W, Sandoz, Taro, Teligent
70. Fluocinonide	Skin conditions	Cream (0.05%, 0.1%) Ointment (0.05%) Emollient Cream (0.05%) Gel (0.05%) Solution/Emulsion (0.05%, 0.1%)	Actavis, Bausch, Glenmark, Perrigo, Sandoz, Taro, Teva
71. Fluoxetine HCL	SSRI	Tablets (10, 15, 20, 60 mg)	Mylan, Par, Teva
72. Fluticasone Propionate	Steroid	Nasal Spray (50 mcg)	Akorn, Apotex, West-Ward, Wockhardt
73. Fosinopril HCTZ	HBP ACE inhibitor	Tablets (10-12.5, 20-12.5 mg)	Aurobindo, Citron, Glenmark, Heritage, Sandoz
74. Gabapentin	Anticonvulsant	Tablets (600, 800 mg)	Aurobindo, Glenmark, Teva
75. Glimepiride	Antidiabetic	Tablets (1, 2, 4 mg)	Dr. Reddy's, Teva
76. Glipizide-Metformin	Antidiabetic	Tablets (2.5-250, 2.5-500, 5-500 mg)	Heritage, Mylan, Teva
77. Glyburide	Antidiabetic	Tablets (1.25, 2.5, 5 mg)	Aurobindo, Citron, Heritage, Teva
78. Glyburide-Metformin	Antidiabetic	Tablets (1.25-250, 2.5-500, 5-500 mg)	Actavis, Aurobindo, Citron, Heritage, Impax, Teva
79. Griseofulvin	Antifungal	Suspension (125 mg/5 ml)	Actavis, Teva

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
80. Halobetasol Propionate	Skin conditions	Cream (0.05%) Ointment (0.05%)	G&W, Perrigo, Sandoz, Taro
81. Haloperidol	Antipsychotic	Tablets (0.5, 1, 2, 5, 10, 20 mg)	Mylan, Sandoz, Zydus
82. Hydrocodone Acetaminophen	Pain	Tablets (5-325, 10-325 mg)	Amneal, Mallinckrodt, Par, Teva
83. Hydrocortisone Valerate	Skin conditions	Cream (0.2%)	G&W, Perrigo, Taro
84. Irbesartan	Hypertension	Tablets (75, 150, 300 mg)	Lupin, Teva
85. Isosorbide Dinitrate	Chest pain	Tablets (5, 10, 20, 30 mg)	Sandoz, Par, West-Ward
86. Ketoconazole	Antifungal	Cream (2%) Tablets (200 mg)	G&W, Mylan, Sandoz, Taro, Teva
87. Ketoprofen	NSAID	Capsules (50, 75 mg)	Mylan, Teva
88. Ketorolac Tromethamine	NSAID	Tablets 10 mg)	Mylan, Teva
89. Labetalol HCL	High blood pressure	Tablets (100, 200, 300 mg)	Actavis, Par, Sandoz, Teva
90. Lamivudine/Zidovudine [Combivir]	HIV	Tablets (150-300 mg, 300-150 mg)	Aurobindo, Camber, Lupin, Teva
91. Latanoprost	Eye Conditions	Ophthalmic Liquid Eye/Solution (0.005%)	Akorn, Bausch, Greenstone, Sandoz
92. Leflunomide	Antirheumatic	Tablets (10, 20 mg)	Apotex, Heritage, Teva
93. Levothyroxine	Thyroid hormone	Tablets (0.025, 0.05, 0.075, 0.088, 0.1, 0.112, 0.125, 0.137, 0.15, 0.175, 0.2, 0.3 mg)	Lannett, Mylan, Sandoz
94. Lidocaine HCL	Anesthetic	Ointment (5%)	Akorn, Sandoz, Taro
95. Lidocaine-Prilocaine	Dermal anesthetic	Cream (2.5-2.5%)	Akorn, Impax, Sandoz
96. Loperamide HCL	Diarrhea	Capsules (2 mg)	Mylan, Teva
97. Meprobamate	Anxiolytic	Tablets (200, 400 mg)	Dr. Reddy's, Heritage
98. Metformin (F)	Antidiabetic	Tablets ER (500, 1000 mg)	Actavis, Lupin
99. Methadone HCL	Pain	Tablets (5, 10 mg)	Mallinckrodt, West-Ward
100. Methazolamide	Ocular conditions	Tablets (25, 50 mg)	Perrigo, Sandoz

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
101.Methotrexate	Immunosuppressive	Tablets (2.5 mg)	Mylan, Par, Teva, West-Ward
102.Methylphenidate	ADHD	Tablets (5, 10, 20 mg) ER Tablets (20 mg)	Actavis, Impax, Mallinckrodt, Par, Sandoz, Sun
103.Methylprednisolone	Steroid	Tablets (4 mg)	Breckenridge, Cadista, Greenstone, Par, Sandoz
104.Metronidazole	Antibiotic	Cream (0.75%) Jelly (0.75%) Lotion (0.75%) Vaginal (0.75%) Gel (1%)	Bausch, G&W, Impax, Sandoz, Taro, Teva
105.Moexipril HCL	High blood pressure	Tablets (7.5, 15 mg)	Glenmark, Teva
106.Moexipril HCL HCTZ	High blood pressure	Tablets (7.5-12.5, 15-12.5, 15-25 mg)	Glenmark, Teva
107.Nadolol	High blood pressure	Tablets (20, 40, 80 mg)	Greenstone, Mylan, Sandoz, Teva
108.Naproxen Sodium	NSAID	Tablets (275, 550mg)	Amneal, Glenmark
109.Neomycin Polymyxin Hydrocortisone	Antibiotic	Solution (3.5 mg-10MU 1%)	Bausch, Sandoz
110.Niacin	High cholesterol	Tablets ER (500, 750, 1000 mg)	Lupin, Teva, Zydus
111.Nimodipine	Antihypertensive	Capsules (30 mg)	Heritage, Sun, Teva
112.Nitrofurantoin	Antibiotic	Macrocrystal (MAC) Capsules (25, 50, 100 mg)	Alvogen, Mylan, Teva
113.Norethindrone/Ethinyl Estradiol [Balziva]	Oral contraceptive	Tablets (0.4-0.035 mg-mcg)	Lupin, Teva
114.Nortriptyline HCL	Depression	Capsules (10, 25, 50, 75 mg)	Actavis, Taro, Teva
115.Nystatin	Antifungal	Cream (100 MU) Ointment (100 MU) Tablet (500 MU)	Actavis, Heritage, Par, Perrigo, Sandoz, Sun, Taro, Teva
116.Nystatin Triamcinolone	Fungal infections	Cream (0.1%) Ointment (0.1%)	Sandoz, Taro

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
117.Omega-3-Acid Ethyl Esters	High triglycerides	Capsules (20 mg/1100 mg, 40 mg/1100 mg)	Apotex, Par, Teva
118.Oxaprozin	NSAID	Tablets (600 mg)	Dr. Reddy's, Greenstone, Sandoz, Teva
119.Oxybutynin Chloride	Overactive bladder	Tablets (5 mg)	Par, Teva, Upsher-Smith
120.Oxycodone Acetaminophen	Pain	Tablets (5-325, 7.5-325, 10-325 mg)	Actavis, Alvogen, Amneal, Aurobindo, Mallinckrodt, Par
121.Oxycodone HCL	Pain	Tablets (15, 30 mg) Oral Solution (20 mg/ml)	Actavis, Glenmark, Lannett, Mallinckrodt, Par, Sun
122.Paricalcitol	Kidney disease	Capsules (1, 2, 4 mcg)	Dr. Reddy's, Teva, Zydus
123.Paromomycin	Antibiotic	Capsules (250 mg)	Heritage, Sun
124.Permethrin	Antiparasite	Cream (5%)	Actavis, Mylan, Perrigo
125.Perphenazine	Antipsychotic	Tablets (2, 4, 8, 16 mg)	Par, Sandoz
126.Phenytoin Sodium	Anticonvulsant	Capsules ER (100 mg)	Amneal, Mylan, Sun, Taro
127.Pilocarpine HCL	Dry mouth	Tablets (5 mg)	Actavis, Impax, Lannett
128.Piroxicam	NSAID	Capsules (10, 20 mg)	Greenstone, Mylan Teva
129.Potassium Chloride	Low potassium	Tablets (8, 10, 20MEQ LA)	Actavis, Mylan, Sandoz, Upsher-Smith, Zydus
130.Prazosin HCL	High blood pressure	Capsules (1, 2, 5 mg)	Mylan, Teva
131.Prednisolone Acetate	Steroid	Ophthalmic Liquid Eye (1%)	Greenstone, Sandoz
132.Prednisone	Steroid	Tablets (1, 2.5, 5, 10, 20 mg)	Actavis, Cadista, Par, West-Ward
133.Prochlorperazine Maleate	Psychotic disorders	Suppositories (25 mg)	G&W, Perrigo
134.Promethazine	Antihistamine	Suppositories (12.5, 25 mg)	Actavis, G&W, Mylan, Perrigo, Taro
135.Propranolol	HPB beta blocker	Capsules (60, 80, 120, 160 mg) Tablets (10, 20, 40, 60, 80 mg)	Actavis, Breckenridge, Heritage, Mylan, Par, Teva, and Upsher-Smith
136.Raloxifene HCL	Osteoporosis	Tablets (60 mg)	Camber, Teva

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
137.Ranitidine HCL	Antacid	Capsules (150, 300 mg) Tablets (150 mg)	Amneal, Dr. Reddy's, Glenmark, Sandoz, Teva
138.Silver Sulfadiazine	Antibiotic	Cream (1%)	Actavis, Ascend
139.Spirolactone HCTZ	High blood pressure	Tablets (25-25 mg)	Greenstone, Mylan, Sun
140.Tacrolimus	Eczema	Ointment (0.03%, 0.1%)	Perrigo, Sandoz
141.Tamoxifen Citrate	Estrogen modulator	Tablets (10, 20 mg)	Actavis, Mylan, Teva
142.Temozolomide	Cancer	Capsules (5, 20, 100, 140, 180, 250 mg)	Sandoz, Teva
143.Terconazole	Fungal infection	Vaginal Cream (0.4%, 0.8%)	Actavis, Taro
144.Theophylline	Bronchodilator	Tablets ER (100, 200, 300, 400, 450, 600 mg)	Heritage, Teva
145.Timolol Maleate	High blood pressure	Ophthalmic Gel (0.25%, 0.5%)	Bausch, Sandoz
146.Tizanidine HCL	Muscle relaxant	Tablets (2, 4 mg)	Apotex, Dr. Reddy's, Mylan, Sandoz, Sun
147.Tobramycin	Antibiotic	Solution (300 mg/5 ml)	Sandoz, Teva
148.Tobramycin Dexamethasone	Antibiotic	Ophthalmic Liquid (0.3-0.1%)	Bausch, Sandoz
149.Tolmetin Sodium	Arthritis and pain	Capsules (400 mg)	Mylan, Teva
150.Tolterodine Tartrate	Overactive bladder	Tablets (1, 2 mg) Tablets ER (2, 4 mg)	Greenstone, Mylan, Teva
151.Trazodone HCL	Sedative	Tablets (100 mg)	Apotex, Par, Sun, Teva
152.Triamcinolone Acetonide	Skin conditions	Cream (0.025%, 0.1%, 0.5%) Ointment (0.25%, 0.1%, 0.5%)	Ascend, Par, Perrigo, Sandoz, Taro
153.Triamterene HCTZ	High blood pressure	Capsules (37.5-25 mg) Tablets (37.5-25, 75-50 mg)	Actavis, Apotex, Lannett, Mylan, Sandoz
154.Trifluoperazine HCL	Antipsychotic	Tablets (1, 2, 5, 10 mg)	Mylan, Sandoz, Upsher-Smith
155.Ursodiol	Gallstone bile acid	Capsules (300 mg)	Actavis, Epic, Lannett

Additional Generic Drugs Named by DPPs			
Generic Drug	Brief Description/Use	Specific allegations as to formulation(s) and/or dosage(s)	Named generic manufacturer defendants
156. Valsartan HCTZ	High blood pressure	Tablets (80-12.5, 160-12.5, 160-25, 320-12.5, 320-25 mg)	Mylan, Sandoz
157. Verapamil	Heart disorder calcium channel blocker	Tablets (80, 120 mg) Capsules SR (120, 180, 240 mg)	Actavis, Heritage, Mylan
158. Warfarin Sodium	Anticoagulant	Tablets (1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg)	Amneal, Taro, Teva, Zydus
159. Zoledronic Acid	Bone disease bisphosphonate	Infusion (4 mg/5ml, 5mg/100ml)	Dr. Reddy's, Heritage, Par

EXHIBIT B

EXHIBIT B
TIMELINE OF DPP NAMED GENERIC DRUGS IN MDL 2724

Timeline	Known Collusive Conduct
Summer 2009	Perphenazine
Fall 2009	
Winter 2009-2010	Atropine Sulfate; Betamethasone Valerate; Fluticasone Propionate
Spring 2010	Neomycin Polymyxin Hydrocortisone; Oxycodone HCL; Permethrin; Piroxicam; Triamcinolone Acetonide
Summer 2010	Adapalene; Potassium Chloride
Fall 2010	Betamethasone Dipropionate; Betamethasone Dipropionate Augmented
Winter 2010-2011	Betamethasone Dipropionate Clotrimazole; Carisoprodol; Hydrocortisone Valerate; Methylprednisolone; Nitrofurantoin; Nortriptyline HCL
Spring 2011	Amiloride HCL/HCTZ; Fluocinonide Solution
Summer 2011	Clarithromycin; Amphetamine Salts (MAS); Chlorpromazine HCL; Dextroamphetamine Sulfate; Metronidazole; Nystatin; Nystatin Triamcinolone
Fall 2011	Clonidine TTS; Latanoprost; Oxybutynin Chloride; Ranitidine HCL; Triamterene HCTZ
Winter 2011-2012	Amantadine HCL; Ciclopirox; Fluocinolone Acetonide; Lidocaine HCL; Loperamide HCL; Prochlorperazine Maleate
Spring 2012	Acetazolamide; Clindamycin Phosphate; Ethinyl Estradiol and Levonorgestrel [Portia and Jolessa]; Irbesartan; Isosorbide Dinitrate; Labetalol HCL; Lamivudine/Zidovudine (Combivir); Silver Sulfadiazine; Tamoxifen Citrate
Summer 2012	Buspirone HCL; Cimetidine; Desonide Lotion; Desoximetasone; Estradiol; Etodolac; Halobetasol Propionate; Ketorolac Tromethamine; Nadolol; Nimodipine; Oxaprozin; Promethazine; Tolterodine
Fall 2012	Diclofenac Potassium; Doxycycline; Ketoprofen; Methotrexate; Paromomycin; Prazosin HCL; Valsartan HCTZ; Verapamil

Timeline	Known Collusive Conduct
Winter 2012-2013	Bromocriptine Mesylate; Budesonide; Methylphenidate; Oxycodone Acetaminophen; Spironolactone HCTZ; Tobramycin Dexamethasone
Spring 2013	Alclometasone Dipropionate; Albuterol; Ammonium Lactate; Captopril; Carbamazepine; Cefdinir; Cefprozil; Cholestyramine; Desonide; Diltiazem HCL; Doxazosin Mesylate; Drospirenone and Ethinyl Estradiol; Fenofibrate; Fluconazole; Meprobamate; Moexipril HCL; Moexipril HCL HCTZ; Prednisone; Propranolol; Terconazole; Tizanidine HCL; Tolmetin Sodium; Zoledronic Acid
Summer 2013	Clomipramine; Divalproex; Enalapril Maleate; Haloperidol; Levothyroxine; Pravastatin; Prednisolone Acetate; Temozolomide; Trifluoperazine HCL
Fall 2013	Balsalazide Disodium; Benazepril HCTZ; Cephalexin (Cefalexin); Desmopressin Acetate; Digoxin; Estradiol and Norethindrone Acetate [Mimvey]; Tobramycin
Winter 2013-2014	Baclofen; Butorphanol Tartrate; Capecitabine; Cefuroxime Axetil; Dexmethylphenidate HCL [Focalin]; Exemestane; Fluocinonide Cream (0.1%); Ketoconazole; Norethindrone and Ethinyl Estradiol [Balziva]; Paricalcitol; Pilocarpine HCL; Timolol Maleate
Spring 2014	Allopurinol; Atenolol Chlorthalidone; Diphenoxylate Atropine HCL; Clotrimazole; Lidocaine-Prilocaine; Niacin; Phenytoin Sodium; Theophylline; Ursodiol
Summer 2014	Amoxicillin Clavulanate; Amitriptyline; Clobetasol; Econazole; Entecavir; Fluocinonide; Fluoxetine HCL; Fosinopril HCTZ; Glimepiride; Glipizide-Metformin; Methazolamide; Glyburide; Glyburide-Metformin; Hydrocodone Acetaminofphen; Leflunomide; Methadone HCL; Omega-3-Acid Ethyl Esters; Tacrolimus; Warfarin Sodium
Fall 2014	Bethanechol Chloride; Celecoxib; Gabapentin; Griseofulvin; Raloxifene HCL
Winter 2014-2015	Naproxen Sodium; Trazodone
Spring 2015	
Summer 2015	Metformin ER (F)

EXHIBIT C

EXHIBIT C**HISTORY OF GOVERNMENT INVESTIGATIONS AND OTHER PUBLIC REPORTS
CONCERNING ANTICOMPETITIVE CONDUCT IN THE
GENERIC DRUG INDUSTRY**

Date	Event
Jan. 2014	National Community Pharmacists Association (“NCPA”) writes to the United States Senate Health Education Labor and Pensions (“HELP”) Committee and the United States House Energy and Commerce Committee requesting hearings on significant spikes in generic drug pricing. ¹
July 2014	The State of Connecticut opens an investigation into the pricing of generic drugs. ²
Oct. 2014	Senator Bernie Sanders (I-VT), Chair of the Subcommittee on Primary Health and Aging, Senate Committee on Health, Education, Labor and Pensions, and Representative Elijah E. Cummings (D-MD), the Ranking Member of the House Committee on Oversight and Government Reform, send letters to 14 generic drug manufacturers requesting information about the escalating prices of generic drugs used to treat everything from common medical conditions to life threatening illnesses. ³ The generic drug manufacturer that received letters include Actavis, Apotex, Dr. Reddy’s, Impax, Heritage, Lannett, Mylan, Par, Sun, Teva, Valeant, West-Ward, and Zydus.
Nov. 2014	DOJ opens a criminal investigation into collusion in the generic drug industry and empanels a grand jury in this District.
Feb. 2015	Senator Sanders and Representative Cummings send a letter requesting that the Office of the Inspector General (“OIG”) of the U.S. Department of Health and Human Services “examine recent increases in the prices being charged for generic drugs and the effect these price increases have had on generic drug spending within the Medicare and Medicaid programs.” ⁴

¹ News Release, *Generic Drug Price Spikes Demand Congressional Hearing, Pharmacists Say* (Jan. 8, 2014), available at <http://www.ncpanet.org/newsroom/news-releases/2014/01/08/generic-drug-price-spikes-demand-congressional-hearing-pharmacists-say>.

² Mark Pazniokas, *How a small-state AG’s office plays in the big leagues*, The Connecticut Mirror (Jan. 27, 2017), available at <https://ctmirror.org/2017/01/27/how-a-small-state-ags-office-plays-in-the-big-leagues/>.

³ U.S. Senator Bernie Sanders Website, Press Release, *Congress Investigating Why Generic Drug Prices Are Skyrocketing* (Oct. 2, 2014), available at <https://www.sanders.senate.gov/newsroom/press-releases/congress-investigating-why-generic-drug-prices-are-skyrocketing>.

⁴ Letter from Sen. Bernard Sanders & Rep. Elijah E. Cummings, U.S. Cong., to Inspector Gen. Daniel R. Levinson, Dep’t of Health & Human Servs. (Feb. 24, 2015), available at <http://www.sanders.senate.gov/download/sanders-cummings-letter?inline=file>.

Date	Event
Apr. 2015	The OIG responds to Senator Sanders and Representative Cummings' letter advising that it would examine pricing for the top 200 generic drugs. ⁵
Apr. 2015	An analyst at Sector & Sovereign Research comments: "A plausible explanation [for artificial price inflation] is that generic manufacturers, having fallen to near historic low levels of financial performance are cooperating to raise the prices of products whose characteristics – low sales due to either very low prices or very low volumes – accommodate price inflation." ⁶
Oct. 2015	Valeant reports that it has been subpoenaed by government regulators seeking details on its drug pricing practices. ⁷
Dec. 2015	The United States Department of Health and Human Services Office of Inspector General issues its report: "Average Manufacturer Prices Increased Faster Than Inflation For Many Generic Drugs."
Feb. 2016	Pennsylvania physicians through the Pennsylvania Medical Society called on state and federal governments to investigate surging generic prices, believing anticompetitive conduct was to blame: "According to Robert Campbell MD, chair of Physicians Against Drug Shortages and immediate past president of the Pennsylvania Society of Anesthesiologists, surging prices have hit hundreds of mainstay generics, including anesthetics, chemotherapeutic agents, antibiotics, and nutritional intravenous solutions. He believes the surging prices are a result of anti-competitive behavior." ⁸
Aug. 2016	The United States Government Accountability Office issues its report finding "extraordinary price increases" on many generic drugs. ⁹
Sept. 2016	Mylan's corporate offices are raided by federal authorities in connection with the DOJ's investigation. ¹⁰

⁵ Letter from Inspector Gen. Daniel R. Levinson, Dep't of Health & Human Servs., to Sen. Bernard Sanders (Apr. 13, 2015), available at <http://www.sanders.senate.gov/download/oig-letter-to-sen-sanders-4-13-2015?inline=file>.

⁶ See Ed Silverman, *Generic Drug Prices Keep Rising, but is a Slowdown Coming?*, WALL STREET JOURNAL (Apr. 22, 2015), available at <http://blogs.wsj.com/pharmalot/2015/04/22/generic-drug-prices-keep-rising-but-is-a-slowdown-coming/>.

⁷ Ransdell Pierson and Bill Berkrot, *Valeant subpoenaed by U.S. prosecutors*, Reuters (Oct. 15, 2015), available at <https://www.reuters.com/article/us-valeant-pharms-subpoena-idUSKCN0S9OXO20151015>.

⁸ Pennsylvania Medical Society, Press Release, *Rising Generic Drug Costs Have Physicians Raising Red Flags* (Feb. 5, 2016), available at <http://www.pnewsire.com/news-releases/rising-generic-drug-costs-have-physicians-raising-red-flags-300216006.html>.

⁹ GAO Report to Congressional Requesters, *Generic Drugs Under Medicare* (Aug. 2016), available at <http://www.gao.gov/assets/680/679055.pdf>.

¹⁰ Mylan SEC Form 10-Q (Nov. 9, 2016), at 58, available at https://www.sec.gov/Archives/edgar/data/1623613/000162361317000026/myl10q_20170930xdoc.htm

Date	Event
Dec. 2016	DOJ files its first criminal charges against Jeffrey Glazer and Jason Malek in their capacities as former executives of Defendant Heritage. ¹¹
Dec. 2016	The Plaintiff States file their original complaint.
Jan. 2017	Glazer and Malek plead guilty to felony charges that they conspired with competitors to manipulate prices and allocate customers for doxycycline and glyburide. Glazer and Malek are known to be cooperating with government investigators since at least this time.
May 2017	Perrigo's corporate offices are raided by federal authorities in connection with the DOJ's investigation. ¹²
Oct. 2017	The Plaintiff States file their proposed amended complaint seeking to expand their case to increase the number of generic drug manufacturer defendants from 6 to 18 and the number of generic drugs from 2 to 15. ¹³ The Plaintiff States further allege an overarching conspiracy involving many more generic drugs and generic drug manufacturers.
Summer 2018	At least Defendants Dr. Reddy's, Impax, Lannett, Mylan, Par, Taro, and Teva report receiving civil investigative demands from the U.S. DOJ requesting information from 2009 to present concerning anticompetitive conduct in the generic drug industry. ¹⁴
May 2019	The States file a new complaint concerning additional drugs.
May 2019	Heritage is charged by DOJ for conspiring to fix prices and allocate customers. \$225,000 criminal penalty. ¹⁵
Dec. 2019	Rising Pharmaceuticals Inc. is charged by DOJ for conspiring to fix prices and allocate customers. \$1.5 million criminal penalty. ¹⁶

¹¹ See *United States of America v. Jeffrey A. Glazer*, No. 2:16-cr-00506-RBS (E.D. Pa.); *United States of America v. Jason T. Malek*, No. 2:16-cr-00508-RBS (E.D. Pa.).

¹² Perrigo Website, Press Release, *Perrigo Discloses Investigation* (May 2, 2017), available at <http://perrigo.investorroom.com/2017-05-02-Perrigo-Discloses-Investigation>.

¹³ 16-AG-27240 (2:17-cv-03768), Doc. No. 3.

¹⁴ Dr. Reddy's 20-F (filed on June 15, 2018); Taro 20-F (filed on June 21, 2018); Teva 10-Q (filed on Aug. 2, 2018); Mylan 10-Q (filed on Aug. 8, 2018); Amneal 10-Q (filed on Aug. 9, 2018); Lannett 10-K (filed on Aug. 28, 2018).

¹⁵ DOJ Website, *Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law*, available at <https://www.justice.gov/opa/pr/pharmaceutical-company-admits-price-fixing-violation-antitrust-law-resolves-related-false>.

¹⁶ DOJ Website, *Second Pharmaceutical Company Admits to Price Fixing*, available at <https://www.justice.gov/opa/pr/second-pharmaceutical-company-admits-price-fixing-resolves-related-false-claims-act>.

Date	Event
Feb. 2020	Former Taro executive Ara Aprahamian is indicted by DOJ for his role in price-fixing and market/customer allocation concerning generic drugs as well as lying to the FBI. ¹⁷
Feb. 2020	Former Sandoz executive Hector Armando Kellum pleads guilty for his role in the criminal antitrust conspiracy. ¹⁸
Mar. 2020	Sandoz is charged by DOJ for conspiring to fix prices, allocate customers, and rig bids. \$195 million criminal penalty. ¹⁹
May 2020	Apotex is charged by DOJ for conspiring to fix prices, allocate customers, and rig bids. \$24.1 million criminal penalty. ²⁰
June 2020	The States file a new complaint concerning additional drugs.
June 2020	Glenmark is charged by DOJ for conspiring to fix prices, allocate customers, and rig bids. ²¹
July 2020	Taro is charged by DOJ for conspiring to fix prices, allocate customers, and rig bids. \$205.6 million criminal penalty. ²²
Aug. 2020	Teva is charged by DOJ for conspiring to fix prices, allocate customers, and rig bids. ²³

¹⁷ DOJ Website, *Generic Drug Executive Indicted on Antitrust and False Statement Charges*, available at <https://www.justice.gov/opa/pr/generic-drug-executive-indicted-antitrust-and-false-statement-charges>.

¹⁸ DOJ Website, *Former Generic Pharmaceutical Executive Pleads Guilty for Role in Criminal Antitrust Conspiracy*, available at <https://www.justice.gov/opa/pr/former-generic-pharmaceutical-executive-pleads-guilty-role-criminal-antitrust-conspiracy>.

¹⁹ DOJ Website, *Major Generic Pharmaceutical Company Admits to Antitrust Crimes*, available at <https://www.justice.gov/opa/pr/major-generic-pharmaceutical-company-admits-antitrust-crimes>.

²⁰ DOJ Website, *Generic Pharmaceutical Company Admits to Fixing Price of Widely Used Cholesterol Medication*, available at <https://www.justice.gov/opa/pr/generic-pharmaceutical-company-admits-fixing-price-widely-used-cholesterol-medication>.

²¹ DOJ Website, *Fifth Pharmaceutical Company Charged in Ongoing Criminal Antitrust Investigation*, available at <https://www.justice.gov/opa/pr/fifth-pharmaceutical-company-charged-ongoing-criminal-antitrust-investigation>.

²² DOJ Website, *Sixth Pharmaceutical Company Charged In Ongoing Criminal Antitrust Investigation*, available at <https://www.justice.gov/opa/pr/sixth-pharmaceutical-company-charged-ongoing-criminal-antitrust-investigation>.

²³ DOJ Website, *Seventh Generic Drug Manufacturer Is Charged In Ongoing Criminal Antitrust Investigation*, available at <https://www.justice.gov/opa/pr/seventh-generic-drug-manufacturer-charged-ongoing-criminal-antitrust-investigation>.

EXHIBIT D

EXHIBIT D

**GENERIC DRUG MANUFACTURERS
KNOWN TO HAVE RECEIVED A DOJ SUBPOENA AND/OR
CIVIL INVESTIGATIVE DEMAND (“CID”) RELATING TO
ANTICOMPETITIVE CONDUCT IN THE GENERIC DRUG INDUSTRY**

1. Aceto (acquired certain generic products from Citron; also received CID)
2. Actavis
3. Aurobindo
4. Citron
5. Dr. Reddy’s (also received CID)
6. Greenstone
7. Heritage
8. Impax (now Amneal) (as well as certain employees; also received CID)
9. Lannett (as well as certain employees; also received CID)
10. Mallinckrodt
11. Mayne
12. Mylan (as well as certain employees; Mylan’s corporate offices were also raided; also received CID)
13. Par (also received CID)
14. Perrigo (Perrigo’s corporate offices were also raided)
15. Sandoz
16. Sun
17. Taro (as well as certain employees; also received CID)
18. Teva (also received CID)
19. West-Ward (Hikma)
20. Zydus

EXHIBIT E

REDACTED – PUBLIC VERSION

EXHIBIT E

TRADE ASSOCIATION CONTACTS AS TO THE NAMED DEFENDANTS

ECRM Retail Pharmacy Generic Pharmaceutical Conference - (February 8-11, 2009)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

GPhA 2009 Annual Meeting – Naples, Florida (February 23-25, 2009)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2009 Annual Meeting – Palm Beach, Fla. (April 18-21, 2009):

- a. **Actavis:** Andrew Boyer, EVP, Commercial Operations; Michael Baker, Executive Vice President, Trade Sales and Development; Paul Bisaro, President and Chief Executive Officer; Michael Reed, Executive Director, Trade Relations; Paul Reed, Senior Director, Trade Sales and Operations; John Shane, Director, Trade Relations; Allan Slavsky, Sales Consultant; Thomas Russillo, President, Generic Operations; Brad Blake, Business Manager; Doug Boothe, CEO; Michael Perfetto, Chief Commercial Officer; Terrence Fullem, VP Commercial Development,
- b. **Amneal:** Jim Luce, EVP, Sales & Marketing; Chirag Patel, CEO & Chair;
- c. **Apotex:** Buddy Bertucci, VP Institutional Sales; Sam Boulton, Director, National Accounts; Jeff Watson, President & COO; Beth Hamilton, Vice President, Generic Product Sales; James Van Lieshout, VP, Trade and Industry Relations; Tammy McIntire Stefanovic, Chief Revenue Officer;
- d. **Aurobindo:** Corrine Hogan, VP Sales & Marketing; Scott White, President;

- e. **Bausch + Lomb:** Jayson Berg, Director, OTC Sales - East; Jeff Distasio, Director of Sales, OTC; Janice Llewellyn, Director of Trade Sales; Jonathan Witmer, VP, OTC Sale;
- f. **Camber:** Briggs Arington, President;
- g. **Dr. Reddy's:** Amit Patel, Senior Vice President & Head, North American Generics; Bill Hill, VP Sales, Rx; Satish Reddy, COO; Paula Gurz, Sr. Director, Marketing Rx & OTC;
- h. **Fougera:** Christopher Bihari, National Sales Director; Kian Kazemi, SVP Sales; Walt Kaczmarek, VP National Accounts (Nycomed); David Klaum, VP Commercial Operations; Lance Wyatt, Sr. Director Contracts & Logistics (Nycomed); Paul McGarty, President; Anthony Thomassey, Director, National Accounts;
- i. **Greenstone:** James Cannon, GM; William Kennally, Regional President – NA; Michael Sweitzer, VP;
- j. **Hi-Tech:** Ed Berrios, VP Sales & Marketing; Michael Corley, VP National Accounts; Thomas Kronovich, VP National Accounts;
- k. **Impax:** Chris Mengler, President; Peter Valko, VP Sales & Marketing;
- l. **Lupin:** Vinita Gupta, CEO (Lupin Ltd.); Robert Hoffman, EVP, US Generics; Paul Kleutghen, Executive Member, Strategic Advisory Board;
- m. **Mallinckrodt:** John Adams, SVP Commercial Operations; Michael Gunning, VP & GM Specialty Generics;
- n. **Mylan:** Robert Potter, Head of Global Sales Excellence; Anthony Mauro, Chief Commercial Officer; Hal Korman, EVP & COO;
- o. **Par:** Paul Campanelli, President & CEO (Endo); Michael Altamuro, Commercial Operations & Marketing; Renee Kenney, Senior Advisor, Generic Sales;
- p. **Perrigo:** Sharon Kochan, Executive Vice President & GM (Perrigo Pharmaceuticals); Jim Tomshack, Senior Vice President, Sales; Jeff Needham, EVP & President Consumer Health;
- q. **Pfizer:** Lou Dallago, VP, US Trade Group; Thomas McPhillips, VP US Trade Group; David Simmons, President & GM, Emerging Markets/Established Products BUs; Walter Slijepcevich, Sr. Director, Pharmacy Development;
- r. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; Rick Peterman, Director, Marketing; Michael Plessinger, Director of Marketing;

- s. **Sandoz:** Jeff George, CEO; Christie Gleeson, National Accounts Manager; Steven Greenstein, Director, Key Customers; Armando Kellum, Vice President, Sales & Marketing; Della Lubke, Director, National Accounts; Christine Mundkur, Sandoz US CEO; Warren Pefley, VP Sales & Marketing; Craig Salmon, President, US Operations; Richard Tremonte, President, Strategic Global Sourcing;
- t. **Sun:** GP Singh Sachdeva;
- u. **Taro:** Mitchell Bashinsky, Business Development; Jim Josway, Vice President, RX Sales; Edward Moniz, OTC Sales; Bill Seiden, Senior Vice President, U.S. Sales & Marketing;
- v. **Teva:** Theresa Coward, Senior Director Sales & Trade Relations; Maureen Cavanaugh, Chief Operating Officer, North America Generics; Jonathan Kafer, Executive Vice President, Sales and Marketing; Darren Alkins, Vice President, Pricing & Contracts; Timothy Crew, SVP North American Generics; John Denman, SVP, Sales & Marketing; Timothy Catlett, SVP Sales & Marketing; David Marshall, VP Operations; Patrick McIntosh, VP Commercial Operations; Shlomo Yanai, CEO;
- w. **Upsher-Smith:** Chris Evenstad, Director, Ventures Marketing; Scott Hussey, SVP Sales; Jim Maahs, VP, Commercial Portfolio Products; Mike McBride, VP Partner Relations;
- x. **URL:** William Everett, National Trade Account Manager; Gregory Hayer, SVP, BD and Market Access;
- y. **Wockhardt:** Michael Craney, President of Sales & Marketing; Habil Khorakiwala, Chair; Kurt Orlofski, President & CEO; and
- z. **Zydus:** Joseph Renner, Chair of the Board; Karen Strelau, Executive Vice President Sales and Marketing.

HDMA 2009 Business Partners Exchange – (June 7-9, 2009):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



NACDS 2009 Pharmacy and Technology Conference – Boston, Mass. (August 8-11, 2009):

- a. **Actavis:** Michael Dorsey, Director National Accounts; Doug Boothe, CEO; Andy Boyer; Executive Vice President, Commercial Operations; Napoleon Clark, Vice President Marketing; Lisa Fiveash, National Account Representative; Anthony Giannone, Executive Director, Sales; Maureen Meehan, Director, National Accounts; Diane Miranda, Vice President, Distribution Services and Generic Marketing; Nimish Muzumdar, Director of Marketing; Toni Picone, Marketing Manager; Vince Rinauder; Director, National Accounts; Gary Salter, Director National Accounts; David Schmidt, Director, National Accounts; Allan Slavsky, Sales Consultant; Richard Rogerson, Sr. Director New Products, Business Analytics & Stystems; Thomas Russillo, President, Generic Operations; Hilary Capato, Sr. Marketing Associate; Steve Cohen, VP National Accounts; Thad Demos, National Accounts Manager; Jin McCormick, VP, Rx Sales & Marketing; Lisa Pehlke, Director, Corporate Accounts;
- b. **Akorn:** John Sabat, SVP of National Accounts; M. Tranter, National Accounts Manager, Sales & Marketing; Ed Welch, Sales Representative;
- c. **Alvogen:** Jeffrey Rumler, EVP, Sales & Marketing;
- d. **Amneal:** Robert Cline, VP Supply Chain Manager; David Hardin, National Account Manager; Liz Koprowski, National Account Manager; Jim Luce, EVP, Sales & Marketing; June Parker, National Accounts Manager; Chirag Patel, Co-CEO & Chair; Chintu Patel, CEO & Co-Chair; Stephen Rutledge, VP Sales;
- e. **Apotex:** Jeff Watson, President & COO; Beth Hamilton, Vice President, Generic Product Sales; Jim Van Lieshout, Trade and Industry Relations; Tina Kaus, National Accounts Director; Tom Axner, National Sales Director, Distribution; Sam Boulton, Director, National Accounts; Ellen Gettenberg, Director, Marketing; Lisa Badura, EVP Trade; Gwen Copeland, Manager National Accounts; Mark Dudick, VP National Accounts; John Flinn, VP Commercial Operations; Paul Krauthauser, SVP Commercial Operations;
- f. **Aurobindo:** Scott White, President; Corinne Hogan, VP Sales & Marketing; Geoff Rouse, Director of Sales; Patricia O'Malley, Director, Sales & Marketing Operation; Paul McMahon, Senior Director, Commercial Operations;
- g. **Bausch + Lomb:** Dean Cowen, National Account Director; Richard Cunningham, Sr. Product Manager – Multisource; Philip Gioia, President & Global API Business; Mick McCanna, National Account Manager; David Raiskin, Commercial

Director Multisource; Elva Ramsaran, National Account Director; Steve Sacheli, Director, National Accounts; Gary Stapleton, VP US Sales & Marketing, Generics;

- h. **Breckenridge:** Scott Cohon, Director of Sales; Phil Goldstein, National Accounts Sales Director; Lou Dretchen, Business Development; Larry Lapila, President; Joan Lyle, Director, National Accounts; Diane Maynard, Director, Sales Administration; Anthony Mihelich, VP, Purchasing; Dave Nielsen, Director, Sales; Martin Schatz, SVP Sales;
- i. **Camber:** Briggs Arrington, President; Brett Barczak, Director, Corporate Accounts; Megan Hinman, Manager Sales Operations; Kon Ostaficiuk, President; Laura Ricardo, Director of Corporate Accounts;
- j. **CorePharma:** Vicki Mangus, Executive Director, Sales; Scott Nemitz, VP Sales; Louis Pastor, Sr. Director, Trade Operations; Janet Penner, President Generics; Christopher Worrell, CEO;
- k. **Dr. Reddy's:** Cindy Stevens, Director, National Accounts; Trish Wetzel, Senior Director, National Accounts; Amit Patel, Senior Vice President & Head, North American Generics; Bob Rodowicz, Director, Institutional Sales & Marketing; Adam Bain, Sr. Marketing Associate; Paula Gurz, Sr. Director, Marketing Rx & OTC; Bill Hill, VP Sales; Srinivas Mallavarapu, Associate Director, Portfolio Management; Michael Olivi, Sr. Director National Accounts Rx; Sally Schimelpfenig, Director, Rx Marketing;
- l. **Endo:** Robert Ammon, Sr. National Account Executive; Javier Avalos, Sr. Director, Managed Markets and Trade Operations; Doug Azzalina, Director, Marketing, Generic Products; Kayla Kelnhofer, National Account Executive; Chris Neurohr, Director, National Accounts;
- m. **Epic:** Thomas Scono, VP of Contracts; Ram Potti, CFO;
- n. **Fougera:** Christopher Bihari, National Sales Director; Kian Kazemi, Senior Vice President, Sales; Karen Paganuzzi, Product Manager; Anthony Thomassey, Director, National Accounts; David Fink, SVP, Nycomed US & GM PharmaDerm; Stephen Haag, National Accounts Executive; Walt Kaczmarek, VP National Accounts;
- o. **G&W Laboratories:** Dana Hughes, National Account Manager, Contract Manufacturing; Wayne Williams, Manager Business Development & Services; Joel Zaklin, Vice President, Sales and Marketing; Tom Faig, National Account Manager;
- p. **Glenmark:** Jeff Johnson, Director, Sales & Marketing; Jessica Cangemi, Director, Sales & Marketing; Jim Brown, Vice President, Sales; Steve Goodman, Director of Marketing - Generics; Terry Coughlin, Executive Vice President and Chief

Operating Officer; Paul Dutra, Executive Vice President; Terry Coughlin, EVP and COO; Steven Goodman, Director Marketing – Generics;

- q. **Greenstone:** James Cannon, GM; Rick Mackenzie, National Accounts Director; Mark Mancinotti, National Accounts Director; Robert Sanderson, Director, National Accounts; Kevin Valade, National Account Director; Christine Versichele, Director of U.S. Generic Channel Strategies; Greg Williams, Director, National Accounts;
- r. **Heritage:** Jason Malek, President; Jeff Glazer, Chief Executive Officer; Chip McCorkle, Director National Accounts; Erika Baylor, VP Sales & Marketing; Claudia Collom, National Account Manager;
- s. **Hi-Tech:** Ed Bernios, VP, Sales and Marketing; Michael Corley, VP, National Accounts; Thomas Kronovich, VP, National Accounts; William Peters, VP and CFO; David Seltzer, Director;
- t. **Impax:** William Ball, Sr. National Account Manager; Danny Darnell, Sr. National Accounts Manager; Todd Engle; Michael Grigsby, Sr. National Account Manager; Gary Skalski, Sr. Director of Sales;
- u. **Jubilant Cadista:** Toby Bane, Manager, National Accounts; Nora Cruse, Marketing Associate; Scott Delaney, President; Lance Giordano, VP Sales & Marketing; Christine Walton, Associate Director, Rx Marketing Generics;
- v. **Lannett:** Arthur Bedrosian, President & Chief Executive Officer; Tracy DiValero, National Account Manager; Rob Foley, Marketing Manager; Rich Matchett, Director, Sales; Jolene McGalliard, National Account Manager; William Schreck, COO; Kevin Smith, Vice President, Sales & Marketing; Kevin Smith, VP Sales & Marketing;
- w. **Lupin:** Frank Aguilar, VP National Accounts; Steve Ater, Director, National Accounts; Dave Berthold, SVP, Generics; Jason Gensburger, Director, Financial Services; Vinita Gupta, CEO (Lupin Ltd.); Robert Hoffman, EVP, US Generics; Paul Kleutghen, Executive Member, Strategic Advisory Board; Edith St. Hilaire, Director of Marketing, Generics; Kelly Wise, Contracts Administrator;
- x. **Mallinckrodt:** John Adams, SVP, Commercial Operations; Steve Becker, Director of National Account; Tim Berry, National Account Manager; Victor Borelli, SVP Sales & Marketing; Chuck Bramlage, President, Pharmaceutical Products; Lisa Cardetti, National Account Manager; Ginger Collier, VP, National Accounts; Michael Gunning, VP & GM Specialty Generics; David Irwin, Director of Sales; Jason Jones, VP, Corporate Sales; Marc Montgomery, Director of Marketing; Katherine Neely, Associate Director Rx Generics; Bonnie New, National Account Manager; Chad Plumlee, National Account Manager;
- y. **Mayne:** Bryce Harvey, President, and Denise Wiesemann, SVP Operations;

- z. **Mylan:** Joseph Duda, Director, Pricing & Contracts; Edgar Escoto, Director, National Accounts; Jon Kerr, Director, National Sales; Hal Korman, EVP & COO; Tony Mauro, Chief Commercial Officer; Kevin McElfresh, Executive Director, National Accounts; Mark Moshier, President; Jim Nesta, Head of Sales; Robert Potter, Head of Global Sales; Kriss Spors, Sr. Manager Strategic Sourcing and Launch Management; Dave Workman, Strategic Pricing and Contracts;
- aa. **Par:** Karen O'Connor, Vice President, National Accounts; Michael Altamuro, Vice President, Commercial Operations & Marketing; Renee Kenney, Senior Advisor, Generic Sales; Michael Burton, Vice President, National Accounts; Paul Campanelli, President & CEO (Endo); Kevin Campbell, Vice President, Sales & Marketing; Rick Guillory, Vice President, National Accounts; Jon Holden, Vice President Sales; Matthew Green, Director, Product Marketing; Melissa Masterson, Sr. Director, Managed Markets; Sandra Bayer, Sr. Director, National Accounts (Qualitest); James Burnett, National Accounts Manager (Qualitest); Gary Larson, National Accounts Manager (Qualitest); Lori Minnihan, Associate Director, Trade Pricing Operations (Qualitest); Charles Propst, Vice President (Qualitest);
- bb. **Perrigo:** Andrea Felix, National Account Executive; Shelly Snyder, National Account Manager; Tony Polman, National Account Manager; H. James Booydegraaf, Associate Director, Marketing; Ori Gutwerg, National Account Executive; Sharon Kochan, Executive Vice President & GM (Perrigo Pharmaceuticals); Matthew Strzeminski, National Account Executive; John Wesolowski, Executive Vice President, President Rx; Dawn Couchman, VP Rx Contracts & Sales Operations; John Shane, Rx Promotional Analyst;
- cc. **Pfizer:** Jennifer Alper, Trade Channel Manager; Lou Dallago, VP, US Trade Group; Hope Emerson, Director Acct. Mgmt.; Manley Fong, Director, Trade Account Management; Schnell Hart, Director, Trade Account Management; William Kennally, Regional President – NA; Thomas McPhillips, VP US Trade Group; Neil Potter, Director, Team Leader, Trade Channel Marketing; Walter Slijepceovich, Sr. Director, Pharmacy Development; Wesley Tanner, Director, Trade Account Management; Richard Vastola, Sr. Manager, Trade Channel Marketing; John Walsh, Director, Trade Group; Gilbert White, Director, Trade Account Manager;
- dd. **Rising:** Beth Castillo, National Accounts Manager; Ron Gold, CEO; Patricia MacBride, National Accounts Manager, Managed Markets; Kee Moore, VP Sales;
- ee. **Roxane:** Linda Antonini, National Account Director; Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; John Kline, National Account Director; Debbie Kutner, National Account Director; Rick Peterman, Director, Marketing; Michael Plessinger, Director of Marketing; Joseph Ruhmel, Vice President, Sales & Marketing; Steve Snyder, National Account Director;
- ff. **Sandoz:** Armando Kellum, Vice President, Sales & Marketing; Della Lubke, Director, National Account; Steven Greenstein, Director, Key Customers; Luis

Jorge, Director of Marketing; Monika Misiuta, Director, Marketing; Christie Gleeson, National Accounts Manager; Christine Mundkur, US CEO; Warren Pefley, VP Sales & Marketing; Thomas Sammler, Head Sales & Marketing; Richard Tremonte, President, Strategic Global Sourcing;

- gg. **Sun:** Wayne Fallis, Director, National Accounts; Steven Smith, Sr. Director of Sales; Thomas Versosky, President; Amber Schuetz, Manager, Contracts and Compliance;
- hh. **Taro:** Doug Statler, Senior Director, Head of Sales; Howard Marcus, Vice President, Sales & Marketing; James Josway, Vice President, RX Sales; Scott Brick, Manager, National Accounts; Sheila Curran, Vice President, Sales Operations; Elizabeth Guerrero, Director, Corporate Accounts, Managed Care; Bill Seiden, Vice President, U.S. Sales & Marketing; Mitchell Blashinsky, Business Development;
- ii. **Teva:** Jessica Peters, National Accounts Manager; Kevin Green, Associate Vice President, National Accounts; Madalen Renner, National Account Manager; Terri Coward, Senior Director Sales and Trade Relations; Darren Alkins, Vice President, Pricing & Contracts; Christine Baeder, SVP Customer and Marketing Operations; Maureen Cavanaugh, Chief Operating Officer NA Gx; Timothy Crew, SVP North American Generics; Robert Cunard; VP Sales; Kevin Galownia; Senior Director, Pricing; Jonathan Kafer, EVP, Sales and Marketing; Teri Mouro Sherman, Director, National Accounts; Dave Rekenhaller, VP Sales; Timothy Catlett, SVP Sales & Marketing; Patrick Faucher, VP Marketing; Patrick McIntosh, VP Commercial Operations; George Morabito, Sr. Director Sales Operations;
- jj. **Torrent:** Jim Devers, VP Sales; Kelly Gegenheimer, VP Sales; Kamesh Venugopal, President;
- kk. **Upsher-Smith:** Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP, Commercial Portfolio Products; Mike McBride, VP Partner Relations; Michael Muzetras, Sr. National Account Manager; Dave Zitnak, National Accounts Sr. Director – Trade; Doug Zitnak, National Accounts Sr. Director – Trade; Rebekah Cavanagh, Associate Product Manager; Christine Hanson, Marketing Manager; Jim Hughes, VP Marketing; Chad Olson, Director, Generic Products;
- ll. **URL:** William Everett, National Trade Account Manager; Mark Greene, Director, National Accounts; Gregory Hayer, SVP, BD and Market Access; Mary Anne McCoy, Sr. Sales Customer Service Manager; John Elliott, Manager, Marketing; Brendan Magrab, EVP, Intell. Product; Brown Massey, Director Sales; Travis Roberts, VP Sales & Marketing;
- mm. **West-Ward:** Jason Grenfell-Gardner, Senior Vice President, Sales & Marketing; Luis Velez, Senior Director of Sales; Mark Ritchey, Vice President, Sales; Paul Markowitz, Director, National Accounts;

- nn. **Wockhardt:** Karen Andrus, Director of Sales; Michael Craney, President of Sales & Marketing; Kevin Knarr, VP Sales & Marketing; Scott Koenig, VP Sales & Marketing Generics; Bob Watson, VP National Accounts; Kurt Orlofski, CEO; and
- oo. **Zydus:** Michael Keenley, President; Ganesh Nayak, Chief Operating Officer & Executive Director; Sharvil Patel, Managing Director; Barbara Purcell, SVP U.S. Diversified Products; Karen Strelau, Executive Vice President, Sales & Marketing; Laura Short, Vice President Sales; Jack Bleau, Director of Trade; Stuart Grow, Executive Assistant to CEO; Kristy Ronco, VP Sales;

HDMA Annual Leadership Forum (October 14, 2009)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ECRM Retail Pharmacy Generic Pharmaceutical Conference - (February 15-18, 2010)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

GPhA 2010 Annual Meeting – Naples, Florida (February 16-18, 2010)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2010 Second Annual CEO Roundtable Fundraiser; Orlando, Florida (April 17, 2010):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2010 Annual Meeting – (April 24, 2010):

- a. **Actavis:** Andrew Boyer, EVP, Commercial Operations; Michael Baker, Executive Vice President, Trade Sales and Development; Paul Bisaro, President and Chief Executive Officer; Michael Reed, Executive Director, Trade Relations; Paul Reed, Senior Director, Trade Sales and Operations; John Shane, Director, Trade Relations; Allan Slavsky, Sales Consultant; Diane Miranda, VP, Distribution Services and Generic Marketing; Thomas Russillo, President, Generic Operations; Brad Blake, Business Manager; Doug Boothe; Steve Cohen, VP National Accounts; Jinping McCormick, VP Rx Sales & Marketing; Michael Perfetto, Chief Commercial Officer;
- b. **Amneal:** Jim Luce, EVP, Sales & Marketing; Chirag Patel, CEO & Chair; Stephen Rutledge;

- c. **Apotex:** Sam Boulton, Director, National Accounts; John Flinn, VP Commercial Operations; Jeff Watson, President & COO; Beth Hamilton, Vice President, Generic Product Sales; James Van Lieshout, VP, Trade and Industry Relations;
- d. **Aurobindo:** Corrine Hogan, VP Sales & Marketing; Scott White, President;
- e. **Bausch + Lomb:** Jayson Berg, Director, OTC Sales - East; John Conos, Director Sales & Category Management; Janice Llewellyn, Director of Trade Sales; Jonathan Witmer, VP, OTC Sale;
- f. **Camber:** Briggs Arington, President; Kon Ostaficiuk, President;
- g. **Dr. Reddy's:** Amit Patel, Senior Vice President & Head, North American Generics; Robert Rodowicz, Director, Institutional Sales & Marketing; John Segura, VP, Marketing & Operations; Cindy Stevens, Director, National Accounts; Tricia Wetzel, Sr. Director, National Accounts, Rx Mid-West;
- h. **Endo:** Javier Avalos, Sr. Director, Managed Markets & Trade Operations;
- i. **Fougera:** Walt Kaczmarek, VP National Accounts (Nycomed); David Klaum, VP Commercial Operations; Lance Wyatt, Sr. Director Contracts & Logistics (Nycomed);
- j. **Glenmark:** Paul Dutra, Executive Vice President;
- k. **Greenstone:** John Calabrese, Director of Sales; James Cannon, GM; Michael Sweitzer, VP;
- l. **Impax:** Chris Mengler, President;
- m. **Jubilant Cadista:** Scott Delaney, President; Lance Giordano, VP Sales & Marketing;
- n. **Lupin:** Vinita Gupta, CEO (Lupin Ltd.); Robert Hoffman, EVP, US Generics; Paul Kleutghen, Executive Member, Strategic Advisory Board;
- o. **Mallinckrodt:** John Adams, SVP Commercial Operations; Ginger Collier, VP National Accounts; Michael Gunning, VP & GM Specialty Generics; Jason Jones, VP
- p. **Mylan:** Robert Potter, Head of Global Sales Excellence; Anthony Mauro, Chief Commercial Officer; Matt Erick, President, Mylan North America & Brazil; Debra O'Brien, Chief Marketing Officer; Hal Korman, EVP & COO;
- q. **Par:** Paul Campanelli, President & CEO (Endo); Michael Altamuro, Commercial Operations & Marketing; Renee Kenney, Senior Advisor, Generic Sales; Pat Lepore, Chair & CEO;

- r. **Perrigo:** Sharon Kochan, Executive Vice President & GM (Perrigo Pharmaceuticals); Jim Tomshack, Senior Vice President, Sales; Mark Walin, Vice President, Consumer Healthcare Sales; John Wesolowski, Executive Vice President, President Rx; Thomas Hernquist, President/CEO; Paul Manning, President; Jeff Needham, EVP & President Consumer Health; Joseph Papa, Chair and CEO;
- s. **Pfizer:** Lou Dallago, VP, US Trade Group; Hope Emerson, Director Acct. Mgmt; William Kennally, Regional President – NA; Thomas McPhillips, VP US Trade Group; David Simmons, President & GM, Emerging Markets/Established Products BUs; Walter Slijepceovich, Sr. Director, Pharmacy Development;
- t. **Qualitest:** Marvin Samson, Chair & CEO;
- u. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; Michael Plessinger, Director of Marketing;
- v. **Sandoz:** Don DeGolyer, Chief Executive Officer & Board Director; Jeff George, CEO; Steven Greenstein, Director, Key Customers; Armando Kellum, Vice President, Sales & Marketing; Paul Krauthauser, Senior Vice President, Commercial Operations; Della Lubke, Director, National Accounts; Chris Neurohr, Director, National Accounts; Warren Pefley, VP Sales & Marketing; Richard Tremonte, President, Strategic Global Sourcing;
- w. **Taro:** Mitchell Bashinsky, Business Development; Jim Josway, Vice President, RX Sales; Edward Moniz, OTC Sales; Bill Seiden, Senior Vice President, U.S. Sales & Marketing;
- x. **Teva:** Theresa Coward, Senior Director Sales & Trade Relations; Maureen Cavanaugh, Chief Operating Officer, North America Generics; Jonathan Kafer, Executive Vice President, Sales and Marketing; Darren Alkins, Vice President, Pricing & Contracts; Timothy Crew, SVP North American Generics; Robert Cunard, VP Sales; John Denman, SVP, Sales & Marketing; Timonthy Catlett, SVP Sales & Marketing; Michael Sine, Sr. Director, Corporate Account Group;
- y. **Upsher-Smith:** Chris Evenstad, Director, Ventures Marketing; Jim Hughes, VP Marketing; Scott Hussey, SVP Sales; Jim Maahs, VP, Commercial Portfolio Products; Mike McBride, VP Partner Relations;
- z. **URL:** William Everett, National Trade Account Manager; Gregory Hayer, SVP, BD and Market Access;
- aa. **Wockhardt:** Michael Craney, President of Sales & Marketing; Mark Hartman, President; and
- bb. **Zydus:** Joseph Renner, Chair of the Board; Kristy Ronco, Vice President, Sales; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President Sales and Marketing.

HDMA 2010 Business and Leadership Conference –Orlando, Florida (June 6-9, 2010):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2010 Pharmacy and Technology Conference – San Diego, California (August 30-31, 2010):

- a. **Actavis:** Ara Aprahamian, Vice President, Sales & Marketing; Michael Dorsey, Director National Accounts; Doug Boothe, President Generics Division; Andy Boyer; Executive Vice President, Commercial Operations; Napoleon Clark, Vice President Marketing; Lisa Fiveash, National Account Representative; Anthony Giannone, Executive Director, Sales; Maureen Meehan, Director, National Accounts; Diane Miranda, Vice President, Distribution Services and Generic

- Marketing; Nimish Muzumdar, Director of Marketing; Toni Picone, Marketing Manager; Vince Rinauder; Director, National Accounts; Gary Salter, Director National Accounts; David Schmidt, Director, National Accounts; Eric Schumacher, Director, Generic Strategic Initiatives; Allan Slavsky, Sales Consultant;
- b. **Alvogen:** Michael Franks, Regional VP Sales; Brian Heinzelman, Director, Business Development; Jeffrey Rumler, EVP, Sales & Marketing;
- c. **Amneal:** David Hardin, National Account Manager; Liz Koprowski, National Account Manager; Jim Luce, EVP, Sales & Marketing; Brown Massey, Director Sales; June Parker, National Accounts Manager; Chirag Patel, Co-CEO & Chair; Chintu Patel, CEO & Co-Chair; Stephen Rutledge, VP Sales; Kammi Wilson, Marketing Manager;
- d. **Apotex:** Jeff Watson, President & COO; Beth Hamilton, Vice President, Generic Product Sales; Jim Van Lieshout, Trade and Industry Relations; Tina Kaus, National Accounts Director; Tom Axner, National Sales Director, Distribution; Sam Boulton, Director, National Accounts; Ellen Gettenberg, Director, Marketing; Bob Simmons, National Director;
- e. **Aurobindo:** Scott White, President; Corinne Hogan, VP Sales & Marketing; Geoff Rouse, Director of Sales; Patricia O'Malley, Director, Sales & Marketing Operation; Paul McMahon, Senior Director, Commercial Operations; Stuart Blake, Director, National Accounts;
- f. **Bausch + Lomb:** Dean Cowen, National Account Director; Richard Cunningham, Sr. Product Manager – Multisource; Philip Gioia, President & Global API Business; Elva Ramsaran, National Account Director; Steve Sacheli, Director, National Accounts; Suzan Trevor, National Account Manager;
- g. **Breckenridge:** Scott Cohon, Director of Sales; Phil Goldstein, National Accounts Sales Director; Joan Lyle, Director, National Accounts; Anthony Mihelich, VP, Purchasing; Dave Nielsen, Director, Sales; Martin Schatz, SVP Sales;
- h. **Camber:** Briggs Arrington; Brett Barczak, Director, Corporate Accounts; Megan Becker, Marketing Manager; Megan Hinman, Manager Sales Operations; Kon Ostaficiuk, President; Laura Ricardo, Director of Corporate Accounts;
- i. **CorePharma:** Vicki Mangus, Executive Director, Sales; Scott Nemitz, VP Sales; Louis Pastor, Sr. Director, Trade Operations; Janet Penner, President Generics; Christopher Worrell, CEO;
- j. **Dr. Reddy's:** Cindy Stevens, Director, National Accounts; Jake Austin, VP, US Sales; John Adams, Senior Vice President, Commercial Operations; Trish Wetzel, Senior Director, National Accounts; Amit Patel, Senior Vice President & Head, North American Generics; Bob Rodowicz, Director, Institutional Sales & Marketing; Hillary Steele, Associate Director, Marketing Communications;

- k. **Endo:** Robert Ammon, Sr. National Account Executive; Javier Avalos, Sr. Director, Managed Markets and Trade Operations; Doug Azzalina, Director, Marketing, Generic Products; John Bullock, Channel Liaison, Specialty Pharmacy; Robert Candea, VP, Specialty Generics S&M; Kayla Kelnhofer, National Account Executive;
- l. **Epic:** Thomas Scono, VP of Contracts; Patrick Berryman, SRVP and COO;
- m. **Fougera:** Christopher Bihari, National Sales Director; Kian Kazemi, Senior Vice President, Sales; Karen Paganuzzi, Product Manager; Anthony Thomassey, Director, National Accounts;
- n. **G&W Laboratories:** Kurt Orlofski, Chief Executive Officer; Jan Bell, National Account Manager, Managed Care; Jim Grauso, EVP, N.A. Commercial Operations; Joel Zaklin, Vice President, Sales and Marketing; Tom Faig, National Account Manager;
- o. **Glenmark:** Dave Irwin, Director of Sales; Jeff Johnson, Director, Sales & Marketing; Jessica Cangemi, Director, Sales & Marketing; Jim Brown, Vice President, Sales; Steve Goodman, Director of Marketing - Generics; Terry Coughlin, Executive Vice President and Chief Operating Officer; Paul Dutra, Executive Vice President;
- p. **Greenstone:** John Calabrese, Director of Sales; James Cannon, GM; Michael Dolan, Director, Operations & Business Development; Andrew Falocco, Account Manager; Lori LaMattina, Sales Operations Manager; Rick Mackenzie, National Accounts Director; Mark Mancinotti, National Accounts Director; Jill Nailor, Sr. Director Sales and National Accounts; Sarah Panella, Rebate Manager; Robert Sanderson, Director, National Accounts; Kevin Valade, National Account Director; Joanne Van Deusen, Manager; Christine Versichele, Director of U.S. Generic Channel Strategies; Greg Williams, Director, National Accounts;
- q. **Heritage:** Jason Malek, President; Jeff Glazer, Chief Executive Officer; Matt Edelson, Senior Director of Sales; Chip McCorkle, Director National Accounts;
- r. **Hi-Tech:** Ed Bernios, VP, Sales and Marketing; Michael Corley, VP, National Accounts; Thomas Kronovich, VP, National Accounts; David Seltzer, Director;
- s. **Impax:** William Ball, Sr. National Account Manager; Danny Darnell, Sr. National Accounts Manager; Todd Engle; Michael Grigsby, Sr. National Account Manager; Gary Skalski, Sr. Director of Sales;
- t. **Jubilant Cadista:** Toby Bane, Manager, National Accounts; Scott Delaney, President; Mark Dudick, VP National Accounts; Neal Miller, Manager, National Accounts; Travis Roberts, VP Marketing & Corporate Strategy; Christine Walton, Associate Director, Rx Marketing Generics;

- u. **Lannett:** Arthur Bedrosian, President & Chief Executive Officer; Tracy DiValero, National Account Manager; Rich Matchett, Director, Sales; Jolene McGalliard, National Account Manager; Dwight Nix, Director, National Accounts; Kevin Smith, Vice President, Sales & Marketing;
- v. **Lupin:** Frank Aguilar, VP National Accounts; Steve Ater, Director, National Accounts; David Bailey, Director, Trade Relations; Dave Berthold, SVP, Generics; Jason Gensburger, Director, Financial Services; Vinita Gupta, CEO (Lupin Ltd.); Robert Hoffman, EVP, US Generics; Paul Kleutghen, Executive Member, Strategic Advisory Board; Paul McGarty, President; Mickey Proctor, SVP, Sales & Managing;
- w. **Mallinckrodt:** John Adams, SVP, Commercial Operations; Steve Becker, Director of National Account; Tim Berry, National Account Manager; Victor Borelli, SVP Sales & Marketing; Chuck Bramlage, President, Pharmaceutical Products; Lisa Cardetti, National Account Manager; Ginger Collier, VP, National Accounts; Michael Gunning, VP & GM Specialty Generics; Jason Jones, VP, Corporate Sales; Marc Montgomery, Director of Marketing; Katherine Neely, Associate Director Rx Generics; Bonnie New, National Account Manager; Chad Plumlee, National Account Manager;
- x. **Mylan:** Danielle Barill, Key Account Manager; J. Mark Bover, Senior Director, Pricing & Contracts; Joseph Duda, Director, Pricing & Contracts; Matt Erick, President, Mylan North America & Brazil, Edgar Escoto, Director, National Accounts; Jon Kerr, Director, National Sales; Dan King, Director, National Accounts; Kevin McElfresh, Executive Director, National Accounts; Dave Workman, Strategic Pricing and Contracts;
- y. **Par:** Karen O'Connor, Vice President, National Accounts; Michael Altamuro, Vice President, Commercial Operations & Marketing; Renee Kenney, Senior Advisor, Generic Sales; Michael Burton, Vice President, National Accounts; Paul Campanelli, President & CEO (Endo); Kevin Campbell, Vice President, Sales & Marketing; Rick Guillory, Vice President, National Accounts; Jon Holden, Vice President Sales; Sandra Bayer, Sr. Director, National Accounts (Qualitest); James Burnett, National Accounts Manager (Qualitest); Gary Larson, National Accounts Manager (Qualitest); Lori Minnihan, Associate Director, Trade Pricing Operations (Qualitest); Charles Propst, Vice President (Qualitest);
- z. **Perrigo:** Andrea Felix, National Account Executive; Shelly Snyder, National Account Manager; Tony Polman, National Account Manager; H. James Booydegraaf, Associate Director, Marketing; Ori Gutwerg, National Account Executive; Sharon Kochan, Executive Vice President & GM (Perrigo Pharmaceuticals); Matthew Strzeminski, National Account Executive; John Wesolowski, Executive Vice President, President Rx;
- aa. **Pfizer:** Robert Costa, Director; Lou Dallago, VP, US Trade Group; Amy Durei, Director, Trade Channel Management; Hope Emerson, Director Acct. Mgmt;

Manley Fong, Director, Trade Account Management; Schnell Hart, Director, Trade Account Management; Thomas McPhillips, VP US Trade Group; Neil Potter, Director, Team Leader, Trade Channel Marketing; Tracy Salas, Associate Manager; Matt Schroeder, Sr. Manager, Trade Channel Management; David Searle, Director, Pharmacy Development; Walter Slijepceovich, Sr. Director, Pharmacy Development; Wesley Tanner, Director, Trade Account Management; Richard Vastola, Sr. Manager, Trade Channel Marketing; John Walsh, Director, Trade Group; Gilbert White, Director, Trade Account Manager;

- bb. **Rising:** Beth Castillo, National Accounts Manager; Ron Gold, CEO; Patricia MacBride, National Accounts Manager, Managed Markets; Kee Moore, VP Sales;
- cc. **Roxane:** Mark Boudreau, Executive Director, Sales; John Kline, National Account Director; Debbie Kutner, National Account Director; Chris Ludgis, Contract Operations Manager; Rick Peterman, Director, Marketing; Joseph Ruhmel, Vice President, Sales & Marketing; Steven Simone, Product Manager; Steve Snyder, National Account Director; Beth Usrey, Product Manager; Mark Zampella, Sales Manager;
- dd. **Sandoz:** Armando Kellum, Vice President, Sales & Marketing; Della Lubke, Director, National Account; Steven Greenstein, Director, Key Customers; Luis Jorge, Director of Marketing; Monika Misiuta, Director, Marketing; Chris Neurohr, Director, National Accounts; Dave Picard, SVP, Global Generic Pharmaceuticals;
- ee. **Sun:** Wayne Fallis, Director, National Accounts; Steven Smith, Sr. Director of Sales; Thomas Versosky, President;
- ff. **Taro:** Doug Statler, Senior Director, Head of Sales; Howard Marcus, Vice President, Sales & Marketing; James Josway, Vice President, RX Sales; Scott Brick, Manager, National Accounts; Sheila Curran, Vice President, Sales Operations; Elizabeth Guerrero, Director, Corporate Accounts, Managed Care; Bill Seiden, Vice President, U.S. Sales & Marketing;
- gg. **Teva:** Jessica Peters, National Accounts Manager; Kevin Green, Associate Vice President, National Accounts; Madalen Renner, National Account Manager; Terri Coward, Senior Director Sales and Trade Relations; Darren Alkins, Vice President, Pricing & Contracts; Christine Baeder, SVP Customer and Marketing Operations; Maureen Cavanaugh, Chief Operating Officer NA Gx; Timothy Crew, SVP North American Generics; Robert Cunard; VP Sales; Kevin Galownia; Senior Director, Pricing; Jonathan Kafer, EVP, Sales and Marketing; Teri Mouro Sherman, Director, National Accounts; Dave Rekenhaller, VP Sales; Michael Sine, Sr. Director, Corporate Account Group;
- hh. **Torrent:** Jim Devers, VP Sales; Kelly Gegenheimer, VP Sales; Kamesh Venugopal, President;

- ii. **Upsher-Smith:** Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP, Commercial Portfolio Products; Mike McBride, VP Partner Relations; Michael Muzetras, Sr. National Account Manager; Beth Pannier, Sr. National Account Manager; Dave Zitnak, National Accounts Sr. Director – Trade; Doug Zitnak, National Accounts Sr. Director – Trade;
- jj. **URL:** William Everett, National Trade Account Manager; Mark Greene, Director, National Accounts; Gregory Hayer, SVP, BD and Market Access; Mary Anne McCoy, Sr. Sales Customer Service Manager;
- kk. **West-Ward:** Jason Grenfell-Gardner, Senior Vice President, Sales & Marketing; Luis Velez, Senior Director of Sales; Mark Ritchey, Vice President, Sales; Paul Markowitz, Director, National Accounts; Tariq Al Tayeb, Manager, Sales & Marketing; Brian Hoffman, VP Business Development;
- ll. **Wockhardt:** Karen Andrus, Director of Sales; Michael Craney, President of Sales & Marketing; Sunil Khera, President – The Americas, Japan & Emerging Markets; Kevin Knarr, VP Sales & Marketing; Scott Koenig, VP Sales & Marketing Generics; Bob Watson, VP National Accounts; and
- mm. **Zydus:** Michael Keenley, President; Ganesh Nyak, Chief Operating Officer & Executive Director; Sharvil Patel, Managing Director; Barbara Purcell, SVP U.S. Diversified Products; Karen Strelau, Executive Vice President, Sales & Marketing; Laura Short, Vice President Sales.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA AMP Implementation Workshop - (November 4, 2010)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ECRM Retail Pharmacy Generic Pharmaceutical Conference - Championsgate, Florida
(March 6-10, 2011)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2011 Annual Meeting –Scottsdale, Arizona (April 30-May 3, 2011):

- a. **Actavis:** Andrew Boyer, EVP, Commercial Operations; Sigurdur Olafsson, President, Chief Executive Officer; Michael Baker, Executive Vice President, Trade Sales and Development; Paul Bisaro, President and Chief Executive Officer; Michael Reed, Executive Director, Trade Relations; Paul Reed, Senior Director, Trade Sales and Operations; John Shane, Director, Trade Relations; Allan Slavsky, Sales Consultant;
- b. **Amneal:** Jim Luce, EVP, Sales & Marketing; Chirag Patel, CEO & Chair; Stephen Rutledge;
- c. **Apotex:** Buddy Bertucci, Vice President, Institutional Sales; Sam Boulton, Director, National Accounts; Lyndon Johnson, Senior Vice President, Sales and Marketing; Jeff Watson, President & COO; Beth Hamilton, Vice President, Generic Product Sales;
- d. **Aurobindo:** Corrine Hogan, VP Sales & Marketing; Scott White, President;
- e. **Bausch + Lomb:** John Conos, Director Sales & Category Management; Joseph Gordon; President, Consumer Health + Vision Care; Melissa Kiewe, Director, Customer Marketing;
- f. **Camber:** Brett Barczak, Director, Corporate Accounts; Kon Ostaficiuk, President;
- g. **Dr. Reddy's:** Amit Patel, Senior Vice President & Head, North American Generics; John Adams, SVP, Commercial Operations; Jeff Burd, SVP, Commercial Operations; Gary Benedict, Executive Vice President; Satish Reddy, Chief Operating Officer;
- h. **Endo:** Javier Avalos, Sr. Director, Managed Markets & Trade Operations; Kayla Kelnhofer, National Account Executive;
- i. **Fougera:** Steve Andrzejewski, CEO; Kian Kazemi, Senior Vice President, Sales; Anthony Thomassey, Director, National Accounts;
- j. **Glenmark:** Paul Dutra, Executive Vice President;
- k. **Jubilant Cadista:** Scott Delaney, President; Mark Dudick, VP National Accounts;
- l. **Lupin:** Dave Berthold, SVP, Generics; Vinita Gupta, CEO (Lupin Ltd.); Robert Hoffman, EVP, US Generics; Paul Kleutghen, Executive Member, Strategic Advisory Board; Paul McGarty, President;
- m. **Mallinckrodt:** Victor Borelli, SVP Sales & Marketing; Ginger Collier, VP National Accounts; Jason Jones, VP Corporate Sales; Jane Williams, VP Sales;
- n. **Mylan:** Robert Potter, Head of Global Sales Excellence; Anthony Mauro, Chief Commercial Officer; Matt Erick, President, Mylan North America & Brazil; Debra O'Brien, Chief Marketing Officer; Lloyd Sanders; Chief Operating Officer;

- o. **Par:** Paul Campanelli, President & CEO (Endo); Michael Altamuro, Commercial Operations & Marketing; Renee Kenney, Senior Advisor, Generic Sales;
- p. **Perrigo:** Sharon Kochan, Executive Vice President & GM (Perrigo Pharmaceuticals); Richard McWilliams, Senior Vice President & General Manager; Jim Tomshack, Senior Vice President, Sales; Mark Walin, Vice President, Consumer Healthcare Sales; John Wesolowski, Executive Vice President, President Rx; Philip Willis, Innovation and Marketing Strategy; Chris Neurohr; Director, National Accounts;
- q. **Pfizer:** Albert Bourla, COO; Lou Dallago, VP, US Trade Group; Hope Emerson, Director Acct. Mgmt; William McPhillips, VP US Trade Group; Thomas McPhillips, VP US Trade Group; Walter Slijepceovich, Sr. Director, Pharmacy Development;
- r. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; Rick Peterman, Director, Marketing; Michael Plessinger, Director of Marketing;
- s. **Sandoz:** Don DeGolyer, Chief Executive Officer & Board Director; Jeff George, CEO; Steven Greenstein, Director, Key Customers; Armando Kellum, Vice President, Sales & Marketing; Paul Krauthauser, Senior Vice President, Commercial Operations; Della Lubke, Director, National Accounts;
- t. **Taro:** Jim Kedrowski, Interim CEO; Mitchell Bashinsky, Business Development; Jim Josway, Vice President, RX Sales; Bill Seiden, Senior Vice President, U.S. Sales & Marketing;
- u. **Teva:** Theresa Coward, Senior Director Sales & Trade Relations; Maureen Cavanaugh, Chief Operating Officer, North America Generics; Jonathan Kafer, Executive Vice President, Sales and Marketing; Darren Alkins, Vice President, Pricing & Contracts; Timothy Crew, SVP North American Generics; Robert Cunard, VP Sales; John Denman, SVP, Sales & Marketing;
- v. **Upsher-Smith:** Chris Evenstad, Director, Ventures Marketing; Jim Hughes, VP Marketing; Scott Hussey, SVP Sales; Jim Maahs, VP, Commercial Portfolio Products; Mike McBride, VP Partner Relations;
- w. **URL:** William Everett, National Trade Account Manager; Mark Greene, Director, National Accounts;
- x. **Wockhardt:** Michael Craney, President of Sales & Marketing; Sunil Khera, President Khera, President-The Americas, Japan & Emerging Markets; and
- y. **Zydus:** Joseph Renner, Chair of the Board; Kristy Ronco, Vice President, Sales; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President Sales and Marketing.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2011 Business and Leadership Conference –Phoenix, Arizona (June 6-7, 2011):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2011 Pharmacy & Technology Meeting –Boston, Massachusetts (August 27-30, 2011):

- a. **Actavis:** Andrew Boyer, EVP, Commercial Operations; Sigurdur Olafsson, Chief Executive Officer; Michael Reed, Executive Director, Trade Relations; Paul Reed, Senior Director, Trade Sales and Operations; John Shane, Director, Trade Relations; Allan Slavsky, Sales Consultant; Napoleon Clark, Vice President, Marketing; Lisa Fiveash, National Account Representative; Anthony Giannone, Executive Director Sales; Maureen Meehan, Director, National Accounts; Diane Miranda, Vice President, Distribution Services and Generic Marketing; Toni Picone, Marketing Manager; Vince Rinaudo, Director, National Accounts; Gary

Salter, Director, National Accounts; David Schmidt, Director, National Accounts; Ara Aprahamian, Vice President, Sales & Marketing; Thad Demos, National Accounts Manager; Michael Dorsey, Director, National Accounts; Jinping McCormick, VP, Rx Sales & Marketing, Generics, US; Lisa Pehlke, Director, Corporate Accounts; Michael Perfetto, Chief Commercial Officer Generic RX/OTC, US and Canada;

- b. **Akorn:** Mick McCanna, National Account Manager; John Sabat, SVP National Accounts; M. Tranter, National Accounts Manager, Sales & Marketing;
- c. **Amneal:** Thomas Balog, Consultant; David Hardin, National Account Manager; Liz Koprowski, National Account Manager; Jim Luce, EVP, Sales & Marketing; Brown Massey, Director Sales; June Parker, National Accounts Manager; Chirag Patel, Co-CEO & Chair; Chintu Patel, CEO & Co-Chair; Stephen Rutledge, VP Sales; Kammi Wilson, Marketing Manager; Jennifer Winterhalter, VP Revenue Management;
- d. **Apotex:** Tom Axner, National Sales Director, Distribution; Tim Berry, Tim, National Account Manager; Buddy Bertucci, Vice President, Institutional Sales; Sam Boulton, Director, National Accounts; Jeff Watson, President & COO; Beth Hamilton, Vice President, Generic Product Sales; Gwen Copeland, Manager, National Accounts; John Crawford, National Account Director; Niki Hinman-Smock, National Account Manager; Tina Kaus, National Account Director; Karen Rice, Marketing Manager; Bob Simmons, National Account Director; James Van Lieshout, Vice President, Trade and Industry Relations;
- e. **Ascend:** John Dillaway, EVP, Sales & Marketing; Amit Ghare, President, International Business; Lynette Piers, Director Sales; Jonathan Rome, President & CEO; Robert Rome, VP Operations; Sujit Sakpal, VP Corporate Development; Schuyler Van Winkle, SVP, National Accounts; Greg Watkins, VP, National Accounts;
- f. **Aurobindo:** Corrine Hogan, VP Sales & Marketing; Scott White, President; Stuart Blake, Director, National Accounts; Patricia O'Malley, Director, Sales & Marketing Operations; Geoff Rouse, Director of Sales;
- g. **Bausch + Lomb:** Dean Cowen, National Account Director; Philip Gioia, President & Global API Business; Michelle Poole, Associate Director, Product Management; Elva Ramsaran, National Account Director; Steve Sacheli, Director, National Accounts; Mary Saharyan, VP & GM, US Generics Sales & Marketing;
- h. **Breckenridge:** Scott Cohon, Director of Sales; Phil Goldstein, National Accounts Sales Director; Larry Lapila, President; Daniel Lavalley, Manager, Professional and Trade Relations; Joan Lyle, Director, National Accounts; Diane Maynard, Director, Sales Administration; Dave Nielsen, Director, Sales; Martin Schatz, SVP Sales;

- i. **Camber:** Briggs Arrington; Brett Barczak, Director, Corporate Accounts; Megan Becker, Marketing Manager; Chris D'India, National Account Manager; Dennis Hicks, Consultant; Stu Messinger, Director National Accounts; Kon Ostaficiuk, President; Dan Piergies, Director Sales Operations; Laura Ricardo, Director of Corporate Accounts; Clayton Smith, Account Manager;
- j. **CorePharma:** Vicki Mangus, Executive Director, Sales; Scott Nemitz, VP Sales; Louis Pastor, Sr. Director, Trade Operations; Janet Penner, President Generics; Christopher Worrell, CEO;
- k. **Dr. Reddy's:** Amit Patel, Senior Vice President & Head, North American Generics; John Adams, SVP, Commercial Operations; Jeff Burd, SVP, Commercial Operations; Jake Austin, VP, US Sales; Nimish Muzumdar, Director of Marketing; Katherine Neely, Associate Director Rx Generics; Katherine Neely, Associate Director Rx Generics; Robert Rodowiz, Director, Institutional Sales & Marketing; Hillary Steele, Associate Director, Marketing Communications; Cindy Steven, Director, National Accounts; Tricia Weitzel, Senior Director, National Accounts, Rx Mid-West;
- l. **Endo:** Javier Avalos, Sr. Director, Managed Markets and Trade Operations; John Bullock, Channel Liaison, Specialty Pharmacy; Kayla Kelnhofer, National Account Executive; Scott Littlefield, Trade Director;
- m. **Epic:** Thomas Scono, VP Contracts;
- n. **Fougera:** Kian Kazemi, Senior Vice President, Sales; Anthony Thomassey, Director, National Accounts; Christopher Bihari, National Sales Director; Stephen Haag; National Accounts Executive; Brian Markison, CEO; Jeff Wasserstein, Senior Vice President Business Development;
- a. **Glenmark:** Paul Dutra, Executive Vice President; Jessica Cangemi, Director, Sales and Marketing; Jeff Johnson, Director, Sales and Marketing; David Irwin, Director, Sales; Stephanie Picca, Manager, Sales and Marketing; Terry Coughlin, Executive Vice President and Chief Operating Officer;
- o. **G&W Laboratories:** Erika Vogel-Baylor, Vice President, Sales & Marketing; Kurt Orlofski, CEO; Thomas Faig, National Account Manager; James Grauso, EVP, N.A. Commercial Operation; Joel Zaklin, Vice President, Sales and Marketing;
- p. **Greenstone:** James Cannon, GM; Renee Day, Director/Team Leader, Portfolio Maximization; Lori LaMattina, Sales Operations Manager; Rick Mackenzie, National Accounts Director; Jill Nailor, Sr. Director Sales and National Accounts; Robert Sanderson, Director, National Accounts; Kevin Valade, National Account Director; Christine Versichele, Director of U.S. Generic Channel Strategies; Christopher Weller, Sr. Manager, Marketing & Strategy; Greg Williams, Director, National Accounts;

- q. **Heritage:** Jeffrey Glazer, Chair & CEO; Jason Malek, President; Matt Edelson, Senior Director of Sales; Anne Sather, National Account Manager; Neal O'Mara, National Account Manager; Chip McCorkle, Director, National Accounts; Neal O'Mara, National Accounts Manager;
- r. **Hi-Tech:** Ed Berrios, VP, Sales and Marketing; Michael Corley, VP National Accounts; Stephanie Jomisko, Director, Contracts & Finance; Thomas Kronovich, VP National Accounts; Chris LoSardo, VP Corporate Development; David Seltzer, Director;
- s. **Impax:** William Ball, Sr. National Account Manager; Danny Darnell, Sr. National Accounts Manager; Todd Engle; Michael Grigsby, Sr. National Account Manager; Gary Skalski, Sr. Director of Sales; Ted Smolenski, Director, Marketing Planning, Generics;
- t. **Jubilant Cadista:** Neeraj Agrawal, CEO – Generics; Toby Bane, Manager, National Accounts; Scott Delaney, President; Mark Dudick, VP National Accounts; Neal Miller, Manager, National Accounts; Travis Roberts, VP Marketing & Corporate Strategy; Christine Walton, Associate Director, Rx Marketing Generics;
- u. **Lannett:** Tracy DiValero, National Account Manager; Rich Matchett, Director, Sales; Jolene McGalliard, National Account Manager; Dwight Nix, Director, National Accounts; Kevin Smith, Vice President, Sales & Marketing;
- v. **Lupin:** Frank Aguilar, VP National Accounts; Steve Ater, Director, National Accounts; David Bailey, Director, Trade Relations; Dave Berthold, SVP, Generics; Bill Chase, Director, Market Access Specialty Products; Brittany Cummins, Territory Sales Manager; Jason Gensburger, Director, Financial Services; Robert Hoffman, EVP, US Generics; Paul McGarty, President; David Shirkey, National Account Manager;
- w. **Mallinckrodt:** Steve Becker, Director of National Account; Jennifer Block, Product Manager; Victor Borelli, SVP Sales & Marketing; Lisa Cardetti, National Account Manager; GMatthew Harbaugh, VP Finance; Charity Keeven, Demand Analyst; Marc Montgomery, Director of Marketing; Bonnie New, National Account Manager; Pete Romer, National Account Manager; David Silver, VP Strategy & Portfolio Mgmt; Betty Jean Swartz, VP Managed Markets & Reimbursement; Jane Williams, VP Sales;
- x. **Mylan:** Robert Potter, Head of Global Sales Excellence; Anthony Mauro, Chief Commercial Officer; Danielle Barill, Key Account Manager, J. Mark Bover, Senior Director, Pricing & Contracts; Edgar Escoto, Director, National Accounts; Jon Kerr, Director National Sales; Kevin McElfresh, Executive Director, National Accounts; Sean Reilly, National Account Manager; Gary Tigh, Director National Accounts; Dave Workman, Vice President, Strategic Pricing and Contracts;

- y. **Par:** Paul Campanelli, President & CEO (Endo); Michael Altamuro, Commercial Operations & Marketing; Renee Kenney, Senior Advisor, Generic Sales; Michael Burton, Vice President, National Accounts; Rick Guillory, Vice President, National Accounts; Jon Holden, Vice President, Sales; Karen O'Connor, Vice President, National Accounts; Sandra Bayer, Sr. Director, National Accounts (Qualitest); James Burnett, National Accounts Manager (Qualitest); Gary Larson, National Accounts Manager (Qualitest); Lori Minnihhan, Associate Director, Trade Pricing Operations (Qualitest); Charles Propst, Vice President (Qualitest); Warren Pefley, VP, Sales & Marketing (Qualitest);
- z. **Perrigo:** Sharon Kochan, Executive Vice President & GM (Perrigo Pharmaceuticals); John Wesolowski, Executive Vice President, President Rx; H. James Booydegraaff, Associate Director, Marketing; Andrea Felix, National Account Executive; Chris Owens, Customer Business Manager; Tony Polman, National Account Manager; Anthony Schott, National Account Mnaager, Retail; Shelly Snyder, National Account Manager;
- aa. **Pfizer:** Lou Dallago, VP, US Trade Group; Amy Durei, Director, Trade Channel Management; Hope Emerson, Director Acct. Mgmt; Manley Fong, Director, Trade Account Management; Schnell Hart, Director, Trade Account Management; Thomas McPhillips, VP US Trade Group; Walter Slijepceovich, Sr. Director, Pharmacy Development; Wesley Tanner, Director, Trade Account Management; John Walsh, Director, Trade Group; Gilbert White, Director, Trade Account Manager;
- bb. **Rising:** Beth Castillo, National Accounts Manager; Ron Gold, CEO; Patricia MacBride, National Accounts Manager, Managed Markets; Kee Moore, VP Sales; Brian Shapiro, VP Business Development;
- cc. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; John Kline, National Account Director; Rick Peterman, Director, Marketing; Michael Plessinger, Director of Marketing; Joseph Ruhmel, Vice President, Sales & Marketing; Steve Snyder, National Account Director;
- dd. **Sandoz:** Don DeGolyer, Chief Executive Officer & Board Director; Jeff George, CEO; Steven Greenstein, Director, Key Customers; Armando Kellum, Vice President, Sales & Marketing; Paul Krauthauser, Senior Vice President, Commercial Operations; Della Lubke, Director, National Accounts;
- ee. **Sun:** Wayne Fallis, Director, National Accounts; Thomas Versosky, President; Donna Hughes, National Account Manager;
- ff. **Taro:** Mitchell Bashinsky, Business Development; Jim Josway, Vice President, Rx Sales; Bill Seiden, Senior Vice President, U.S. Sales & Marketing; Scott Brick, Manager, National Accounts; Howard Marcus, VP Sales & Marketing; Brant Schofield, Vice President, Sales & Marketing;

- gg. **Teva:** Theresa Coward, Senior Director Sales & Trade Relations; Maureen Cavanaugh, Chief Operating Officer, North America Generics; Darren Alkins, Vice President, Pricing & Contracts; Timothy Crew, SVP North American Generics; Robert Cunard, VP Sales; John Denman, SVP, Sales & Marketing; Christine Baeder; SVP Customer and Marketing Operations; Kevin Green, Associate Vice President, National Accounts; Teri Mouro Sherman, Director, National Accounts; Jessica Peters, Director, Trade Operations; Dave Rekenthaler, VP Sales;
- hh. **Torrent:** Jim Devers, VP Sales; Kelly Gegenheimer, VP Sales; Kamesh Venugopal, President;
- ii. **Upsher-Smith:** Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP, Commercial Portfolio Products; Glenn MacEachem, Director – Product Marketing; Mike McBride, VP Partner Relations; Michael Muzetras, Sr. National Account Manager; Chad Olson, Director, Generic Products; Beth Pannier, Sr. National Account Manager; Mary Rotunno, National Account Manager; Carol Weeklund, Associate Director, Marketing Operations; Dave Zitnak, National Accounts Sr. Director – Trade; Doug Zitnak, National Accounts Sr. Director – Trade;
- jj. **URL:** William Everett, National Trade Account Manager; Mark Greene, Director, National Accounts; Gregory Hayer, SVP, BD and Market Access; Mary Anne McCoy, Sr. Sales Customer Service Manager;
- kk. **West-Ward:** Jason Grenfell-Gardner, Senior Vice President, Sales & Marketing; Luis Velez, Senior Director of Sales; Mark Ritchey, Vice President, Sales; Paul Markowitz, Director, National Accounts; Tareq Darwazeh, National Account Senior Manager; Spiro Gavaris, Vice President, Sales and Marketing;
- ll. **Wockhardt:** Karen Andrus, Director of Sales; Michael Craney, President of Sales & Marketing; Sunil Khera, President – The Americas, Japan & Emerging Markets; Kevin Knarr, VP Sales & Marketing; Scott Koenig, VP Sales & Marketing Generics; Bob Watson, VP National Accounts; and
- mm. **Zydus:** Joseph Renner, Chair of the Board; Kristy Ronco, Vice President, Sales; Jack Bleau, Director of Trade; Michael Keenley, President; Ganesh Nayak, Chief Operating Officer & Executive Director; Sharvil Patel, Managing Director; Elizabeth Purcell, Sr. Director, Marketing and Portfolio Management; Lisa Ribando, Senior Contact Manager; Kristy Ronco, Vice President, Sales; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President Sales and Marketing.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ECRM Retail Pharmacy Generic Pharmaceutical Conference – Atlanta, Georgia (January 29-February 1, 2012).

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2012 Annual Meeting – Palm Beach, Florida (April 24-27, 2012):

- a. **Actavis:** Andrew Boyer, EVP, Commercial Operations; Sigurdur Olafsson, Chief Executive Officer; Michael Reed, Executive Director, Trade Relations; Paul Reed, Senior Director, Trade Sales and Operations; John Shane, Director, Trade Relations; Allan Slavsky, Sales Consultant; Michael Perfetto, Chief Commercial Officer Generic RX/OTC, US and Canada; Paul Bisaro, President and Chief Executive Officer; Robert Stewart, President and CEO;
- b. **Amneal:** Jim Luce, EVP, Sales & Marketing; Chirag Patel, CEO & Co-Chair; Stephen Rutledge;

- c. **Apotex:** Buddy Bertucci, Vice President, Institutional Sales; Sam Boulton, Director, National Accounts; Jeff Watson, President & COO; Beth Hamilton, Vice President, Generic Product Sales; James Van Lieshout, Vice President, Trade and Industry Relations; Peter Hardwick, Chief Commercial Officer; Lyndon Johnson, SVP, Sales & Marketing;
- d. **Aurobindo:** Robert Cunard, CEO; James Grauso, EVP, N.A. Commercial Operations;
- e. **Bausch + Lomb:** Joseph Gordon, President, Consumer Health + Vision Care; Todd LaRue, VP of Sales US; Thomas Allison, Sr. Director of National Accounts; Eddie Andruss, Assoc. Director of National Accounts;
- f. **Camber:** Brett Barczak, Director, Corporate Accounts; Kon Ostaficiuk, President;
- g. **Dr. Reddy's:** Amit Patel, Senior Vice President & Head, North American Generics; John Adams, SVP, Commercial Operations; Jeff Burd, SVP, Commercial Operations; Abhijit Murkerjee, President, Global Generics;
- h. **Endo:** Javier Avalos, Sr. Director, Managed Markets and Trade Operations; Scott Littlefield, Trade Director;
- i. **Fougera:** Kian Kazemi, Senior Vice President, Sales; Anthony Thomassey, Director, National Accounts; Christopher Bihari, National Sales Director; Brian Markison, CEO; Jeff Bailey, Chief Operating Officer;
- b. **Glenmark:** Paul Dutra, Executive Vice President;
- j. **G&W Laboratories:** Erika Vogel-Baylor, Vice President, Sales & Marketing; Kurt Orlofski, CEO;
- k. **Greenstone:** James Cannon, GM; Jill Nailor, Sr. Director Sales and National Accounts;
- l. **Impax:** Doug Boothe, President Generics Division;
- m. **Jubilant Cadista:** Scott Delaney, President, Mark Dudick, VP, National Accounts; Travis Roberts, VP, Sales & Marketing;
- n. **Lupin:** Dave Berthold, SVP, Generics; Vinita Gupta, CEO (Lupin Ltd.); Robert Hoffman, EVP, US Generics; Paul McGarty, President;
- o. **Mallinckrodt:** Ginger Collier, VP, National Accounts; David Silver, VP Strategy & Portfolio Mgmt; Betty Jean Swartz, VP, Managed Markets & Reimbursement; Jane Williams, VP Sales;

- p. **Mylan:** Robert Potter, Head of Global Sales Excellence; Anthony Mauro, Chief Commercial Officer; Joseph Duda, Director, Pricing and Contracts; Matt Erick, President, Mylan North America & Brazil;
- q. **Par:** Paul Campanelli, President & CEO (Endo); Michael Altamuro, Commercial Operations & Marketing; Renee Kenney, Senior Advisor, Generic Sales; Thomas Haughey, President;
- r. **Perrigo:** Sharon Kochan, Executive Vice President & GM (Perrigo Pharmaceuticals); John Wesolowski, Executive Vice President, President Rx; Joseph Papa, Chair and CEO; Jim Tomshack, Senior Vice President, Sales; Philip Wilis, Innovation and Marketing Strategy;
- s. **Pfizer:** Lou Dallago, VP, US Trade Group; Hope Emerson, Director Acct. Mgmt; William Kennally, Regional President – NA; Thomas McPhillips, VP US Trade Group; David Moules, VP US Payer & Channel Customers; David Simmons, President & GM, Emerging Markets/Established Products Business Unites; Walter Slijepceovich, Sr. Director, Pharmacy Development;
- qq. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; Michael Plessinger, Director of Marketing;
- t. **Sandoz:** Don DeGolyer, Chief Executive Officer & Board Director; Jeff George, CEO; Armando Kellum, Vice President, Sales & Marketing;
- u. **Taro:** Mitchell Bashinsky, Business Development; Jim Josway, Vice President, Rx Sales; Bill Seiden, Senior Vice President, U.S. Sales & Marketing; Jim Kedrowski, Interim Chief Executive Officer; Russell Mainman, Director, Generic Business Unit;
- v. **Teva:** Theresa Coward, Senior Director Sales & Trade Relations; Maureen Cavanaugh, Chief Operating Officer, North America Generics; Darren Alkins, Vice President, Pricing & Contracts; Timothy Crew, SVP North American Generics; John Denman, SVP, Sales & Marketing; Christine Baeder; SVP Customer and Marketing Operations; Jonathan Kafer, EVP, Sales & Marketing; Jeremy Levin, President & CEO; William Marth, President & CEO North America and Europe, Heritage Pharma Holdings; Michael Sine, Sr. Director, Corporate Account Group;
- w. **Upsher-Smith:** Mark Evenstad, CEO; Jim Hughes, VP Marketing; Scott Hussey, SVP Sales; Jim Maahs, VP, Commercial Portfolio Management; Mike McBride, VP Partner Relations;
- x. **URL:** Mark Greene, Director, National Accounts; Gregory Hayer, SVP, BD and Market Access;
- y. **Wockhardt:** Michael Craney, President of Sales & Marketing; and

- z. **Zydus:** Joseph Renner, Chair of the Board; Kristy Ronco, Vice President, Sales; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President Sales and Marketing.

GPhA Board of Directors Meeting: - Washington, D.C. (May 17, 2012)

- a. **Actavis:** Charlie Mayr; Tom Long, VP Government Affairs; Ted Piper, Manager, Government Affairs (Watson); John LaRocca, Chief Legal Counsel;
- b. **Amneal:** Chirag Patel, Co-CEO;
- c. **Apotex:** Jeff Watson, President NA; Steve Giuli, Director of Government Affairs & Industry Relations;
- d. **Dr. Reddy's:** Nick Cappuccino;
- e. **Fougera:** David Klaum, SVP and GM;
- f. **Heritage:** Jeff Glazer, CEO;
- g. **Impax:** Carole Ben-Mainon, President, Global Pharmaceuticals;
- h. **Mylan:** Tony Mauro, Senior Vice President; Lara Ramsburg, Government Relations; Daniel Lubowitz, Federal Government Relations;
- i. **Sandoz:** Don DeGolyer, President & CEO NA; Mary Sibley, Policy Consultant;
- j. **Teva:** Debra Barrett, SVP Global Government Affairs and Public Policy; Terri Stewart, Sr. Director of Policy, Government Affairs; and
- k. **Zydus:** Joe Renner, Owner.

HDMA 2012 Business and Leadership Conference –San Antonio, Texas (June 13, 2012):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2012 Pharmacy and Technology Conference –Denver, Colorado (August 25-28, 2012):

- a. **Actavis:** Andrew Boyer, EVP, Commercial Operations; Michael Reed, Executive Director, Trade Relations; Paul Reed, Senior Director, Trade Sales and Operations; John Shane, Director, Trade Relations; Allan Slavsky, Sales Consultant; Michael Perfetto, Chief Commercial Officer Generic RX/OTC, US and Canada; Napoleon Clar, VP, Marketing; John Elliot, Manager, Marketing; Lisa Fiveash, National Account Representative; Anthony Giannone, Executive Director, Sales; Maureen Meehan, Director, National Accounts; Toni Picone, Marketing Manager; Vince Rinaudo, Director, National Accounts; David Schmidt, Director, National Accounts; Michael Baker, Executive Vice President, Trade Sales and Development; Ara Aprahamian, Vice President, Sales & Marketing; Steve Cohen, Vice President, National Accounts; Michael Dorsey, Director, National Accounts; Jinping McCormick, VP, Rx Sales & Marketing, Generics, US; Lisa Pehlke, Director, Corporate Accounts;
- b. **Akorn:** Mick McCanna, National Account Manager; John Sabat, SVP of National Accounts; M. Tranter, National Accounts Manager, Sales & Marketing;
- c. **Alvogen:** Michael Franks, Regional VP, Sales; Todd Graverson, EVP Sales; Jeffrey Rumler, EVP, Sales & Marketing;
- d. **Amneal:** Andy Cline, Account Executive; David Hardin, National Account Manager; Liz Koprowski, National Account Manager; Jim Luce, EVP, Sales & Marketing; Brown Massey, Director Sales; June Parker, National Accounts Manager; Chirag Patel, Co-CEO & Chair; Chintu Patel, CEO & Co-Chair; Stephen Rutledge, VP Sales; Kammi Wilson, Marketing Manager; Kenika Withrow, National Accounts and Contract Specialist;
- e. **Apotex:** Buddy Bertucci, Vice President, Institutional Sales; Sam Boulton, Director, National Accounts; Beth Hamilton, Vice President, Generic Product Sales; James Van Lieshout, Vice President, Trade and Industry Relations; Tom Axner, National Sales Director, Distribution; Tim Berry, National Account Manager; Gwen Copeland, Manager, National Accounts; John Crawford, National Account Director; Tina Kaus, National Account Director; Bob Simmons, National Account Director; Debbie Veira, National Account Manager; Pat Walden, Senior Marketing Manager;
- f. **Ascend:** Grant Butler, Sr. Executive VP National Sales; John Dillaway, EVP, Sales & Marketing; Amit Ghare, President, International Business; Robert Rome, VP Operations; Sujit Sakpal, VP Corporate Development; Schuyler Van Winkle, SVP, National Accounts; Greg Watkins, VP, National Accounts;

- g. **Aurobindo:** Robert Cunard, CEO; James Grauso, EVP, N.A. Commercial Operations; Stuart Blake, Director, National Accounts; Geoff Rouse, Director of Sales;
- h. **Bausch + Lomb:** Dean Cowen, National Account Director; Cheryl Perets, US Pharmaceuticals Sales Coordinator; Barbara Purcell, VP US Generic Sales & Marketing; Elva Ramsaran, National Account Director; Steve Sacheli, Director, National Accounts; Mary Saharyan, VP & GM, US Generics Sales & Marketing; Suzan Trevor, National Account Manager; Srini Venkatesh, VP Pharmaceuticals and Consumer Products Development;
- i. **Breckenridge:** Scott Cohon, Director of Sales; Phil Goldstein, National Accounts Sales Director; Larry Lapila, President; Joan Lyle, Director, National Accounts; Diane Maynard, Director, Sales Administration; Dave Nielsen, Director, Sales; Martin Schatz, SVP Sales;
- j. **Camber:** Briggs Arrington; Brett Barczak, Director, Corporate Accounts; Megan Becker, Marketing Manager; Chris D'India, National Account Manager; Stu Messinger, Director National Accounts; Kon Ostaficiuk, President; Dan Piergies, Director Sales Operations; Laura Ricardo, Director of Corporate Accounts; Clayton Smith, Account Manager;
- k. **CorePharma:** Scott Nemitz, VP Sales; Louis Pastor, Sr. Director, Trade Operations; Janet Penner, President, Generics; Christopher Worrell, CEO;
- l. **Dr. Reddy's:** Jake Austin, VP, US Sales; Nimish Muzumdar, Director of Marketing; Katherine Neely, Associate Director Rx Generics; Amanda Rebrick, Associate Director, Marketing; Hillary Steele, Associate Director, Marketing Communications; Cindy Stevens, Director, National Accounts; Tricia Wetzel, Senior Director, National Accounts, Rx Mid-West; John Adams, SVP, Commercial Operations; Jeff Burd, SVP, Commercial Operations;
- m. **Endo:** Javier Avalos, Sr. Director, Managed Markets and Trade Operations; John Bullock, Channel Liaison, Specialty Pharmacy; Jason Jones, Director of Trade and Distribution; Kayla Kelnhofer, National Account Executive; Scott Littlefield, Trade Director;
- n. **Epic:** Nekela Bornell, Manager, Customer Service; Ashok Nigalaye, Chair & CEO; Thomas Scono, VP of Contracts;
- o. **Fougera:** Kian Kazemi, Senior Vice President, Sales; Anthony Thomassey, Director, National Accounts; Christopher Bihari, National Sales Director; Ilene Russo, Product Manager;
- p. **G&W:** Erika Baylor, VP Sales & Marketing; Aaron Greenblatt, CEO; Chip McCorkle, Director, National Accounts; Kurt Orlofski, CEO; Michelle Sisco, Sales Analyst;

- q. **Glenmark:** Paul Dutra, Executive Vice President; Mitchell Blashinsky, Business Development; Jessica Cangemi, Director, Sales & Marketing; Terry Coughlin, EVP and COO; David Irwin, Director of Sales; Lyndon Johnson, Director, Sales & Marketing; Jolene McGalliard, National Account Manager;
- r. **Greenstone:** James Cannon, GM; Renee Day, Director/Team Leader, Portfolio Maximization; Andrew Falocco, Account Manager; Lori LaMattina, Sales Operations Manager; Jill Nailor, Sr. Director Sales and National Accounts; Robin Strzeminski, National Account Director; Kevin Valade, National Account Director; Christine Versichele, Director of U.S. Generic Channel Strategies; Greg Williams, Director, National Accounts;
- s. **Heritage:** Robert Glazer, Chair & CEO; Jason Malek, President; Matt Edelson, Senior Director of Sales; Anne Sather, National Account Manager; Neal O'Mara, National Account Manager; Gina Gramuglia, National Account Manager;
- t. **Hi-Tech:** Ed Berrios, VP, Sales and Marketing; Michael Corley, VP National Accounts; Stephanie Jomisko, Director, Contracts & Finance; Thomas Kronovich, VP National Accounts; Chris LoSardo, VP Corporate Development; David Seltzer, Director;
- u. **Impax:** William Ball, Sr. National Account Manager; Danny Darnell, Sr. National Accounts Manager; Todd Engle, VP Sales & Marketing; Michael Grigsby, Sr. National Account Manager; Gary Skalski, Sr. Director of Sales; John Kane, Sr. Director of Managed Markets and Trade; Italo Pennella, National Account Manager; Dan Rozmiarek, Trade Account Manager;
- v. **Jubilant Cadista:** Toby Bane, Manager, National Accounts; Scott Delaney, President; Mark Dudick, VP National Accounts; Neal Miller, Manager, National Accounts; Travis Roberts, VP Marketing & Corporate Strategy; Christine Walton, Associate Director, Rx Marketing Generics;
- w. **Lannett:** Arthur Bedrosian, President and Chief Executive Officer; Tracy DiValero, National Account Manager; Dwight Nix, Director, National Accounts; Kevin Smith, Vice President, Sales & Marketing; Laura Carotenuto, National Accounts Representative; Justin McManus, Senior Director, Sales & Business Development;
- x. **Lupin:** David Bailey, Director, Trade Relations; Dave Berthold, SVP, Generics; Bill Chase, Director, Market Access Specialty Products; Jason Gensburger, Director, Financial Services; Vinita Gupta, CEO (Lupin Ltd.); Nilesh Gupta, Group President & Executive Director; Robert Hoffman, EVP, US Generics; Steve Randazzo, SVP; David Shirkey, National Account Manager; Edith St. Hilaire, Director of Marketing, Generics Division; Lauren Walten, National Account Manager;

- y. **Mallinckrodt:** Steve Becker, Director of National Account; Jennifer Block, Product Manager; Victor Borelli, SVP Sales & Marketing; Lisa Cardetti, National Account Manager; Ginger Collier, Sr. Director, Marketing; Ryan Dunelew, Director, Contracting; Walt Kaczmarek, COO; Stuart Kim, Sr. Regulatory Counsel; Marc Montgomery, Director of Marketing; Bonnie New, National Account Manager; Pete Romer, National Account Manager; Betty Jean Swartz, VP Managed Markets & Reimbursement; Kevin Vorderstrasse, Director Strategic Marketing; Jane Williams, VP Sales;
- z. **Mylan:** Robert Potter, Head of Global Sales Excellence; Joseph Duda, Director, Pricing and Contracts; Matt Erick, President, Mylan North America & Brazil; Mike Aigner, Director, National Accounts; John Barannick, Director, Trade Relations; Matt Cestra, Senior Director, Marketing; Rosalind Davis, Senior Manager, Contracts; Edgar Escoto, Director, National Accounts; Kevin McElfresh, Executive Director, National Accounts; Rob O’Neal, Head of Global Commercial Excellence & Incentive Comp; Sean Reilly, National Account Manager; Gary Tighe, Director National Accounts; Lance Wyatt, Director, National Accounts;
- aa. **Par:** Michael Altamuro, Commercial Operations & Marketing; Renee Kenney, Senior Advisor, Generic Sales; Michael Burton, Vice President, National Accounts; Rick Guillory, Vice President, National Accounts; Jon Holden, Vice President, Sales; Karen O’Connor, Vice President, National Accounts; Sandra Bayer, Sr. Director, National Accounts (Qualitest); James Burnett, National Accounts Manager (Qualitest); Lori Minnihan, Associate Director, Trade Pricing Operations (Qualitest); Charles Propst, Vice President (Qualitest); Warren Pefley, VP, Sales & Marketing (Qualitest); Kelly Bachmeier, Director, National Accounts (Qualitest); Walter Busbee, Director of National Accounts (Qualitest); Spike Pannell, National Account Manager (Qualitest);
- bb. **Perrigo:** John Wesolowski, Executive Vice President, President Rx; H. James Booydegraaff, Associate Director, Marketing; Andrea Felix, National Account Executive; Ori Gutwerg, National Account Executive; Katie McCormack, National Account Manager; Tony Polman, National Account Manager; Shelly Snyder, National Account Manager;
- cc. **Pfizer:** Lou Dallago, VP, US Trade Group; Manley Fong, Director, Trade Account Management; Schnell Hart, Director, Trade Account Management; Farinaz Hashernifard, Director, Strategy, Planning and Operations; Thomas McPhillips, VP, US Trade Group; Neil Potter, Director, Team Leader, Trade Channel Marketing; Walter Sljepceovich, Sr. Director, Pharmacy Development; Wesley Tanner, Director, Trade Account Management; John Walsh, Director, Trade Group; Gilbert White, Director, Trade Account Management;
- dd. **Rising:** Beth Castillo, National Accounts Manager; Ron Gold, CEO; Patricia MacBride, National Accounts Manager, Managed Markets; Kee Moore, VP Sales; Brian Shapiro, VP Business Development;

- ee. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; John Kline, National Account Director; Rick Peterman, Director, Marketing; Joseph Ruhmel, Vice President, Sales & Marketing; Steven Simone, Product Manager; Steve Snyder, National Account Director;
- ff. **Sandoz:** Armando Kellum, Vice President, Sales & Marketing; Steven Greenstein, Director, Key Customers; Della Lubke, Director, National Accounts; Chris Neurohr, Director, National Accounts;
- gg. **Sun:** Wayne Fallis, Director, National Accounts; Thomas Versosky, President; Susan Knoblauch, Senior Manager, Sales; Grace Shen, VP, Marketing; Steven Smith, Sr. Director of Sales;
- hh. **Taro:** Jim Josway, Vice President, Rx Sales; Bill Seiden, Senior Vice President, U.S. Sales & Marketing; Scott Brick, Manager, National Accounts; Sheila Curran, Vice President, Sales Operations; Howard Marcus, VP Sales & Marketing; Doug Statler, Sr. Director/Head of Sales;
- ii. **Teva:** Theresa Coward, Senior Director Sales & Trade Relations; Maureen Cavanaugh, Chief Operating Officer, North America Generics; Darren Alkins, Vice President, Pricing & Contracts; Timothy Crew, SVP North American Generics; John Denman, VP Sales & Marketing; Christine Baeder; SVP Customer and Marketing Operations; Christopher Doerr, Vice President, Trade Relations; Kevin Galownia, Senior Director, Pricing; Scott Goldy, Director, National Accounts; Kevin Green, Associate Vice President, National Accounts; Jennifer Guzman, Director, Marketing, Health Systems; Teri Mouro Sherman, Director, National Accounts; Jessica Peters, Director, Trade Operations; Dave Rekenenthaler, VP Sales;
- jj. **Torrent:** Jim Devers, VP Sales; Kelly Gegenheimer, VP Sales;
- kk. **Upsher-Smith:** Chris Evenstad, Director, Ventures Marketing; Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP, Commercial Portfolio Products; Glenn MacEachem, Director – Product Marketing; Mike McBride, VP Partner Relations; Michael Muzetras, Sr. National Account Manager; Chad Olson, Director, Generic Products; Beth Pannier, Sr. National Account Manager; Mary Rotunno, National Account Manager; Carol Weeklund, Associate Director, Marketing Operations; Dave Zitnak, National Accounts Sr. Director – Trade; Doug Zitnak, National Accounts Sr. Director – Trade;
- ll. **URL:** William Everett, National Trade Account Manager; Mark Greene, Director, National Accounts; Gregory Hayer, SVP, BD and Market Access; Mary Anne McCoy, Sr. Sales Customer Service Manager;
- mm. **West-Ward:** Jason Grenfell-Gardner, Senior Vice President, Sales & Marketing; Luis Velez, Senior Director of Sales; Mark Ritchey, Vice President, Sales; Paul Markowitz, Director, National Accounts; Tareq Darwazeh, National Account Senior Manager; Spiro Gavaris, Vice President, Sales and Marketing; Brittany

Cummins, Territory Sales Representative; Brian Hoffmann, VP Business Development;

- nn. **Wockhardt:** Karen Andrus, Director of Sales; Michael Craney, President of Sales & Marketing; Sunil Khera, President – The Americas, Japan & Emerging Markets; Kevin Knarr, VP Sales & Marketing; Scott Koenig, VP Sales & Marketing Generics; Bob Watson, VP National Accounts; and
- oo. **Zydus:** Joseph Renner, Chair of the Board; Kristy Ronco, Vice President, Sales; Jack Bleau, Director of Trade; Michael Keenley, President; Patricia Kwilos, VP of Marketing; Ganesh Nayak, Chief Operating Officer & Executive Director; Sharvil Patel, Managing Director; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President Sales and Marketing.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2012 Annual Board & Membership Meeting (September 30, 2012)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2013 Regional Chain Conference – (February 3-5, 2013):

- a. **Actavis:** Michael Baker, Executive Vice President, Trade and Sales Department, Paul Reed, Senior Director, Trade Sales and Development;
- b. **Pfizer:** Lou Dallago, VP US Trade Group; Walter Slijepceovich, Sr. Director, Pharmacy Development;
- c. **Teva:** Theresa Coward, Senior Director Sales and Trade Relations;
- d. **Upsher-Smith:** Michael Muzetras, Sr. National Account Manager; Beth Pannier, Sr. National Account Manager, Mary Rotunno, National Account Manager;
- e. **URL:** William Everett, National Trade Account Manager; Mark Greene, National Trade Account Manager.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

GPhA Annual Meeting – Orlando, Florida (February 20-22, 2013):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ECRM Retail Pharmacy Generic Pharmaceuticals Conference – Sheraton Dallas Hotel in Dallas, Texas (February 24-27, 2013):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2013 Annual Meeting – Sands Expo Convention Center, Palm Beach, Florida (April 20-23, 2013):

- a. **Actavis:** Andrew Boyer, President and CEO, North America Generics; Sigurdur Olafsson, President, Global Generics Medicines; Robert Stewart, Chief Operating Officer; Michael Baker, Executive Vice President, Trade and Sales Department; Vivek Bachhawat, Vice President, Pacific; Paul Bisaro, Board Member; Jean-Guy Goulet, Regional President, Canada Generics; Michael Reed, Executive Director, Trade Relations; Paul Reed, Senior Director, Trade Sales and Development; John Shane, Director, Trade Relations; Allan Slavsky, Sales Consultant;
- b. **Amneal:** Jim Luce, EVP, Sales & Marketing; Chirag Patel, Co-CEO & Chairman; Chintu Patel, CEO & Co-Chair; Stephen Rutledge, VP Sales;
- c. **Apotex:** Corey Anquetil, Director Strategic Sales, North America; Buddy Bertucci, Vice President, Institutional Sales; Sam Boulton, Director, National Accounts; Lyndon Johnson, Senior Vice President, Sales and Marketing; Jeff Watson, President Global Generics; Beth Hamilton, Vice President, Marketing and Portfolio Strategy, Sales and Marketing; David Kohler, Vice President and General Manager; Eric Organ, Vice President, Commercial Operations;
- d. **Ascend:** Schuyler Van Winkle, SVP, National Accounts; Greg Watkins, VP, National Accounts;
- e. **Aurobindo:** Robert Cunard, CEO; James Grauso, Executive Vice President, North America Commercial Operations;
- f. **Camber:** Brett Barczak, Director, Corporate Accounts; Kon Ostaficiuk, President;
- g. **Dr. Reddy's:** John Adams, Senior Vice President, Sales and Marketing; Jeff Burd, Vice President, Sales and Marketing; Gary Benedict, Executive Vice President;
- h. **Endo:** John Bullock, Channel Liaison, Specialty Pharmacy; Brent Bumpas, National Account Director-Trade; Scott Littlefield, Trade Director;
- i. **G&W Laboratories:** Erika Baylor, Vice President, Sales & Marketing; Aaron Greenblatt, Chief Executive Officer; Kurt Orlofski, President & Chief Operating Officer;

- j. **Glenmark:** Jim Brown, Vice President, Sales; Mitchell Blashinsky, Vice President, Sales and Marketing; Paul Dutra, Executive Vice President;
- k. **Greenstone:** James Cannon, GM; Greg Williams, Director, National Accounts;
- l. **Jubilant Cadista:** Scott Delaney, Chief Commercial Officer; Mark Dudick, VP National Accounts; Travis Roberts, VP, Marketing & Corporate Strategy;
- m. **Lupin:** Dave Berthold, SVP, Generics; Vinita Gupta, CEO (Lupin Ltd.); Robert Hoffman, EVP, US Generics; Paul McGarty, President;
- n. **Mallinckrodt:** Ginger Collier, Sr. Director, Marketing; Walt Kaczmarek, COO; Jane Williams, VP Sales;
- o. **Mylan:** Joseph Duda, President; Robert Potter, Senior Vice President, National Accounts and Channel Development, Senior Vice President of National Accounts and Channel Development; Anthony Mauro, Chief Commercial Officer; James Nesta, Vice President of Sales; Jeffrey May, Vice President, North America Product Strategy;
- p. **Par:** Jon Holden, Vice President of Sales; Paul Campanelli, President; Michael Altamuro, Vice President Marketing and Business Analytics; Renee Kenney, Senior Advisor, Generic Sales; Scott Littlefield, Trade Director (Endo); Brent Bumpas, National Account Director, Trade (Endo);
- q. **Perrigo:** Scott Jamison, Executive Vice President and General Manager; Christopher Kapral, Senior Vice President, Consumer Healthcare Sales; Joseph Papa, Chairman and CEO; Jim Tomshack, Senior Vice President, Sales; Mark Walin, Vice President, Consumer Healthcare Sales; John Wesolowski, Acting General Manager; Philip Willis, Innovation and Marketing Strategy;
- r. **Pfizer:** Lou Dallago, VP US Trade Group; Farinaz Hashemifard, Director, Strategy, Planning and Operations; David Moules, VP, US Payer & Channel Customers; Walter Slijepceovich, Sr. Director, Pharmacy Development;
- s. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; Michael Plessinger, Director of Marketing;
- t. **Sandoz:** Don DeGolyer, CEO; Jeff George, Global Head of Sandoz; Richard Tremonte, Senior Vice President, Global Generic Pharmaceuticals; Samuele Butera, Vice President and Head, Biopharmaceuticals; Dave Picard, Vice President, Biosimilars and Injectables;
- u. **Sun:** GP Singh Sachdeva, President (Sun Pharmaceuticals, USA); Bill Everett, National Trade Account Manager;
- v. **Taro:** Jim Kedrowski, Interim CEO; Ara Aprahamian, Vice President Sales and Marketing; Michael Perfetto, Chief Commercial Officer, Generics Rx OTC, US

and Canada; Carlton Holmes, Vice President Marketing; Elizabeth Ivey, Vice President, Sales and Marketing;

- w. **Teva:** Jeremy Levin, President and CEO; Theresa Coward, Senior Director of Sales; David Rekenhaller, Vice President, Sales; Maureen Cavanaugh, Senior Vice President and Chief Operating Officer, North America Generics; Allan Oberman, President and CEO Teva Americas Generics; Jonathan Kafer, Executive Vice President, Sales and Marketing; Barry Fishman, President and CEO, Teva Canada; Jeffrey Herzfeld, Senior Vice President US Specialty Medicines; David Marshall, Vice President of Operations; Michael Sine, Director, Corporate Account Group;
- x. **Upsher-Smith:** Mark Evenstad, CEO; Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP, Commercial Portfolio Management; Mike McBride, VP, Partner Relations;
- y. **URL:** William Everett, National Trade Manager;
- z. **Valeant:** Thomas Allison, Senior Director of National Accounts; Eddie Andruss, Assoc. Director of National Accounts; Sultana Kazanas, National Account Manager;
- aa. **Wockhardt:** Michael Craney, President of Sales & Marketing; and
- bb. **Zyodus:** Michael Keenley, President; Joseph Renner, President and CEO; Kristy Ronco, Vice President, Sales; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President Sales and Marketing.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2013 Business and Leadership Conference – Orlando, Florida (June 2-5, 2013):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2013 Total Store Expo – Sands Expo Convention Center, Las Vegas, Nevada (August 10-13, 2013):

- a. **Actavis:** Michael Baker, Executive Vice President, Trade and Sales Department; Andrew Boyer, President and CEO, North America Generics; Napoleon Clark, Vice President of Marketing; Michael Dorsey, Director of National Accounts; Marc Falkin, Vice President of Purchasing; Anthony Giannone, National Accounts Director; Megan Gorman, Senior Marketing Manager; Maureen Meehan, Director of National Accounts; Cindy Stevens, Director of National Accounts; Nancy Baran, Director, Customer Relations; Kathleen Conlon, Director, Contract Administration; Lisa Fiveash, National Account Representative; Rob Hooper, Senior Marketing Manager; Richard Rogerson, Senior Director, New Products; Allan Slavsky, Sales Consultant; Michael Reed, Executive Director, Trade Relations; Paul Reed, Senior Director, Trade Sales and Development; John Shane, Director, Trade Relations; Michael Dorsey, Director, National Accounts;
- b. **Akorn:** Scott Chapman, SVP and GM; Laura O'Connor, Manager, OTC Projects & Implementation; Georgiana Olwell, Global Brand Manager; Mick McCanna; John Sabat, SVP of National Accounts; M. Tranter, National Accounts Manager, Sales & Marketing;

- c. **Alvogen:** Michael Franks, Regional VP, Sales; Todd Graverson, Regional VP, Sales; Jeffrey Rumler, EVP, Sales & Marketing;
- d. **Amneal:** Andy Cline, Account Executive; David Hardin, National Account Manager; Liz Koprowski, National Account Manager; Jim Luce, EVP, Sales & Marketing; Brown Massey, Director Sales; June Parker, National Accounts Manager; Chirag Patel, Co-CEO & Chair; Chintu Patel, CEO & Co-Chair; Shannon Rivera, VP Pricing & Analytics; Stephen Rutledge, VP Sales; Kammi Wilson, Marketing Manager;
- e. **Apotex:** Tom Axner, National Sales Director, Distribution; Tim Berry, National Account Manager; Gwen Copeland, Manager, National Accounts; John Crawford, National Account Director; Sam Boulton, Director, National Accounts; Jeffrey Hampton, Senior Vice President and National Manager, US and Latin America; Niki Hinman Smock, National Account Manager; David Kohler, Vice President and General Manager; Chirag Patel, Marketing Director, National Accounts; Shannon Price, Senior Marketing Director; Bob Simmons, National Accounts Director; Debbie Veira, National Accounts Manager; Pat Walden, Senior Marketing Manager; Corey Anquetil, Director, Strategic Sales National Accounts; Beth Hamilton, Vice President, Marketing and Portfolio Strategy, Sales and Marketing; Tina Kaus, National Accounts Director; James Van Lieshout, Senior Director, Commercial Operations; Pat Walden, Senior Marketing Manager;
- f. **Ascend:** Grant Butler, Sr. Executive VP National Sales; Troy Devens, Director of National Accounts; John Dillaway, EVP, Sales & Marketing; Amit Ghar, President, International Business; Sujit Sakpal, VP Corporate Development; Schuyler Van Winkle, SVP, National Accounts; Greg Watkins, VP, National Accounts;
- g. **Aurobindo:** Stuart Blake, Director, National Accounts; Robert Cunard, CEO; Patrick Santangelo, Senior Director, Sales; Anthony Thomassey, Director National Accounts;
- h. **Bausch + Lomb:** Tanya Buchan, Director of Sales, National Accounts; Dean Cowen, National Account Director; Joseph Gordon, GM, Consumer Health Care; Todd LaRue, VP Sales, US; Barbara Purcell, VP US Generic Sales & Marketing; Elva Ramsaran, National Account Director; Steve Sacheli, Director, National Accounts; Suzan Trevor, National Account Manager; Robert Vukic, Regional Business Director, East;
- i. **Breckenridge:** Scott Cohon, Director of Sales; Sonia De La Rosa, Director, Business Development; Phil Goldstein, National Accounts Sales Director; Benjamin Hall, CEO; Larry Lapila, President; Joan Lyle, Director, National Accounts; Jim McManimie, SVP Sales; Diane Nazar, Director Sales Administration; Dave Nielsen, Director, Sales; Martin Schatz, SVP Sales; Mark Smith, Business Development;

- j. **Camber:** Brett Barczak, Director, Corporate Accounts; Megan Becker, Marketing Manager; Chris D'India, National Account Manager; Stu Messinger, Director of National Accounts; Kon Ostaficiuk, President; Dan Piergies, Director, Sales Operations; Laura Ricardo, Director of Corporate Accounts; Clayton Smith, Account Manager;
- k. **Citron:** Vimal Kavuru, CEO;
- l. **Dr. Reddy's:** Chris Costa, Vice President of Sales; Victor Borelli, Vice President and Head, National Accounts, North America Generics; Jinping McCormick, Vice President Rx Marketing, US Generics; Nimish Muzumdar, Director of Marketing; Larry Knupp, Director of National Accounts; Gary Benedict, Executive Vice President; Umang Vohra, Executive Vice President and Head of North America Generics;
- m. **Endo:** Brent Bumpas, National Account Director Trade; Scott Littlefield, Trade Director; Kevin O'Brien, Sr. Director of Payer Markets;
- n. **Epic:** Thomas Scono, VP of Contracts; Angelo Voxakis;
- o. **G&W Laboratories:** Erika Baylor, Vice President, Sales & Marketing; Lauren Connolly, National Account Manager; Aaron Greenblatt, Chief Executive Officer; Kurt Orlofski, President & Chief Operating Officer; Michelle Sisco, Sales Analyst;
- p. **Glenmark:** Jim Brown, Vice President, Sales; Mitchell Blashinsky, Vice President, Sales and Marketing; Paul Dutra, Executive Vice President; Jessica Cangemi, Director, Sales and Marketing; Jeff Johnson, Director, Sales and Marketing; David Irwin, Director, Sales; Stephanie Picca, Manager, Sales and Marketing; Terry Coughlin, Executive Vice President and Chief Operating Officer;
- q. **Greenstone:** James Cannon, GM; Lori LaMattina, Sales Operations Manager; Jill Nailor, Sr. Director Sales and National Accounts; Thomas Nassif, Sr. Manager, Marketing & Strategy; Robin Strzeminski, National Account Director; Kevin Valade, National Account Director; Christine Versichele, Director of U.S. Generic Channel Strategies; Christopher Weller, Sr. Manager, Marketing & Strategy; Greg Williams, Director, National Accounts;
- r. **Heritage:** Allen Duneheew, President and CEO; Matt Edelson, Senior Director of Sales; Jeffrey Glazer, CEO; Jason Malek, Senior Vice President; Neal O'Mara, National Accounts Manager; Anne Sather, National Account Manager; Gina Gramuglia, Commercial Operations;
- s. **Hi Tech:** Ed Bernos, VP Sales & Marketing; Michael Corley, VP, National Accounts; Stephanie Jomisko, Director, Contracts & Finance; Thomas Kronovich, VP, National Accounts; David Seltzer, Director;
- t. **Impax:** William Ball, Sr. National Account Manager (Global); Danny Darnell, Sr. National Account Manager (Global); Todd Engle, VP, Sales & Marketing (Global);

Michael Grigsby, Sr. National Account Manager (Global); Gary Skalski, Sr. Director of Sales (Global); Chris Gerber, Director of Pricing and Contracts; Italo Pennella, Trade Account Manager; Dan Rozmiarek, Trade Account Manager;

- u. **Jubilant Cadista:** Toby Bane, Manager, National Accounts; Scott Delaney, Chief Commercial Officer; Mark Dudick, VP National Accounts; Jaclyn Emershaw, Customer Support Associate; Mark Greene, Director National Accounts; Neal Miller, Manager, National Accounts; Travis Roberts, VP Marketing & Corporate Strategy; Christine Walton, Associate Director, Rx Marketing Generics;
- v. **Lannett:** Arthur Bedrosian, President and CEO; William Schreck, Chief Operating Officer; Justin McManus, Director, National Accounts; Kevin Smith, Vice President, Sales and Marketing; Tracy Sullivan, National Accounts Manager; Lauren Carotenuto, National Accounts Representative; Michael Block, Business Development Manager;
- w. **Lupin:** Dave Berthold, SVP, Generics; Kevin Brochhausen, Customer Service Supervisor; Bill chase, Director, Market Access Specialty Products; Jason Gensburger, Director, Financial Services; Robert Hoffman, EVP, US Generics; Paul McGarty, President; Rakhee Naik, Director – Supply Chain & Logistics; Steve Randazzo, SVP; David Shirkey, National Account Manager; Lauren Walten, National Account Manager;
- x. **Mallinckrodt:** Steve Becker, Director of National Account; Lisa Cardetti, National Account Manager; Ginger Collier, Sr. Director, Marketing; Joe Duarte, Director, Access Marketing; Walt Kaczmarek, COO; Kian Kazemi, VP Sales; Marc Montgomery, Director of Marketing; Bonnie New, National Account Manager; Pete Romer, National Account Manager; Kevin Vorderstrasse, Director Strategic Marketing; Jane Williams, VP Sales;
- y. **Mylan:** James Nesta, Vice President of Sales; Michael Aigner, Director, National Accounts; Joseph Duda, President; Kevin McElfresh, Executive Director, National Accounts; Robert O’Neill, Vice President; Robert Potter, Senior Vice President, North America and Channel Development; Lance Wyatt, National Accounts Director; Matt Cestra, Senior Director Marketing; Rodney Emerson, Director, Pricing and Contracts; Edgar Escoto, National Accounts Director; Stephen Krinke, National Accounts Manager; Damon Pullman, West Regional Account Manager; Sean Reilly, Key Account Manager; John Baranick, Director, Trade Relations; Ron Graybill, Vice President Managed Markets; Adrienne Helmick, Associate Product Manager, Marketing; Chad Holland, Vice President, Commercial Operations; Heather Paton, Vice President Sales; Bipan Singh, Director, Marketing; Tom Theiss, Director, Trade Relations; Christine Waller, Senior Manager, North America Communications;
- z. **Par:** Jon Holden, Vice President of Sales; Michael Altamuro, Vice President Marketing and Business Analytics; Renee Kenney, Senior Advisor, Generic Sales, Senior Advisor Generic Sales; Karen O’Connor, Vice President, National

Accounts; Rick Guillory, Vice President of National Accounts; Gerald Burton, Vice President of National Accounts; Christine Caronna, Director National Accounts; Warren Pefley, Vice President, Sales and Marketing (Qualitest); Charles “Trey” Probst, Vice President (Qualitest); Kelly Bachmeier, Director, National Accounts (Qualitest); Sandra Bayer, Senior Director, National Accounts (Qualitest); James Burnett, National Accounts Manager (Qualitest); Walter Busbee, Director National Accounts (Qualitest); Lori Minnihan, Associate Director, Trade Pricing Operations (Qualitest); Spike Pannell, National Account Manager (Qualitest); Darren Hall, Director, National Accounts (Qualitest);

- aa. **Perrigo:** Christopher Kapral, Senior Vice President, Consumer Healthcare Sales; Christian Strong, Senior Vice President, Diabetes Care; Mark Walin, Vice President, Consumer Healthcare Sales; John Wesolowski, Acting General Manager; Philip Willis, Innovation and Marketing Strategy; Tom Cotter, Vice President, OTC Marketing; Andrea Felix, National Account Executive; Kara Goodnature, Marketing Manager; Ori Gutwarg, National Account Executive; Pete Haakenstad, National Account Manager; Larry Hudson, Animal Health; H. James Booydegraaff, Associate Director, Marketing; Andy Kjeelberg, Vice President, Consumer Healthcare Sales; John Klingemeyer, Vice President, Consumer Healthcare Sales; Shelley Kocur, Senior Director, Service and Customer Supply Chains; Elizabeth Lowney, Strategic and Pipeline Plan Manager; Katie McCormack, National Account Manager; Richard McWilliams, Senior Vice President and General Manager; Kristine Milbocker, Trade Relations Planner; Troy Pelak, Vice President, Consumer Healthcare Sales; Tony Polman, National Account Executive; Neal Wilmore, Vice President Commercial Operations, Animal Health; Michael Yacullo, Vice President, Consumer Healthcare Sales; Tom Zimmerman, Vice President and General Manager;
- bb. **Pfizer:** Lou Dallago, VP, US Trade Group; Manley Fong, Director, Trade Account Management; Schnell Hart, Director, Trade Account Management; Farinaz Hashernifard, Director, Strategy, Planning and Operations; Neil Potter, Director, Team Leader, Trade Channel Marketing; Walter Sljepceovich, Sr. Director, Pharmacy Development; John Walsh, Director, Trade Group; Gilbert White, Director, Trade Account Management;
- cc. **Rising:** Beth Castillo, National Accounts Manager; Patricia MacBride, National Accounts Manager, Managed Markets; Brian Shapiro, VP Business Development;
- dd. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; John Kline, National Account Director; Rick Peterman, Director, Marketing; seph Ruhmel, Vice President, Sales & Marketing; Steve Snyder, National Account Director;
- ee. **Sandoz:** Peter Goldschmidt, President Sandoz US and Head North America; Armando Kellum, Vice President, Sales and Marketing; Paul Krauthauser, Senior Vice President, Sales and Marketing; Della Lubke, National Account Executive;

Steven Greenstein, Director, Key Customers; Christopher Bihari, Director, Key Customers; Anuj Hasija, Executive Director, Key Customers;

- ff. **Sun:** William Everett, National Trade Account Manager; Wayne Fallis, Director, National Accounts; Steven Goodman, Director Marketing, Generics; Susan Knoblauch, Senior Manager, Sales; GP Singh Sachdeva, President (Sun Pharmaceuticals, USA); Grace Shen, Vice President, Marketing; Steven Smith, Senior Director of Sales;
- gg. **Taro:** Ara Aprahamian, Vice President, Sales and Marketing; Sheila Curran, Vice President, Sales Operations; Howard Marcus, Vice President Sales and Marketing; Michael Perfetto, Group Vice President and Chief Commercial Officer of the Generic Rx Business; Doug Statler, Senior Director, Head of Sales; Elizabeth Guerrero, Director, Corporate Accounts, Managed Care; Carlton Holmes, Vice President Marketing; Tim Kiernan, Director of Marketing Analytics;
- hh. **Teva:** Theresa Coward, Senior Director of Sales; David Rekenhaller, Vice President, Sales; Maureen Cavanaugh, Senior Vice President and Chief Operating Officer North America Generics; Kevin Galowina, Head of Marketing Operations; Jessica Peters, Manager of Corporate Accounts; Allan Oberman, President and CEO Teva Americas Generics; Jennifer Chang, Director, Marketing; Scott Goldy, Director, National Accounts; Christine Baeder, Senior Vice President, Customer and Marketing Operations; Christopher Doerr, Senior Director, Trade Operations; Kevin Green, Associate Vice President, National Accounts; Jeffrey Herzfeld, Senior Vice President, US Specialty Medicines; Jonathan Kafer, Executive Vice President, Sales and Marketing; Kayla Kelnhofer, National Account Executive; Jennifer King, Director, New Product Marketing; David Marshall, Vice President of Operations; Jerry Moore, Director, State Government Affairs; Teri Sherman, Director National Accounts; Jason Nagel, Associate Director; John Wodarczyk, Director, Customer Relations;
- ii. **Torrent:** Jim Devers, VP Sales; Kelly Gegenheimer, VP Sales; Sanjay Gupta, President & CEO; Chip McCorkle, Director, National Accounts;
- jj. **Upsher-Smith:** Tina Fehr, Associate Director, Consumer Products; JoAnn Gaio, Sr. National Account Manager; Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP, Commercial Portfolio Products; Mike McBride, VP Partner Relations; Michael Muzetras, Sr. National Account Manager; Chad Olson, Director, Generic Products; Beth Pannier, Sr. National Account Manager; Mary Rotunno, National Account Manager; Marilyn Swanson, Product Manager; Carol Weeklund, Associate Director, Marketing Operations; Dave Zitnak, National Accounts Sr. Director – Trade; Doug Zitnak, National Accounts Sr. Director – Trade;
- kk. **Valeant:** Thomas Allison, Senior Director of National Accounts; Eddie Andruss, Assoc. Director of National Accounts; Tricia Green, Senior Brand Manager; Jona

Mancuso, Brand Manager; John Reed, Director, Marketing; Sultana Kazanas, National Account Manager;

- ll. **West-Ward:** Spiro Gavaris, Vice President of Sales and Marketing; Sam Goodman, Marketing Manager; Tareq Darwazeh, National Accounts Senior Manager; Paul Markowitz, Director, National Accounts; Ernesto Cividanes, Manager, Trade Relations;
- mm. **Wockhardt:** Kevin Andrus, Director of Sales; Sivakumar Chinniah, VP Operations; Michael Craney, President of Sales & Marketing; Sunil Khera, President – The Americas, Japan, & Emerging Markets; Kevin Knarr, VP Sales & Marketing; Scott Koenig, VP Sales & Marketing, Generics; Vinima Shekhar, AVP-OTC; Bob Watson, VP, National Accounts; and
- nn. **Zydus:** Michael Keenley, President; Joseph Renner, President and CEO; Kristy Ronco, Vice President, Sales; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President Sales and Marketing; Elizabeth Purcell, Senior Director, Marketing and Portfolio Management; Ganesh Nyak, Chief Operating Officer and Executive Director; Daniel Lukasiewicz, Senior Manager, Marketing Operations; Sharvil Patel, Deputy Managing Director.

GPhA Board of Directors Meeting: - Washington, D.C. (September 23, 2013)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2013 Annual Board and Membership Meeting – White Sulphur Springs, West Virginia
(September 29 – October 2, 2013):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2013 Foundation and Reception Dinner – New York, New York (December 3, 2013):

- a. **Actavis:** Andrew Boyer, President and CEO, North America Generics; Marc Falkin, Senior Vice President, Sales; Anthony Giannone, Executive Director, Sales; Paul Reed, Senior Director, Trade Sales and Development; Michael Reed, Executive Director, Trade Relations; John Shane, Director, Trade Relations;
- b. **Apotex:** Jeff Watson, President, Global Generics; Tim Berry, National Account Manager; Sam Boulton, Director of National Accounts; Jeffrey Hampton, Senior Vice President and General Manager, US and Latin America; Beth Hamilton, Vice President, Marketing and Portfolio Strategy, Sales and Marketing; James Van Lieshout, Senior Director, Commercial Operations;
- c. **Mylan:** Joseph Duda, President; Robert Potter, Senior Vice President North America National Accounts and Channel Development; Rob O’Neill, Head of Sales; Dave Workman, Vice President, Strategic Pricing and Contracts; James Nesta, Vice President of Sales;
- d. **Perrigo:** Christopher Kapral, Senior Vice President, Consumer Healthcare Sales;
- e. **Sandoz:** Peter Goldschmidt, President Sandoz US and Head North America; Armando Kellum, Vice President, Sales and Marketing; Kirko Kirkov, Executive Director, Key Customers; and
- f. **Teva:** Theresa Coward, Senior Director of Sales; David Rekenthaler, Vice President, Sales; Maureen Cavanaugh, Senior Vice President and Chief Operating Officer, North America Generics; David Marshall, Vice President of Operations.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

GPhA Annual Meeting – Orlando, Florida (February 19-21, 2014):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

ECRM Retail Pharmacy Efficient Program Planning Session – Omni Amelia Island Plantation Resort, Amelia Island, Florida (February 23-26, 2014):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Jeff McClard, Senior Director of National Accounts; Nick Gerebi, Director of National Accounts; William Zackesky, Director of Sales;

- c. **Wockhardt:** John Lopez, Associate Vice President;

HDMA Sixth Annual CEO Roundtable Fundraiser – New York, New York (April 1, 2014):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2014 Annual Meeting – Scottsdale, Arizona (April 26-29, 2014):

- a. **Actavis:** Andrew Boyer, President and CEO, North America Generics; Marc Falkin, Vice President of Purchasing; Sigurdur Olafsson, President; Paul Reed, Senior Director of Trade and Sales Development; Robert Stewart, Chief Operating Officer; Paul Bisaro, Board Member; Jean-Guy Goulet, Regional President, Canada Generics; Michael Reed, Executive Director, Trade Relations; John Shane, Director, Trade Relations;
- b. **Amneal:** Jim Luce, EVP, Sales & Marketing; Chirag Patel, Co-CEO & Chair; Shannon Rivero, VP, Pricing & Analytics; Stephen Rutledge, VP Sales;

- c. **Apotex:** Jeff Watson, President, Global Generics; Sam Boulton, Director of National Accounts; Jeremy Desai, President and CEO; Jeffrey Hampton, Senior Vice President and General Manager, US and Latin America; David Kohler, Vice President and General Manager; Corey Anquetil, Director, Strategic Sales North America; Buddy Bertucci, Vice President, Institutional Sales; Beth Hamilton, Vice President, Marketing and Portfolio Strategy, Sales and Marketing; James Van Lieshout, Sr. Director, Commercial Operations;
- d. **Ascend:** Schuyler Van Winkle, SVP, National Accounts; Greg Watkins, VP, National Accounts;
- e. **Aurobindo:** Robert Cunard, CEO; Paul McMahon, Senior Director Commercial Operations;
- f. **Breckenridge:** Brian Guy, VP Business Development; Larry Lapila, President; Martin Schatz, SVP Sales;
- g. **Camber:** Brett Barczak, Director, Corporate Accounts; Kon Ostaficiuk, President;
- h. **Citron:** Vimal Kavuru, CEO; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President, Sales and Marketing;
- i. **Corepharma:** Thomas Versosky, President; Christopher Worrell, CEO;
- j. **Dr. Reddy's:** Victor Borelli, Vice President and Head, National Accounts, North America Generics; Jinping McCormick, Vice President Rx Marketing, US Generics; Michael Allen, Vice President and Head, Rx Products, North America Generics;
- k. **Endo:** Brent Bumpas, National Account Director – Trade; Scott Littlefield, Trade Director;
- l. **G&W Laboratories:** Erika Baylor, Vice President, Sales & Marketing; Aaron Greenblatt, Chief Executive Officer; Kurt Orlofski, President & Chief Operating Officer;
- m. **Glenmark:** Jim Brown, Vice President of Sales; James Grauso, Executive Vice President, North America Sales;
- n. **Greenstone:** James Cannon, GM; Jill Nailor, Sr. Director Sales and National Account;
- o. **Heritage:** Jeffrey Glazer, CEO;
- p. **Jubilant Cadista:** Scott Delaney, Chief Commercial Officer; Mark Dudick, VP, National Accounts; Travis Roberts, VP, Marketing & Corporate Strategy;

- q. **Lupin:** Dave Berthold, SVP, Generics; Robert Hoffman, EVP, US Generics; Paul McGarty, President;
- r. **Mallinckrodt:** Ginger Collier, Sr. Director, Marketing; Walt Kaczmarek, COO; Kian Kazemi, VP Sales; Todd Killian, VP, Global Market Access; Jane Williams, VP Sales;
- s. **Mylan:** Joseph Duda, President; Anthony Mauro, Chief Commercial Officer; James Nesta, Vice President of Sales; Hal Korman, Executive Vice President and Chief Operating Officer; Robert Potter, Senior Vice President, North America and Channel Development; Rob O'Neill, Head of Sales; John Munson, Vice President Global Accounts Mylan;
- t. **Par:** Jon Holden, Vice President of Sales; Paul Campanelli, President; Renee Kenney, Senior Advisor, Generic Sales; Scott Littlefield, Trade Director (Endo); Brent Bumpas, National Account Director, Trade (Endo); Michael Altamuro, Vice President, Marketing and Business Analytics; Antonio Pera, Chief Commercial Officer;
- u. **Perrigo:** Scott Jamison, Executive Vice President and General Manager; Christopher Kapral, Senior Vice President, Consumer Healthcare Sales; Mark Walin, Vice President, Consumer Healthcare Sales; John Wesolowski, Acting General Manager; Andy Kjellberg, Vice President, Consumer Healthcare Sales; Jeff Needham, Executive Vice President and General Manager, Consumer Healthcare; Tony Polman, National Account Executive;
- v. **Pfizer:** Lou Dallago, VP US Trade Group; Paul Engel, Sr. Director/Team Leader; David Moules, VP, US Payer & Channel Customers; Walter Slijepceovich, Sr. Director, Pharmacy Development;
- w. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; Rick Peterman, Director, Marketing; Randy Wilson, General Manager;
- x. **Sandoz:** Peter Goldschmidt, President Sandoz, US and Head, North America; Steven Greenstein, Director, Key Customers; Anuj Hasija, Executive Director Key Customers; Armando Kellum, Vice President, Sales and Marketing; Kirko Kirkov, Executive Director, Key Customers; Scott Smith, Vice President Sales and Marketing; Dave Picard, Vice President, Biosimilars and Injectables;
- y. **Sun:** GP Singh Sachdeva, President (Sun Pharmaceuticals, USA); Steve Smith, Senior Director of Sales; Steven Goodman, Director Marketing, Generics;
- z. **Taro:** Ara Aprahamian, Vice President, Sales and Marketing; Michael Perfetto, Chief Commercial Officer Generic RX, OTC, US and Canada; Alex Likvornik, Senior Director, Strategic Pricing and Marketing; Michael Perfetto, Chief Commercial Officer for Generic RX, OTC; Elizabeth Ivey, Vice President, Sales and Marketing;

- aa. **Teva:** Maureen Cavanaugh, Senior Vice President and Chief Operating Officer, North America Generics; Allan Oberman, President and CEO Teva Americas Generics; Theresa Coward, Senior Director, National Sales; Christopher Doerr, Director, Trade Operations; David Rekenhaller, Vice President Sales, US Generics; Christine Baeder, Senior Director, Customer Operations; Jeffrey Herzfeld, Senior Vice President US Specialty Medicines; David Marshall, Vice President of Operations; Michael Reid, Vice President, Corporate and Retail Sales; Michael Sine, Director, Corporate Account Group;
- bb. **Upsher-Smith:** Mark Evenstad, CEO; Rusty Field, President; Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP Commercial Portfolio Management; Mike McBride, VP, Partner Relations;
- cc. **Valeant:** Thomas Allison, Senior Director of National Accounts; Eddie Andruss, Assoc. Director of National Accounts; Tricia Green, Senior Brand Manager; Jona Mancuso, Brand Manager; John Reed, Director, Marketing; Sultana Kazanas, National Account Manager; and
- dd. **Zydus:** Michael Keenley, President; Joseph Renner, President and CEO; Kristy Ronco, Vice President, Sales; Scott Goldy, Director, National Account; Kevin Green, Vice President, National Accounts.

MMCAP 2014 National Member Conference – Bloomington, Minnesota (May 12-15, 2014):

- a. **Actavis:** Mark Blitman, Executive Director of Sales for Government Markets;
- b. **Apotex:** Bob Simmons, National Account Director;
- c. **Amneal:** Andy Cline, Account Executive;
- d. **Ascend:** Troy Devens, Director, National Accounts;
- e. **Breckenridge:** Scott Cohon, National Director of Sales;
- f. **G&W:** Jovany Andrade;
- g. **Greenstone:** China Gonzalez,
- h. **Heritage:** Anne Sather, National Account Manager;
- i. **Lannett:** Tracy Sullivan, National Account Manager;
- j. **Mylan:** Janet Bell, Director, National Accounts;
- k. **Perrigo:** Pete Hakenstad, National Account Manager;
- l. **Teva:** Nick Gerebi, National Account Manager; and

m. **Upsher Smith:** Michelle Brassington, Sr. Regional Account Manager;

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2014 Business and Leadership Conference – JW Marriott Desert Ridge, Phoenix, Arizona (June 1-4, 2014):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2014 Total Store Expo – Boston Convention Center, Boston, Massachusetts (August 23-26, 2014):

- a. **Actavis:** Andrew Boyer, President and CEO, North America Generics; David Buchan, Executive Vice President Commercial, North America Generics and International; Napoleon Clark, Vice President of Marketing; Ashley Delponte, Manager, Trade Marketing, Sales and Marketing; Michael Dorsey, Director of National Accounts; Marc Falkin, Vice President of Purchasing; Megan Gorman, Senior Marketing Manager; Rob Hooper, Senior Marketing Manager; Randy Hurst, Senior Vice President and General Manager; Christina Koletto, Manager, Pricing Senior; Maureen Meehan; Director National Accounts; Paul Reed, Senior Director, Trade Sales and Development; Richard Rogerson, Senior Director New Products, Business Analytics and Systems; Violet Saakyan, Marketing Manager; Eric Schultz, Senior Marketing Manager; Cindy Stevens, Director of National Accounts; Nancy Baran, Director, Customer Relations; Kathleen Conlon, Director, Contract Administration; Mark Devlin, Senior Vice President, Managed Markets; Anthony Giannone, Executive Director, Sales; Christine Maiolo, Associate Director, Sales Operations; David Myers, Senior Manager, Products and Communications; Kaminie Persuad, Sales Coordinator; Michael Reed, Executive Director, Trade Relations; Allan Slavsky, Sales Consultant;
- b. **Akorn:** Ed Bernios, VP, Sales & Marketing (Hi-Tech Pharm); Michael Corley, VP National Accounts; Scott Grossenbach, Director of Financial Operations; Thomas Kronovich, VP National Accounts; Bruce Kutinsky, COO; Mick McCanna, Raj Rai, CEO; John Sabat, SVP National Accounts; M. Tranter, National Accounts Manager Sales & Marketing;
- c. **Alvogen:** Michael Franks, Regional VP, Sales; Todd Graverson, Regional VP, Sales; Ron Liu; Jeffrey Rumler, EVP, Sales & Marketing; David Thang;
- d. **Amneal:** Andy Cline, Account Executive; Ashton Elmore, Account Executive; David Hardin, National Account Manager; Liz Koprowski, National Account Manager; Allen Lowther, Director of Pricing; Jim Luce, EVP, Sales & Marketing; Brown Massey, Director Sales; June Parker National Accounts Manager; Chirag Patel, Co-CEO & Chair; Chintu Patel, CEO & Co-Chair; Shannon Rivera, VP Pricing & Analytics; Stephen Rutledge, VP Sales; Kammi Wilson, Marketing Manager;
- e. **Apotex:** Carlo Berardi, Sales; Tim Berry, National Account Manager; Gwen Copeland, National Accounts Manager; John Crawford, National Account Director; Sam Boulton, Director of National Accounts; Jeffrey Hampton, Senior Vice President and General Manager, US and Latin America; David Kohler, Vice President and General Manager; Doug Kinna, Sales; Chirag Patel, Marketing

Director, National Accounts; Debbie Veira, National Account Manager; Beth Hamilton, Vice President, Marketing and Portfolio Strategy, Sales and Marketing; Tina Kaus, National Account Director; James Van Lieshout, Senior Director, Commercial Operations; Christina De Lima, Marketing Analyst; Chirag Patel; Director, Marketing; Corey Anquetil; Director, Strategic Sales;

- f. **Ascend:** John Dillaway, EVP, Sales & Marketing; Amit Ghare, President, International Business; Jeffrey Katz, Medical Director; Venkatesh, Srinivasan, President & CEO; Schuyler Van Winkle, SVP, National Accounts;
- g. **Aurobindo:** Robert Cunard, CEO; Tim Gustafson, Director, National Accounts; Jon Kerr, Director, National Accounts; Paul McMahon, Senior Director, Commercial Operations; Ramprasad Reddy, Chairman Aurobindo Pharma Ltd;
- h. **Breckenridge:** Scott Cohon, Director of Sales; Sonia De La Rosa, Director, Business Development; Phil Goldstein, National Accounts Sales Director; Benjamin Hall, CEO; Larry Lapila, President; Joan Lyle, Director, National Accounts; Jim McManimie, SVP Sales; Diane Nazar, Director Sales Administration; Dave Nielsen, Director, Sales; Martin Schatz, SVP Sales;
- i. **Camber:** Briggs Arrington; Brett Barczak, Director, Corporate Accounts; Megan Becker, Marketing Manager; Kirk Hessels, Director of Marketing; Rich Matchett, Director Sales; Stu Messinger, Director National Accounts; Kon Ostaficiuk, President; Dan Piergies, Director Sales Operations; Amanda Rebnicky; Laura Ricardo, Director of Corporate Accounts; Pete Romer, Director of National Accounts; John Segura, VP Marketing & Operations; Clayton Smith, Account Manager; Robert Weinstein;
- j. **Citron:** Vimal Kavuru, CEO; Laura Short, Vice President, Sales; Karen Strelau, Executive Vice President, Sales and Marketing;
- k. **Dr. Reddy's:** Chris Costa, Vice President of Sales; Victor Borelli, Vice President and Head, National Accounts, North America Generics; Jinping McCormick, Vice President Rx Marketing, US Generics; Nimish Muzumdar, Director of Marketing; Larry Knupp, Director of National Accounts; Umang Vohra, Executive Vice President and Head of North America Generics; Jake Austin, Director National Accounts; Stephanie Jomisko, Director, Contracts and Finance;
- l. **Epic:** Nekela Bornell, Manager, Customer Service; Mike Lupo, VP Sales & Marketing; Ashok Nigalaye, Chair & CEO; Karen McSharry, Accounts Manager; Thomas Scono, VP Contracts;
- m. **G&W Laboratories:** Erika Baylor, Vice President, Sales & Marketing; Lauren Connolly, National Account Manager; Aaron Greenblatt, Chief Executive Officer; Kevin Knarr, Vice President, Sales & Marketing; Kurt Orlofski, President & Chief Operating Officer; Michelle Sisco, Sales Analyst;

- n. **Glenmark:** Jim Brown, Vice President, Sales; Jessica Cangemi, Director, Sales and Marketing; Jeff Johnson, Director, Sales and Marketing; David Irwin, Director, Sales; Robert Matsuk, President, North America; James Grauso, Executive Vice President, North America Commercial Operations; Matt Van Allen, Senior Director, Commercial Operations;
- o. **Greenstone:** James Cannon, GM; Christopher, Kutyla, Sr. Director, Business Alliance Team; Lori LaMattina, Sales Operations Manager; Jill Nailor, Sr. Director Sales and National Accounts; Thomas Nassif, Sr. Manager, Marketing & Strategy; Robin Strzeminski, National Account Director; Kevin Valade, National Account Director; Greg Williams, Director, National Accounts;
- p. **Heritage:** Heather Beem, National Accounts Manager, Institutional; Katie Brodowski, Associate Director Institutional Sales; Matt Edelson, Senior Director of Sales; Jeffrey Glazer, CEO; Jason Malek, Senior Vice President; Gina Gramuglia, Commercial Operations; Neal O'Mara, National Accounts Manager; Anne Sather, National Account Manager;
- q. **Impax:** William Ball, Sr. National Account Manager (Global); Danny Darnell, Sr. National Accounts Manager (Global); Todd Engle, VP, Sales & Marketing (Global); Michael Grigsby, Sr. National Account Manager (Global); Gary Skalski, Sr. Director of Sales (Global); Chris Gerber, Director of Pricing and Contracts; Italo Pennella, Trade Account Manager; Dan Rozmiarek, Trade Account Manager;
- r. **Jubilant Cadista:** John Boyd, Associate Product Manager; Scott Delaney Chief Commercial Officer; Mark Dudick, VP National Accounts; John Elliott; Associate Director, Marketing; Jaclyn Emershaw, Customer Support Associate; Kevin Fortier, Director, National Accounts; Neal Miller, Manager, National Accounts; Travis Roberts, VP Marketing & Corporate Strategy;
- s. **Lannett:** Justin McManus, Director, National Accounts; Kevin Smith, Vice President Sales and Marketing; Tracy Sullivan, National Accounts Manager;
- t. **Lupin:** Dave Berthold, SVP Generics; Kevin Brochhausen, Customer Service Supervisor; Bill Chase, Director, Market Access Specialty Products; Alicia Evolga, Director of Marketing; Jason Gensburger, Director, Financial Services; Robert Hoffman, EVP, US Generics; Dana Mariani, Associate Business Analyst; Paul McGarty, President; Lauren Walten, National Account Manager;
- u. **Mallinckrodt:** Lisa Cardetti, National Account Manager; Ginger Collier, Sr. Director, Marketing; Vanessa Harris, Sr. Director, Managed Markets and Trade; Walt Kaczmarek, COO; Kian Kazemi, VP Sales; Marc Montgomery, Director of Marketing; Bonnie New, National Account Manager; Trudy Nickelson, Dir. Key Accts, Generic Sales; Jane Williams, VP Sales;

- v. **Mayne:** Stefan Cross: President; Gloria Schmidt, Director of National Accounts; Chris Schneider, Executive Vice President, Generic Product Division; Melissa Gardner, National Account Executive;
- w. **Mylan:** Anthony Mauro, President; Kevin McElfresh, Executive Director, National Accounts; Joseph Duda, President; Robert Potter, Senior Vice President, National Accounts and Channel Development; Michael Aigner, Director, National Accounts; Gary Tighe, National Accounts Director; Lance Wyatt, National Accounts Director; Michael Scouvar, Head of Marketing North America; John Baranick, Director, Trade Relations; Rameshwan Bhavsar, Manager, Managed Markets; Edgar Escoto, Director, National Accounts; Dawna Johnson, Coordinator, Sales and Marketing; Sherry Korczynski, Vice President, Epipen Marketing; Stephen Krinke, National Account Manager; James Nesta, Vice President, Sales; Heather Paton, Vice President Sales; Sean Reilly, National Account Manager; Tom Theiss, Director, Trade Relations; Kathleen Theiss, Manager;
- x. **Par:** Jon Holden, Vice President of Sales; Rick Guillory, Vice President of National Accounts; Gerald Burton, Vice President, National Accounts; Christine Caronna, Director, National Accounts; Renee Kenney, Senior Advisor, Generic Sales; Lori Minnihan, Manager, Pricing and Analytics; Charles “Trey” Propst, Vice President, National Accounts; Michael Reiney, Vice President, Sales; Jeremy Tatum, Demand Manager; Antonio Pera, Chief Commercial Officer; Michael Altamuro, Vice President, Marketing and Business Analytics; Karen O’Connor, Vice President, National Accounts; Warren Pefley, Vice President, Sales and Marketing; Sandra Bayer, Senior Director, National Accounts (Qualitest); Kelly Bachmeier, Director, National Accounts (Qualitest); Spike Pannell, National Account Manager (Qualitest); Walter Busbee, Director of National Accounts (Qualitest); Darren Hall, Director, National Accounts (Qualitest); Brent Bumpas, National Account Director, Trade (Endo); Scott Littlefield, Trade Director (Endo); Kevin O’Brien, Senior Director Payer Markets (Endo);
- y. **Perrigo:** Christopher Kapral, Senior Vice President, Consumer Healthcare Sales; Mark Walin, Vice President, Consumer Healthcare Sales; John Wesolowski, Acting General Manager; Ori Gutwarg, National Account Executive; H. James Booydegraaff, Associate Director, Marketing; Andy Kjeelberg, Vice President, Consumer Healthcare Sales; John Klingenmeyer, Vice President, Consumer Healthcare Sales; Katie McCormack, National Account Manager; Richard McWilliams, Senior Vice President and General Manager; Kristine Milbocker, Trade Relations Planner; Troy Pelak, Vice President, Consumer Healthcare Sales; Tony Polman, National Account Executive; Michael Yacullo, Vice President, Consumer Healthcare Sales; Tom Zimmerman, Vice President and General Manager; Jon Baker, Vice President, Consumer Healthcare Sales; Monica Giraldo-Alzate, Assistant Category Manager; Kristine Norman, Account Executive;
- z. **Pfizer:** Robert Catanzanti, Sales Lead; Steve DiPietro, Customer Team Lead; Jennifer Foley, Sales Lead; Tom Kitzinger, VP, Sales – Key Accounts; George Leone, Sales Lead; Anthony Luciano, VP, Sales Strategy & Shopper; Lisa Paley,

Chief Customer Officer; Greg Pukas, Director Rx to OTC Switch; Amy Reibrich; Sales Lead; Richard Rezek, Sales Strategy Director; Sheila Rose, Sr. Director, Customer Care; Kristin Smith, Sr. Manager, Sales Comms & Trade Relations; Mark Stevens, Team Leader; Justin Weigold, Customer Team Manager; Robert Costa, Director; Lou Dallago, VP, US Trade Group; Hope Emerson, Director, Strategy & planning US Trade Group; Paul Engel, Sr. Director/Team Leader; Manley Fong, Director, Trade Account Management; Schnell Hart, Director, Trade Account Management; Farinaz Hashernifard, Director, Strategy, Planning and Operations; Neil Potter, Director, Team Leader, Trade Channel Marketing; Solimar Rivera, Trade Manager; Walter Sljepceovich, Sr. Director, Pharmacy Development; John Walsh, Director, Trade Group; Gilbert White, Director, Trade Account Management;

- aa. **Rising:** Scott Goerner, VP Sales; Paul Krauthauser, SVP Sales & Marketing; Patricia MacBride, National Accounts Manager, Managed Markets; Satish Srinivasan, President & COO; Kevin Walker, National Account Manager; Mike White, Director Sales;
- bb. **Roxane:** Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; John Kline, National Account Director; Rick Peterman, Director, Marketing; Michael Plessinger, Director of Marketing; Joseph Ruhmel, Vice President, Sales & Marketing; Steve Snyder, National Account Director;
- cc. **Sandoz:** Lisa Badura, Director, Key Customers; Christopher Bihari, Director, Key Customers; Steven Greenstein, Director, Key Customers; Anuj Hasija, Executive Director Key Customers; Armando Kellum, Vice President, Sales and Marketing; Della Lubke, National Account Executive; Scott Smith, Vice President Sales and Marketing; Arunesh Verma, Executive Director Marketing; Sean Walsh, Director, Key Customers; Kenneth Baker, Director, Managed Markets;
- dd. **Sun:** Susan Knoblauch, Senior Manager, Sales; Grace Shen, Vice President, Marketing; GP Singh Sachdeva, President (Sun Pharmaceuticals, USA); Donna Hughes, National Account Manager; Steven Smith, Senior Director of Sales; Steven Goodman, Director of Generics Marketing; Anand Shah, Director, Strategic Pricing and Marketing; Jolene McGalliard, National Account Manager; Wayne Fallis, Director, National Accounts;
- ee. **Taro:** Ara Aprahamian, Vice President, Sales and Marketing; Scott Brick, Manager, National Accounts; Kevin Kriel, Executive Director, Marketing and Business Development, US and Canada; Christopher Urbanski, Director, Corporate Accounts; Carol Augias, Director, Customer Service; Kirk Edelman, Director, Customer Logistics; Alex Likvornik, Senior Director, Strategic Pricing and Marketing; Michael Perfetto, Chief Commercial Officer Generic Rx OTC;
- ff. **Teva:** David Rekenhaller, Vice President, Sales; Maureen Cavanaugh, Senior Vice President and Chief Operating Office, North America Generics; Kevin Galowina, Head of Marketing Operations; Jessica Peters, Manager of Corporate Accounts;

Nisha Patel, Director of National Accounts; Jocelyn Baker, Director, National Accounts; Jennifer Chang, Director, Marketing; Theresa Coward, Senior Director Sales and Trade Relations; Dan Driscoll, Vice President Institutional Sales and Marketing; Cassie Dunrud, Associate Director, National Accounts; Kayla Kelnhofer, National Account Executive; Tim McFadden, Vice President, Marketing; Christine Baeder, Senior Vice President, Customer and Marketing Operations; Bryan Bart, Product Manager; Christopher Doerr, Senior Director, Trade Operations; Jason Grossman, Associate Director; Jennifer King, Director, New Product Marketing; Jason Nagel, Associate Director;

- gg. **Torrent:** Jim Devers, VP Sales; Kelly Gegenheimer, VP Sales; Lokesh Kalra, CFO; Chip McCorkle, Director, National Accounts; Noopur Shah, Product Manager;
- hh. **Upsher-Smith:** Jennifer Colvin, VP, Marketing; Chris Evenstad, Director, Ventures Marketing; Tina Fehr, Associate Director, Consumer Products; Rusty Field, President; JoAnn Gaio, Sr. National Account Manager; Emily Harris, Product Manager; Scott Hussey, SVP Sales; Kathy Leith, Associate Director, CNS Products; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP, Commercial Portfolio Products; Mike McBride, VP Partner Relations; Michael Muzetras, Sr. national Account Manager; Chad Olson, Director, Generic Products; Beth Pannier, Sr. National Account Manager; Mary Rotunno, National Account Manager; Carlton Swan, Sales; Marilyn Swanson, Product Manager; Sami Yusuf, Sr. Director, Corporate Development; Dave Zitnak, National Accounts Sr. Director – Trade; Doug Zitnak, National Accounts Sr. Director – Trade;
- ii. **Valeant:** Thomas Allison, Senior Director of National Accounts; Dean Cowen, National Account Director; Laizer Kornwasser, EVP & Company Group Chairman; Todd LaRue, Vice President of Sales, U.S.; Brian Phillips, Senior Director of Sales; Barbara Purcell, VP US Generics Sales & Marketing; Elva Ramsaran, National Account Director, John Reed, Director, Marketing, Cerave; Natalie Rush, Director, Trade Relations; Steve Saxheli, Director, National Accounts;
- jj. **West-Ward:** Spiro Gavaris, Vice President of Sales and Marketing; Sam Goodman, Marketing Manager; Joel Rosenstack, Senior Director, Marketing; Elizabeth Guerrero, Director, National Accounts; Paul Markowitz, Director, National Accounts; Doug Statler, Senior Director, Head of Sales; Tom Ross, Managed Care Account Manager; and
- kk. **Zydus:** Scott Goldy, Director, National Accounts; Kevin Green, Associate Vice President, National Accounts; Michael Keenley, President; Ganesh Nayak, Chief Operating Officer and Executive Director; Elizabeth Purcell, Senior Director, Marketing and Portfolio Management; Joseph Renner, President and Chief Executive Officer; Kristy Ronco, Vice President, Sales; Maria Bianco-Falcone, Senior Director Contracting.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2014 Annual Board and Membership Meeting – Montage, Laguna Beach, California
(September 27 – October 1, 2014):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2014 Foundation and Reception Dinner – New York, New York (December 3, 2014):

- a. **Actavis:** Andrew Boyer, Senior Vice President, Generic Sales, Marketing, National Accounts; Marc Falkin, Vice President, Marketing, Pricing and Contracts; Brent Saunders, President, CEO and Chairman; Mark Devlin, Senior Vice President, Managed Markets; Paul Reed, Senior Director, Trade Sales and Development; Michael Reed, Executive Director, Trade Relations;

- b. **Apotex:** James Van Lieshout, Vice President Sales and Senior Director, Commercial Operations; Tim Berry, National Account Manager; Sam Boulton, Director, National Accounts; James Van Lieshout, Vice President, Market Access; Beth Hamilton, Vice President, Marketing and Portfolio Strategy; Jeffrey Hampton, Senior Vice President and General Manager;

- c. **Mylan:** Anthony Mauro, Chief Commercial Officer; Robert Potter, Senior Vice President North America National Accounts and Channel Development; Edgar Escoto, Director, National Accounts; Michael Aigner, Director National Accounts;
- d. **Perrigo:** Christopher Kapral, Senior Vice President, Consumer Healthcare Sales;
- e. **Sandoz:** Armando Kellum, Vice President, Sales and Marketing; Scott Smith, Vice President, Sales and Marketing;
- f. **Valeant:** Todd LaRue; VP of Sales, US; and
- g. **Teva:** Theresa Coward, Senior Director of Sales; David Rekenthaler, Vice President, Sales; Maureen Cavanaugh, Senior Vice President and Chief Operating Officer North America Generics; Jessica Peters, Director National Accounts; Christine Baeder, Senior Director, Customer Operations.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

GPhA 2015 Annual Meeting – Miami, Florida (February 9-11, 2015):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HCSCA National Pharmacy Forum – Marriott Waterside Hotel and Marina, Tampa, Florida (February 16-18, 2015):

- d. **Actavis:** John Fallon, Executive Director of Sales;
- e. **Breckenridge:** David Giering, Manager, Marketing & Trade Relations;
- f. **Mallinckrodt:** Frank Cholaj, Sr. Director, Corporate Account Solutions; Taryn Church, Sr. Director, Corporate Account Solutions; Ben Erickson, National Director, Corporate Account Solutions;
- g. **Mylan:** Lee Rosencrance, District Manager; Martin Wingerter, Director of National Accounts; Janet Bell, Director of National Accounts; Mark Pittenger, Senior Director of National Accounts; Heather Paton, Vice President, Institutional Sales;
- h. **Teva:** Brad Bradford, Director of National Accounts; Jeff McClard, Senior Director of National Accounts; Nick Gerebi, Director of National Accounts, Cam Bivens, Director of National Accounts; and
- i. **West-Ward:** Neal Gervais, National Account Director; Joseph Schrick, Director, National Accounts; Anthony Massaro, Associate Product Manager; Mark Zampella, Director, National Accounts.

ECRM 2015 Retail Pharmacy Efficient Program Planning Session – Hilton Beach Golf Resort and Spa, Destin, Florida (February 22-25, 2015):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2015 Annual CEO Roundtable Fundraiser – New York, New York (April 14, 2015)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2015 Annual Meeting – The Breakers, Palm Beach, Florida (April 25-28, 2015):

- a. **Actavis:** Andrew Boyer, Senior Vice President, Generic Sales, Marketing, National Accounts; Marc Falkin, Vice President, Marketing, Pricing and Contracts; Robert Stewart, Chief Operating Officer; Paul Bisaro, Board Member; Jean-Guy Goulet, Regional President, Canada Generics; Michael Reed, Executive Director, Trade Relations; Daniel Motto, Senior Vice President, Global Business Development; Sanjiv Patel, Chief Vice President, Allergan Global Strategic Market; Brent Saunders, President and CEO; Mark Devlin, Senior Vice President, Managed Markets; William Meury, Executive Vice President Branded Pharmaceuticals; Paul Reed, Senior Director, Trade Sales and Development;

- b. **Akorn:** Bruce Kutinsky, COO; Raj Rai, CEO; Carla Trepelkin, Sr. Manager, Corporate Marketing & Marketing Services;
- c. **Apotex:** Corey Anquetil, Director Strategic Sales, North America; Sam Boulton, Director, National Accounts; Beth Hamilton, Vice President, Marketing and Portfolio Strategy, Sales and Marketing; David Kohler, Vice President and General Manager; Jeremy Desai, President and CEO; Jeffrey Hampton, Senior Vice President and General Manager; Peter Hardwick, Senior Vice President, Sales and Marketing; Steven Lydeamore, President, Global Specialty Pharma; Eric Organ, Vice President, Commercial Operations; James Van Lieshout, Vice President, Market Access; Jeff Watson, Global Generics;
- d. **Ascend:** John Dillaway, EVP, Sales & Marketing; Schuyler Van Winkle, SVP, National Accounts; Greg Watkins, VP National Accounts;
- e. **Breckenridge:** Brian Guy, VP Business Development; Larry Lapila, President; Martin Schatz, SVP Sales;
- f. **Camber:** Brett Barczak, Director, Corporate Accounts; Victor Mazzacone, VP Sales; Kon Ostaficiuk, President;
- g. **Citron:** Vimal Kavuru, CEO; Laura Short, VP Sales; Karen Strelau, EVP Sales & Marketing;
- h. **Dr. Reddy's:** Victor Borelli, Vice President and Head, National Accounts, North America Generics; Jinping McCormick, Vice President Rx Marketing, US Generics; Michael Allen, Vice President, Global Pharmaceutical Sourcing; Milan Kalawadia, Vice President, Head of US OTC Division;
- i. **Endo:** Brent Bumpas, National Account Director – Trade; Scott Littlefield, Trade Director;
- j. **G&W Laboratories:** Darren Atkins; VP Business Development & Alliance Management; Erika Baylor; Vice President, Sales & Marketing; Aaron Greenblatt; Chief Executive Officer; Kurt Orlofski; President & Chief Operating Officer;
- k. **Glenmark:** Jim Brown, Vice President, Sales; James Grauso, Executive Vice President;
- l. **Greenstone:** Jill Nailor, Sr. Director Sales & National Accounts; John Ocejo, Sr. Director, Customer Support Services;
- m. **Impax:** Doug Boothe, President Generics Division;
- n. **Mallinckrodt:** Walt Kaczmarek, COO; Kian Kazemi, VP Sales; Marc Montgomery, Director of Marketing;

- o. **Mylan:** Robert Potter, Senior Vice President, National Accounts and Channel Development; Rob O'Neill, Head of Sales; Anthony Mauro, Chief Commercial Officer; Robert Tighe, National Accounts Director; John Munson, Vice President Global Accounts; James Nesta, Vice President, Sales;
- p. **Par:** Michael Altamuro, Vice President Marketing and Business Analytics; Jon Holden, Vice President of Sales; Antonio Pera, Chief Commercial Officer;
- q. **Perrigo:** Scott Jamison, Executive Vice President and General Manager; Christopher Kapral, Senior Vice President, Consumer Healthcare Sales; Mark Walin, Vice President, Consumer Healthcare Sales; John Wesolowski, Acting General Manager; Andy Kjellberg, Vice President, Consumer Healthcare Sales; Jeff Needham, Executive Vice President and General Manager, Consumer Healthcare; Colter Van Stedum, Vice President Rx Strategic Business Alliances, Corporate Development; Michael Yacullo, Vice President, Consumer Healthcare Sales;
- r. **Pfizer:** Robert Catanzanti, Sales Lead; Stefano Curti, Global President, Marketing and R&D; Steve DiPietro, Customer Team Lead; Jennifer Foley, Sales Lead; Tom Kitzinger, VP, Sales – Key Accounts; Kevin Macero, Sales Lead; Lisa Paley, Chief Customer Officer; Greg Pukas, Director Rx to OTC Switch; Amy Reibrich; Sales Lead; Kristin Smith, Sr. Manager, Sales Comms & Trade Relations; Mark Stevens, Team Leader; Suneet Varma, President & GM; Patricia Walsh, Sr. Director, PCH NA BT; Lou Dallago, VP, US Trade Group; Paul Engel, Sr. Director/Team Leader; David Moules, VP US Payer & Channel Customers; Walter Sljepceovich, Sr. Director, Pharmacy Development;
- s. **Roxane:** Christopher Bonny, Executive Director, Commercial Business Development; Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; Rick Peterman, Director, Marketing; Randy Wilson, General Manager;
- t. **Sandoz:** Peter Goldschmidt, President Sandoz US and Head, North America; Armando Kellum, Vice President, Sales and Marketing; Scott Smith, Vice President, Sales and Marketing; Arunesh Verma, Executive Director, Marketing; Anuj Hasija, Executive Director, Key Accounts; Kirko Kirkov, Executive Director, Key Customers;
- u. **Sun:** Steven Smith, Senior Director of Sales; Anand Shah, Director, Strategic Pricing and Marketing; Dan Schober, Vice President, Trade Sales;
- v. **Taro:** Ara Aprahamian, Vice President, Sales and Marketing; Michael Perfetto, Chief Commercial Officer, Generics RX, OTC US and Canada;
- w. **Teva:** Christine Baeder, Senior Vice President, Customer and Marketing Operations; Maureen Cavanaugh, Senior Vice President and Chief Operating Office, North America Generics; Theresa Coward, Senior Director Sales and Trade

Relations; Christopher Doerr, Senior Director, Trade Operations; Jeffrey Herzfeld, Senior Vice President US Specialty Medicines; Michael Sine, Director, Corporate Account Group; Douglas Sommerville, Senior Vice President and General Manager, Teva Canada; Adam Levitt, Senior Vice President, Commercial Operations; Brenden O’Grady, President and CEO, North America; Michael Reid, Vice President, Corporate and Retail Sales;

- x. **Upsher-Smith:** Jennifer Colvin, VP Marketing; Mark Evenstad, CEO; Rusty Field, President; Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Jim Maahs, VP, Commercial Portfolio Management; Chad Martinson, CFO; Mike McBride, VP Partner Relations;
- y. **Valeant:** Thomas Allison; Senior Director of National Accounts; Dean Cowen; National Account Director; Laizer Kornwasser; EVP & Company Group Chairman; Todd LaRue; Vice President Of Sales, U.S.; Brian Phillips; Senior Director Of Sales; Barbara Purcell; VP US Generics Sales & Marketing;
- z. **West-Ward:** Spiro Gavaris, Vice President of Sales and Marketing; Doug Statler, Senior Director, Head of Sales; Joel Rosenstack, Senior Director, Marketing; and
- aa. **Zydus:** Scott Goldy, Director, National Accounts; Kevin Green, National Accounts Manager; Michael Keenley, President; Joseph Renner, President and CEO; Kristy Ronco, Vice President, Sales.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

HDMA 2015 Business and Leadership Conference – San Antonio, Texas (June 7-10, 2015):

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2015 Total Store Expo – Denver, Colorado (August 22-25, 2015):

- a. **Actavis:** Andrew Boyer, President and CEO, North America Generics; Napoleon Clark, Vice President of Marketing; Michael Dorsey, Director of National Accounts; Marc Falkin, Vice President of Purchasing; Megan Gorman, Senior Marketing Manager; Rob Hooper, Senior Marketing Manager; Randy Hurst, Senior Vice President and General Manager; Maureen Meehan; Director National Accounts; Richard Rogerson, Senior Director New Products, Business Analytics and Systems; Kathleen Conlon, Director, Contract Administration; Anthony Giannone, Executive Director, Sales; David Myers, Senior Manager, Products and Communications; Kaminie Persuad, Sales Coordinator; Allan Slavsky, Sales Consultant; Richard Rogerson, Senior Director New Products; Alexis Evolga, Manager, Pricing;
- b. **Akorn:** Scott Grossenbach, Director of Financial Operations; Jonathan Kafer; EVP, Sales & Marketing; Bruce Kutinsky, Chief Operating Officer; Mick McCanna, Executive Director of National Accounts; Brett Novak, SVP, Sales & Marketing; M. Tranter, National Accounts Manager, Sales & Marketing; Carla Trepelkin, Sr. Manager, Corporate Marketing and Marketing Services;
- c. **Alvogen:** Michael Franks, Regional VP, Sales; Todd Graverson, Regional VP, Sales; Jeffrey Rumler, EVP Sales & Marketing;

- d. **Amneal:** Andy Cline, Account Executive; Ashton Elmore, Account Executive; David Hardin, National Accounts Manager; Liz Koprowski, National Account Manager; Allen Lowther, Director of Pricing; Jim Luce, EVP, Sales & Marketing; Brown Massey, Director Sales; June Parker, National Accounts Manager; Chirag Patel, Co-CEO & Chair; Shannon Rivero, VP, Pricing & Analytics; Stephen Rutledge, VP Sales; Kammi Wilson, Marketing Manager;
- e. **Apotex:** Corey Anquetil, Director, Strategic Sales, North America; Michael Bohling, Director, Marketing; Gwen Copeland, Manager, National Accounts; John Crawford, National Account Director; Beth Hamilton, Vice President, Marketing; Jeffrey Hampton, Senior Vice President and General Manager; Tina Kaus, National Account Director; Ryan Kelly, Manager, National Accounts; Chirag Patel, Director, Marketing; Bob Simmons, National Account Director; Debbie Veira, National Account Manager; Pat Walden, Senior Marketing Manager; Jane Williams, National Account Director; Sam Boulton, Director, National Accounts; Erin Organ, Vice President, Commercial Operations; Olivia Smith, Marketing Communications Coordinator;
- f. **Ascend:** John Dillaway, EVP, Sales & Marketing; Jenny Fox, Director of National Accounts; Vankatesh Srinivasan, President & CEO; Schuyler Van Winkle, National Accounts; Kylan Ward, Director of National Accounts; Greg Watkins, VP, National Accounts;
- g. **Aurobindo:** Robert Cunard, CEO; Mitchell Goldberg, Director, Marketing; Tim Gustafson, Director, National Sales; Jon Kerr, Director, National Sales; Paul McMahon, Sr. Director, Commercial Operations; Crystal Mechler, Director, National Accounts; Ramprasad Reddy, Chair (Aurobindo Pharma Ltd.); Patrick Santangelo, Sr. Director, Sales Administration;
- h. **Breckenridge:** Scott Cohon, Director of Sales; Sonia De La Rosa, Director, Business Development; David Giering, Manager, Marketing & Trade Relations; Phil Goldstein, National Accounts Sales Director; Benjamin Hall, CEO; Larry Lapila, President; Joan Lyle, Director, National Accounts; Jim McManimie, SVP Sales; Diane Nazar, Director, Sales Administration; Dave Nielsen, Director, Sales; Martin Schatz, SVP Sales;
- i. **Camber:** Brett Barczak, Director, Corporate Accounts; Megan Becker, Marketing Manager; James Haselton, National Sales Associate; Kirk Hessels, Director of Marketing; Rich Matchett, Director, Sales; Victor Mazzacone, VP Sales; Stu Messinger, Director of National Accounts; Kon Ostaficiuk, President; Laura Ricardo, Director of Corporate Accounts; Pete Romer, Director of National Accounts; Clayton Smith, Account Manager; Edward Smith, Director, Sales Operations;
- j. **Citron:** Kaitlin Alexander, Corporate Account Specialist; Vimal Kavuru, CEO; Susan Knoblauch, Director National Accounts; Ravi Sachdev Baeringer, Advisor; Laura Short, VP Sales; Karen Strelau, EVP Sales & Marketing;

- k. **Dr. Reddy's:** Victor Borelli, Vice President and Head, National Accounts, North America Generics; Larry Knupp, Director of National Accounts; Jake Austin, Director National Accounts; Ashish Girota, Assoc. Director, Strategic Planning; Jeff Jorgenson, Director OTC National Accounts; Jinping McCormick, VP, RX Marketing, Generics, US; Cynthia Medalle, Sr. Director, Head Specialty Rx; Katherine Neely, Associate Director Rx Generics; James Park, Director, Rx Marketing; David Vitols, Director, National Accounts – OTC; Tricia Wetzels, Sr. Director, National Accounts, Rx Med-West;
- l. **Endo:** Brent Bumpas, National Account Director-Trade; Scott Littlefield, Trade Director;
- m. **Epic:** Nekela Bornell, Manager, Customer Service; Mike Lupo, VP, Sales & Marketing; Ashok Nigalaye, Chair & CEO; Thomas Scono, VP of Contracts;
- n. **G&W Laboratories:** Erika Baylor; Vice President, Sales & Marketing; Aaron Greenblatt; Chief Executive Officer; Kurt Orlofski; President & Chief Operating Officer; Michelle Sisco; Sales Analyst;
- o. **Glenmark:** Jim Brown, Vice President, Sales; Jessica Cangemi, Director, Sales and Marketing; Jeff Johnson, Director, Sales and Marketing; Robert Matsuk, President, North America; James Grauso, Executive Vice President, North America Commercial Operations; Sanjeev Krishan, Executive Vice President; Robert Matsuk, President, North America;
- p. **Greenstone:** James Cannon, General Manager; Cynthia Dever, Sr. Manager, Marketing & Strategy; Lori LaMattina, Sales Operations Manager; Jill Nailor, Sr. Director Sales and National Accounts; Robin Strzeminski, National Account Director; Kevin Valade, National Account Director; Greg Williams, Director, National Accounts;
- q. **Heritage:** Jeffrey Glazer, CEO; Jason Malek, Senior Vice President; Gina Gramuglia, Commercial Operations; Neal O'Mara, National Accounts Manager; Anne Sather, National Account Manager;
- r. **Impax (Global Pharm):** William Ball, Sr. National Account Manager; Danny Darnell, Sr. National Accounts Manager; Todd Engle, VP, Sales & Marketing; Michael Grigsby, Sr. National Account Manager; Italo Pennella, Trade Account Manager; Thomas Sammler, Head, Sales & Marketing;
- s. **Jubilant Cadista:** Mark Dudick, VP National Accounts; John Elliott, Associate Director, Marketing; Kevin Fortier, Director, National Accounts; Mark Greene, Director, National Accounts; Neal Miller, Manager, National Accounts; Travis Roberts, VP Marketing & Corporate Strategy; GP Singh Sachdeva, CEO Jubilant Pharma; Deborah Smith, Marketing Coordinator;

- t. **Lannett:** Kevin Smith, Vice President Sales and Marketing; Tracy Sullivan, National Accounts Manager; Michael Bogda, President; Breanna Stillman, Sales Analyst; Grace Wilks, Director, National Accounts;
- u. **Lupin:** Dave Berthold, SVP Generics; Kevin Brochhausen, Customer Service Supervisor; Bill Chase, Director, Market Access Specialty Products; Alicia Evolga, Director of Marketing; Jason Gensburger, Director, Financial Services; Robert Hoffman, EVP, US Generics; Esther Hwang, Sales & Marketing Coordinator; Paul McGarty, President; Kevin Walker, National Account Manager; Lauren Walten, National Account Manager;
- v. **Mallinckrodt:** Lisa Cardetti, National Account Manager; Michael Holmes, National Director, Corporate Account Solutions; Walt Kaczmarek, Chief Operating Officer; Kian Kazemi, VP Sales; Marc Montgomery, Director of Marketing; Bonnie New, National Account Manager; Trudy Nickelson, Dir. Key Accounts, Generic Sales; Roberg Own, VP Business Operations; Elva Ramsaran, National Account Director; Jane Williams, VP Sales;
- w. **Mayne:** Chris Schneider, Executive Vice President, Generic Product Division; Melissa Gardner, National Account Executive; Rodney Emerson, Director Pricing and Contracts; Gloria Schmid, Director of National Accounts;
- x. **Mylan:** Anthony Mauro, President; Kevin McElfresh, Executive Director, National Accounts; Robert Potter, Senior Vice President, National Accounts and Channel Development; Michael Aigner, Director, National Accounts; Gary Tighe, National Accounts Director; Michael Scouvar, Head of Marketing North America; Dawna Johnson, Coordinator, Sales and Marketing; James Nesta, Vice President, Sales; Heather Paton, Vice President Sales; Sean Reilly, National Account Manager; Joe Aigner, Director, National Accounts; Edgar Escoto, Director, National Accounts; Sean Foster, Vice President, North America Marketing; Becky Gamble, Vice President, Managed Markets; John Shane, Director, Trade Relations;
- y. **Par:** Jon Holden, Vice President of Sales; Rick Guillory, Vice President of National Accounts; Gerald Burton, Vice President, National Accounts; Christine Caronna, Director, National Accounts; Lori Minnihhan, Manager, Pricing and Analytics (Qualitest); Charles “Trey” Propst, Vice President, National Accounts (Qualitest); Michael Reiney, Vice President, Sales (Qualitest); Jeremy Tatum, Director Market Insights (Qualitest); Antonio Pera, Chief Commercial Officer; Michael Altamuro, Vice President, Marketing and Business Analytics; Karen O’Connor, Vice President, National Accounts; Warren Pefley, Vice President, Sales and Marketing (Qualitest); Sandra Bayer, Senior Director, National Accounts (Qualitest); Kelly Bachmeier, Director, National Accounts (Qualitest); Spike Pannell, National Account Manager (Qualitest); Walter Busbee, Director of National Accounts (Qualitest); Darren Hall, Director, National Accounts (Qualitest);
- z. **Perrigo:** Pete Haakenstad, National Account Manager; H. James Booydegraaff, Associate Director, Marketing; Katie McCormack, National Account Manager;

Tony Polman, National Account Executive; Andrea Felix, National Account Executive; Paul Hoeksema, Manager, Corporate Accounts; John Shane, Rx Promotional Analyst; John Wesolowski, Acting General Manager; Doug Boothe, President, Generic Division; Christopher Karpral, Senior Vice President, Consumer Healthcare Sales; Andy Kjellberg, Vice President Consumer Healthcare Sales; Mark Walin, Vice President Consumer Healthcare Sales; Michael Yacullo, Vice President Consumer Healthcare Sales;

- aa. **Pfizer:** Robert Costa, Director; Lou Dallago, VP US Trade Group; Hope Emerson, Director, Strategy & Planning US Trade Group; Paul Engel, Sr. Director/Team Leader; Manley Fong, Director, Trade Account Management; Schnell Hart, Director, Trade Account Management; Neil Potter, Director, Team Leader, Trade Channel marketing; Matt Schroeder, Sr. Manager, Trade Channel Manager; David Searle, Director, Pharmacy Development; Walter Slijepceovich, Sr. Director, Pharmacy Development; John Walsh, Director, Trade Group; Gilbert White, Director, Trade Account Management;
- bb. **Rising:** Steven Greenstein, VP Sales; Paul Krauthauser, SVP Sales & Marketing; Patricia MacBride, National Accounts Manager, Managed Markets; Connie Pak, Associate Director, Marketing; Satish Srinivasan, President & COO;
- cc. **Roxane:** Christopher Bonny, Executive Director, Commercial Business Development; Mark Boudreau, Executive Director, Sales; Paul Kersten, VP General Manager; John Kline, National Account Director; Chris Ludgis, Contract Operations Manager; Rick Peterman, Director, Marketing; Michael Plessinger, Director of Marketing; Joseph Ruhmel, Vice President, Sales & Marketing; Steve Snyder, National Account Director;
- dd. **Sandoz:** Christopher Bihari, Director, Key Customers; Anuj Hasija, Executive Director Key Customers; Scott Smith, Vice President Sales and Marketing; Arunesh Verma, Executive Director Marketing; Sean Walsh, Director, Key Customers; Kenneth Baker, Director, Managed Markets; Kirko Kirkov, Executive Director, Key Customers; Frank Davey, Director; Harmonie Franklin, Director, William Giannone, Associate Director, Key Customers; Jason Jones, Director, Key Customers; Bilal Khan, Director, Key Customers; Della Lubke, National Account Executive; Tom Parker, Marketing Director; Chad Schwinn, Director, Key Accounts; Andrew Wahba, Associate Director, Key Customers;
- ee. **Sun:** Steven Smith, Senior Director of Sales; Steven Goodman, Director of Generics Marketing; Anand Shah, Director, Strategic Pricing and Marketing; Jolene McGalliard, National Account Manager; Steven Goodman, Director Marketing; Blynda Masters; Director, Customer Service; Dan Schober, Vice President, Trade Sales; Michael Tulusso, Director, Sales;
- ff. **Taro:** Ara Aprahamian, Vice President, Sales and Marketing; Scott Brick, Manager, National Accounts; Christopher Urbanski, Director, Corporate Accounts; Carol Augias, Director, Customer Service; Kirk Edelman, Director, Customer

Logistics; Alex Likvornik, Senior Director, Strategic Pricing and Marketing; Michael Perfetto, Chief Commercial Officer Generic Rx OTC; John Francis, Vice President, Sales and Marketing; Stephen Jones, Director, Supply Chain; Lisa Pehlke, Director, Corporate Accounts; Richard Trevor, Corporate Accounts Director;

- gg. **Teva:** Maureen Cavanaugh, Senior Vice President and Chief Operating Office, North America Generics; Kevin Galowina, Head of Marketing Operations; Jessica Peters, Manager of Corporate Accounts; Nisha Patel, Director of National Accounts; Jocelyn Baker, Director, National Accounts; Theresa Coward, Senior Director Sales and Trade Relations; Cassie Dunrud, Associate Director, National Accounts; Christine Baeder, Senior Vice President, Customer and Marketing Operations; Bryan Bart, Product Manager; Christopher Doerr, Senior Director, Trade Operations; Jason Nagel, Associate Director; Michelle Osmian, Senior Director Customer Service; John Wodarczyk, Director, Customer Operations; Robert Neild, Associate Director, Customer Operations;
- hh. **Torrent:** Jim Devers, VP, Sales; Kelly Gegenheimer, VP, Sales; Sanjay Gupta, President & CEO; Chip McCorkle, Director, National Accounts; Samir Mehta; Noopur Shah;
- ii. **Upsher-Smith:** Donald Ammorosi, VP; Jennifer Colvin, VP, Marketing; Denise Dolan, Associate Director, Core Brands and Generic Products; Chris Evenstad, Director, Ventures Marketing; Tina Fehr, Associate Director, Consumer Products; Rusty Field, President; Rich Fisher, VP, Business Development; JoAnn Gaio, Sr. National Account Manager; Scott Hussey, SVP Sales; Brad Leonard, Sr. Director of National Accounts; Mike McBride, VP Partner Relations; Michael Muzetras, Sr. national Account Manager; Chad Olson, Director, Generic Products; Beth Pannier, Sr. National Account Manager; Sarah Shannon, Manager, Generic Portfolio; Marilyn Sanson, Product Manager; Sami Yusuf, Sr. Director, Corporate Development; Dave Zitnak, National Accounts Sr. Director – Trade; Doug Zitnak, National Accounts Sr. Director – Trade;
- jj. **Valeant:** Thomas Allison, Senior Director of National Accounts; Dean Cowen, National Account Director; Todd LaRue, Vice President Of Sales, U.S.; Michelle Nilsson, Associate Sales Director; Brian Phillips, Senior Director Of Sales; Barbara Purcell, VP US Generics Sales & Marketing; Natalie Rush, Director, Trade Relations; Steve Sacheli, Director, National Accounts; Brian Stolz, Senior VP, Generics;
- kk. **West-Ward:** Spiro Gavaris, Vice President of Sales and Marketing; Sam Goodman, Marketing Manager; Joel Rosenstack, Senior Director, Marketing; Elizabeth Guerrero, Director, National Accounts; Nicki Hanson, Director of Sales, National Accounts; Ernesto Cividanes, Manager, Trade Relations; and
- ll. **Zydus:** Scott Goldy, Director, National Accounts; Kevin Green, Associate Vice President, National Accounts; Michael Keenley, President; Ganesh Nayak, Chief

[REDACTED]

HDMA International Pharmaceutical Distribution Conference: (November 12-13, 2015)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NACDS 2015 Foundation Reception and Dinner – New York, New York (December 3, 2015):

- a. **Actavis:** Andrew Boyer, Senior Vice President, Generic Sales, Marketing, National Accounts; Marc Falkin, Vice President, Marketing, Pricing and Contracts; Anthony Giannone, Executive Director, Sales;
- b. **Amneal:** Chirag Patel, President and Co-Chair; Jim Luce, EVP Sales & Marketing;
- c. **Apotex:** James Van Lieshout, Vice President, Market Access; Beth Hamilton, Vice President, Marketing and Portfolio Strategy; Jeffrey Hampton, Senior Vice President and General Manager; Steve Giuli, Director, Government Affairs;
- d. **Dr. Reddy's:** Jinping McCormick, VP Sales & Marketing, Retail Rx Products, NA Generics; Victor Borelli, VP Sales, NA Generics; Milan Kalawadia, VP Head of US OTC Divisions; Alok Sonig, EVP and Head NA;
- e. **Mallinckrodt:** Walt Kaczmarek, President, Multi-Source Pharmaceuticals; Kian Kazemi, VP Sales;
- f. **Mylan:** Mike Aigner, National Account Director; Edgar Escoto, Director National Accounts; Angela Lanham, Manager Customer Relations; Tony Mauro, Chief Commercial Officer; Jim Nesta, VP National Accounts; Bob Potter, SVP Sales & Marketing; Bob Tighe, CFO; Christine Waller, Head of NA Communications;
- g. **Par:** Jon Holden, VP Sales; Tony Pera, Chief Commercial Officer;
- h. **Pfizer:** Rich Rezek, Sr. Director Sales Strategy; Lou Dallago;
- i. **Roxane:** Joseph Ruhmel, Vice President, Sales & Marketing;
- j. **Sandoz:** Greg Oakes, VP & Head, Biopharmaceuticals, NA; Scott Smith, Vice President, Sales and Marketing; Robert Spina, Vice President, Pricing and Contracts;
- k. **Teva:** Maureen Cavanaugh, Senior Vice President and Chief Operating Officer North America Generics; Allan Slavsky, Sales Consultant; Christine Baeder, Senior Director, Customer Operations; and
- l. **Valeant:** Thomas Allison, Senior Director of National Accounts; Todd LaRue, Vice President of Sales, U.S.

EXHIBIT F

EXHIBIT F

GENERIC PHARMACEUTICAL ASSOCIATION BOARD OF DIRECTORS 2010-2017¹									
Board Member²	Company	2010³	2011⁴	2012⁵	2013⁶	2014⁷	2015⁸	2016⁹	2017¹⁰
Barrett, Debra	Teva		x ^(b)	x ^(b)	x		x	x	
Barr, Siobhan	MDS Pharma Services	x							
Ben-Maimon, Carole	Impax			x ^(b)	x	x			
Bisaro, Paul	Watson	x ^(a)	x ^(a)	x ^(b)					
Boothe, Doug	Actavis (2012 and prior); Perrigo (2013 and after)	x	x ^(b)	x ^(b)	x	x	x		
Bresch, Heather	Mylan							x ^(a)	x
Brugger, Steve	Momenta Pharmaceuticals	x							
Caprariello, Chuck	Ranbaxy	x	x	x ^(b)	x	x	x		
Csontos, Andras	Gedeon Richter	x							
Cunard, Robert	Aurobindo							x	
Davis, Miles	Sovereign Laboratories	x							

¹ As of 2017, the Generic Pharmaceutical Association is called the Association for Accessible Medicines.

² An “(a)” denotes the Chair of the Board; a “(b)” denotes other Board Executive and/or Committee Member.

³ <https://www.gphaonline.org/gpha-media/press/gpha-announces-2010-2011-executive-committee> (identifying only Board Executive Committee members); https://www.gphaonline.org/media/cms/AnnualReport_10.pdf at p. 3.

⁴ <https://www.gphaonline.org/gpha-media/press/gpha-elects-2011-board-of-directors-new-executive-committee-at-annual-meeting-in-orlando>.

⁵ <https://www.gphaonline.org/gpha-media/press/gpha-announces-2012-board-of-directors>.

⁶ <https://www.gphaonline.org/gpha-media/press/gpha-announces-2013-board-of-directors>.

⁷ <https://www.gphaonline.org/gpha-media/press/gpha-announces-2014-board-of-directors>.

⁸ <https://www.gphaonline.org/gpha-media/press/gpha-announces-2015-board-of-directors>.

⁹ <https://www.gphaonline.org/gpha-media/press/gpha-welcomes-new-board-member-mike-roya-ceo-west-ward-pharmaceuticals>; <https://www.gphaonline.org/gpha-media/press/gpha-announces-2016-board-of-directors>.

¹⁰ <https://accessiblemeds.org/board-directors> (in February 2017, GPHA renamed itself the Association for Accessible Medicines).

GENERIC PHARMACEUTICAL ASSOCIATION BOARD OF DIRECTORS 2010-2017¹									
Board Member²	Company	2010³	2011⁴	2012⁵	2013⁶	2014⁷	2015⁸	2016⁹	2017¹⁰
DeGolyer, Don	Sandoz		x ^(b)	x ^(b)	x ^(b)				
Ducker, John	Fresenius-Kabi USA			x	x	x	x	x	x
Felicelli, Robert	Baxter Healthcare								x
Ferran, Rosendo	New Chemic	x ^(b)							
Glazer, Jeffrey	Heritage Pharmaceuticals	x		x	x	x	x		
Goldschmidt, Peter	Sandoz					x	x	x	
Graver, Lisa	Alvogen Inc.								x
Hanson, David	Interchem Corporation	x							
Kaemmerer, Peter	Sagent Pharmaceuticals								x
Kedrowski, Jim	Sun							x	
Klaum, David	Fougera		x ^(b)	x					
Krauthauser, Paul	Aurobindo								x
Lalwani, Nikhil	Cipla USA, Inc. (InvaGen)								x
LePore, Patrick	Par	x	x						
Liang, Bertrand	Pfenex Inc.							x	
Lynch, Carol	Sandoz								x
Macdonald, Marcy	Impax						x	x	
Maloney, Ed	Paddock Laboratories	x							
Manzano, Stephen	Sun								x
Marth, William	Teva	x ^(b)							

GENERIC PHARMACEUTICAL ASSOCIATION BOARD OF DIRECTORS 2010-2017¹									
Board Member²	Company	2010³	2011⁴	2012⁵	2013⁶	2014⁷	2015⁸	2016⁹	2017¹⁰
Matsuk, Robert	Glenmark								x
Mauro, Tony	Mylan	x^(b)	x^(b)	x^(a)	x^(a)	x			
Mayr, Charlie	Actavis				x				
McClintic Coates, Marcie	Mylan						x		
McGarty, Paul	Lupin					x	x	x	
McGarty, Paul	Nycomed	x^(b)							
Moore, Thomas	Hospira Inc.			x^(b)	x	x			
Mumtaz, Sofia	Lupin								x
Mundkur, Christine	Sandoz	x^(b)							
Murphy, Thomas	Ben Venue Labs	x	x						
O'Grady, Brendan	Teva								x
Oberman, Allan	Teva					x			
Patel, Chirag	Amneal Pharmaceuticals			x	x	x	x	x	
Pera, Tony	Par						x	x	
Perez, Silvia	3M Health Care								x
Price, Gerald	Accord Healthcare								x
Raya, Michael	West-Ward							x	
Reed, Julie	Hospira Inc.						x		
Renner, Joseph	Zydus Pharmaceuticals	x^(b)	x	x	x	x	x	x	x
Richards, Scott	Mayne								x

GENERIC PHARMACEUTICAL ASSOCIATION BOARD OF DIRECTORS 2010-2017¹									
Board Member²	Company	2010³	2011⁴	2012⁵	2013⁶	2014⁷	2015⁸	2016⁹	2017¹⁰
Seiden, Bill	Taro Pharmaceutical Industries	x							
Silberg, Tom	APP Pharmaceuticals	x	x						
Singh, Harsher	Luitpold Pharmaceuticals								x
Sonig, Alok	Dr. Reddy's							x	x
Spear, KL	Spear Pharmaceuticals	x							
Stafford, Ambrose	Stafford Pharma	x							
Stec, Richard	Perrigo							x	
Stevenson, George	Kremers-Urban Pharmaceuticals				x				
Stewart, Robert	Amneal								x
Ursino, Vincent	Vinchem, Inc.	x							
Watson, Jeff	Apotex			x	x	x	x	x ^(b)	x ^(a)
Wheeler, Craig	Momenta Pharmaceuticals		x ^(b)	x ^(b)	x ^(b)	x ^(a)	x ^(a)	x	x
Zorich, George	ZEDpharma, Inc.	x							

EXHIBIT G

EXHIBIT G

**SUMMARY OF ECONOMIC FACTORS INDICATING
COLLUSION IN THE GENERIC DRUG INDUSTRY**

- (1) **High Level of Industry Concentration** – A small number of competitor-manufacturers control a substantial market share for each of the Named Generic Drugs.
- (2) **Sufficient Numbers to Drive Competition** – While there are a small enough number of competitors to foster collusion, the number of manufacturers was large enough that – given decades of experience with competitive generic pricing, and accepted models of how generic manufacturers vigorously compete on price – one would have expected prices to remain at historical levels near manufacturers’ marginal cost levels or to decrease. Given the number of generic manufacturers here, both history and accepted economics teach that – absent collusion – prices would remain at competitive levels or continue to decline.
- (3) **High Inelasticity of Demand and Lack of Substitutes** – For the majority of patients that rely on them, these drugs are necessary and therefore must be purchased regardless of price hikes. While there are other drugs sold, there are significant barriers to changing treatments, and patients and physicians are likely to prioritize medical considerations over price. This makes demand highly inelastic.
- (4) **Absence of Material Non-Conspiring Competitors** – Defendant manufacturers have maintained a substantial market share for these drugs throughout the Class Period despite their supracompetitive pricing. Thus, these Defendants have market power in these markets, which enables them to increase prices or maintain artificially inflated prices without loss of market share or substantial revenue to non-conspirators.
- (5) **Opportunities for Contact and Communication Among Manufacturers** – As described above, Defendants participate in the committees and events of the GPhA, HDMA, MMCAP, NACDS, ECRM, and other industry groups, which provide and promote opportunities to communicate. The grand jury subpoenas to Defendants targeting inter-Defendant communications, further supports the existence of communication lines between competitors with respect to, among other things, generic pricing.

- (6) **Size of Price Increases** – The magnitude of the price increases involved in this case further differentiates them from parallel price increases. Companies seeking to test increases need to take measured approaches. But here the increases on some generic drugs are not 5% or even 10% jumps – but increases of far greater magnitude. A rational company would not implement such large increases unless certain that its ostensible competitors would follow.
- (7) **Reimbursement of Generic Drugs** – Non-collusive parallel price increases are inhibited for generic drugs. The reimbursement for generic drugs to retail pharmacies is limited by MAC pricing, which is based on the lowest acquisition cost for each generic drug paid by retail pharmacies purchasing from a wholesaler for each of a drug’s generic equivalent versions. As a result, there is an enhanced incentive to compete on price embedded in the generic reimbursement system.

EXHIBIT H

EXHIBIT H

SAMPLE OF DEFENDANTS' INVESTOR COMMUNICATIONS

I. ACTAVIS

1. During Actavis' October 29, 2013 earnings call, Actavis Director Sigurdur Olafsson stated: "But there's opportunities to take pricing increases, and that is what has changed since maybe five years ago when there wasn't an opportunity."

2. During Actavis' August 5, 2014 earnings call, Actavis EVP David Buchen stated: "We have a very broad portfolio and we take pricing opportunities where we can."

3. During Actavis' May 11, 2015 earnings call, Actavis CEO Brenton Sanders stated:

So let me tackle generic pricing. . . . We haven't seen much of a change despite all the fanfare and publicity around drug pricing in generics. There are obviously a few products that go up. But the model for generics is price decreases as more competitors come into the market. That's just the way the business works. . . . That being said, the environment has remained pretty stable and favorable. So we don't expect that to change short term either.

4. On August 6, 2015, Saunders stated on an earnings call that the generics business "is doing very well, and the units that comprise it are firing on all cylinders as we prepare for the combination with Teva."

5. Actavis reported rising revenues in its United States generics business during the Class Period.

II. AKORN

6. During Hi-Tech's March 7, 2013 earnings call, Hi-Tech Chairman and CEO David Seltzer stated:

So we happen to have -- number one, we happen to be doing a significant amount of topicals than -- compared to several years back. So we have the Clobetasol items that we pretty much brought all in-house on the manufacturing side. . . .

We definitely see opportunity. I mean, I think everybody knows and understands that there's been some significant price changes in that market over the last couple of years.

7. During Akorn's August 5, 2014 earnings call, Akorn CEO Raj Rai had the following exchange with an analyst:

Q (analyst): Raj, can you just go into a little bit more detail on the pricing increases on clobetasol. Are you seeing other opportunities across the portfolio, how much of an impact in terms of flow through from that increase are you going to see in the P&L and any pushback that you have heard around that, that would be helpful? Thank you.

A (Raj Rai, CEO): [T]his is sort of a new development and with the price increase came some additional contracts and we are in the process of implementing those contracts. So, I think the situation is still little bit fluid and we will have more to discuss in our next conference call when we have fully implemented these new contracts. But the opportunity as it stands is real and it's going to increase our sales substantially in the next quarter. I mean the process has already begun and as Tim mentioned that there are some costs associated with the price increases, so the third quarter would sort of be flat but I think we will start to see the benefit of the price increase and volumes coming through in the fourth quarter.

And the question on other products, yes I think there is a general, we are seeing lot of price increases that are happening in the generic space and it affect some of our products as well. So, I would say overall, there is a healthier pricing environment than it was there, I would say six to eight months ago.

8. On November 6, 2014, Akorn's CFO Timothy Dick stated:

I mean, we mentioned when we discussed Clobetasol in our Q2 conference call that historically for Hi-Tech, it would have been about \$10 million product and there was – annually. And there was obviously some questions earlier in the Q&A that we're talking about sales that \$100 million plus.

Dick also had this exchange with an analyst:

Q (analyst): And as far as, the next time a competitor takes up price, do you anticipate that you would match in a much faster timeframe because of this experience, or is every situation different?

A (Dick): I think every situation warrants a different strategy. So I think, yes, I mean, your assessment is correct. I mean, we did – we took the price increase they took for a reason.

9. During the same call, Rai stated:

I think prices are stable. And as I said even in my prepared remarks, I think the market dynamics are pretty favorable to generics. And we haven't really seen anything that causes a heartburn or it made a cause of concern as far as pricing is concerned. So I would say, it's a healthy environment.

10. On February 26, 2015, an analyst commented during an Akorn earnings call:

“[A]s we look at clobetasol contribution in '15, maybe it's around 20% to 30% of operating profit.”

11. In its 2015 annual report, Akorn reported: “Our gross profit increased by \$334.7 million, an increase of 128.0% over gross profit of \$261.4 million in 2014. Our overall gross profit margin was 60.5% in 2015 compared to 47.1% in 2014.” The company attributed its \$109.7 million increase in revenue on existing products as the direct result of the “price changes due to the competitive nature of our business and industry.”

12. During Akorn's August 4, 2016 earnings call, Akorn CFO Duane Portwood stated: “net revenue for the quarter ended June 30, 2016, was \$281 million, an increase of \$60 million or 27% over the prior-year quarter. The increase in revenue was driven by organic growth, with approximately two-thirds attributable to price.”

13. Hi-Tech reported rising revenues in its United States generics business during the Class Period.

III. BAUSCH

14. During an April 2015 conference call Bausch's (then known as Valeant) CEO was asked by an investor whether Valeant's growth was driven by price increases or volume.

Valeant's CEO stated that Valeant's growth was based more on volume than price increases.

However, internal emails following the conference call revealed that Valeant's CEO's statement was false and that price increases represented the overwhelming majority of Valeant's growth.¹

15. Valeant reported rising revenues in its United States during the Class Period.

IV. DR. REDDY'S

16. During Dr. Reddy's October 31, 2013 earnings call, Dr. Reddy's Vice Chairman Kallam Satish Reddy stated: "I'm pleased to announce the highest ever quarterly performance of Dr. Reddy's, backed by strong growth across the key geographies of the Global Generics segment . . . [t]he recent generic launch[] of [] divalproex ER . . . in the U.S. demonstrates our ability to build a sustainable limited competition portfolio . . . and has resulted in enhancement of our gross margin and operating margins as well."

V. GLENMARK

17. In Glenmark's FY 2013-14 Annual Report, it reported: "another year of strong growth fueled by good performances across our markets like the US[.]"

18. Glenmark reported rising revenues in its United States generics business during the Class Period.

VI. IMPAX

19. On November 4, 2013, the then-President of Impax, Carole Ben-Maimon, acknowledged in an earnings call that Impax had increased the price of Digoxin after Lannett had increased its price, after noting its medical necessity to patients. In response to a question concerning Impax's "huge price increase on digoxin following Lannett's pricing action," Ben-Maimon stated: "The price increase on dig[oxin] speaks for itself, but clearly, as a medically necessary drug, our focus there is really just to make sure that a high quality product is available

¹ Charley Grant, *Valeant's Sales Growth: Driven by Price Increases or Volume Growth*, THE WALL STREET JOURNAL (Feb. 2, 2016), available at <https://blogs.wsj.com/moneybeat/2016/02/02/valeants-sales-growth-driven-by-price-increases-or-volume-growth/>.

to the customer.” Ben-Maimon’s comments make clear that Impax had no intention of competing for market share for Digoxin by offering lower prices; it simply would ensure there was sufficient supply, at its newly increased pricing for its customers. During the same call, Impax’s CFO Bryan Reasons stated that Impax “did take some nice pricing moves” on generic products and Ben-Maimon stated that it was important generally to “recogniz[e] the potential for price.”

20. Ben-Maimon demonstrated Impax’s continued acceptance of Lannett’s invitation to increase prices and noted Impax’s commitment to maintaining price increases during a February 20, 2014 earnings call with analysts. Ben-Maimon stated regarding Digoxin, “the market has been pretty stable . . . [w]e’re pretty comfortable that what we have done is rational and will result in ongoing profitability for that product.” Ben-Maimon also stated:

Obviously, we can't really talk about, for competitive reasons, about specific products with specific prices. But as you've seen across the industry, pricing has improved and the ability to take some price increases has clearly been available. Obviously, we're really careful and we want to make sure that we do that in a very rational way so that we make sure that the price -- that what we're doing sticks and that we actually do make more money in the long run. But we're pretty confident that what we did through towards the end -- throughout the end of last year and the beginning of this year will result in more profitability from many other products that we have been able to take some price on.

21. On a May 2, 2014 Impax earnings call, Reasons noted that a “strong quarter in the generic division” was driven in part by “some pricing initiatives.”

22. On an August 6, 2014 Impax earnings call, Ben-Maimon again spoke about pricing:

Yes. So of course, we look at any opportunity to raise price when it's appropriate. I can't say that -- we didn't talk specifically about specific products here, but we look at our portfolio regularly, if not every single day and look for opportunities in the marketplace to take advantage of services or increased share or price.

23. Later during the same call, Ben-Maimon mentioned that: “So on pricing, obviously, we don’t comment on specific products or what’s going on in the market. There are opportunities and we continue to evaluate our portfolio and take advantage where we can.”

24. On a November 4, 2014 Impax earnings call, Impax’s CEO Frederick Wilkinson, continued to echo Lannett’s message on increasing prices:

[L]et me address pricing. We really don’t talk much about pricing publicly, and whether we’re going for competitive reasons but surprising to say we’ve done what most of the other generic competitors have done, we look at opportunities, we look at how competition shifts, we look at where there may be some market movement that will allow us to take advantages on price increases and we’ve implemented those and we’ll continue to evaluate our line product-by-product probably a week and monthly basis to see if there are some opportunities to participate in that practice.

Wilkinson also acknowledged the federal investigation of pricing in the pharmaceutical industry during that earnings call.

25. Impax reported rising revenues in its United States generics business during the Class Period.

VII. LANNETT

26. On February 7, 2013, Lannett’s CEO Arthur P. Bedrosian stated in an earnings call:

[C]ould just say that we’re very capable of raising prices and we tend to sometimes lead the market. We see opportunities to raise a price, we take it. We don’t sit back and wait for someone else to do it. So you might say we’re a little more aggressive in the pricing arena. I’d just rather not focus on which products they were, which could negatively impact us and send the wrong message to my competitors who might think they can get my customers away by lowering the price.

27. On September 10, 2013, Bedrosian stated in an earnings call:

We’re not a price follower. We tend to be a price leader on price increasing and the credit goes to my sales vice president. He takes an aggressive stance towards raising prices. He understands one of

his goals, his objectives as a sales vice president is to increase profit margins for the company. And he's the first step in that process. I can reduce costs and manufacturing efficiencies, but it has to be combined with sales increase, a profit increase, as I should say, by the salespeople. And he's done a good job there. With 1 or 2 exceptions, we've tended to lead in the way of price increases. We believe that these prices are important. We need to try raising them. Sometimes, it doesn't stick and we have to go back and reduce our price, and other times it does. I am finding a climate out there has changed dramatically and I see more price increases coming from our competing – competitors than I've seen in the past. And we're going to continue to lead. We have more price increases planned for this year within our budget. And hopefully, our competitors will follow suit. If they don't, that's their issue. But our plan is to raise prices on any product that we think we can or we haven't raised a price.

28. During the same call, Bedrosian stated:

We're seeing more responsibility on the part of all of our competitors, I believe, because all of us are facing the same costs. . . . So I would expect that all the companies are not going to behave like they have in the past. And I suspect you're going to see more price increases in the generic marketplace or certainly less price erosion in the marketplace because of that.

29. During the same call, Bedrosian was asked by analyst for a reaction to a competitor's recent and significant price increase on Levothyroxine. Bedrosian responded: "You mean after I sent them the thank you note?" He then went on to say:

I'm always grateful to see responsible generic drug companies realize that our cost of doing business is going up as well. . . . So whenever people start acting responsibly and raise prices as opposed to the typical spiral down of generic drug prices, I'm grateful. Because Lannett tends to be active in raising prices.

30. On November 7, 2013, Bedrosian stated during an earnings call:

I don't really see anything significant on the horizon that could cause us any pain, quite frankly. We're still conservatively run. We're still careful how we spend money. We still realize we're in a commodity business. While we're enjoying the success of the company, it's not getting to our heads in any way.

31. On the same call, Lannett's CFO Martin P. Galvan signaled that these were just the "earlier days of the increase," and Bedrosian explained "these price increases that are going on in the industry, I think they're going to stick for all the companies."

32. On February 6, 2014, both Bedrosian and Galvan confirmed that the price increases were driving growth at Lannett. Galvan further stated that "We do believe strongly that there's sustainability in some of the price increases."

33. On November 3, 2014, Bedrosian described one of Lannett's "rational" competitors as one that would not do "anything crazy" such as "just going out and trying to grab market share." He went on to state, just after all Defendants had implemented their first round of Baclofen price increases:

So from my perspective, what we're seeing here is an opportunity to raise prices because everybody has accepted the fact that our costs are going up dramatically and less concerned about grabbing market share. We're all interested in making a profit, not how many units we sell.

So it's really a combination to those things. So I don't think Levo and Digoxin are the only products that would sit here and tell you I could raise prices on, because I believe any of the products in our product line, including products that we may have just gotten approved have those same opportunities underlying them. We look at the market and sometimes we're the first ones to raise a price, sometimes we're not. But we look at everything in line as a potential product to have a price increased on.

34. On February 4, 2015, Bedrosian stated during an earnings call:

If you're saying that the price increases that we've had in place, are they sustainable, and are they maintaining? My answer would be yes, they continue to hold up.

As far as whether we talked about any increases for this year, we don't usually give a guidance for that. We predict what our revenues will be for the year. We're not seeing any declines, generally speaking on the price increase products. So they continue to, let's say, level off at their new pricing.

35. Bedrosian further stated during the same call:

So I'm expecting these pricings to really sustain themselves to continue. I see people raising prices further, because the generic prices were so low, when you're 10% of the brand, that's not because the brand overpriced the product by 90%. It's because the generic marketplace has so much competition sometimes, people get desperate just to unload their inventory that they cut the prices. We don't see that kind of behavior sustainable, and we don't see it going further into the future. I think you're going to find more capital pricing, more – I'll say less competition, in a sense. You won't have price wars. You are still going to have competition, because there's a lot of generic companies in the market. I just don't see the prices eroding like they did in the past.

36. On May 6, 2015, Galvan stated, in response to an analyst question, that recent “quarter-over-quarter strength” was driven by Baclofen.

37. A May 2015 presentation by Bedrosian and Lannett's CFO noted that one of Lannett's strengths was a “track record of selecting products with high profit potential and manageable competition.”²

38. On August 25, 2015, Bedrosian again signaled continuing price increases because they have been “sustainable” and because “it's a more rational market we're in.”

39. On August 23, 2016, Bedrosian summarized that price competition “usually doesn't get you to results you want. So, I think a lot of people have learned that lesson by now.”

40. He described a problem of “some of the dumber newer companies [that] continue to go down that path” of competing on price. Echoing the attitude of many price-fixers who seek to rationalize their misconduct, he equated “expertise” with raising prices, and contrasted it with “crazy behaviors” of companies who seek to gain market share by cutting prices. Bedrosian also said that these “occasional” competitors who attempted to compete on price were fortunately “maturing in the market in realizing they need to make profit as well.”

² Lannett PowerPoint Presentation, at 7 (May 2015).

41. Lannett reported rising revenues in its United States generics business during the Class Period.

VIII. LUPIN

42. On October 27, 2015, Lupin's Group President and CEO Vinita Gupta stated during an earnings call:

My sense that most of our competitors have similar challenges that they have that they have had a lot of competitive pressures, they have had a lot of margin pressures coming out of consolidation and because of the fact that companies have been lacking meaningful product approvals, I think the majority of the industry is looking forward to more approvals when I look at some of our peers in the industry, all of them talk about similar challenges. So one would think that our competitors or peers would be rationale [sic] and be strategic in the way they price products.

43. Lupin reported rising revenues in its United States generics business during the Class Period.

IX. MALLINCKRODT

44. During a November 7, 2013 earnings call, Mallinckrodt CEO Mark Trudeau advised, "I would see the Generics business in 2014 as being a real source of growth for the business. We mentioned both on the volume side but significant on the price side we think as well."

45. On February 6, 2014 earnings call, Mallinckrodt CEO Mark Trudeau reported, "[W]e have significant power in our generics portfolio...The strategic pricing actions that we took starting in 2013 are really starting to pay off for us...."

46. During a May 8, 2014 earnings call, when asked about the sustainability of price increases for generics, Mallinckrodt CEO Mark Trudeau explained, "With regards to our pricing, you can see the positive impact of our pricing actions. It's largely in our other controlled substance line or category in our report. And you can see that we've had significant growth in

that category. That reflects pricing actions that we took in late 2013 and early 2014. We're seeing the same type of impact, or we expect to see the same type of impact in the rest of our business going forward."

47. At the Deutsche Bank Health Care Conference on May 6, 2015, Mallinckrodt CEO Mark Trudeau was asked about price increases on generic drugs and he responded, "With regards to price increases, we don't specifically describe the magnitude of any individual price. What I would say is that we've enjoyed good pricing, particularly in our generics business."

48. Mallinckrodt's price increases were noted with approval by other industry players. During a presentation at the Leerink Swann Global Health Care Conference on February 13, 2014, Lannett CEO Art Bedrosian stated, "I'm grateful to Mallinckrodt for what they're doing with price increases. I'll be happy to put them on my Christmas card list."

49. Mallinckrodt reported rising revenues in its United States generics business during the Class Period.

X. MAYNE

50. In an August 28, 2015 FY15 Results Presentation, Mayne reported that U.S. "revenue uplift [was] driven by," among other products, Doxycycline.

51. In a September 9, 2015 Company Presentation, Mayne reported that it would be able to optimize Doxycycline sales through "[f]urther product pricing improvements."

XI. MYLAN

52. On October 25, 2012, Mylan's CEO Heather Bresch stated in an earnings call: "You've heard me quarter after quarter coming and saying we weren't going to chase the bottom, that there's been irrational behavior and that we would continue to hold steady and control what we can control."

53. On February 27, 2013, Mylan's CFO, John Sheehan, stated in an earnings call:

2013 will yet be another strong year for Mylan. In the U.S., we are anticipating a high volume of new product launches, and we expect to once again be agile enough to quickly seize new supply opportunities when they become available. In addition, favorable changes to the regulatory environment, including increased resources to expedite product reviews and greater oversight with respect to manufacturing, as well as an anticipated more stable pricing environment resulting in part from continued consolidation within the industry, are just two of the favorable macroeconomic factors that we see in 2013.

54. On May 2, 2013, Bresch stated in an earnings call: "From my perspective, we see the generic industry alive and well. We still see a lot of runway room here in the United States."

55. On May 1, 2014, Bresch stated in an earnings call: "We continue to see stability really across our entire generic line on pricing."

56. On August 7, 2014, Bresch stated in an earnings call:

As far as pricing, look, I think that, that stability in our North American – that core business is certainly why we're able to deliver the results we have today, which, like I said, despite those product delays, we see growth year-over-year. We've seen North America continue to maximize opportunities.

57. In or around 2014, a group of executives at Mylan voiced their concerns about price increases. It was reported in a June 4, 2017 *The New York Times* article that Mylan's senior executives, including Mylan's CEO Heather Bresch, brushed off these concerns. *The New York Times* also reported that in response to pricing concerns Mylan's Chairman Robert Croury:

[R]eplied that he was untroubled. He raised both his middle fingers and explained, using colorful language, that anyone criticizing Mylan, including its employees, out to go copulate with themselves. Critics in Congress and on Wall Street, he said, should do the same. And regulators at the Food and Drug Administration? They, too, deserved a round of anatomically challenging self-fulfillment.

58. On October 30, 2015, Sheehan stated in an earnings call:

With respect to gross margin, I guess I would start by pointing out that since 2010 our gross margins have increased from 45% up to the high end of the guidance range that we indicated we would be at this year of 55%. So the gross margins have been sustained. They have steadily increased over the last five, six years. . . . It also has been driven by the positive pricing environment that we've seen, especially over the last couple of years in North America.

59. During the same call, Bresch stated: "Look, I would say as far as price increases, we've had a very consistent approach. We have absolutely had opportunities around generic pricing."

60. On February 10, 2016, Bresch stated in an earnings call her belief that Mylan had been "a very responsible generic player with hundreds of products into the market and have shown very responsibly [sic] price erosion."

61. Mylan reported rising revenues in its United States generics business during the Class Period.

XII. PAR

62. On February 28, 2014, Endo's CFO Suketu Upadhyay stated in an earnings call that:

[O]ur US generic pharmaceuticals business remained a source of strong organic growth in 2014. We believe the base of Qualitest products will continue to experience low-double digit revenue growth. That growth is primarily driven by an increase in demand for products but it also is a result of selected pricing opportunities within the higher barrier to entry categories.

63. During Endo's May 1, 2014 earnings call, Endo CEO Rajiv De Silva stated that Endo's generics business (Par) was performing strongly in part because "we have been able to take advantage of some pricing opportunities."

64. On July 31, 2014, Endo's CEO Rajiv De Silva stated in an earnings call that in the generics business "there are certain specific situations and market opportunities which we take advantage of, as do our competitors."

65. On March 2, 2015, Silva stated in an earnings call that “pricing actions give us some gross margin benefit.”

66. In a May 18, 2015 presentation by Endo International plc concerning its acquisition of Par, Endo noted that “consolidation and maturation of competitors have stabilized the pricing environment” for generic pharmaceuticals in the U.S.

67. On August 8, 2016, Par’s President Paul Campanelli stated in response to a question about the generics environment: “And typically you want to just be very careful about trying to go after too much share. You just have got to take a balanced approach.”

68. Par reported rising revenues in its United States generics business during the Class Period.

XIII. PERRIGO

69. On October 31, 2013, Perrigo’s CFO Judy L. Brown stated that: “Pricing initiatives were well received this quarter.”

70. On May 7, 2014, Perrigo’s Chairman and CEO Joseph C. Papa stated that he “absolutely agree[d] that there are some opportunities for us in different business segments.”

71. On August 14, 2014, Perrigo’s Chairman and CEO Joseph C. Papa stated during an earnings call that: “I think there are some opportunities on pricing in the Rx category.”

72. Perrigo stated in its 2014 Annual Report that it intended to: “[B]roaden[] leadership in our core base business of extended topical products with limited competition and attractive margins.

73. On February 7, 2015, Papa stated during an earnings call that: “On the question of pricing . . . I will say the Rx side does have, as I sit here today, the greatest upside.” Papa also noted that Perrigo “achieved record results, growing sales 12% with an adjusted operating margin of 46%.”

74. Later during the same call, industry analyst Gregg Gilbert from Deutsche Bank commented that: “Obviously, the generic side of your business and many other companies has benefited from an enhanced pricing environment, if we could call it that, in the last several years.” In response, Papa affirmed the continued enhanced pricing trend: “The next year we’re going to look at Rx and raise those prices.”

75. In 2014 and 2015, Perrigo reported rising profits and record sales in its United States generics business due in part to “pricing initiatives.”

XIV. SANDOZ

76. On January 29, 2014, the Sandoz Division Head Jeffrey George stated:

So I think overall what I would say is that we’ve been quite pleased with the acquisition of Fougera. It is a business that has performed very well for us, with strong double-digit growth and very good margins given the limited competition nature of a lot of these markets.

77. On April 23, 2015, Novartis CEO Joe Jiminez stated that Sandoz “delivered strong financial results” and “the U.S. was up 13% . . . driven by . . . our Fougera dermatology business.”

78. On July 21, 2015, Jiminez stated during an earnings call: “Sandoz delivered very strong financial results with sales and profit up double-digit; as you can see this is driven by the division increased focus on core markets particularly the U.S., which is up 23%.”

79. Sandoz reported rising revenues in its United States generics business during the Class Period.

XV. SUN

80. On November 14, 2013, during an earnings call, Sun’s Managing Director Dilip Shanghvi sated in response to an analyst question concerning generic drug manufacturers’ “opportunities [to take] price hikes across portfolio that seems to becoming a little more

widespread sort of a thing” that “price increases [are] becoming kind of more widespread than what it used to be historically, so clearly there would be some impact going forward.”

81. During the same earnings call, another Sun executive stated that Sun has been “warning” about “sustaining the price [increases], but we have been proved wrong so far.”

82. On February 13, 2014, Sanghvi stated in an earnings call that Sun continued “to enjoy the benefits of favourable [sic] pricing for certain generic products in the US.” On the same call, an analyst also noted that Sun “had some good price increases in select products after [Sun’s] purchase of [the URL/Mutual] portfolio.”

83. In 2013, Sun’s subsidiary URL “had undertaken price hikes in March” and, as a result of these price increases, Sun estimated “\$60-80 million (of \$128 million in total revenue for URL estimated . . . for FY[20]14) to come from [Doxycycline] , with operating margins in the range of 50-55 percent.”³

84. In 2013 and 2014, Sun reported that its costs were stable. In its quarterly reports during that period, Sun’s directors reported that the company’s material cost and other expenditures as a percentage of net sales, as well as staff costs, were substantially the same or lower than the same periods in the prior year. For example, Sun reported that net sales increased 40% in fiscal year 2013 compared to 2012 even while “[m]aterial cost, as a percentage of the net sales is 18.5% which is lower as compared to the previous year.” Staff costs and other expenditures were also reported to be lower in 2013. Similarly, Sun reported that second quarter 2013-14 costs were also “in-line with Q2 last year.”

85. Sun reported rising revenues in its United States generics business during the Class Period.

³ Ujjval Jauhari, *Sun Pharma’s Prospects Remain Bright*, BUSINESS STANDARD (Sept. 12, 2013), available at http://www.business-standard.com/article/markets/sun-pharma-s-prospects-remain-bright-113091200894_1.html.

XVI. TARO

86. During a November 10, 2014, earnings call, Taro CEO Kal Sundaram attributed the company's significant growth to price increases:

Our sales and earnings growth is attributable to upward price adjustments and prudent life cycle management of our portfolio, while our overall volumes remain relatively constant.

...

In 2010, as per IMS data, Taro was ranked third among the genetic dermatology companies in USA. In terms of sales, now it is ranked number one for the past three years. U.S. remains the dominant market for Taro. Taro's earnings per share also has grown 50% CAGR, compounded annual growth, since 2010. Taro's sales and earnings growth is attributable to upward price adjustments and the prudent life cycle management of our product portfolio while our overall volumes remain relatively constant and we remain cautious about the long-term sustainability of these prices. Our sales and earnings growth is attributable to upward price adjustments and prudent life cycle management of our portfolio, while our overall volumes remain relatively constant.

...

Again market to volume fluctuations can happen for very different reasons as and when a new generation product comes, it will have impact on the older generation product. And once again I am saying generics remain to be sort of, what do you say cost value for money and competitive. I don't think there will be any significant—we have seen any significant impact of volume shifting because of price adjustments.

87. On the same call, Taro Group Vice President and CFO Michael Kalb noted:

Net sales for Q2 were \$251 million, up 22% over Q2 last year. As we anticipated in last quarter's earnings release we are realizing the benefits of the previous quarter's price adjustments in the current quarter. Gross profit increased 24% to \$198 million year-on-year resulting in a 130 basis points expansion in our gross margins to 79%.

88. Sundaram has also emphasized Taro's strategy of relying upon high-priced generics in a May 27, 2016 earnings call, stating that: "We are a specialty generic company, so

by definition, our portfolio will be sort little narrow, but set of focused. [sic] We operate in niche market[s], smaller volumes, but better priced.”

89. On September 13, 2016, The Economic Times reported that “While Taro has been gaining approvals for its products, a significant portion of its revenue growth has come from price increases.”⁴

90. Taro reported rising revenues in its United States generics business during the Class Period.

XVII. TELIGENT

91. According to Teligent’s 2015 Annual Report, Econazole accounted for 45% of the company’s total revenues in 2015 and 38% in 2014.

92. On October 29, 2013, during an earnings call, President and CEO of Teligent Jason Grenfell-Gardner noted that “there are certainly some markets there which had seen price appreciation. And that’s a trend that’s been happening throughout the topical market in various ways. . . We hope at this point that trend will continue.”

93. On July 24, 2014—just as Econazole prices were beginning to rise—Jason Grenfell-Gardner, President and CEO of what was then IGI Laboratories, stated on a second quarter earnings call that: “[P]rices go up and prices down. What we as a management team have to do is to ensure that we remain alert and we try to maximize the value we can.”

94. On October 24, 2014, during an earnings call Grenfell-Gardner stated that maximizing value through price increases helped to significantly increase the company’s revenues: “Year-to-date in 2014, we recognized \$9.3 million in sales of IGI label products, that’s

⁴ Divya Rajagopal, *Taro Pharmaceutical Industries under anti-trust scanner for price hike*, THE ECONOMIC TIMES (Sept. 13, 2016), available at <http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/taropharmaceutical-industries-under-anti-trust-scanner-for-price-hike/articleshow/54302910.cms>.

an increase of 123% over the same period last year. This growth has been driven partially . . . from significant price increases for core products in the portfolio.”

95. During a February 27, 2014 third quarter earnings call, Teligent’s CFO Jennifer Collins noted that gross margins had increased and that revenue was up due in part to revenue from Econazole.

96. Grenfell-Gardner and Jennifer Collins, Teligent’s CFO, continued to recognize the “positive market conditions” for Econazole in the April 28, 2015, earnings call for the first quarter of 2015. The company’s 56% increase in revenue over the same period in 2014 was attributed by Collins to Econazole, noting that the product represented 53% of the company’s total revenue for the first quarter of 2015.

XVIII. TEVA

97. On May 2, 2013, the President and CEO of Teva Americas Generics Allan Oberman stated in an earnings call: “We have continued to aggressively take pricing looking to lead the industry forward on products that are low margin products to try and return a decent value to our company, to our shareholders.”

98. On August 1, 2013, Oberman stated in an earnings call:

Then I will just marry that with the comments that we have made about our generic strategy earlier in the year that we are focused on creating shareholder value and not necessarily driving after volume share. I mentioned in the past, we have taken price increases in order to enhance value.

99. On February 6, 2014, Teva’s President and CEO Eyal Desheh stated in an earnings call that “our U.S. generic business is definitely the most profitable part with gross margin of about 50%.” Desheh went on to comment that the “U.S. generic business is highly profitable” and Oberman added that “at the gross profit levels that Eyal was talking about, [the

U.S. generics business] is a very valuable business to Teva and we see it continuing to be on a go-forward basis.”

100. On July 31, 2014, Teva’s President and CEO of the Global Generic Medicines Group Sigurdur Olafsson stated during an earnings call in response to a question from an analyst concerning the sustainability of pricing in the United States:

I think the Company due to the consolidation and due to the environment, Company take pricing actions whenever they can. The same applies a little bit outside now. We have taken the decision that in some of our markets we look at the portfolio and we take a pricing decision and see if we stay for this molecule or not. So I think the size of Teva helps us in this. This is very important part of the commercial execution going forward to keep this in mind. There has to be a balance in the whole thing, but we being the largest company, being probably [indiscernible] of the overall generic business, this is a very important tool today to maximize the value of the business.

101. On October 29, 2015, Olafsson stated during an earnings call that the “pricing environment has been quite favorable for generics versus six years ago.”

102. Teva reported rising revenues in its United States generics business during the Class Period.

XIX. WEST-WARD

103. In 2013, Hikma, parent company to West-Ward, reported “[s]trong cash flow.”⁵

104. On March 12, 2014, Hikma announced strong revenue growth and forecasted continued growth in 2014. Said Darwazah, Hikma’s CEO was “confident about the prospects for 2014,” and noted that in 2013, “[o]ur Generics business delivered very strong revenue . . . and generated significant cash flow.”⁶

⁵ Hikma Pharmaceuticals Preliminary Results (2013).

⁶ Press Release, Hikma Pharmaceuticals plc, *Hikma anticipated potentially reduced doxycycline revenue in the U.S. market in 2014 due to increased competition* (Mar. 12, 2014).

105. In Hikma's Q2 2014 earnings call, Hikma's CFO stated: "I don't know how many of you have covered U.S. generic companies. But when I look at competitors, I look at the -- most companies that are either U.S. based or have a strong position in the U.S. are doing very well the last few years. So the market forces are changing, I believe, in the market."

106. In December 2013, Darwazah told Bloomberg Business that some of West-Ward's huge increases prices were justified because it was "'forced' to raise prices because its competitors raised theirs."⁷ This assertion only confirms Bedrosian's statement that his generic drug competitors were no longer interested in competing on price.

107. West-Ward reported rising revenues in its United States generics business during the Class Period.

XX. WOCKHARDT

108. In its 2015-2016 annual report, Wockhardt noted that growth in the United States would be driven in part by "price increases."

XXI. ZYDUS

109. On October 31, 2013, Cadila (Zydus' parent company) Executive Director Ganesh Nayak stated during an earning call: "This quarter, the major growth has come from price improvement and not actually from new product."

110. During the same call, Cadila's Chairman and Managing Director Pankaj Patel noted:

Up to last quarter, we were [seeing] pricing pressure, but now we see that, on selective products we are able to actually up the price. So it is the kind of a mixed scenario at this moment. We are seeing some visibility where pricing are firming up given the kind of challenges companies are facing, many players are going out of the market, and as a result there are opportunities to basically products with low margins to increase prices. So at least in 3 or 4 products,

⁷ Alan Katz, *Surprise! Generic Drug Prices Spike*, BLOOMBERG (Dec. 12, 2013), available at <https://www.bloomberg.com/news/articles/2013-12-12/generic-drug-prices-spike-inpharmaceutical-market-surprise>.

we have seen price being better and increases are ranging between 10-15% and we also see that the trend is likely to continue given the revised wisdom the industry is getting.

111. Cadila reported rising revenues in its United States generics business (*i.e.*, Zydus) during the Class Period.

EXHIBIT I

Sample Telephone Record Summary

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page	AG	Complaint
7-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:00:04			81
7-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:00:41			81
7-May-12	Text	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:00:00			81
7-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:00:03			81
7-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:01:10			81
7-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:01:36			81
7-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:03:40			81
7-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:00:04			81
7-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:00:40			81
8-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:00:17			81
8-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:00:04			81
8-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:02:32			81
8-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:01:23			81
8-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:00:02			81
8-May-12	Voice	Green, Kevin (Zydu)	Outgoing	Grauso, Jim Aurobindo		0:02:00			81
8-May-12	Voice	Green, Kevin (Teva)	Outgoing	Grauso, Jim Aurobindo		0:01:00			81
8-May-12	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Teva)		0:04:23			81
8-May-12	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Teva)		0:07:57			81
8-May-12	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Teva)		0:04:47			81
8-May-12	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Teva)		0:02:29			81
8-May-12	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Teva)		0:04:31			81
8-May-12	Voice	Berthold, David (Lupin)	Outgoing	Green, Kevin (Teva)		0:00:24			81
9-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:03:10			81
9-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:07:27			81
9-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:06:07			81
9-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:01:01			81
9-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:01:39			81
9-May-12	Voice	Grauso, Jim (Aurobindo)	Outgoing	Green, Kevin (Teva)		0:13:00			81
10-May-12	Voice	Berthold, David (Lupin)	Incoming	Grauso, Jim Aurobindo		0:10:15			81
10-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:00:03			81
10-May-12	Voice	Berthold, David (Lupin)	Outgoing	Grauso, Jim Aurobindo		0:13:29			81
10-May-12	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Teva)		0:05:52			81
6-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:11			287
6-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:01:18			287
6-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:05			287
6-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:05:22			287

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
6-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:20:01	287
7-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:01:03	287
7-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:43	287
7-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:11:35	287
12-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:01:35	287
12-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:06	287
12-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:22:22	287
13-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:03:30	287
13-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:11:26	287
13-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:19	287
13-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:57	287
13-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:05:22	287
14-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:07:36	287
17-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:09	287
17-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:03:32	287
19-Sep-12	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:02:40	287
19-Sep-12	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:51	287
1-Oct-12	Voice	Rekenthaler, David (Teva)	Outgoing	B.P. (Mylan)		0:01:00	58
1-Oct-12	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:00:06	58
1-Oct-12	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:00:10	58
1-Oct-12	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:00:04	58
1-Oct-12	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:05:00	58
4-Oct-12	Voice	Green, Kevin (Teva)	Incoming	Nesta, Jim (Mylan)		0:11:00	58
6-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	8:47:46	0:10:57	89
11-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	15:24:26	0:01:30	89
11-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	19:25:44	0:02:38	89
18-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Green, Kevin (Teva)	18:03:08	0:00:36	89
18-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	18:44:27	0:04:05	89
20-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	7:59:16	0:02:22	89
21-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	16:31:40	0:00:00	89
21-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Green, Kevin (Teva)	16:42:27	0:00:27	89
21-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	16:43:56	0:04:04	89
22-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	10:20:36	0:00:00	89
22-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Green, Kevin (Teva)	10:45:41	0:00:10	89
22-Mar-13	Text	R.H. (Greenstone)	Outgoing	Green, Kevin (Teva)	10:51:04	0:00:00	89
22-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	10:56:51	0:02:13	89
27-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	17:26:41	0:00:00	89
28-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	8:57:21	0:00:00	91
28-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Green, Kevin (Teva)	11:09:50	0:04:52	91
28-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	11:15:18	0:00:00	91
28-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	11:15:39	0:01:23	91
28-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Green, Kevin (Teva)	11:22:04	0:00:45	91

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG	Complaint
28-Mar-13	Voice	R.H. (Greenstone)	Incoming	Green, Kevin (Teva)	12:15:08	0:00:00		91
28-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Green, Kevin (Teva)	12:18:28	0:04:45		91
28-Mar-13	Voice	R.H. (Greenstone)	Outgoing	Green, Kevin (Teva)	13:38:50	0:03:15		91
28-Mar-13	Text	R.H. (Greenstone)	Incoming	Nailor, Jill (Greenstone)	18:52:14	0:00:00		91
28-Mar-13	Text	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	18:59:45	0:00:00		91
28-Mar-13	Text	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	18:59:47	0:00:00		91
28-Mar-13	Text	R.H. (Greenstone)	Incoming	Nailor, Jill (Greenstone)	19:00:29	0:00:00		91
28-Mar-13	Text	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	19:07:29	0:00:00		91
28-Mar-13	Text	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	19:07:31	0:00:00		91
28-Mar-13	Text	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	21:15:51	0:00:00		91
28-Mar-13	Text	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	21:15:53	0:00:00		91
28-Mar-13	Text	R.H. (Greenstone)	Incoming	Nailor, Jill (Greenstone)	23:23:53	0:00:00		91
2-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:06:00		300
2-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:06:00		300
4-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:02:00		300
4-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 {Sandoz}		0:06:00		300
4-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	M.A. (Mylan)		0:15:00		300
9-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:00:06		300
9-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:07:00		300
12-Apr-13	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)		0:01:10		159
13-Apr-13	Text	Patel, Nisha (Teva)	Incoming	CW-5 (Glenmark)		0:00:00		159
15-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:01:00		300
15-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:18:00		300
15-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:09:00		300
16-Apr-13	Voice	CW-3 (Sandoz)	Outgoing	Aprahamian, Ara (Taro)		0:01:00		300
16-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 {Sandoz}		0:11:00		300
17-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 {Sandoz}		0:04:00		300
17-Apr-13	Voice	D.S.(Taro)	Incoming	CW-4 (Sandoz)		0:02:00		300
17-Apr-13	Voice	D.S.(Taro)	Outgoing	CW-4 {Sandoz}		0:12:00		300
18-Apr-13	Text	Patel, Nisha (Teva)	Incoming	B.L. (Upsher-Smith)		0:00:00		159
18-Apr-13	Text	Patel, Nisha (Teva)	Incoming	B.L. (Upsher-Smith)		0:00:00		159
18-Apr-13	Text	Patel, Nisha (Teva)	Outgoing	B.L. (Upsher-Smith)		0:00:00		159
18-Apr-13	Text	Patel, Nisha (Teva)	Outgoing	B.L. (Upsher-Smith)		0:00:00		159
18-Apr-13	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)		0:06:05		159
18-Apr-13	Text	Patel, Nisha (Teva)	Outgoing	R.T. (Sandoz)		0:00:00		159
18-Apr-13	Text	Patel, Nisha (Teva)	Outgoing	R.T. (Sandoz)		0:00:00		159
18-Apr-13	Text	Patel, Nisha (Teva)	Outgoing	R.T. (Sandoz)		0:00:00		159
19-Apr-13	Voice	CW-3 {Sandoz}	Outgoing	Aprahamian, Ara (Taro)		0:01:00		300
19-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 {Sandoz}		0:13:00		300
19-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 {Sandoz}		0:09:00		300
19-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	M.A. (Mylan)		0:01:00		300
22-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	M.A. (Mylan)		0:04:00		300

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
24-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:01:00	300
24-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:05:00	300
25-Apr-13	Voice	CW-3 (Sandoz)	Outgoing	Aprahamian, Ara (Taro)		0:01:00	300
26-Apr-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:08:00	300
30-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:02:00	300
30-Apr-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:14:00	300
2-May-13	Voice	Patel, Nisha (Teva)	Incoming	CW-5 (Glenmark)	7:02:23	0:05:02	201
2-May-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)	7:56:12	0:00:06	201
2-May-13	Voice	Patel, Nisha (Teva)	Incoming	CW-5 (Glenmark)	10:00:09	0:07:18	201
2-May-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)	18:40:29	0:11:39	201
2-May-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)		0:15:48	161
2-May-13	Voice	Patel, Nisha (Teva)	Incoming	CW-5 (Glenmark)		0:07:18	161
2-May-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)		0:00:06	161
2-May-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)		0:11:39	161
2-May-13	Voice	Patel, Nisha (Teva)	Incoming	CW-5 (Glenmark)		0:05:02	161
2-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)		0:00:03	161
6-May-13	Voice	Green, Kevin (Teva)	Outgoing	Berthold, David (Lupin)		0:01:00	53
6-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:22:02	53
6-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:32	53
6-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:22:02	202
6-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:32	202
6-May-13	Voice	Patel, Nisha (Teva)	Incoming	J.C. (Glenmark)		0:06:45	202
6-May-13	Voice	Patel, Nisha (Teva)	Incoming	J.C. (Glenmark)		0:08:39	202
6-May-13	Voice	Patel, Nisha (Teva)	Incoming	J.C. (Glenmark)		0:20:44	202
7-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Berthold, David (Lupin)		0:02:53	53
7-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:10:31	53
7-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:00:18	53
7-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:00:06	53
7-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:11:12	53
7-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:10:31	202
7-May-13	Voice	Patel, Nisha (Teva)	Incoming	J.C. (Glenmark)		0:01:03	202
7-May-13	Voice	Patel, Nisha (Teva)	Outgoing	J.C. (Glenmark)		0:08:00	202
8-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Berthold, David (Lupin)		0:00:05	53
8-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Berthold, David (Lupin)		0:08:55	53
8-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:00:05	53
8-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:00:05	53
8-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:00:20	53
8-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:03:46	53
8-May-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:08:00	302
8-May-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:09:00	302
8-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:03:20	302
8-May-13	Voice	Aorahamian, Ara (Taro)	Outgoing	M.A. (Mylan)		0:01:00	302

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
9-May-13	Voice	Green, Kevin (Teva)	Outgoing	Berthold, David (Lupin)		0:01:00	53
9-May-13	Voice	Green, Kevin (Teva)	Incoming	Berthold, David (Lupin)		0:12:00	53
9-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:04:05	53
10-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:07:26	54
10-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:17:28	54
10-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:17	54
10-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:02:19	54
10-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:10:46	54
10-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:00:28	54
10-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Patel, Nisha (Teva)		0:05:25	54
10-May-13	Voice	Aorahamian, Ara (Taro)	Incoming	M.A. (Mylan)		0:06:00	302
10-May-13	Voice	Aorahamian, Ara (Taro)	Outgoing	M.A. (Mylan)		0:01:00	302
10-May-13	Voice	Aorahamian, Ara (Taro)	Outgoing	M.A. (Mylan)		0:01:00	302
13-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 {Sandoz}		0:04:06	302
14-May-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 {Sandoz}		0:09:00	302
14-May-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 {Sandoz}		0:02:00	302
15-May-13	Voice	Green, Kevin (Teva)	Outgoing	K.R. (Zydus)		0:16:00	203
15-May-13	Voice	Green, Kevin (Teva)	Outgoing	M.F. (Zydus)		0:05:00	203
15-May-13	Voice	Green, Kevin (Teva)	Incoming	M.K. (Zydus)		0:03:00	203
15-May-13	Voice	Aorahamian, Ara (Taro)	Incoming	M.A. (Mylan)		0:02:00	302
15-May-13	Voice	Aorahamian, Ara (Taro)	Outgoing	M.A. (Mylan)		0:01:00	302
16-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:00:04	55
16-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:00:07	55
16-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:02:07	55
16-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:03:12	55
16-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:34	55
16-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:36	55
16-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:05:29	55
16-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:00:04	203
16-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:00:07	203
16-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:02:07	203
16-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:03:12	203
16-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:00	203
16-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:36	203
16-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:05:29	203
16-May-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)		0:05:57	203
16-May-13	Voice	Green, Kevin (Teva)	Outgoing	M.K. (Zydus)		0:04:00	203
16-May-13	Voice	D.S. (Taro)	Outgoing	CW-4 (Sandoz)		0:22:00	302
17-May-13	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:00:21	55
17-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:09	55
17-May-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:11:12	55
17-May-13	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Teva)		0:10:06	55

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
17-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:04:25	55
17-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:11:50	55
17-May-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)		0:16:02	55
17-May-13	Text	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:00:00	55
17-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:00:04	55
17-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:00:05	55
17-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)		0:02:23	55
17-May-13	Voice	Berthold, David (Lupin)	Outgoing	Nesta, Jim (Mylan)		0:02:21	55
17-May-13	Voice	D.S. (Taro)	Incoming	CW-4 (Sandoz)		0:01:00	302
17-May-13	Voice	D.S. (Taro)	Incoming	CW-4 (Sandoz)		0:02:00	302
17-May-13	Voice	D.S. (Taro)	Outgoing	CW-4 (Sandoz)		0:01:00	302
20-May-13	Voice	Patel, Nisha (Teva)	Incoming	B.H. (Apotex)		0:21:56	205
20-May-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:06	306
21-May-13	Voice	Patel, Nisha (Teva)	Incoming	B.H. (Apotex)		0:11:28	205
21-May-13	Voice	Nesta, Jim (Mylan)	Incoming	J.A. (Dr. Reddy's)		0:00:00	306
21-May-13	Voice	Nesta, Jim (Mylan)	Incoming	J.A. (Dr. Reddy's)		0:00:42	306
23-May-13	Voice	Patel, Nisha (Teva)	Incoming	B.H. (Apotex)		0:06:13	205
23-May-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:37	306
23-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:01:25	306
23-May-13	Text	Nesta, Jim (Mylan)	Outgoing	J.A. (Dr. Reddy's)		0:00:00	306
23-May-13	Text	Nesta, Jim (Mylan)	Outgoing	J.A. (Dr. Reddy's)		0:00:00	306
24-May-13	Voice	Patel, Nisha (Teva)	Incoming	B.H. (Apotex)		0:00:39	205
24-May-13	Voice	Patel, Nisha (Teva)	Outgoing	B.H. (Apotex)		0:12:07	205
24-May-13	Voice	Nesta, Jim (Mylan)	Outgoing	J.A. (Dr. Reddy's)		0:00:20	306
9-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	M.F. (Zydus)		0:12:00	274
10-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	M.K. (Zydus)		0:02:00	274
11-Jun-13	Text	K.R. (Zydus)	Outgoing	Green, Kevin (Teva)		0:00:00	206
11-Jun-13	Text	K.R. (Zydus)	Incoming	Green, Kevin (Teva)		0:00:00	206
11-Jun-13	Text	K.R. (Zydus)	Outgoing	Green, Kevin (Teva)		0:00:00	206
11-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	K.R. (Zydus)		0:01:00	206
11-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	M.K. (Zydus)		0:03:00	206
11-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	M.K. (Zydus)		0:26:00	206
11-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	K.R. (Zydus)		0:01:00	274
11-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	M.K. (Zydus)		0:26:00	274
11-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	M.K. (Zydus)		0:03:00	274
12-Jun-13	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)		0:00:00	176
12-Jun-13	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)		0:00:23	176
12-Jun-13	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)		0:03:20	176
12-Jun-13	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)		0:03:25	176
12-Jun-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)		0:09:21	176
12-Jun-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)		0:19:04	176
12-Jun-13	Voice	Green, Kevin (Teva)	Incoming	K.R. (Zydus)		0:01:00	206

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
12-Jun-13	Voice	Green, Kevin (Teva)	Incoming	K.R. (Zydus)		0:14:00	206
12-Jun-13	Voice	Green, Kevin (Teva)	Incoming	K.R. (Zydus)		0:22:00	206
12-Jun-13	Voice	Green, Kevin (Teva)	Incoming	K.R. (Zydus)		0:01:00	274
12-Jun-13	Voice	Green, Kevin (Teva)	Incoming	K.R. (Zydus)		0:14:00	274
12-Jun-13	Voice	Green, Kevin (Teva)	Incoming	K.R. (Zydus)		0:22:00	274
13-Jun-13	Voice	K.R. (Zydus)	Outgoing	Green, Kevin (Teva)		0:07:11	206
13-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	M.F. (Zydus)		0:16:00	206
13-Jun-13	Voice	Green, Kevin (Teva)	Outgoing	M.F. (Zydus)		0:16:00	274
24-Jun-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)	13:25:29	0:00:06	183
24-Jun-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	13:32:25	0:10:13	183
25-Jun-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)	13:43:27	0:00:06	183
25-Jun-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	16:02:58	0:00:32	183
25-Jun-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	16:51:43	0:00:03	183
26-Jun-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)	9:55:29	1:00:25	183
27-Jun-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)	10:47:23	0:00:06	183
27-Jun-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	11:04:04	0:01:03	183
27-Jun-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	15:42:07	0:04:20	183
28-Jun-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	10:59:56	0:03:53	183
8-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:08:34	194
8-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)		0:11:24	194
8-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	Grauso, Jim Aurobindo		0:08:34	194
8-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)		0:00:08	194
9-Jul-13	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)		0:16:16	194
9-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)		0:00:07	194
9-Jul-13	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)		0:00:05	194
9-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	Malek, Jason (Heritage)		0:21:08	194
10-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	15:29:50	0:15:38	194
10-Jul-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)	15:46:55	0:02:18	194
10-Jul-13	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Teva)	15:59:38	0:07:05	194
10-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:04:26	194
10-Jul-13	Text	Patel, Nisha (Teva)	Incoming	CW-5 (Glenmark)		0:00:00	194
10-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)		0:00:04	194
11-Jul-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)	12:11:34	0:00:08	194
11-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	12:12:47	0:00:17	194
11-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	12:38:48	0:04:03	194
11-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teva)	12:43:51	0:00:00	194
11-Jul-13	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Teva)	13:20:15	0:01:52	194
11-Jul-13	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:54	194
11-Jul-13	Voice	Patel, Nisha (Teva)	Incoming	CW-5 (Glenmark)		0:07:29	194
18-Jul-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)	14:32:56	0:00:31	294
18-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)	14:41:59	0:01:21	294
19-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)	13:13:44	0:00:04	294

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
19-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)	13:14:20	0:01:57	294
19-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)	13:24:49	0:03:11	294
29-Jul-13	Voice	Patel, Nisha (Teve)	Outgoing	CW-1 (Sandoz)	8:44:23	0:09:08	210
30-Jul-13	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)	7:56:00	0:01:00	210
30-Jul-13	Voice	Patel, Nisha (Teve)	Incoming	Aprahamian, Ara (Taro)	13:05:11	0:09:51	210
31-Jul-13	Voice	Patel, Nisha (Teve)	Outgoing	Aprahamian, Ara (Taro)	13:17:12	0:03:33	210
31-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teve)	14:10:33	0:04:52	200
31-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teve)	14:50:57	0:01:09	200
31-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teve)	14:54:39	0:03:21	200
31-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teve)	14:59:57	0:06:53	200
31-Jul-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teve)	16:46:59	0:01:27	200
1-Aug-13	Voice	Patel, Nisha (Teve)	Incoming	Aprahamian, Ara (Taro)	11:01:31	0:09:05	210
1-Aug-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teve)	11:23:47	0:05:48	200
1-Aug-13	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Teve)	12:21:43	0:00:59	200
1-Aug-13	Voice	Patel, Nisha (Teve)	Incoming	Green, Kevin (Teve)	12:29:55	0:02:36	200
1-Aug-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)	12:43:00	0:14:00	210
1-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	Aprahamian, Ara (Taro)	14:35:17	0:03:24	210
1-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	CW-1 (Sandoz)	16:41:05	0:14:34	210
2-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	CW-1 (Sandoz)	8:59:51	0:05:23	210
2-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	CW-1 (Sandoz)	10:15:46	0:08:27	210
2-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	CW-1 (Sandoz)	10:59:57	0:00:28	210
2-Aug-13	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)	13:26:00	0:06:00	210
2-Aug-13	Voice	Patel, Nisha (Teve)	Incoming	Aprahamian, Ara (Taro)	17:33:12	0:00:00	210
2-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	Aprahamian, Ara (Taro)	17:34:43	0:00:55	210
2-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	Aprahamian, Ara (Taro)	17:35:47	0:00:02	210
2-Aug-13	Voice	Patel, Nisha (Teve)	Incoming	Aprahamian, Ara (Taro)	17:36:12	0:05:40	210
8-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	Berthold, David (Lupin)	7:27:26	0:00:33	197
8-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	CW-1 (Sandoz)	7:34:46	0:11:41	197
8-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	Aprahamian, Ara (Taro)	7:59:48	0:00:01	197
8-Aug-13	Text	Patel, Nisha (Teve)	Outgoing	Aprahamian, Ara (Taro)	8:01:07	0:00:00	197
8-Aug-13	Voice	Patel, Nisha (Teve)	Incoming	Aprahamian, Ara (Taro)	8:04:04	0:12:15	197
8-Aug-13	Voice	Patel, Nisha (Teve)	Incoming	Nesta, Jim (Mylan)	9:08:05	0:00:00	197
8-Aug-13	Voice	Patel, Nisha (Teve)	Incoming	Nesta, Jim (Mylan)	9:08:28	0:00:07	197
8-Aug-13	Voice	Patel, Nisha (Teve)	Outgoing	Nesta, Jim (Mylan)	9:27:19	0:00:37	197
3-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:00	292
3-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:02:09	292
3-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:02:09	303
3-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:00	303
4-Oct-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:00	292
4-Oct-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:10:56	292
4-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:00	292
4-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:05	292

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG	Complaint
4-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:24		292
4-Oct-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:10:56		303
4-Oct-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:00:00		303
4-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:00		303
4-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:05		303
4-Oct-13	Voice	Nesta, Jim (Mylan)	Outgoing	CW-4 (Sandoz)		0:00:24		303
14-Oct-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:11:19		292
14-Oct-13	Voice	Nesta, Jim (Mylan)	Incoming	CW-4 (Sandoz)		0:11:19		303
2-Dec-13	Voice	Patel, Nisha (Teva)	Outgoing	R.H. (Greenstone)	14:02:54	0:00:05		225
2-Dec-13	Voice	Patel, Nisha (Teva)	Incoming	R.H. (Greenstone)	14:10:13	0:06:09		225
2-Dec-13	Voice	Patel, Nisha (Teva)	Incoming	R.H. (Greenstone)	14:18:50	0:01:37		225
21-Jan-14	Voice	Patel, Nisha (Teva)	Incoming	Nailor, Jill (Greenstone)	14:40:25	0:00:00		92
21-Jan-14	Voice	Patel, Nisha (Teva)	Incoming	Nailor, Jill (Greenstone)	14:40:48	0:00:12		92
21-Jan-14	Text	Patel, Nisha (Teva)	Outgoing	R.H. (Greenstone)	16:38:41	0:00:00		92
21-Jan-14	Voice	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	17:11:38	0:00:28		92
21-Jan-14	Voice	R.H. (Greenstone)	Incoming	Nailor, Jill (Greenstone)	17:33:42	0:03:12		92
21-Jan-14	Voice	Patel, Nisha (Teva)	Incoming	R.H. (Greenstone)	17:37:55	0:18:09		92
21-Jan-14	Voice	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	17:57:37	0:00:00		92
21-Jan-14	Voice	Nailor Jill (Greenstone)	Outgoing	Rekenthaler, David (Teva)	18:23:09	0:00:00		92
21-Jan-14	Voice	Nailor Jill (Greenstone)	Outgoing	Rekenthaler, David (Teva)	18:26:58	0:00:46		92
22-Jan-14	Text	Nailor Jill (Greenstone)	Incoming	Rekenthaler, David (Teva)	9:47:36	0:00:00		92
22-Jan-14	Voice	Nailor Jill (Greenstone)	Incoming	Teva Pharmaceuticals	11:25:37	0:09:53		92
22-Jan-14	Voice	Patel, Nisha (Teva)	Outgoing	Nailor, Jill (Greenstone)	15:33:20	0:00:00		92
22-Jan-14	Voice	Patel, Nisha (Teva)	Outgoing	Nailor, Jill (Greenstone)	15:33:26	0:00:04		92
22-Jan-14	Text	Patel, Nisha (Teva)	Outgoing	Nailor, Jill (Greenstone)	15:33:47	0:00:00		92
22-Jan-14	Text	Patel, Nisha (Teva)	Outgoing	Nailor, Jill (Greenstone)	15:33:49	0:00:00		92
22-Jan-14	Text	Patel, Nisha (Teva)	Incoming	Nailor, Jill (Greenstone)	16:00:44	0:00:00		92
22-Jan-14	Text	Patel, Nisha (Teva)	Incoming	Nailor, Jill (Greenstone)	16:00:46	0:00:00		92
22-Jan-14	Text	Patel, Nisha (Teva)	Outgoing	Nailor, Jill (Greenstone)	16:00:59	0:00:00		92
22-Jan-14	Text	Patel, Nisha (Teva)	Outgoing	Nailor, Jill (Greenstone)	16:01:01	0:00:00		92
22-Jan-14	Voice	Patel, Nisha (Teva)	Incoming	Nailor, Jill (Greenstone)	16:26:26	0:11:09		92
4-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)		0:23:21		218
4-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:00:22		218
4-Feb-14	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:10:04		218
4-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)		0:00:00		218
4-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	CW-5 (Glenmark)		0:00:10		218
4-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	Malek, Jason (Heritage)		0:00:00		218
4-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	Malek, Jason (Heritage)		0:00:29		218
4-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	R.H. (Greenstone)		0:15:53		218
5-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)		0:00:01		218
5-Feb-14	Voice	Patel, Nisha (Teva)	Incoming	Malek, Jason (Heritage)		1:02:06		218
5-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	R.H. (Greenstone)		0:00:04		218

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
5-Feb-14	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)		0:30:28	218
5-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)		0:00:04	218
6-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)		0:00:00	218
6-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)		0:00:03	218
6-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)		0:00:05	218
7-Feb-14	Voice	Patel, Nisha (Teva)	Incoming	S.C. (Breckenridge)		0:04:53	218
7-Feb-14	Voice	Patel, Nisha (Teva)	Outgoing	S.C. (Breckenridge)		0:01:20	218
3-Mar-14	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Zydus)		0:00:05	122
3-Mar-14	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Zydus)		0:00:07	122
3-Mar-14	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Zydus)		0:00:04	122
3-Mar-14	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Zydus)		0:00:04	122
3-Mar-14	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Zydus)		0:00:03	122
3-Mar-14	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Zydus)		0:00:03	122
3-Mar-14	Voice	Nesta, Jim (Mylan)	Incoming	Green, Kevin (Zydus)		0:00:05	122
3-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:00:00	122
3-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:00:04	122
3-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:00:04	122
3-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:19:43	122
3-Mar-14	Voice	Rekenthaler, David (Teva)	Incoming	Nesta, Jim (Mylan)		0:14:00	122
3-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Green, Kevin (Zydus)		0:20:00	122
3-Mar-14	Voice	Nesta, Jim (Mylan)	Outgoing	Rekenthaler, David (Teva)		0:13:30	122
3-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:00:04	129
3-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:00:00	129
3-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:00:04	129
3-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:19:43	129
3-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Green, Kevin (Zydus)		0:20:00	129
4-Mar-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:11:56	119
4-Mar-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:01:03	119
4-Mar-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:00:19	119
4-Mar-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:00:00	122
4-Mar-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:00:04	122
4-Mar-14	Voice	Berthold, David (Lupin)	Outgoing	Green, Kevin (Zydus)		0:13:26	122
4-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:00:04	122
4-Mar-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:00:00	129
4-Mar-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:00:04	129
4-Mar-14	Voice	Berthold, David (Lupin)	Outgoing	Green, Kevin (Zydus)		0:13:26	129
4-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:00:04	129
5-Mar-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:10:37	119
5-Mar-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:00:00	119
5-Mar-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:00:02	119
5-Mar-14	Voice	Nesta, Jim (Mylan)	Outgoing	Green, Kevin (Zydus)		0:08:15	122
6-Mar-14	Voice	R.H. (Greenstone)	Outgoing	Patel, Nisha (Teva)	10:00:22	0:00:29	95

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
6-Mar-14	Voice	R.H. (Greenstone)	Incoming	Patel, Nisha (Teva)	10:29:29	0:03:23	95
6-Mar-14	Voice	R.H. (Greenstone)	Outgoing	Patel, Nisha (Teva)	12:14:29	0:00:00	95
6-Mar-14	Voice	R.H. (Greenstone)	Outgoing	Patel, Nisha (Teva)	12:14:52	0:00:03	95
6-Mar-14	Voice	R.H. (Greenstone)	Incoming	Patel, Nisha (Teva)	12:33:08	0:01:10	95
6-Mar-14	Voice	R.H. (Greenstone)	Incoming	Patel, Nisha (Teva)	15:07:50	0:05:10	95
6-Mar-14	Voice	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	15:20:18	0:00:00	95
6-Mar-14	Voice	R.H. (Greenstone)	Outgoing	Nailor, Jill (Greenstone)	15:20:29	0:00:43	95
6-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Nailor, Jill (Greenstone)	17:32:25	0:00:00	95
6-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Nailor, Jill (Greenstone)	17:32:48	0:01:02	95
6-Mar-14	Voice	M.D. (Actavis)	Outgoing	Taro Pharmaceuticals		0:21:10	119
6-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:07:20	122
6-Mar-14	Voice	Green, Kevin (Zydus)	Outgoing	M.A. (Mylan)		0:01:00	122
6-Mar-14	Voice	Green, Kevin (Zydus)	Outgoing	M.A. (Mylan)		0:01:00	122
6-Mar-14	Voice	Green, Kevin (Zydus)	Outgoing	M.A. (Mylan)		0:03:00	122
6-Mar-14	Voice	Green, Kevin (Zydus)	Incoming	M.A. (Mylan)		0:12:00	122
6-Mar-14	Voice	Green, Kevin (Zydus)	Outgoing	M.A. (Mylan)		0:01:00	122
6-Mar-14	Voice	Green, Kevin (Zydus)	Incoming	M.A. (Mylan)		0:17:00	122
7-Mar-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:15:10	119
7-Mar-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:09:42	119
10-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	S.G. (Zydus)	7:46:00	0:02:00	219
10-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	7:59:46	0:00:02	219
10-Mar-14	Text	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	8:00:03	0:00:00	219
10-Mar-14	Voice	Rekenthaler, David (Teva)	Incoming	S.G. (Zydus)	8:23:00	0:16:00	219
10-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)	10:46:30	0:05:08	219
10-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Malek, Jason (Heritage)	17:48:05	0:00:00	219
10-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Malek, Jason (Heritage)	17:48:28	0:00:30	219
10-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)		0:05:08	119
10-Mar-14	Text	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)		0:00:00	119
10-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)		0:00:02	119
11-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)	9:25:06	0:06:25	219
11-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	15:25:00	0:01:00	219
12-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	12:36:00	0:03:00	219
12-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	12:40:00	0:01:00	219
12-Mar-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:00:00	249
12-Mar-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:00:06	249
12-Mar-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:01:39	249
12-Mar-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:00:00	249
12-Mar-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:00:16	249
13-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	R.H. (Greenstone)	13:41:03	0:00:00	219
13-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	R.H. (Greenstone)	13:41:24	0:00:21	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	8:05:47	0:00:00	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)	8:07:44	0:20:38	219

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
14-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	8:35:27	0:00:00	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	8:41:11	0:19:00	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Rekenthaler, David (Teva)	9:00:43	0:10:43	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)	9:11:50	0:07:54	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)	9:53:49	0:00:00	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)	9:54:11	0:00:22	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	10:31:09	0:12:37	219
14-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	12:36:59	0:05:31	219
14-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	16:11:00	0:01:00	219
15-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	10:27:00	0:11:00	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	8:57:19	0:05:53	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	9:06:23	0:05:04	219
17-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	10:23:00	0:07:00	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)	10:26:51	0:07:44	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	R.H. (Greenstone)	10:40:04	0:00:05	219
17-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	CW-2 (Rising)	10:44:00	0:05:00	219
17-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	CW-2 (Rising)	10:56:00	0:03:00	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	11:07:35	0:00:01	219
17-Mar-14	Text	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	11:08:08	0:00:00	219
17-Mar-14	Voice	Rekenthaler, David (Teva)	Outgoing	Green, Kevin (Zydus)	11:17:00	0:20:00	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	R.H. (Greenstone)	11:35:28	0:15:25	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	11:53:08	0:00:00	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	11:53:31	0:00:05	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)	12:17:50	0:00:00	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)	12:18:13	0:00:22	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	12:19:10	0:19:13	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)	12:36:50	0:00:00	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	12:38:42	0:09:51	219
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	16:46:25	0:11:13	219
17-Mar-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:06:16	129
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:05:04	129
17-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:11:13	129
17-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:05:53	129
17-Mar-14	Voice	Green, Kevin (Zydus)	Outgoing	Rekenthaler, David (Teva)		0:01:00	129
17-Mar-14	Voice	Green, Kevin (Zydus)	Outgoing	Rekenthaler, David (Teva)		0:03:00	129
17-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:07:44	214
18-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:04:12	129
18-Mar-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:07:00	129
18-Mar-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:12:39	129
18-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:06:26	129
18-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:12:19	214
19-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:06:20	214

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
20-Mar-14	Voice	Green, Kevin (Zydus)	Incoming	Berthold, David (Lupin)		0:26:00	129
20-Mar-14	Voice	Green, Kevin (Zydus)	Outgoing	Berthold, David (Lupin)		0:01:00	129
20-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:12:34	214
24-Mar-14	Voice	Patel, Nisha (Teva)	Incoming	Berthold, David (Lupin)		0:04:55	215
24-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:05:14	215
24-Mar-14	Voice	Patel, Nisha (Teva)	Outgoing	Berthold, David (Lupin)		0:11:49	215
23-Apr-14	Voice	Nesta, Jim (Mylan)	Outgoing	K.S. (Lannett)	18:31:26	0:00:03	298
23-Apr-14	Voice	Nesta, Jim (Mylan)	Incoming	K.S. (Lannett)	18:59:53	0:00:34	298
23-Apr-14	Voice	Nesta, Jim (Mylan)	Outgoing	K.S. (Lannett)	19:57:39	0:00:50	298
23-Apr-14	Voice	Nesta, Jim (Mylan)	Incoming	K.S. (Lannett)	21:04:47	0:05:07	298
6-May-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:00:12	132
6-May-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:08:00	132
7-May-14	Voice	Green, Kevin (Zydus)	Incoming	Berthold, David (Lupin)		0:08:00	130
7-May-14	Voice	Green, Kevin (Zydus)	Outgoing	Berthold, David (Lupin)		0:01:00	130
7-May-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:05:37	130
7-May-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:00:00	130
7-May-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:00:03	130
7-May-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:09:21	130
7-May-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:09:21	132
7-May-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:00:00	132
7-May-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:05:36	132
7-May-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)		0:00:03	132
8-May-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:37:49	130
8-May-14	Text	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)		0:00:00	132
8-May-14	Text	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)		0:00:00	132
8-May-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)		0:16:45	132
8-May-14	Voice	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)		0:00:00	132
8-May-14	Text	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)		0:00:00	132
8-May-14	Text	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)		0:00:00	132
8-May-14	Text	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)		0:00:00	132
8-May-14	Text	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)		0:00:00	132
8-May-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)		0:37:49	132
8-May-14	Voice	Aorahamian, Ara (Taro)	Outgoing	Patel, Nisha (Teva)		0:01:00	132
9-May-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:00:00	130
9-May-14	Voice	Berthold, David (Lupin)	Incoming	Green, Kevin (Zydus)		0:00:05	130
9-May-14	Voice	Berthold, David (Lupin)	Outgoing	Green, Kevin (Zydus)		0:11:15	130
11-May-14	Voice	Green, Kevin (Zydus)	Incoming	Patel, Nisha (Teva)		0:13:00	132
11-May-14	Voice	Green, Kevin (Zydus)	Outgoing	Patel, Nisha (Teva)		0:07:00	132
11-May-14	Voice	Green, Kevin (Zydus)	Outgoing	Patel, Nisha (Teva)		0:01:00	132
12-May-14	Voice	Aorahamian, Ara (Taro)	Outgoing	M.D. (Actavis)		0:01:00	249
12-May-14	Voice	Aorahamian, Ara (Taro)	Outgoing	M.D. (Actavis)		0:01:00	249
19-May-14	Voice	Patel, Nisha (Teva)	Outgoing	Grauso, Jim (Glenmark)	11:46:15	0:00:00	136

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
19-May-14	Voice	Patel, Nisha (Teva)	Outgoing	J.C. (Glenmark)	11:47:03	0:24:09	136
19-May-14	Voice	Patel, Nisha (Teva)	Incoming	Brown, Jim (Glenmark)	12:21:00	0:12:53	136
19-May-14	Voice	Patel, Nisha (Teva)	Incoming	Brown, Jim (Glenmark)	13:37:08	0:00:00	136
19-May-14	Voice	Patel, Nisha (Teva)	Incoming	Brown, Jim (Glenmark)	13:37:31	0:00:26	136
19-May-14	Voice	Patel, Nisha (Teva)	Outgoing	Brown, Jim (Glenmark)	13:50:15	0:06:51	136
2-Jun-14	Voice	Rekenthaler, David (Teva)	Incoming	Green, Kevin (Zydus)	9:33:00	0:02:00	261
2-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	11:25:26	0:05:48	261
4-Jun-14	Text	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	9:11:28	0:00:00	258
4-Jun-14	Text	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)	9:16:52	0:00:00	258
4-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	9:56:52	0:25:57	258
11-Jun-14	Voice	Rekenthaler, David (Teva)	Incoming	Green, Kevin (Zydus)	4:37:00	0:08:00	258
11-Jun-14	Voice	Rekenthaler, David (Teva)	Incoming	Green, Kevin (Zydus)	4:37:00	0:08:00	261
11-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	15:36:37	0:00:07	258
11-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	15:36:37	0:00:07	261
11-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	15:42:26	0:14:31	258
11-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	15:42:26	0:14:31	261
12-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	7:57:50	0:09:18	258
13-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	8:13:10	0:16:38	258
13-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	8:13:10	0:16:38	261
17-Jun-14	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:01:00	247
18-Jun-14	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:01:00	247
18-Jun-14	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:01:00	247
19-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	8:38:09	0:00:01	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	8:41:07	0:00:04	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)	13:56:47	0:00:00	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	14:08:53	0:00:00	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	14:24:45	0:00:09	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	14:25:32	0:00:04	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)	15:40:08	0:00:00	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Incoming	Aprahamian, Ara (Taro)	16:01:31	0:13:35	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	16:23:36	0:00:05	260
19-Jun-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	17:24:07	0:13:15	260
19-Jun-14	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:01:00	247
20-Jun-14	Voice	Aorahamian, Ara (Taro)	Incoming	CW-3 (Sandoz)		0:04:00	247
20-Jun-14	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:02:00	247
20-Jun-14	Voice	Aorahamian, Ara (Taro)	Outgoing	CW-3 (Sandoz)		0:10:00	247
1-Jul-14	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)	7:54:45	0:00:03	248
1-Jul-14	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)	9:59:38	0:01:34	248
1-Jul-14	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)	15:05:31	0:00:03	248
1-Jul-14	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)	15:10:28	0:00:11	248
1-Jul-14	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)	15:13:36	0:01:59	248
1-Jul-14	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)	15:21:17	0:07:14	248

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
1-Jul-14	Voice	Patel, Nisha (Teva)	Incoming	CW-1 (Sandoz)	17:58:19	0:19:46	248
10-Jul-14	Voice	Patel, Nisha (Teva)	Incoming	V.B. (Dr. Reddy's)	13:28:12	0:12:14	267
18-Jul-14	Voice	Patel, Nisha (Teva)	Outgoing	V.B. (Dr. Reddy's)	16:20:45	0:00:10	267
21-Jul-14	Voice	Patel, Nisha (Teva)	Incoming	V.B. (Dr. Reddy's)	9:51:53	0:04:14	267
22-Jul-14	Voice	Patel, Nisha (Teva)	Incoming	V.B. (Dr. Reddy's)	9:19:44	0:06:33	267
24-Jul-14	Voice	Patel, Nisha (Teva)	Outgoing	V.B. (Dr. Reddy's)	10:31:30	0:00:04	267
24-Jul-14	Voice	Patel, Nisha (Teva)	Incoming	V.B. (Dr. Reddy's)	10:40:28	0:04:03	267
4-Aug-14	Voice	Rekenthaler, David (Teva)	Incoming	Nesta, Jim (Mylan)		0:06:00	256
4-Aug-14	Voice	Rekenthaler, David (Teva)	Outgoing	Nesta, Jim (Mylan)		0:01:00	256
7-Aug-14	Voice	Rekenthaler, David (Teva)	Incoming	Nesta, Jim (Mylan)		0:14:00	256
11-Aug-14	Voice	Rekenthaler, David (Teva)	Outgoing	Nesta, Jim (Mylan)		0:02:00	256
11-Aug-14	Voice	Rekenthaler, David (Teva)	Incoming	Nesta, Jim (Mylan)		0:06:00	256
18-Aug-14	Voice	Rekenthaler, David (Teva)	Outgoing	Nesta, Jim (Mylan)		0:01:00	256
18-Aug-14	Voice	Rekenthaler, David (Teva)	Incoming	Nesta, Jim (Mylan)		0:13:00	256
21-Aug-14	Voice	Rekenthaler, David (Teva)	Outgoing	Nesta, Jim (Mylan)		0:06:00	256
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)	7:11:03	0:11:13	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	8:02:19	0:00:00	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	8:02:42	0:00:03	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	Aprahamian, Ara (Taro)	8:27:27	0:02:25	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	CW-1 (Sandoz)	8:31:03	0:00:33	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zydus)	8:32:42	0:20:31	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)	8:41:01	0:00:00	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)	8:41:06	0:00:25	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	Rogerson, Rick (Actavis)	8:58:01	0:16:23	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Incoming	Green, Kevin (Zydus)	9:23:26	0:18:34	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	Brown, Jim (Glenmark)	10:34:34	0:00:06	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Incoming	Brown, Jim (Glenmark)	16:29:08	0:07:52	251
27-Aug-14	Voice	Patel, Nisha (Teva)	Outgoing	Green, Kevin (Zvdus)	17:09:15	0:00:06	251
3-Sep-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)		0:01:00	269
3-Sep-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)		0:02:00	269
4-Sep-14	Voice	Rekenthaler, David (Teva)	Incoming	Falkin, Marc (Actavis)		0:01:00	269
4-Sep-14	Voice	Rekenthaler, David (Teva)	Incoming	Falkin, Marc (Actavis)		0:15:00	269
4-Sep-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)		0:01:00	269
8-Sep-14	Voice	Rekenthaler, David (Teva)	Incoming	Falkin, Marc (Actavis)		0:21:00	269
8-Sep-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)		0:01:00	269
8-Sep-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)		0:02:00	269
8-Sep-14	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)		0:05:00	269
9-Sep-14	Voice	Patel, Nisha (Teva)	Incoming	Rogerson, Rick (Actavis)		0:04:32	269
12-Sep-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:00:00	249
12-Sep-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:00:22	249
12-Sep-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:00:19	249
24-Sep-14	Voice	Ostaficiuk, Kon (Camber)	Incoming	Rekenthaler, David (Teva)	5:28:00	0:02:00	331

Date	Call Type	Target Name	Direction	Contact Name	Time	Duration	Page AG Complaint
24-Sep-14	Voice	Ostaficiuk, Kon (Camber)	Outgoing	Rekenthaler, David (Teva)	8:19:00	0:02:00	331
24-Sep-14	Voice	Ostaficiuk, Kon (Camber)	Outgoing	Berthold, David (Lupin)	8:21:00	0:02:00	331
24-Sep-14	Voice	Ostaficiuk, Kon (Camber)	Incoming	Berthold, David (Lupin)	8:23:00	0:10:00	331
24-Sep-14	Voice	Ostaficiuk, Kon (Camber)	Incoming	Rekenthaler, David (Teva)	10:35:00	0:07:00	331
12-Oct-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:07:59	249
12-Oct-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:00:07	249
12-Oct-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:02:37	249
12-Nov-14	Voice	Aorahamian, Ara (Taro)	Outgoing	M.D. (Actavis)		0:02:00	249
12-Nov-14	Voice	Aorahamian, Ara (Taro)	Outgoing	Patel, Nisha (Teva)		0:16:00	249
17-Dec-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:02:35	249
17-Dec-14	Voice	Falkin, Marc (Actavis)	Outgoing	Rekenthaler, David (Teva)		0:08:00	249
18-Dec-14	Voice	Falkin, Marc (Actavis)	Incoming	Rekenthaler, David (Teva)		0:02:40	249
8-Jan-15	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	7:18:00	0:10:00	265
13-Jan-15	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	15:39:00	0:01:00	265
14-Jan-15	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	3:10:00	0:01:00	265
14-Jan-15	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	3:10:00	0:01:00	265
14-Jan-15	Voice	Rekenthaler, David (Teva)	Outgoing	Nesta, Jim (Mylan)	3:12:00	0:01:00	265
14-Jan-15	Voice	Rekenthaler, David (Teva)	Outgoing	Nesta, Jim (Mylan)	5:39:00	0:09:00	265
14-Jan-15	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	6:29:00	0:03:00	265
14-Jan-15	Voice	Rekenthaler, David (Teva)	Outgoing	Falkin, Marc (Actavis)	6:29:00	0:03:00	265